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Antibodies against melanoma antigens have been detected in patients but, despite
known regulatory and activatory functions attributed to humoral immunity, the roles
of B cells in solid tumours such as melanoma are inadequately understood. Insights
into humoral responses and mechanisms of tumour-induced immune escape may in-
form the design of more effective antibodies.
The aims of this thesis are three-fold: a) to gain insights into regulatory mechanisms
in tumour microenvironments that influence antibody expression; b) to examine
whether humoral immune responses are associated with clinical outcomes with a view
of defining biomarkers for melanoma; and c) to design antibody therapeutic strategies
that may be less prone to tumour-induced immunomodulatory mechanisms.
Th2-biased microenvironments favour production of IgG4 subclass antibodies, mainly
through local expression of IL-10. Since IL-10 is expressed locally in melanoma tu-
mours, B cell infiltration, IgG expression, cytokine production and IgG subclass
distribution in melanoma tissues (n=57) were investigated and compared to samples
from health volunteers (n=26). Consistent with Th2-biased inflammation, CD22+
and IgG4
+ B cells infiltrated melanoma lesions. When cultured together ex vivo, B
cells secreted increased VEGF and IgG4, while tumour cells enhanced IL-10 secre-
tion. Two antibodies (IgG1, IgG4) against the tumour-associated antigen CSPG4
were engineered to examine the functional significance of IgG4 subclass. Despite ac-
cumulation in tumours, anti-CSPG4 IgG4, in contrast to anti-CSPG4 IgG1, did not
trigger effector cells to kill tumours in vitro and in vivo. IgG4 mediated IgG1 block-
ade through the reduction of FcγRI activatory signalling, reducing immune effector
v
cell capacity, and significantly impairing the potency of IgG1 in a humanised mouse
model of cutaneous melanoma.
Since IgG4 may impair anti-tumoural immunity, correlations between IgG4 serum
levels and clinical outcomes were studied. Increased IgG4/IgGtotal ratios (G4-levels)
in melanoma patient sera (n=173) were seen compared to those of healthy volun-
teers (n=104). G4-levels were predictive of disease progression (ROC Curve analysis
z=0.62; p=0.0065). Using 0.034 as a cut-off for G4-levels (Youden Index) higher ex-
pression correlated with decreased progression-free survival (median 694 days; hazard
ratio 2.559; 95% CI 1.555 to 4.211; p=0.0004) and overall survival (median 879 days;
hazard ratio 1.871; 95% CI 1.0.45 to 3.349; P=0.035). These findings suggest that
IgG4 may be further evaluated as a putative biomarker in sera of patients with
melanoma.
Tumour immune evasion may be overcome by employing antibodies less prone to
Fcγ-mediated blockade, such as those of the IgE class. Two antibodies, anti-CSPG4
IgG1 and anti-CSPG4 IgE induced significant tumor cell death by differential mecha-
nisms: antibody-dependent cell-mediated phagocytosis and antibody-dependent cell-
mediated cytotoxicity, respectively, by human monocytes in vitro. Anti-CSPG4 IgE
was however superior to IgG1 (p<0.05) in restricting subcutaneous human melanoma
tumour growth in a humanized mouse model. IgE efficacy was confirmed in an or-
thotropic patient tumour in mice populated with autologous patient PBMCs. In
summary, this thesis reports a novel pathway of tumour evasion through melanoma
favouring production of IgG4 subclass antibodies; provides evidence that IgG4 can
be considered as a putative biomarker in melanoma and demonstrates a possible
strategy to overcome Fcγ-mediated blockade by designing an IgE antibody against
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1.1 Cancer and melanoma: facts and figures
1.1.1 Incidence and epidemiology
Cancer is a generic term for over one hundred different diseases, characterised by
uncontrolled growth of malignantly transformed cells, invasion of adjacent tissues
and metastasis to other organs and sites in the body through the lymphatic system
and blood circulation. The incidence of cancer has been steadily increasing in the
past decades and reached a rate of 175.5/100000 in 2008. It accounted for 13% of all
deaths worldwide in 2008 [WHO, 2013] and for 28% of all deaths in the United King-
dom [CRUK, 2013]. Epidemiological studies have shown that approximately 30% of
all cancers are caused by external factors such as the consumption of tobacco, dietary
conditions like obesity or infectious agents [Jemal et al., 2010]. Public health cam-
paigns are therefore aimed at influencing population behaviour. For instance, in the
case of the skin cancer, melanoma, intensive sun exposure increases the likelihood
of its occurrence and therefore campaigns aimed at triggering behavioural adjust-
ment can lead to preventive benefits. While screening for the detection of cancers
at early stages has had positive impact on clinical outcomes and reduced mortality,
1
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many forms of cancer including malignant melanoma remain ”global killers” as lim-
ited effective therapies are available. Projections by the World Health Organisation
(WHO) indicate that deaths from cancer will continue to rise reaching an estimated
13.1 million by 2030 [Globocan, 2013]. Malignant melanoma is the most lethal form
of skin cancer and despite accounting for only 5% of all types of skin cancers it is
responsible for the majority of skin cancer-related deaths [Lens and Dawes, 2004].
Also being the fastest rising cancer in the UK, melanoma is a major therapeutic chal-
lenge and effective treatments are urgently needed. This introductory section sets
out to give a general overview of cancer and melanoma in discussing melanoma inci-
dence and epidemiology (herein, 1.1.1), elaborating on melanoma pathophysiology,
incidence and epidemiology (1.1.2), and ultimately introducing therapeutic concepts
(1.1.3) and specific forms of therapy in melanoma (1.1.4).
1.1.2 Melanoma pathophysiology, incidence and epidemiology
1.1.2.1 Pathophysiology
Melanoma develops from melanocytes, skin cells originating from neural crest pro-
genitor cells. Since melanocytes produce melanin they are morphologically highly
pigmented. Having a dendritic shape they are found primarily in the basal layer
of the epidermis but can also be present in other epithelial sites including the eye.
Melanocytic dendrites are used to transport melanin to adjacent keratinocytes. In
taking up melanin, keratinocytes protect themselves against DNA damage induced
by intensive sun exposure. The main risk factor for neoplastic changes causing the
occurrence of melanoma is exposure to UV sunlight. DNA changes triggering ma-
lignancy are predominantly caused by UV light exposure in the wavelength of 290–
320nm (UVB), which induces the incorporation of dipyrimidine into the DNA. These
changes occur in melanoma more frequently in oncogenes such as CDK4, CDKN2a,
BRAF, KIT, PTEN, RAS, Rb, p16. Pale skin is a major risk factor for melanoma,
but also multiple melanocytic naevi, sun sensitivity, immunosuppression, atypical
mole syndrome and giant congenital melaocytic naevi add to the risk. Since only
10% of all melanoma cases have positive family history [Yeh and Bastian, 2009] ma-
lignant melanoma appears to be largely an acquired rather than an inherited disease.
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1.1.2.2 Incidence and epidemiology
The incidence rates of melanoma are rising constantly. Especially in the Caucasian
population, melanoma has risen faster than any other malignancy over the last
two decades [Gilbert et al., 2011]. Currently melanoma has an incidence rate of
12.4/100,000 and a mortality rate of 3/100,000 in the UK (worldwide ASR 3.1/10000
and 0.8/10000 respectively) (CRUK, 2012). Higher reported incidence rates most
likely reflect better surveillance and early diagnosis programmes. Further improved
early detection would permit identifying more patients at earlier disease stages, al-
lowing for surgical intervention and thus translating into enhanced overall survival
rates [Verdecchia et al., 2009]. Currently 20% of patients diagnosed with melanoma
develop metastatic disease for which prognosis remains extremely poor with a me-
dian survival ranging from 8 to 18 months [Balch et al., 2009]. Treatment options for
these patients are limited despite recently discovered promising therapies [Chapman
et al., 2011,Hodi et al., 2010].
1.1.2.3 Classification and staging
Cutaneous melanoma is classified in a clinical context into four types: 1) lentigoma-
ligna melanomas with a papula or nodular structure; 2) superficial spreading (ma-
lignant) melanomas with large flat irregular pigmented lesions that grow laterally
before invading the dermis; 3) nodular (malignant) melanomas with rapidly grow-
ing nodules that tend to ulcerate and bleed; 4) acral lentigo (malignant) melanomas
mainly present at sites of friction in the body, e.g. sole, palm. Similarly, staging of
melanoma is determined according to defined criteria (TMN Classification). These
parameters include the extent of dermal invasion (Breslow and Clarke scores); the
presence of blisters and ulceration on the surface of the skin, the mitotic rate of
melanoma cells in lesions and the presence of local or distant metastases. Although
a more advanced disease stage correlates with worse prognosis and chances of sur-
vival, there have been reported cases of spontaneous melanoma lesion regressions
and remissions of systemic disease attributed to immunological responses in patients
with melanoma [Balch et al., 2009].
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1.1.3 Therapeutics
Conventional therapies for most cancers include surgery, chemotherapeutic and ra-
diation treatments, which kill tumour cells, but also damage healthy cells and tis-
sues. As a result of significant advances in our understanding of cancer cell biology,
and through identification of an array of tumour-associated antigens (TAA), and
specific melanoma-associated antigens, targeted therapies designed to selectively de-
stroy melanoma cells have been emerging, and such agents include small molecule
therapies. Melanoma-associated antigens, which could serve as suitable targets for
therapies have been identified and are classified in three groups [Fritsch, 2003]:
- Differentiation antigens that are involved in the differentiation of the cell, cell pro-
liferation or cell migration e.g. gangliosides, tyrosinase, Melan-A/MART-1, gp100,
TRP-1, TRP2, High-Molecular Weight Melanoma Associated Antigen (CSPG4).
- Cancer testis antigens are a category of immumogenic cancer antigens with re-
stricted expression to the male germ cells in the testis e.g. NY-ESO1, MAGE-1,
MAGE-2, BAGE, GAGE [Scanlan et al., 2002].
- Mutated melanoma antigens: BRAF, NRAS, c-kit, GNA11, GNAQ CDK4, MUM-1
Novel therapies against some of these can differentiate between malignant and non-
malignant cells more effectively compared to conventional chemotherapeutic treat-
ments. Some of these drugs build on differences in cell cycle regulation between
healthy and malignant cells, whereas others specifically inhibit tumour cell-associated
protein kinases, and others interfere with DNA replication that may induce disrup-
tion of the cell cycle of tumour cells and trigger apoptosis. An alternative focus of
targeted therapies is the disruption of tumour-associated vasculature and inhibition
of angiogenesis aiming at depriving tumours of vital blood supply and restricting
potential escape routes of metastatic cells. Antibodies offer an important emerg-
ing treatment modality that is increasingly used to target different types of cancers.
Antibodies have been called ”magic bullets” since they are designed to recognise anti-
gens with strong specificity and high affinity, targeting only cells that express these
targets and ultimately selectively destroying cancer cells. Antibodies kill tumours
through a variety of mechanisms. These include direct effects such as downstream
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signalling to block vital growth signals, disrupting cell surface antigen association
with growth factors, blocking intracellular signalling cascades regulating cell prolif-
eration and engender apoptosis. Antibodies could also activate various components
of the immune system with potent tumour killing capacity including recruitment
and activation of immune effector cells, by activating either arm of the complement
system. Antibodies could also directly act by modulating regulatory mechanisms
by targeting immune cells such as Tregs or cell surface molecules that are important
checkpoints restricting T cell activation. Other types of antibodies include those con-
jugated to radionuclides and bi-specific antibodies, engineered to recognise more than
one target molecule. Bi-specific antibodies are examples of agents with enhanced im-
mune cell activatory functions. They comprise of two variable regions with different
specificities and a Fc region recognising Fc receptors. This characteristic enhances
the contact between a T cell, a cell that expresses Fc receptors and a tumour cells
(i.e. catumaxomab). This established link between two immune cells and a tumour
cell can induce tumour cell death [Staerz et al., 1985]. Approximately 920 anti-cancer
therapeutic candidates entered commercially-sponsored clinical studies between 1990
and 2006 [Reichert and Wenger, 2008] (Figure 1.1). Of these candidates 44% were
small molecule drugs, 14% natural products [Butler, 2008], and 21% gene therapy
approaches, recombinant proteins and synthetic peptides. Finally, and of greatest
relevance to this thesis, monoclonal antibodies (mAbs) comprised 21% of this new
generation of anti-cancer therapeutics [Reichert and Wenger, 2008] (Figure 1.1).
Figure 1.1: Composition of anti-tumour therapeutics in studies from 1990–2006. Data was
taken from [Reichert and Valge-Archer, 2007].
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1.1.4 Current therapies for melanoma
1.1.4.1 Treatment of localised disease
Localized disease in melanoma is currently treated through surgical removal, using
safety margins of 0.5 cm for tumour in situ and 2 cm for tumour with a Breslow
thickness up to 2 mm or thicker [Thompson et al., 2005]. Routine elective lym-
phadenectomy is currently not a standard of care because it has not been proven
to be efficacious in comparison to observation alone [Morton et al., 2006]. However,
sentinel lymph node biopsy has been suggested by several groups to be of benefit
for patients with melanoma lesions >1 mm in size with or without ulceration, al-
lowing for more accurate staging and therefore clearer information on prognosis. In
contrast, complete dissection of regional lymph nodes after positive sentinel lymph
node biopsy has not proven to be effective in improving overall survival (OS) [Mor-
ton et al., 2006]. New European guidelines recommend the use of radiotherapy for
localized disease if the tumour cannot be fully dissected [Dummer et al., 2012]. In
terms of systemic intervention, adjuvant pegylated IFNα-2b (5 years) or high dose
IFNα-2b (1 year) have been approved by the FDA for patients with positive lymph
nodes and low disease burden (micrometastasis). These adjuvant treatments have
shown improved disease free survival (DFS), relapse free survival (RFS) and ambigu-
ous success for OS [Dummer et al., 2012,Mocellin et al., 2010,Eggermont et al., 2008].
Adjuvant chemotherapy, mistletoe extract, viscum album and hormone therapies did
not prove to be beneficial in localized disease [Dummer et al., 2012,Kleeberg et al.,
2004]. Vemurafenib, an inhibitor for a mutant form of the kinase BRAF, found in
approximately half of melanomas did not appear efficacious for localized disease, as
treatment has been associated with an enhanced risk of keratoakanthomas, squamous
cell carcinomas (SCC) and the development of new melanomas [Oberholzer et al.,
2012,Su et al., 2012,Zimmer et al., 2012].
1.1.4.2 Treatment of loco-regional disease
In cases of loco-regional disease with high tumour burden (stage IIIc), surgical re-
moval of the tumour lesion and lymph nodes with additional guidance provided for
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the subsequent choice of treatment from additional imaging such as Positron Emis-
sion Tomography (PET) and computed tomography (CT) have been collectively
proven to help treatment decisions [Dummer et al., 2011]. In contrast, treatment with
radiotherapy or restricted area perfusion with melphalan and/ or with the cytokine
tumour necrosis factor α (TNF-α) did not improve survival outcomes [Burmeister
et al., 2012,Hong and Fogarty, 2012].
1.1.4.3 Treatment of systemic metastasis
1.1.4.4 Approved treatments
Historically standard treatments for patients include cytotoxic drugs such as dacar-
bazine (DITC), a reference drug in metastatic melanoma that was never tested in
a prospective phase III trial. Other chemotherapeutic agents are temozolomide,
taxanes, fotemustine and platin derivatives as single agents or in combination with
immune-modulators such as IFNα-2b or IL-2 [Petrella et al., 2007]. However, no sur-
vival benefits have been demonstrated for treatment with polychemotherapy [Dum-
mer et al., 2012]. In 2011 the FDA and EMA approved two therapies for the treat-
ment of metastatic melanoma, namely vemurafenib, a kinase inhibitor and ipili-
mumab, an anti-checkpoint blockade antibody (anti-CTLA-4). Vemurafenib inhibits
the mutated form of the BRAF kinase, detected in 50% of all melanomas [Tsai
et al., 2008,Flaherty et al., 2010,Chapman et al., 2011]. Although vemurafenib was
designed to block the V600E (glutamate for valine) mutated form of BRAF it has
also been described to inhibit other mutations such as the V600K (lysine for valine)
mutation [Turajlic et al., 2013]. Although recent studies show prolonged progres-
sion free survival (12.5 vs. 9.5 months) and overall survival (13.6 vs. 9.7 months
in comparison to dacarbazine (DITC) (Chapman JCO 2012) the majority of treated
patients develop secondary resistance to the drug [Flaherty et al., 2010]. This resis-
tance is associated both with mechanisms overcoming the blockade of BRAF kinase
inhibitors as well as with alternative activation of the MAP kinase pathway [Khattak
et al., 2013a,Khattak et al., 2013b,Mao et al., 2013,Long et al., 2013], which together
with enhanced risk of keratoakanthomas and squamous cell carcinomas (SCC) sug-
gest that combination therapies using different kinase inhibitors to overcome these
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shortcomings are worthy of study and are currently being evaluated (experimental
therapy described in section below). Ipilimumab is an IgG1 monoclonal antibody
that recognises the ckeckpoint cell surface molecule CTLA-4 on T cells and blocks
the binding between CTLA-4 and CD80/CD86, thereby activating the numerous T
cells present in melanoma. This can result in universal activation of all T cells, in-
cluding those against the tumour. Ipilimumab has shown efficacy in several phase
III clinical trials in untreated and treated metastatic patients in combination with a
range of therapies such as peptide vaccines and also as a mono-therapy [Hodi et al.,
2010,Robert et al., 2011]. Subsequent trials using combination therapy such as IL-2
and ipilimumab [Prieto et al., 2012] have indicated some promising outcomes, but
are still under evaluation. Moreover, Khattak et al. showed in an initial study
that ipilimumab restricted tumour volume in metastatic uveal melanoma, indicat-
ing this as a suitable treatment of different subtypes of melanoma [Khattak et al.,
2013b]. In summary ipilimumab is now approved by the regulatory authorities in
metastatic melanoma. Suggested combination therapy of the two clinically approved
agents ipilimumab and vemurafenib are being evaluated but some drawbacks due to
hepatotoxicity have been reported [Ribas et al., 2013].
1.1.4.5 Experimental treatments
Therapeutic approaches using alternative CLTA-4 inhibitory antibodies other than
ipilimumab, and novel selective inhibitors for mutant forms of BRAF such as dabrafenib
as well as c-kit and MARK/ERK kinase (MEK) inhibitors have individually shown
impressive outcomes in prospective randomised trials. Furthermore, antibodies against
alternative immune cell regulatory proteins such as PD-1, PD-L1, CD137, OX40 or
CD40 are being investigated [McArthur and Ribas, 2013]. For example, adminis-
tration of the anti-PD-1 antibody nivolumab demonstrated objective responses in
approximately 30% of individuals treated in a phase I trial [Topalian et al., 2012].
Furthermore, combination therapy with nivolumab and ipilimumab in a dosing study
demonstrated clinical safety and showed enhanced efficacy that appeared to be supe-
rior compared to that published on either antibody alone [Wolchok et al., 2013]. In a
more recent study, Hamid et al. report that the monoclonal antibody lambrolizumab
(anti-PD-1) triggered sustained tumour regressions in patients that had refractory
disease after ipilimumab treatment, while only displaying minor toxic effects (grade
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1 and grade 2) [Hamid et al., 2013]. Likewise, the identification of new mutations in
melanoma such as alternative BRAF, NRAS, c-kit, GNA11 and GNAQ mutations
has led to the development of different kinase inhibitors. The kinase inhibitors de-
brafenib and tremetenib improved response rate and survival in patients carrying
the appropriate mutation in randomised phase III trials [Chapman et al., 2011,Fla-
herty et al., 2012, Ascierto et al., 2011]. In conclusion, a new generation of agents,
such as kinase inhibitors and immune-modulatory agents, especially antibodies, are
paving the way for a higher therapeutic benefit with enhanced quality of life during
treatment for patients. Antibody immunotherapy is highly associated with the im-
munological response in the tumour; and the success or failure of treatments may be
related to the immunological status of patients, including the specific immune bias
in tumour microenvironments. Thus, a better understanding of the immunomodula-
tory and immunosuppresive forces at play in tumours may inform treatment design
and patient stratification.
1.2 Relationship between the immune response and
cancer cells
The immune system is believed to play a crucial role in the development of can-
cer. This section elaborates on how tumours interact with the immune system and
specifically with the humoral arm of adaptive immunity, and how cancer cells may
evade immune responses (1.2.1); how signals such as cytokines polarize and down-
regulate components of the humoral immune response generally in diseases (1.2.2)
and how immunoediting occurs in melanoma (1.2.1). This discussion is the basis for
the subsequent exploration of designing more effective antibodies, specifically for the
treatment of cancer (1.3).
1.2.1 Cancer immunoediting
Cancer cells are involved in a network of interactions with their environment, in-
cluding surrounding healthy stromal cells, extracellular matrix components and im-
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portantly, immune cells. These interactions impact on the ability of tumour cells to
survive, divide, shape their microenvironment and also metastasize to distant sites
in the body. To date, considerable attention has been focused on understanding the
relationship between cancer cells with immune cells both in situ and systemically,
from the perspective that cancer cells can modulate or even suppress effective im-
mune responses [Waldmann, 2003,Waldmann and Morris, 2006]. The hypothesis of
tumour-induced editing of the immune response (immunoediting) is based on the in-
ference that tumour and anti-tumoural immune defences interact in different stages:
in the first instance, the immune system detects the presence of aberrated cells and
immune cells home into the tumour to eliminate it (Elimination); if elimination is
not achieved, tumour and immune system reach a state of equilibrium (Equilib-
rium); subsequently the tumour may overcome this equilibrium and evade immune
clearance by triggering the release of an array of mediators by tumour cells as well
as by inflammatory and stromal cells that promote tumour growth and metastasis
(Evasion) [Schreiber et al., 2011, Vesely and Schreiber, 2013] (Figure 1.2). Investi-
gating different aspects of these interactions between host immunity and cancer has
informed the development of numerous strategies to activate the immune responses
to target and eradicate cancer cells.
1.2.2 Immune cells and cytokines influenced by tumours
Influenced by tumour cells tumour associated lymphocytes such as dendritic cells,
macrophages and monocytes alter their phenotypes, immune activatory status, tu-
mouricidal or tumour-promoting capacities, together with their immune polarization
(Th1/ Th2) and Fc receptor expression in the tumour microenvironment. Eluci-
dating the nature of these alterations has formed the focus of extensive study, not
only in the tumour microenvironment but also in patients’ circulation. Numerous
mechanisms, mostly associated with Th2-type inflammation, have been reported to
play major roles in promoting tumour development. For instance, the immunomod-
ulatory cytokine IL-10 acts in different ways such as promoting T regulatory cells
(Tregs), which are associated with poorer patient prognosis (Nicholaou 2009; Wang
2012). Tregs in turn, may suppress maturation of antigen-presenting cells and can
modulate the functions of NK cells or macrophages [Terabe et al., 2004,Rabinovich
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Figure 1.2: There are three stages of cancer immunoediting. Cancer immunoediting is the
result of different stages that function either independently or in sequence to control and
modulate cancer. Once normal cells are transformed by acquiring mutations preferentially
in oncogenes and failed intrinsic tumour suppression, the immune system may function as
an extrinsic tumour-suppressor. In the first stage, elimination, immune cells and molecules
such as antibodies recognize transformed cells and destroy them, resulting in a return
to normal physiological tissue. However, if the immune system is unable to completely
eliminate the tumour cells, surviving tumour may enter into the equilibrium stage, where
immune cells are still able to prevent tumour outgrowth. The acquisition of further muta-
tions may subsequently result in the evasion of tumour cell recognition, killing, or control
by immune cells and leads to clinically detectable malignancies in the escape stage.
et al., 2007, Couper et al., 2008, Emmerich et al., 2012, Gerlini et al., 2004]. It has
been repeatedly shown that particularly tumour-associated macrophages (TAMs)
are polarized towards an alternatively activated M2-phenotype in the tumour mi-
croenvironment, that is induced by cytokines such as IL-4, IL-13 and IL-10. These
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M2-macrophages are thought to promote tumour growth and invasion by tissue re-
modelling via the release of stromal remodelling agents such as matrix metallopro-
teinases or by secreting suppressive mediators such as prostaglandins, IL-10 and
indoleamine dioxygenase (IDO-1) [Mantovani and Sica, 2010, Sica and Mantovani,
2012]. Another myeloid cell type that is known to induce dysfunction in immune
cells is the myeloid derived suppressor cell (MDSC). MDSCs are known to produce
nitric oxide, which induces apoptosis in T cells and limits availability of the essential
amino acid cysteine leading to the production of suppressive cytokines such as IL-
10 [Poschke et al., 2011,Kerkar and Restifo, 2012,Pietra et al., 2012]. Furthermore,
”alternative activation” of several types of TH cells such as TH1 cells that would
normally provide immune activatory signals by secreting IFNγ. In tumours, TH1
cells functions are modulated by the induction of programmed cell death receptor
(PD-1) on (cytotoxic) T cells [Tanchot et al., 2012,Sharpe et al., 2007] or TH17 cells
that can induce angiogenesis and recruitment of neutrophils that secrete elastase, a
tumour promoting mediator [Coussens et al., 2013]. In addition to the secretion of
cytokines, tumour cells protect themselves against directly induced toxicity by ex-
pressing decoy molecules such as FcγRIIb or PD-L1 on their surface to avoid immune
cell targeting [Cassard et al., 2008, Dong et al., 2002, Iwai et al., 2002]. A thorough
evaluation of the cellular constituents in tumours and of the key cytokines such as
the pro-angiogenic vascular endothelial growth factor (VEGF) or the pleotropic im-
munomodulatory cytokine IL-10, can help decipher the processes of tumour cell-led
immunosuppression and provide a better understanding of the initiation of evasion
and inform the design of better immunotherapeutic approaches [Hicklin and Ellis,
2005]. It is now well established that a chronic inflammatory environment can sup-
port tumour progression. Coussens and colleagues have provided insights into the
role of the humoral response in this context. The group describes auto-antibodies
that build immune complexes with complement or Fc receptors on immune cells
such as mast cells or macrophages, promoting vascularisation and immunosuppres-
sion [de Visser et al., 2005, Tan and Coussens, 2007, Andreu et al., 2010]. Likewise,
B cells that produce IL-10 and/or TNFα have been reported to induce myeloid de-
rived suppressor cells [Schioppa et al., 2011]. In a more recent publication a novel
B cell subtype with a regulatory phenotype (Bregs), which is activated by IL-21 was
described. These Bregs induce suppression in a Treg-like manner via granzyme B
and could therefore play a pivotal role in tumour evasion [Lindner et al., 2013]. On
the contrary, several studies reported that the number of infiltrating CD20+ B cells
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correlated with increased disease survival [Nielsen et al., 2012,Lada´nyi et al., 2011].
These seminal reports indicate that modulation of humoral immunity could lead to
suppression or promotion of anti-tumour responses in cancer. On the other hand,
histologically-detected tumour infiltrating lymphocytes (TIL) in different cancers
generally correlates with better clinical prognoses. Extensive studies have been per-
formed in colorectal cancer showing that T cell subsets such as CD8+ cells are highly
predictive of disease progression [Angell and Galon, 2013, Page`s et al., 2009, Mlec-
nik et al., 2011, Galon et al., 2006]. These findings are now paving the way for
prospective-retrospective studies in other cancers where similar observations are al-
ready being made. These findings may suggest that despite immunosuppression, the
immune response may harbour the potential to mount a substantial defence against
tumours. This can be translated into better clinical outcomes, providing the basis
for the design of immunoactivatory therapies.
1.2.3 Modulation of immune responses in melanoma
Spontaneous tumour regressions and remissions reported in patients with melanoma,
along with clinical features of vitiligo-like depigmentation, halo naevi in a small co-
hort of patients and increased prevalence of melanoma in immunosuppressed individ-
uals all point to important and potentially clinically-significant interactions between
melanoma and immune responses. Although the immune system appears to recog-
nise melanoma cells there are several escape mechanisms by which the tumour is
able to circumvent immune-mediated clearance. These include a) modulation of
immune cell mechanisms such as suppressing immune cell activation and matura-
tion, b) recruitment and induction of immune regulatory cells (e.g. Tregs) and pro-
inflammatory cells (e.g. alternatively-activated macrophages), c) up-regulation of
immunomodulatory molecules (e.g. CTLA4, PD-1), d) promoting production of im-
munosuppressive cytokines (e.g. IL-10, TGF-β) [Urosevic and Dummer, 2003, Beck
et al., 2001] and e) regulating the migration and differentiation of stromal cells in
the tumour micro-environment (e.g. metalloproteinases) [Lin et al., 2004,Mantovani
et al., 2005]. Analysis of immune cell subsets such as FoxP3 (Tregs), CD11c
+ (con-
ventional dendritic cells) and CD86+ (mature dendritic cells) in primary tumours
(n=54) and/or sentinel lymph nodes (n=84) revealed that FoxP3 infiltrates had a
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negative impact on anti-tumour immunity, whereas conventional dendritic cells were
down-regulated. These findings imply that the immune cell profiles correlate with
primary tumour >2.0 mm and with disease progression in sentinel lymph nodes, as
well as with clinical outcomes [Ma et al., 2012]. Interestingly, CD20+ infiltrate in-
crease among the immune cell infiltrates correlated positively with survival [Lada´nyi
et al., 2011, Erdag et al., 2012], suggesting that humoral immunity may exert both
anti-tumoural and tumour-promoting effects in melanoma. Additionally, cytotoxic
T-lymphocytes specific for melanoma-associated antigens have been reported in the
blood of patients with advanced disease. These T cells can target and kill tumour
cells, cause apoptosis of melanoma cells and activate other immune cells such as
macrophages and NK-cells that can then also seek out and kill tumour cells by
a number of mechanisms [Fritsch, 2003, Palucka et al., 2007]. The recruitment of
immune inflammatory cells may also oppose tumour development and it is consid-
ered an attempt by the host to suppress tumour growth. Clinical and scientific
observations suggest that activating the immune response may hold promise for the
treatment of melanoma. This premise has formed the focus of many studies and
has given rise to various systemic immune therapies for melanoma such as IFNα-
2b, IL-2 and also more recently, anti-CTLA4 antibodies, which have found clinical
applications. Despite these promising developments and reported anti-tumoural im-
mune responses in patients, some of the above tumour-induced immunomodulatory
mechanisms may explain why, immunotherapeutic strategies aimed at producing a
more efficient host immune response have shown only partial efficacy in subsets of
patients. The challenge in cancer immunotherapy is to redress the fine balance be-
tween tumour-promoting and tumour-suppressing immune inflammatory elements in
order for the immune system to mount an effective response against cancer.
1.3 Antibodies and B cells
Antibodies and B cells are involved in immune protection from pathogens, but on
the other hand, they could participate in the pathogenesis of diseases (1.2). To
understand this complex process it is essential to elaborate on what is an antibody
(1.3.1), how an antibody mediates immune response through Fc receptors on immune
cells (1.3.2), how B cells produce antibodies in the first place (1.3.3), how different
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classes of antibodies are created through class switch recombination (1.3.4) and how
antibody classes are polarized by cytokines such as IL-10 (1.3.5). The description of
these aspects is the basis for the subsequent discussion of IgG4 polarization in the
context of disease (1.4).
1.3.1 Antibody Structure
In 1890, Behring and Kitasato discovered the presence of ”something” in the blood
that was able to neutralize diphtheria toxin, reporting that transfusing sera already
containing the antitoxin activity protected the recipient animal from infection with
the same toxin (Behring E, 1890). This was further elucidated by Paul Ehrlich’
description of the interaction between the antitoxin and diphtheria toxin that lead
to the introduction of the term ”antibody” (Antiko¨rper) in 1891 [Ehrlich, 1891].
More than 100 years since the discovery of antibodies, these molecules demonstrate
a diverse range of applications. One example of application is their use as treatment
modalities for a range of diseases including a number of human malignancies. There
are nine different identifiable antibody (immunoglobulin) classes and subclasses in the
human proteome: IgM, IgG1, IgG2, IgG3, IgG4, IgD, IgA1, IgA2 and IgE (Figure 1.3).
All antibody molecules share the same basic structure of a heterodimeric protein,
but display remarkable variability in the regions that bind antigens. Every antibody
has a symmetric core structure consisting of two identical light chains (L chains,
each about 24 kD) and two identical heavy chains (H chains, each ∼55 or 70 kD)
(Figure 1.4).
One light chain is covalently attached to one heavy chain by a disulfide bond (with the
exeption of IgA2m(1) antibodies) and the two heavy chains are covalently attached
to each other by disulfide bonds. The heavy chain consists of one amino terminal
(N-terminus) variable (V) region and contains four or three carboxy terminal (C-
terminus) constant (C) regions. The light chain consists of only one V region and
one C region [Putnam, 1969].
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Figure 1.3: Representation of the five immunoglobulin classes, distinguished by their heavy
chain structure: IgM, IgD, IgA, IgG and IgE. Heavy chains consist of one variable do-
main (VH)(red) and multiple constant domains (dark green), three for IgA, IgG and IgD
(CH1,CH2, and CH3) and four for IgE and IgM (CH1, CH2,CH3, and CH4). The light
chains are composed of one variable domain (VL) (pink) but have a single constant domain
(CL) (pale green) for all antibody classes.
Variable regions are named so for containing regions of variability in amino acid
sequences that define the specificity and affinity of antibody binding to its target
antigen. The V region of one heavy chain (VH) is juxtaposed with the V region of
one light chain (VL) to form an antigen-binding site; each antibody has two sets
of these pairs (Figure 1.4). The heavy chain C regions do not participate in anti-
gen recognition but components of C regions interact with other effector cells of the
immune system by recognising specific receptors (FcR) on the surface of these cells
and mediating many of the biological functions of antibodies (Figure 1.4) [Murphy
and Walport, 2005]. Antibodies can have one of two types of light chains, κ or λ,
distinguished by their carboxy terminal regions. An antibody has either two iden-
tical κ light chains or λ light chains. In humans about 60% of antibodies have κ
light chains and about 40% have λ light chains. The diversity of antigen receptor
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-multiportein complexes (the antigen receptor shares the same antigen recognition
side as the antibody that will develop from the B cell) on the surface of B cells
made up by the heavy and light immunoglobulin chains- repertoire and its ability
to induce cell differentiation upon specific antigen contact is a key component of the
adaptive immune response. The gene locus for the variable region of antibodies com-
bines 44 Variable, 27 Diverse, and 6 Joining gene segments (VDJ for the heavy chain
and VJ for the light chains) to generate an enormous antibody repertoire based on
nearly random recombination of the single gene segments on chromosom 14 [Bassing
et al., 2002]. Therefore VDJ recombination contributes to the diversity of antigen
recognition sites (variable regions) on antibodies. Assembly of different antigen re-
ceptor genes form arrays of gene segments achieved through the recombination at the
complementarity-determining region 3 (CDR3), CDR3 being one of the main genomic
regions forming the interaction sites between antigen receptor and antigen. This re-
arrangement is initiated mainly by two genes recombination activating gene 1 and 2
(RAG1, RAG2) [Schatz et al., 1989,Oettinger et al., 1990]. RAG1 and RAG2 recog-
nize and bind to recombination signal sequences (RSS) and induce double-stranded
breaks. The described mechanism of coordinated gene rearrangements enables hu-
man B cells to generate a hugely diverse repertoire (7128 combinations) of antibody
specificities. Antibodies activate the immune cells through eliciting the interaction
of the Fc regions of the antibody and Fc receptors on immune cells, also known as
cross linking of Fc receptors. Therefore the functions of antibodies can be highly
dependent on immune cell-mediated mechanisms induced by the interaction between
Fc regions with Fc-receptors.
1.3.2 Fc receptors on immune cells
Fc receptors are proteins that recognise Fc regions of immunoglobulins. They are
mainly expressed on the surface of immune cells and help mediate antibody functions,
including antibody dependent cell-mediated cytotoxicity (ADCC) and antibody de-
pendent cell-mediated phagocytosis (ADCP). Additionally they are able to induce
complement-dependent cytotoxicity (CDC) [Scott et al., 2012]. These activities can
be directed against microbes, viruses and also against neoplastic cells [Weng and
Levy, 2003, Weng et al., 2004]. As this thesis focuses on IgG and IgE antibodies,
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this section elucidates the functional characteristics and distribution of their cognate
(Fcγ and Fc) receptors.
1.3.2.1 Fcγ receptors (FcγRs)
FcγRs are a group of transmembrane glycoproteins that bind the constant region of
IgG antibodies. Crystallographic analysis suggests that there is a 1:1 stoichiometry
interaction between IgG and FcγR [Nimmerjahn and Ravetch, 2008]. According to
their structure and biological properties, FcγRs are subdivided in 3 major classes:
FcγRI, FcγRII and FcγRIII. These receptors have an immunoreceptor tyrosine-based
activation motif (ITAM) with the exception of FcγRIIb, which hosts an immunore-
ceptor tyrosine inhibition motif (ITIM). Monocytes, macrophages, dendritic cells,
basophils and mast cells all have distinct repertoires of activating (FcγRI, FcγRIIa
and FcγRIII) and inhibitory (FcγRIIb) FcγRs. In contrast, natural killer cells (NK
cells) express only the activating receptor FcγRIIIa and B cells express only the in-
hibitory receptor FcγRIIb during certain stages of their development. Although NK
cells express only the activation receptor FcγRIIIa, NK infiltration into tumour does
not always correlate with a positive prognosis. This apparent oxymoron was par-
tially resolved by Aloulou and colleagues describing in their manuscript that ITAM
domains are also capable of inducing inhibitory functions (ITAMi) and blocking im-
mune cell activation [Aloulou et al., 2012]. With the exception of FcγRIIa, FcγRIIb
and FcγRIIc all other FcγRs depend on a ligand binding the α-chain and a signal-
transduction adaptor molecule that contains ITAMs (Figure 1.5).
Their activation is triggered by the phosphorylation of ITAMs by kinases of the
SRC family and leads to downstream activation of major pathways such as the RAS-
RAF-MAPK [Nimmerjahn and Ravetch, 2008]. The diversity in receptor distribution
is also reflected in the heterogeneous function that IgG might play during physio-
logical processes or pathogenesis. For instance, macrophages/monocytes could be
engaged in different ways by different IgG subclasses, promoting or inhibiting patho-
logical processes. These aspects are subject to further investigation in the context
of melanoma, and form part of this thesis.
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Figure 1.4: Variable regions have been given their name because they contain regions
of variability in amino acid sequences that define the specificity and affinity of antibody
binding to its target antigen. The V region of one heavy chain (VH) is juxtaposed with
the V region of one light chain (VL) to form an antigen-binding site; each antibody has
two sets of these pairs. The C region domains do not participate in antigen recognition.
The heavy chain C regions interact with other effector cells of the immune system by
recognising specific receptors (FcR) on the surface of these cells and mediate many of the
biological functions of antibodies. Antibodies can have one of two types of light chains, κ
or λ, distinguished by their carboxy terminal regions. An antibody has either two identical
κ light chains or λ light chains. In humans about 60% of antibodies have κ light chains
and about 40% have λ light chains.
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Figure 1.5: Humans have one high-affinity Fcγ receptor (FcγRI) and several Fcγ receptors
with low to medium affinity for the antibody Fc fragment. With respect to the type of sig-
nals triggered by FcR crosslinking, there is one single-chain inhibitory receptor, FcγRIIb,
signalling through an immunoreceptor tyrosine based inhibitory motif (ITIM) in its cy-
toplasmic domain. With the exception of human FcγRIIa and FcγRIIc, signalling of the
other FcR is usually mediated by a ligand-binding immunoreceptor tyrosine based activat-
ing motifs (ITAMs). In addition, humans have a glycosyl-phosphatidylinositol (GPI)-linked
receptor (expressed by neutrophils), called FcγRIIIb.
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1.3.2.2 Fc receptors (FcRs)
The two known Fc receptors on the surface of specialised immune cells are FcRI
(also known as the high-affinity receptor) and CD23 (otherwise known as FcRII or
the low affinity receptor) [Gould and Sutton, 2008]. Every IgE antibody binds only
one FcRI (1:1 stoichiometry interaction) [Dhaliwal et al., 2012]. FcRI exists in
two forms: the αβγ2 tetramer and αγ2 trimer [Kraft and Kinet, 2007]. FcRI and
FcγRs share the same γ subunit and therefore share some signalling properties like
the immunoreceptor tyrosine-based activation motif (ITAM). The high affinity IgE
receptor (FcRI) has a nanomolar affinity (Ka = 109–1011M−1) and is expressed on
a variety of immune cells including basophils, mast cells, Langerhans cells, myeloid
DCs, plasmacytoid DCs, monocytes, macrophages and eosinophils. Crosslinking
of FcRI receptors by antigen engagement between two different antibodies acti-
vates a signalling cascade mediating immune cell activity. Moreover, FcRI has
been identified on intestinal epithelial cells, were the receptor is believed to play a
role in immunosurveillance or protein trafficking [Untersmayr et al., 2010]. The low
affinity receptor CD23 has a micromolar affinity (Ka = 107–108M−1) for IgE and is
mainly expressed or up-regulated on activated immune cells, including B cells, mono-
cytes and macrophages, eosinophils, natural killer T cells, T cells, follicular DCs and
platelets [Gould and Sutton, 2008]. CD23 can also be found on non-immune cells in-
cluding airway epithelial cells [Dullaers et al., 2012]. There are two variants of CD23
that are induced by splicing differences. CD23a is found on activated B cells and is
thought to play key roles in antigen-IgE complex endocytosis, antigen processing and
presentation to T cells [Gould and Sutton, 2008]. CD23b is inducible by IL-4 on a
variety of immune cells such as monocytes and B cells. Engagement of CD23b by IgE
antibody-antigen complexes on immune cells such as monocytes and macrophages
prompts production and release of modulatory or cytotoxic mediators including nitric
oxide and TNFα. Furthermore, this receptor has been described to induce antibody
depended phagocytosis, especially in the context of parasitic infections [Vouldoukis
et al., 2011].
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Figure 1.6: Diagram of the proposed down stream singalling events accruing while FcRI
and FcRII (CD23) are activated. Cross-linking of FcRI leads to activation of ITAM
domain and phosphorylation of different downstream kinases, whereas activation of CD23
leads to the downstream signalling through tyrosine kinases and Iκk.
1.3.3 B cells: development, activation and antibody produc-
tion
B lymphocytes producing antibodies are primarily responsible for the humoral arm
of the adaptive immune response. Their principle functions are those of antigen-
presenting cells (APCs) and their capacity to eventually develop into memory B cells
or antibody-secreting plasma cells after activation by antigen interaction. There are
several stages in B lymphocyte differentiation, each representing key genetic changes
in the antibody loci. These changes are important for the evolution of B cells ex-
pressing antibodies with high affinities to a wide range of antigens, including those
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expressed on the surface of pathogens but also those on the surface of tumour cells.
B cell development starts in the bone marrow with formation of lymphoid progenitor
cells, which undergo rearrangement of their variable regions (immunoglobulin heavy
chain and light chain genes are rearranged). These eventually give rise to imma-
ture and mature resting B1 cells that both express surface-bound immunoglobulin
complexes (IgM+) also termed B Cell Receptors (BCR). IgM (BCR)-expressing im-
mature B cells migrate to the spleen (transitional B cells), where some differentiate
into mature B lymphocytes, while others that fail to receive adequate stimulatory
signals undergo apoptosis in a process termed clonal deletion [Honjo and Neuberger,
2004] (Figure 1.7).
Figure 1.7: Development of B cells from progenitor cells to activated antibody-secreting B
cells. In the bone marrow progenitor cells are matured to unique B cell receptor expressing
cell by recombination of the variable, diversity and joining (VDJ) regions. After these
cells have moved out of the bone marrow, they can be activated through interactions with
T cells. This activation works by signalling between the TCR-MHCII, CD40-CD40L and
interleukin receptor on the B cell.
B lymphocytes entering the peripheral blood express different cell surface proteins
throughout their lifespan. These include CD40, CD19, CD20, CD22 and CD27; some
of these molecules can function as co-stimulatory or inhibitory molecules. Late pro-B
cells in the bone marrow through to mature B cells, express CD19 and CD20 (Honjo,
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2004), but these markers are not expressed on early pro-B cells or plasma cells. Ma-
ture B cells but not plasma cells express CD22 [O’Keefe et al., 1999, Depoil et al.,
2008]. Mature memory B cells are known to express a combination of CD22, CD27,
CD40 and CD79. In addition to antigen-specific signals other antigen-independent
(polyclonal) activation signals have been described which induce activation, matu-
ration and/or differentiation of B cells in tissue and blood. B cell activation occurs
among others through toll-like receptor (TLR-7, TLR-9) engagement by specific nu-
cleotide patterns or through the interaction between CD40 on B cells and CD40L
expressed on T helper cells. This is a crucial co-stimulatory signal leading to B
lymphocyte proliferation and differentiation to antibody-producing plasma cells. Al-
though the impact of the above-mentioned stimulatory elements on B lymphocyte
differentiation and antibody production is still being elucidated, studies have shown
that B lymphocytes can respond to one or a combination of these signals while anti-
gen recognition alone may not be adequate or necessary for B cell activation [Murphy
and Walport, 2005].
1.3.4 Signals triggering class switching in B cells
Immunoglobulin class switching or class switch recombination (CSR) occurs in ma-
turing B cells in response to antigen and co-stimulatory signals. Mature B cells
expressing a µ constant (µC) or δ constant (δC) immunoglobulin constant region
can switch to another antibody isotype triggered by an interchromosomal recombi-
nation event. This occurs mostly after activation through antigen cross-presented to
B cells by an antigen presenting cell, and additional signals including CD40 (a mem-
ber of the TNF-receptor superfamily responsible for T cell-dependent immunoglob-
ulin class switch) as well as CD19 (a cell surface protein that assembles with the
BCR to decrease the threshold of activation). The accompanied cytokine environ-
ment (modulated by T helper cells) leads to a switch towards a particular antibody
class or subclass e.g. IgG (1-4), IgA (1-2) or IgE antibodies (Figure 1.8) [Murphy
and Walport, 2005, Pieper et al., 2013]. CSR involves only the constant region of
the immunoglobulin heavy chain while the variable region and therefore antigenic
specificity is maintained. However, as maturation of the variable regions is closely
associated with CSR, these two processes can also happen simultaneously. It is also
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possible that CSR leads to the production of different immunoglobulin isotypes (e.g.
IgG1, IgG2 etc), recognising the same antigen (Figure 1.8).
Figure 1.8: Schematic representation of the mechanism of class switch recombination in
activated B cells. The black symbols between the constant regions represent the s-regions
Both short-lived plasma cells and high affinity memory B-lymphocytes require high-
affinity class-switched antibodies. Deletion of the switch regions (S regions being the
tandem repeats of pentametric nucleotides that flank each constant region and are
rich in Guanine) is a key event for initiation of CSR. Although several proteins are
involved in CSR, the enzyme Activation-Induced Cytidine Deaminase (AID) [Mura-
matsu et al., 2000, Revy et al., 2000] is essential, and it is responsible for initiating
the process by converting cytosine to uracil. The uracil is excised by the uracil DNA
glycosylase UNG resulting in single strand DNA breaks. Subsequent mismatch re-
pair proteins then convert the resulting single-strand DNA breaks to double-strand
breaks with DNA ends appropriate for end-joining recombination. Interestingly, at
least two full rounds of cell proliferation seem to be required for CSR of IgG and IgA
antibodies [Rush et al., 2005]. Moreover AID mRNA is actively regulated by Stat6
and NfKB induction, triggered by synergistic signalling of IL-4, CD40 and PAX5.
As these proteins provide very rapid signals, they are considered to be responsible
for the short expression of AID mRNA. Interaction between CD40L (CD154) on
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T helper cells and CD40 on B cells is required for antibody class switching from
IgM to one of the mature antibody classes [Armitage et al., 1993, Spriggs et al.,
1992,Banchereau et al., 1994]. The absence of this interaction is thought to lead to
hyper-IgM syndrome in humans, which is associated with immunodeficiency [DiSanto
et al., 1993]. Other signals such as those from the B cell activation factor (BAFF),
produced by myeloid cell, antigen presenting cells as well as T cells can also play a
role in antibody class switching in humans by signalling through its receptors TACI
and BAFF-R [Darce et al., 2007a, Darce et al., 2007b]. The enzyme AID is also
involved in a subsequent process of programmed mutation in the variable regions
of the human immunoglobulin locus, and specifically in ”hypervariable regions” of
CDRs. This process leads to affinity-matured antibodies in the tissue and is defined
as Somatic Hypermutation (SHM). SHM mainly in the form of single base substitu-
tions gives rise to clones with different affinities, and allows for selection of B cells
that express immunoglobulins with high affinity for a specific target antigen [Di Noia
and Neuberger, 2007].
1.3.5 Cytokines influencing class switching and production of
antibodies by B cells
A number of cytokines and growth factors also contribute to and regulate class
switching of B cells from IgM/IgD- to IgG/IgA/IgE-expressing cells. For instance, re-
search on animal models has revealed that interleukin-4 (IL-4) and interferon gamma
(IFNγ) are common regulatory cytokines of IgE and IgG1 class-switching respec-
tively, since animals missing IL-4 or Stat-6 (a kinase involved in the IL-4 signalling
pathway) have substantially low levels of IgG1 and no IgE class antibodies [Takeda
et al., 1996,Ozaki et al., 2002]. In a murine model, tumour growth factor β (TGFβ)
induced class-switching to IgA, while IL-2 and IL-5 promoted IgA secretion [Cazac
and Roes, 2000]. In contrast IL-6 may support IgG2a and IgG2b [Kopf et al., 1998].
The cytokine interleukin-13 (IL-13) is particularly interesting as it is thought to be
involved in Th2-mediated allergic inflammation. IL-13 along with IL-4 can induce
expression of IgE and IgG4 antibodies, and can also promote activation of inflam-
matory cells such as macrophages [Wynn, 2003]. IL-13 can signal through its own
receptors (IL13-Ra/b) but also via the IL-4 receptor [Wynn, 2003], and can stimulate
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the spontaneous secretion of IgE and IgG4 in the blood of patients with nephrotic
syndrome, indicating that IL-13 alone can modulate immune responses, without the
involvement of IL-4 (Kimata et al., 1995). In the context of melanoma it has been
reported that patient lymph nodes infiltrated by melanoma cells have higher ex-
pression levels of IL-13 mRNA when compared to lymph nodes with no tumour cell
metastases [Torisu-Itakura et al., 2007]. This might indicate that IL-13 is involved
in mechanisms of immune modulation in melanoma.
1.3.5.1 The role of IL-10 in class switching towards IgG4
One of the most interesting cytokines in immune regulation is interleukin 10 (IL-10)
with its pleiotropic activities in T-, B-, NK-cells and macrophages. As one of the
strongest suppressors of immune activation, IL-10 was first described as cytokine
synthesis inhibitory factor (CSIF) for down-regulating IFN-γ in T- and NK-cells.
The involvement of IL-10 with B cells and the alteration of their antibody reper-
toires were investigated in the last decade. Analysing the modulatory potential of
artificially generated T cell clones with different IL-10 profiles on CD19+ B cells,
Satoguina et al. showed that IgG4 production correlated with IL-10 and that adding
recombinant IL-10 to IL-10-deprived co-cultures induced IgG4 polarisation [Satogu-
ina et al., 2005]. As these correlations were modest (r2=0.352) the authors postu-
lated that IL-10 is not the only causal factor. In a subsequent study the same group
showed that cell-cell contact involving the glucocorticoid-induced tumour necrosis
factor and its ligand in the presence of IL-10 but not TGF-β were instrumental in
IgG4 production [Satoguina et al., 2008]. These two studies suggested that IL-10 is
a key factor contributing to polarisation of B cells to produce IgG4. Research into
allergen immunotherapy in patients with seasonal allergies revealed that an early
induction of IL-10 and late production of IgG4 antibodies occurs in patient circu-
lation as a result of these treatments, giving rise to the idea that these antibodies
could be partly inhibitory when competing with other antibodies for recognition of
the allergen [Francis et al., 2008,James et al., 2012]. In a more recent study, van de
Veen et al. confirmed that allergen tolerance has two essential features, one being
the aforementioned IL-10 producing B-cells and IgG4 expressing B cells [van de Veen
et al., 2013]. Also in cancer, pioneering work by Daveau and colleagues reporting
an IgG4 increase in the sera of melanoma patients compared to healthy volunteers is
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indicative of potential roles of IL-10 and IgG4 in cancer. The above-discussed studies
suggest that there may be various immune modulatory mechanisms at play in dif-
ferent disease settings and possibly in melanoma, which may determine the nature,
specificity and strength of the humoral response against cancer antigens. IL-10 is
one component of the immune response likely to be involved, and therefore its role
and impact in redirecting antibody responses in cancer are investigated as part of
this thesis.
1.4 IgG4 antibodies in inflammatory diseases, allergy
and cancer
This section describes the characteristics of the antibody subclass IgG4 (1.4.1) and
explores its role across three different disease entities - inflammatory diseases (1.4.2),
allergy (1.4.3) and cancer (1.4.4) - to understand its biological involvement in these
diseases. This is the basis for the subsequent discussion of antibody and B cell
responses in melanoma (1.5).
1.4.1 IgG4 antibody structure and functional implications
There are four subclasses of IgGs (1-4) and IgG4 has been discovered fourth in serum,
hence the name. The concentration of IgG4 ranges from 10 µg/ml to 1 mg/ml, ac-
counting normally for 2 - 3% of the total concentration of IgG (10 mg/ml)antibodies
in the blood [Aucouturier et al., 1984,French, 1986]. IgG4 is distinct from the other
IgG subclasses for its low or negligible immune cell activation potential. It only me-
diates reduced or no ADCC via Fcγ receptors. Moreover it is unable to bind C1q pro-
tein complexes and consequently cannot activate the classical complement pathway.
Although IgG4 shares 95% structural homology with IgG1, its affinity to FcγRI and
FcγRII is reduced mostly due to the Koff (dissociation from the receptor). Structural
differences between IgG1 and IgG4 have been localized to a few amino acid differences.
In particular the amino acid position 331 (P331S; Proline→Serine) is important for
the binding of the antibody to C1q while L234F (Leucine→Phenylalanine) as well
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as P331S are important amino acids for the affinity to Fcγ receptor I [Bruhns et al.,
2009,Tao et al., 1993,Brekke et al., 1994,Canfield and Morrison, 1991]. However, the
most striking difference between IgG1 and IgG4 lies in the hinge regions involving two
proline residues in the IgG1 and a proline and serine residue in the IgG4 sequences
at the core of the hinge. These changes establish equilibrium between inter-heavy
chain disulphide bonds (classical disulphide) and intra-chain disulphide bonds (non-
classical disulphide) giving IgG4 its unique ability to exist as a ”half molecule”. This
initial form (”half molecule”) is ultimately responsible for the reported bi-specificity
of IgG4 antibodies [Bloom et al., 1997, Schuurman et al., 2001, Angal et al., 1993]
(Figure 1.9).
Figure 1.9: IgG4 Fab-arm exchange occurs between two IgG antibodies by the exchange of
a heavy chain-light chain pair. The resulted molecule does acquire two distinct Fab arms
and therefore become bispecific.
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Bi-specific IgG4 antibodies were found in vitro in the presence of reducing reagents
and developed spontaneously in vivo by injecting equal amounts of two recombinant
IgG4 antibodies. This process is presumably unique to IgG4 antibodies was termed
”Fab-arm exchange” [van der Neut Kolfschoten et al., 2007]. More recent studies
have reported that a change in residue 409 (Lysine→Arginine) in the CH3 region is
a key component of ”Fab-arm exchange”, making CH3 a second domain on which
”Fab-arm exchange” depends [Davies et al., 2013, Labrijn et al., 2011, Rose et al.,
2011]. Class switching and physiological IgG4 responses can be induced by prolonged
or repeated antigen exposure in combination with a Th2 cytokine environment. Es-
pecially the cytokines IL-10, IL-13 and IL-21 have been reported to favour IgG4 over
IgE [Satoguina et al., 2008,Maehara et al., 2012].
1.4.2 IgG4 antibodies in inflammatory diseases
The cutaneous blistering diseases pemphigus vulgaris and pemphigus foliaceus were
among the first diseases where IgG4 antibodies were first reported to mediate an im-
mune reaction against desmoglein 1. Destruction of the junction protein desmoglein
1 leads to the milder form of the disease [Rock et al., 1989, Warren et al., 2003].
Additionally, IgG4 autoantibodies against the M-type phospholipase A2 receptor or
the metalloproteinase ADAMTS13 were reported to play a major role in idiopathic
membranous glomerulonephritis [Beck and Salant, 2010] and thrombocytopenic pur-
pura [Ferrari et al., 2009] respectively. The identification of a newly recognised condi-
tion termed IgG4-related disease adds to the IgG4-associated pathologies. This fibro-
inflammatory condition can be characterized by several features: a tendency to form
sclerotic lesions at multiple body sites; a dense lymphocytic infiltrate rich in T cells
and IgG4 producing plasma cells; and optional elevated serum IgG4 concentrations.
The disease was initially discovered in the pancreas leading to the classification of
Type 1 and Type 2 autoimmune pancreatitis, whereby Type 1 is used as a synonym
for IgG4-related autoimmune pancreatitis [Hamano et al., 2001]. As IgG4-related
pancreatitis is frequently observed in associated extrapancreatic fibro-inflammatory
lesions harbouring IgG4 cells, the term IgG4-related diseases was expanded to include
conditions in other organ systems like the biliary tree, salivary glands, periorbital
tissues, kidneys, lungs, lymph nodes, meninges, aorta, breast, prostate, thyroid, peri-
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cardium and skin. The common characteristics shared by IgG4 across different sites
are found to be the histopathological features described above as the features of
fibro-inflammatory condition. Moreover IgG4-related disease features a high num-
ber of infiltrating IgG4 positive cells in various organs accompanied by a diffuse T
cell infiltrate that includes activated Tregs, distinguishing it from other autoimmune
diseases. Additionally, these infiltrating cells do not appear to form part of any or-
ganised structure resembling a classical germinal centre-like formation [Stone et al.,
2012,Zen and Nakanuma, 2010,Deshpande et al., 2011,Deshpande et al., 2012,Cornell
et al., 2007, Kasashima et al., 2008]. Unrelated disorders like Mikulicz’s syndrome
(benign lymphoepithelial lesion), Ku¨ttner’s tumour (chronic sclerosing sialadenitis),
multifocal fibrosclerosis and eosinophilic angiocentric fibrosis are now also considered
to belong to IgG4-related disease group [Geyer et al., 2010,Deshpande et al., 2011].
As the disease location and pathophysiology has a high variability, the main diag-
nostic criteria remain the histopathological assessment. Three features have been
defined for the diagnosis of IgG4-related disease: 1) Dense lymphoplasmacytic infil-
trate with IgG4 positivity, 2) Fibrosis arranged at least focally in a storiform pattern
and 3) Obliterative phlebitis.
1.4.3 Increased IgG4 levels in allergic patients receiving im-
munotherapy
Specific immunotherapy (SIT) involves the administration of allergens to achieve
clinical tolerance with the aim of easing the symptoms in patients with allergic
conditions. Long-term clinical benefits of SIT persist even after discontinuation of
therapy, indicating the involvement of a cellular memory component to this therapy.
The mechanism behind the therapy has been extensively studied, but still remains
a focus of research and debate. Research on SIT has to-date focused on altered
T lymphocyte responses and induction of allergen specific IgG4 antibodies. Two
individual patterns of change, which may occur sequentially, have been described.
The first event is induced within 1-4 weeks and entails the generation of regulatory T
cells secreting IL-10 and TGFβ, accompanied by suppression of allergen-induced late
cutaneous responses. Subsequently, around week 10 post-challenge, elevated serum
titres of allergen-specific IgG4 and IgA are observed. While these titres appear pro-
1.4. IgG4 antibodies in inflammatory diseases, allergy and cancer 34
portional to the dose of administered antigen rather than to clinical improvements,
some reports suggest that the capacity of IgG4 antibodies to block IgE functions
correlate with clinical responses [Canonica et al., 2009, Shamji et al., 2012]. These
events coincide with a decrease of allergen-specific IgE antibodies and a shift in the
allergen specific T cell response from predominantly a Th2 to Th1 type [Canonica
et al., 2009]. Serum obtained from patients following SIT has been shown to inhibit
allergen-IgE binding to B cells, thus affirming the effect mediated largely by IgG4
antibodies in patient sera. This in vitro system introduced the idea that SIT triggers
production of ”blocking antibodies” that inhibit IgE functions such as IgE-facilitated
antigen presentation (FAP) on B cells. Similarly, basophil histamine release assays
or basophil activation assays have demonstrated the functional ability of IgG4 to
inhibit IgE-dependent activation and mediator release either by competing with IgE
for the antigen and/or by stimulation of surface IgG-inhibitory receptors present on
basophils and mast cells [Shamji et al., 2012, James et al., 2012]. Interestingly, IgA
antibodies could not block allergen-IgE binding to B cells. The contribution of IgA
in the responses to SIT may lie in engagement of surface IgA receptors and release
of the inhibitory cytokine IL-10, which may participate in the induction of immune
tolerance to allergens [Pilette et al., 2007]. The mechanisms triggering elevated IgE-
neutralizing antibodies following SIT are not completely understood, although it is
known that prolonged exposure to antigenic stimuli can direct production of IgG4 by
B cells. B cells can switch from IgG4 to IgE but not vice versa, as these sections of
the gene are spliced out during class switching recombination. Thus, it is assumed
that IgG4 must be produced by switching from IgM, IgG1−3 or IgA1, or by prolif-
eration of pre-existing IgG4
+ B cells during SIT. It has been suggested that Th2
cytokine environments with elevated levels of IL-10 can drive the differentiation of
IgG4-switched B cells to IgG4-secreting plasma cells [Satoguina et al., 2005]. In addi-
tion to IL-10, the immunoregulatory cytokine IL-21 has been found to increase IgG4
production in vitro [Wood et al., 2004]. The IgE-neutralizing and tolerogenic prop-
erties of IgG4 may be partly due to competing with allergen-specific IgE for antigen
specificity. However, since only a fraction of IgG4 antibodies are allergen specific after
immunotherapy, other mechanisms may be involved. Van der Neut Kolfschoten and
colleagues used recombinant IgG4 antibodies against grass and cat allergens, which
when co-injected in a mouse graft, became bi-specific by ”Fab-arm exchange” [van der
Neut Kolfschoten et al., 2007]. The resulting bi-specific IgG4 antibodies might reduce
binding of IgE antibodies for allergens and interrupt IgE-FcRI-multivalent allergen
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complex formation on the surface of immune effector cells. These properties could
therefore moderate IgE-mediated inflammatory cascades, consistent with the obser-
vations that IgE effector cells such as eosinophils, mast cells or basophils are reduced
after SIT against house dust mite and grass pollen [Passalacqua et al., 1999]. An
additional mechanism by which SIT can tolerize allergic immune responses may be
due to the ineffective Fc-mediated functions of IgG4. Lacking complement activator
properties and mediating ineffective FcR signals, IgG4 antibodies could have reduced
capacity to trigger cytotoxicity or phagocytosis and may thus fail to activate immune
responses.
1.4.4 IgG4 and cancer
Although IgG4 has recently been associated with a group of fibro-inflammatory con-
ditions termed IgG4-related disease, the presence of IgG4 antibodies or IgG4+ B cells
in cholangiocarcinoma, pancreatic cancer, lymphoma and squamous cell carcinoma
have previously been described [Harada et al., 2012, Stone et al., 2012, Strehl et al.,
2011]. IgG4 has attracted interest in pancreatic cancer as initial studies postulate
that this antibody subclass could be used to distinguish between autoimmune pan-
creatitis and pancreatic cancer [Raina et al., 2008,Kasashima et al., 2008,Kamisawa
et al., 2008, Kawa et al., 2012]. Furthermore, a study in extrahepatic cholangio-
carcinoma demonstrated abundant IgG4
+ immune cell infiltration and postulated
that cancer cells that expressed HLA-DR and secreted IL-10 could act in a simi-
lar capacity to regulatory T cells and modulate the humoral response in favour of
IgG4 [Harada et al., 2012]. In a preliminary study, squamous cell carcinoma has been
reported to have an IgG4 immune infiltrate component; however the roles of these
infiltrates was not further investigated [Strehl et al., 2011]. While IgG4 has been
intensely investigated in allergen immunotherapy, its role in the pathogenesis of can-
cers remains poorly understood. Different association studies indicate the presence
or involvement of this antibody class in various cancers including melanoma, thus
suggesting the merit of further investigating the potential contributions of IgG4 in
redirection of immune responses and tumour-induced immune escape.
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1.5 Antibody and B cell responses in melanoma
Although immunological research in melanoma has focused mainly on T cells, the im-
mune cell infiltrate comprises an array of different stromal as well as immune inflam-
matory cells such as macrophages, neutrophils, NK cells and also B cells [Clemente
et al., 1996, Erdag et al., 2012]. In general, the antigen-specific B cell response is
not yet fully explored in melanoma. This section describes what is known about
humoral responses and specifically IgG4 in circulation (1.5.1) and in tumour lesions
of patients with melanoma (1.5.2 - 1.5.3).
1.5.1 Circulating B cell and antibody responses in patients
with melanoma
Attempts to study the humoral response in melanoma have focused on circulating
antibodies in patient sera [Stockert et al., 1998, Trefzer et al., 2006]. These studies
reported a humoral response against specific tumour-associated antigens (TAA) such
as the cancer-testis antigen NY-ESO-1 as well as against autologous tumour cells.
Moreover, they demonstrated that a tumour-antigen specific response takes place in
the context of melanoma at least in the temporal setting. Interestingly, Sittler et
al. demonstrated that whole-cell vaccine therapy that triggers antibodies directed
against auto-antigens does not induce autoimmunity, indicating that even though
some tumour antigens might be also expressed by normal somatic cells the vaccine-
induced autoantibodies are neither lethal nor cause toxicity [Sittler et al., 2008]. The
presence of tumour cell-reactive B cells in the peripheral blood of patients indicates
that these cells might mature in the tumour microenvironment or could also be the
product of adaptive immune responses occurring elsewhere in the body such as in
draining lymph nodes [Yamaguchi et al., 1987,Kirkwood and Robinson, 1990]. Until
recently, it was not clear whether serum autoantibodies in melanoma signified a local
or systemic memory response. Our group reported the presence of a tumour-reactive
mature memory B cell response in the circulation of 21 patients with melanoma. This
reactivity was found against a multitude of cell-surface antigens expressed across dif-
ferent melanoma cell lines, but less so against antigens on the surface of primary
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human melanocytes. We also observed appreciable frequency of tumour cell reac-
tive antibodies expressed by mature memory B cells in human melanoma against
cell surface antigens on allogeneic melanoma cells studied by limiting dilution anal-
ysis. We furthermore established that tumour-reactive B cell frequency was higher
in early disease stage patients (stage II) and decreased in late stage disease patients
(stages III - IV). These data are in agreement with reports of a collapsed memory
B cell compartment in the circulation of patients with advanced melanoma [Car-
penter et al., 2009]. In our study, we also demonstrated that a patient derived IgG
monoclonal antibody can activate human monocytic cells to kill tumour cells by cy-
totoxicity, while a non-reactive monoclonal antibody derived from the same patient
did not display any tumour killing activity [Gilbert et al., 2011]. Taken together,
our data suggested that although a tumour-reactive memory B cell compartment
exists in the circulation of patients with melanoma and patient-derived antibodies
harbour the potential to activate effector functions against cancer, this memory B
cell compartment diminishes with disease progression. We reasoned that humoral
immunity is not oblivious to the presence of melanoma, however, B cell responses
might be subject to suppressive signals, most likely orchestrated though numerous
inflammatory mediators in tumours and the circulation which may be triggered by
the presence of melanoma
1.5.2 B cell infiltrates in melanoma lesions
As mentioned above, a number of studies analysed the presence and prognostic signif-
icance of B cell infiltrates in the tumour microenvironment of colorectal cancer, breast
cancer and melanoma. Maletzki et al. showed that B cells infiltrating colorectal
cancer produce cancer cell specific antibodies. Mahmoud and colleagues correlated
the number of infiltrating CD20+ cells with overall survival benefit in breast cancer
patients, while Erdag showed that the immune cell infiltrates containing a bigger
proportion of CD20+ cell have better clinical outcome in melanoma [Maletzki et al.,
2012, Mahmoud et al., 2012, Punt et al., 1994, Erdag et al., 2012]. An initial study
analysing the outcome of a bioengineered GM-CSF tumour cell vaccine reported that
higher titres of IgG antibodies against the H+-ATPase (ATP6S1) correlates with tu-
mour destruction and prolonged patient survival [Hodi et al., 2002]. This study
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suggests that potent humoral responses can induce immune cell mediated tumour
cell destruction. Despite this limited evidence of the benefit of B cell infiltrates in
cancer, the roles of melanoma-specific antibody-producing B cells are not yet fully
elucidated and similarly to T cells, B cells may also be subject to tumour-induced
modulatory signals which may impair their capacity to trigger effective anti-tumoural
functions.
1.5.3 Impairment of immune responses by antibodies through
alternatively activated B cells and antibodies
Dysregulation of the immune response has been described in metastatic melanoma
and other cancers with CD4+ T helper cells primed towards a more dominant TH2
phenotype producing cytokines such as IL-4, IL-5, IL-6, IL-10 and IL-13 [Tan and
Coussens, 2007]. In addition, it is believed that infiltrating Tregs and Bregs may
induce immune suppressive conditions independently of TH1 TH2 or TH17 environ-
ments by means of secreting cytokines such as TGF-β, granzyme B and IL-10 [Lind-
ner et al., 2013]. It has been suggested that the humoral arm of the immune response
may be biased by the immunoregulatory cytokine IL-10, which polarizes B cells to
produce IgG4 antibodies, but until recently, this was not demonstrated in any can-
cer including melanoma [Platts-Mills et al., 2004, Satoguina et al., 2005]. However,
descriptive evidence that the humoral immune responses may be redirected in the
context of melanoma was published a number of years ago by Daveau et al. who
reported dysregulation of IgG4 levels in the sera of melanoma patients compared
to sera of healthy volunteers [Daveau et al., 1977]. Ten years later, in a compre-
hensive study, Neuberger and colleagues compared the effectiveness of a matched
set of chimeric antibodies with different subclasses showing that IgG4 mediated in-
effective complement activation and antibody dependent cytotoxicity [Bru¨ggemann
et al., 1987]. These poor effector functions were thought to be solely attributable
to the very low affinity of IgG4 to its cognate Fcγ receptors and its poor ability to
bind complement [van der Zee et al., 1986]. However, Bruhns et al. have shown in a
recent study that IgG4 has a comparatively high affinity to FcγRI, one of the main
activatory receptors of IgG (for affinity of IgG4 see Table 1.2) [Bruhns et al., 2009].
The discovery of ”Fab arm exchange” by van der Neut Kolfschoten et al. revolu-
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tionised the field of antibody-antibody interaction research as the authors confirmed
that IgG4 has the unique capacity to exchange Fabs with other antibodies, reducing
those antibodies’ affinity to their target antigens and significantly reducing the bi-
ological functions of those antibodies’ [van der Neut Kolfschoten et al., 2007]. The
”Fab arm exchange”, unique to IgG4, may contribute to the anti-inflammatory ac-
tivities attributed to this antibody subclass. New interest in IgG4 emerged following
the recognition of a new group of fibro-inflammatory conditions termed IgG4-related
disease [Stone et al., 2012]. As this condition is associated with sclerotic diseases,
several studies have been conducted to investigate if IgG4 could be used as a predic-
tive marker for autoimmune pancreatitis (AIP) [Ghazale et al., 2008, Oseini et al.,
2011,Choi et al., 2007,Hirano et al., 2006,Hamano et al., 2001]. The control cohorts
of these studies included patients with pancreatic cancer, but while AIP samples were
distinct from pancreatic cancer samples, it is notable that serum IgG4 is elevated in
pancreatic cancer compared to healthy controls. These findings suggested that IgG4
might be of importance in malignant conditions. A more recent study confirmed the
functional relevance of IL-10 in inducing IgG4
+ plasma cells in extrahepatic cholan-
giocarinoma [Harada et al., 2012]. A follow-up study showed a positive correlation
between the presence of IgG4
+ cells with FoxP3+ cells but no correlation between
IgG4
+ cells with CD8+ cells, suggesting that alternatively-activated humoral immune
responses are associated with other regulatory elements in the tumour microenviron-
ment [Kimura et al., 2012]. Taken together, the above studies confirm that IgG4
production represents a biologically significant mechanism that contributes to reduc-
ing the potency of immune responses and this may be a mechanism found in some
malignancies. Therefore this antibody subclass is of special interest to the work
presented in this thesis.
1.6 Discovering novel antibodies for cancer treat-
ment
Antibodies recognising cancer antigens were originally derived from immunizing mice
with tumour cell lysates, proteins or epitopes of tumour-associated proteins. The
first antibodies were produced using hybridoma technology, which for the first time
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yielded sufficient amounts of antibody for further investigations of antibody effi-
cacy in cancer therapy. The first mAbs had some drawbacks: derived from mice
upon administration in patients, the human immune system mounted a brisk human
anti-mouse antibody (HAMA) response with production of host antibodies that neu-
tralised the on-target therapeutic effects of these antibodies and cleared them from
the circulation; thereby vastly-reducing their therapeutic effects against cancer and
causing toxicities. The advent of recombinant DNA technology enabled the construc-
tion of chimaeric (mouse variable and human constant regions) [Sahagan et al., 1986],
humanized [Jones et al., 1986, Carter et al., 1992] and human antibodies. All these
types of antibodies can trigger neutralising antibody responses [Winter and Harris,
1993,Jakobovits et al., 2007,Lanzavecchia et al., 2007]. Indeed, HACA (human anti-
chimeric antibody) and HAHA (human anti-human antibody) responses have been
reported in patients. Phage display is an in vitro technology established for the dis-
covery of fully-human antibodies. It is designed to mimic the natural immune process
of antibody affinity maturation in an in vitro setting. This process uses filamentous
bacteriophages that display single-chain variable region antibody fragments (scFv)
on their surface. Immune selection is then mimicked by direct binding of the phage
to a specific antibody or antigen. The phagemids bound to the antigen are eluted
after removal of unbound phages in a series of panning steps. Panning can enrich
the most specific phage by 20-10,000 fold per round, eventually leading to the selec-
tion of the variable region sequences with the highest affinity to the target antigen.
Similarly to the equivalent in vivo immune process, the V gene in this phage can
also be subject to random mutations allowing for the selection of mutants with high
affinity for the antigen. A limitation of this technique is that to obtain a fully ”affin-
ity matured” antibody, the produced antibody heavy chains must be matched with
random light chains [Winter and Harris, 1993]. Recently technologies using human
transgenic mice such as the Xenomouse© were introduced to produce fully-human
antibodies through a process of immunizing animals in vivo. These mice express the
human immunoglobulin gene loci and secrete human antibodies, which are subse-
quently immortalized by standard hybridoma technology in vitro [Jakobovits et al.,
2007]. More recent developments include the use of humanised mice (HIS-mice) that
have been injected with human CD38+ lymphocyte progenitors and subsequently im-
munized with antigen. As these mice develop a human immune system, it is thought
that this approach better mimics the antigen processing and antibody maturation
leading to a more ”natural” antibody response [Becker et al., 2010]. Following speci-
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ficity screening, positive antibodies from the HIS-mouse are recombinantly produced
using a novel transfection and expression system allowing for a quicker evaluation of
the discovered agent [Kwakkenbos et al., 2010]. The approach to derive antibodies
from human B lymphocytes is also of interest in this context. Although the idea and
attempts to implement it dates back over four decades, maintaining and immortal-
ising B cells ex vivo has proven challenging. In 2004, Traggiai et al. proposed a new
method to obtain fully-human antibodies by isolating B cells from human blood,
growing them in culture, immortalizing them with Epstein Barr virus (EBV), while
simultaneously activating them with the toll-like receptor 9 (TLR-9) agonist CpG
2006 ODN. Supernatants from these B cell cultures were screened against the SARS
virus to select B cells, which secreted antibodies specific to virus envelope proteins.
Using this approach, the team was able to screen and generate 35 neutralizing mon-
oclonal antibodies against the SARS coronavirus from a convalescent patient. From
these results it was concluded that the B cell pool of a patient can be interrogated at
any time after priming with the only limiting factor being the large number of cells,
which need to be screened to access specific antibodies [Traggiai et al., 2004,Lanzavec-
chia et al., 2006]. These technologies, together with recombinant protein expression
platforms have allowed for the development of many strategies to engineer, examine
and apply antibodies as therapeutic agents in cancer and other diseases.
1.6.1 Monoclonal antibody approaches for cancer therapy
Most monoclonal antibodies used in immunotherapy of cancer patients recognise
epitopes of tumour-associated antigens (TAA) on the surface of tumour cells therefore
binding to tumour cells rather than somatic cells with high specificity and affinity.
These interactions result in tumour cell destruction by a number of mechanisms.
There are more than 15 approved antibodies for the treatment of cancers such as
non-Hodgkin lymphoma, leukaemia, breast and colorectal carcinomas (Table 1.3).
Moreover, 165 novel antibody candidates (54% in Phase I; 39% in Phase II and 7%
in Phase III) are being tested in clinical trials for various indications [Reichert and
Dhimolea, 2012,Reichert, 2011,Weiner et al., 2010,Scott et al., 2012]. Only about half
of the candidates are full-length IgG antibodies, while the others comprise antibody
drug conjugates (ADC), multi-specific or otherwise engineered forms of antibodies.
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These numbers indicate that non-canonical antibodies are currently being developed
at fast pace. Furthermore, efforts to enhance efficacy by improving Fc Receptor
affinity, specificity and effector functions are receiving increased attention [Woof,
2012].
1.6.2 Antibody modalities in clinical use for cancer therapy
Most of the antibodies now in clinical use target surface proteins highly expressed
on cancerous cells (TAA) with the most targeted antigens including the epithelial
cell adhesion molecule (EpCAM), mucin-1 (MUC1), epidermal growth factor recep-
tor (EGFR), carcinoembryonic antigen (CEA), CD20, CD33, CD52, CD22, Lewis Y,
prostate-specific membrane antigen (PSMA), human epidermal growth factor recep-
tor 2 (HER2/neu), as well as elements found in tumour-associated vasculature such as
the vascular endothelial growth factor (VEGF). The anti-CD20 mAb Rituximab was
the first mAb to be approved for cancer therapy. The United States Food and Drug
Administration (FDA) approved it for the treatment of B cell lymphomas in 1997.
Today, anti-CD20 antibodies are integrated into standard treatment regimes and can
significantly improve patient survival for CD20-positive B cell malignancies [Fisher
et al., 2005, Swenson et al., 2005, Cheson and Leonard, 2008]. Trastuzumab, which
is licensed for the treatment of HER2/neu-positive breast carcinomas, constitutes
a milestone for the potential efficacy of antibody therapies for the treatment of
solid tumours [Reichert and Valge-Archer, 2007]. In a review article, Reichert et
al. reported that antibodies that are currently clinically evaluated target 92 distinct
antigens. Only one antibody is tested for each of 65 antigens while the remaining
27 antigens are targeted by an average of three antibodies each. Despite a growing
interest in novel TAAs, well-validated targets such as EGFR, HER2/neu and CD20
are among the top five most frequently selected targets for antibody immunothera-
pies (targeted by 33 mAbs in clinical studies). Presently more than 15 antibodies are
licensed for the treatment of different malignancies [Reichert and Dhimolea, 2012].
Notwithstanding the mentioned successes, there are still no effective approved an-
tibodies for the treatment of many tumours, suggesting that antibody therapeutics
have not yet reached their full potential. Therefore an unmet clinical need persists
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for more effective antibodies that can recognise and kill tumour cells, especially in
the context of solid tumours such as melanoma.
1.6.3 Antibody-mediated mechanisms of action against can-
cer cells
Antibodies can mediate tumour cell death and inhibit tumour progression by a num-
ber of mechanisms. These include direct effects blocking vital growth signals, dis-
rupting cell surface antigen association with growth factors, blocking intracellular
signalling cascades to reduce tumour cell proliferation and engendering apoptosis.
Antibodies are also capable of activating various components of the immune system
with potent tumour killing capacity. These include: 1) recruitment and activation of
effector cells (T-lymphocytes, dendritic cells, granulocytes, NK cells and monocytes)
through recognition of Fc receptors on these cells; some of these cells may kill tumour
cells by cytotoxicity and/or phagocytosis (Figure 1.10); 2) modulation of regulatory
mechanisms by targeting regulatory immune cells such as Tregs (e.g. anti-CD25) or
by targeting cell surface molecules that are important checkpoints restricting T cell
activation (e.g. anti-CTLA4 blockade).
Antibodies can also exert anti-tumoural functions by activating the classical pathway
of the complement system [Bru¨ggemann et al., 1987,Christiansen and Rajasekaran,
2004,Nestle, 2006,Schadendorf et al., 2006]. Monoclonal antibodies licensed for the
treatment of cancer are known to kill tumour cells by one or more of the above
mechanisms.
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Figure 1.10: Different antibody dependent/induced mechanisms against cancer cells. In-
dicating three of the most important antibody mediated mechanisms antibody dependent
immune effector cell mediated cytotoxicity (ADCC), antibody dependent immune effector
cell mediated phagocytosis (ADCP) and induction of direct cell death (e.g. apoptosis/
growth arrest) by cell signaling activation.
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The mechanisms employed by antibodies to target and kill cancer cells are impor-
tant measures of potential efficacy in cancer therapy. Hence, implementation of
appropriate assays to elucidate the mechanisms by which antibody candidates exert
anti-tumoural effects as well as functional assays to evaluate their mechanisms of
action and potency are highly desirable and expected to inform the design and eval-
uation of effective future therapies for cancer. This work has therefore also focused
on evaluating the effector functions of antibodies and on developing strategies to de-
sign antibodies with improved efficacy. A number of functional assays to characterise
and evaluate the mechanisms of action and anti-tumoural efficacy of these antibodies
engineered with Fc regions of different antibody classes and subclasses are employed
and described herein (Chapter 5).
1.6.4 Identifying antibodies for the treatment of melanoma
Potential targets for antibody therapeutics include known surface melanoma-assoc-
iated antigens for example MART-1/MelanA, which are commonly overexpressed
by melanoma cells but may also be expressed by melanocytes. Targeting these cell
surface antigens has resulted in manifestations of autoimmune-like responses in pa-
tients such as vitiligo (Boon and van der Bruggen, 1996; Schneeberger et al., 2000).
Other targets of antibody immunotherapies have in the past included the cancer
testis family of antigens MAGE, BAGE, RAGE or NY-ESO 1 [Boon and van der
Bruggen, 1996, Schneeberger et al., 2000]. Although antibody immunotherapy for
melanoma has had some success in pre-clinical models and showing promising clini-
cal outcomes [Pedicord et al., 2011,Curran et al., 2010,Chapman et al., 2011,Wolchok
et al., 2013], none of the above antigens have served as targets for therapeutics that
achieved regulatory approval for clinical use. The strategies for antibody therapies
described below have reached clinical trials in patients with melanoma, with the first
antibody against one of these now approved for clinical use.
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1.6.4.1 Antibodies targeting melanoma vasculature
Antibodies targeting tumour-associated vasculature in order to deprive the tumour
of vital nutrients have been developed. The monoclonal antibody bevacizumab that
recognises the human vascular endothelial growth factor-A (VEGF-A) is an example
of this type of treatment. Bevacizumab inhibits the biological activity of VEGF-A
by preventing vascularisation of tumours. This antibody has been tested in combi-
nation with the alkylating chemotherapeutic agent fotemustine or with IFN-α2b as
a first line treatment for advanced melanoma in randomised phase II trials. Despite
reporting early data on suppression of angiogenesis and lymphangiogenesis, the au-
thors highlighted that a high proportion of the patients (5/20) had to discontinue
treatment due to toxicity [Del Vecchio et al., 2010].
1.6.4.2 Checkpoint molecule blockade approaches
Antibodies targeting negative regulators of immune activation have had striking
successes in recent years. Blocking the negative regulation of T cells these antibodies
enable tumour-cell specific T cells to target cancer cells, thus aiming to overcome
the immunosuppressive effects of tumour microenvironments. Examples of these
checkpoint blockade antibodies are those targeting CTLA 4 and PD-1.
1.6.4.3 Anti-CTLA 4
Antibodies recognising the cytotoxic T lymphocyte-associated antigen 4 (anti-CTLA4)
are now promising agents for the treatment of melanoma, they target a key element
in T cell immune regulation (CTLA4), which is a main negative regulator for T cell
immunity . Anti-CTLA4 antibodies (e.g. tremelimumab, ipilimumab) interfere with
CD28-B7.1 (CD80) co-stimulatory signals provided to T cells during antigen pre-
sentation competing with CD28 for B7.1 recognition. A recent double-blind phase
III study showed that ipilimumab with or without a gp100 peptide improved pa-
tient survival [Hodi et al., 2010]. However, adverse events, mostly resembling auto-
immune-like reactions are associated with this treatment (e.g. colitis, diarrhoea,
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pruritus, dermatitis and fatigue) that can be severe but are mostly reversible with
appropriate treatment [Ribas et al., 2005,Kirkwood et al., 2008,Weber et al., 2008].
An additional mechanism of anti-CTLA4 antibody (ipilimumab) function is IgG1
mediated ADCC against Tregs, which are cells shown to overexpress CTLA-4 anti-
gen on their surface. By eliminating Tregs in proximity to tumour cells, the tumour
microenvironment shifts from being suppressive to becoming more inflammatory.
This shift may enhance the potential of cytotoxic CD8+ T cells to eradicate tumour
cells [Curran et al., 2010].
1.6.4.4 Co-inhibitory ligands and receptors
Research interest has also focused on other co-inhibitory ligands/ receptors such as
4-1BB (CD137), OX40 (CD134) and PD-1. These molecules are expressed upon
activation of immune cells such as T and B cells, and are thought to modulate
immune responses in cancer [Pollok et al., 1993, Weinberg et al., 2000, Greenwald
et al., 2005,Watts, 2005]. Monoclonal antibodies against PD-1 have so far met with
limited success (approximately 30% of melanomas treated with nivolumab had a
partial response) while some are currently being further evaluated in clinical tri-
als [Brahmer et al., 2010, Topalian et al., 2012]. More recent studies report that
concurrent therapy with nivolumab and ipilimumab provided superior clinical activ-
ity compared to that induced by ipilimumab alone. Treatment with the anti-PD-1
antibody lambrolizumab (anti-PD-1) included patients who had disease progression
during treatment with ipilimumab and treatment resulted in high rate of sustained
tumour regressions [Hamid et al., 2013,Wolchok et al., 2013].
1.6.5 Why directly targeting a tumour associated antigen with
a monoclonal antibody may provide benefits for the treat-
ment of melanoma
Anti-CTLA4 therapeutics paved the way for the first successful antibody agent to
be used for the treatment of metastatic melanoma. Yet, this therapy is directed
against a checkpoint blockade molecule (CTLA4), which is expected to activate all
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T cells expressing CTLA4 irrespective of whether they are directed against tumour
cells or not. Thus, autoimmune-like toxicities are inevitable. Furthermore, by not
selectively targeting immune responses against only cancer cells, such antibodies may
not be as efficient as possible. For instance, specific targeting of tumour cells that
overexpress the tumour-associated antigen HER2/neu in breast cancer is thought to
be efficacious for a number of reasons: a) because of the exquisite specificity against
tumour cells, b) the longevity of the anti-tumour effects in restricting proliferation
and survival of tumour cells c) focusing effector cells specifically against tumour
cells and triggering ADCC and ADCP, d) because the target antigen, HER2/neu,
is also thought to be expressed by breast cancer cells with stem cell characteristics,
providing a unique opportunity for an antibody to directly target this cell subset nor-
mally resistant to most treatments including chemotherapies, and e) treatment with
trastuzumab is also thought to trigger adaptive immune response against the target
antigen, offering the opportunity to develop a memory response against HER2/neu-
expressing tumour cells [Hudis, 2007,Marcucci et al., 2013]. Melanoma is thought to
be a highly immunogenic tumour due to naturally occurring immune cell infiltrates,
which include cells producing melanoma reactive antibodies and cytotoxic T cells
against melanoma antigens in patients. Also, the enhanced prevalence of melanoma
in immune compromised patients implies its immunogenic nature of melanoma [Lacy
et al., 2012]. Despite this active natural immune response in melanoma, immune cells
do not impede tumour development or growth, suggesting that the immune system
may be redirected and possibly not sufficiently activated, not least because most
tumour antigens are also self-antigens. Nonetheless, not only antibodies reactive to
melanoma-associated antigens have been found in the blood of melanoma patients,
but also a mature memory B cell compartment expressing antibodies that recognise
tumour cells exists in these patients [Gilbert et al., 2011,Zippelius et al., 2007]. Im-
portantly, the presence of these naturally occurring antibodies is not associated with
any toxicity or autoimmunity, suggesting that passive immunotherapy targeting self-
antigens can be applied to treat melanoma. Thus, developing strategies to directly
target tumour-associated antigens holds considerable promise, expected to benefit
from tumour cell targeting and expected favourable toxicity profiles.
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1.6.5.1 CSPG4: a tumour-associated antigen with multiple functional roles
in melanoma
The chondroitin sulphate proteoglycan 4 (CSPG4) also called high molecular weight
melanoma-associated antigen (HMW-MAA) or melanoma-associated chondroitin sul-
phate proteoglycan (MCSP) is a known cell-surface tumour-associated antigen and
promising target for antibody therapy. This 280kDa cell-surface proteoglycan was
discovered more than three decades ago, it is overexpressed by more than 80% of
melanomas and is also thought to be highly immunogenic [Wilson et al., 1981] (Fig-
ure 1.11). CSPG4 plays a central role in cancer pathogenesis and progression of
melanoma cells by linking multiple oncogenic pathways required for malignant pro-
gression. These properties make it an attractive target for therapies, including mon-
oclonal antibodies: (i) CSPG4 expression promotes epithelial to mesenchymal transi-
tion at the radial growth phase of melanoma, facilitating progression to the vertical
growth phase, this is associated with distant tumour metastases and significantly
worse prognosis [Yang et al., 2009]. (ii) CSPG4 interacts with integrins (mostly
α4β1) and promotes adhesion, motility and survival of tumour cells, aiding metas-
tasis through focal adhesion kinase (FAK) activation of Src, as well as triggering
activation of PI3K/AKT and NFκB pathways, which promotes enhanced survival,
chemoresistance, cell motility and migration of melanoma tumour cells [Yang et al.,
2004, Chekenya et al., 2008]. (iii) CSPG4 promotes MAPK signalling through re-
ceptor tyrosine-dependent and independent pathways, triggering activation of the
ERK 1,2, which provide migration, proliferation and epithelial to mesenchymal tran-
sition all of which promote tumour cell progression and metastasis. Activation of the
MAPK/ ERK 1,2 signalling pathway by CSPG4 also synergises with the effects of
constitutively active mutant BRAFV 600E on the same signalling cascade. Although
BRAFV 600E alone is not sufficient to maintain high constitutive activation of ERK
1,2, the combination of CSPG4 expression and BRAFV 600E provide an important ad-
ditional trigger that drives cancer progression through constitutive activation of the
MAPK/ ERK 1,2, signalling cascade [Satyamoorthy et al., 2003, Yang et al., 2009].
(iv) CSPG4 is also present on angiogenesis-associated pericytes, which can activate
endothelial cell to enhance vessel formation. Thus, anti-CSPG4 antibodies may in-
hibit another central component that may promote tumour survival and metastasis
in the tumour microenvironment [Burns et al., 2010]. (v) CSPG4 plays also sim-
ilar roles in facilitating disease progression in other cancers (oligodendrocytomas,
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gliomas, triple-negative breast carcinomas and squamous cell carcinomas), providing
opportunities to develop anti-CSPG4 treatments that may be further applied to other
indications. (vi) Recent studies report expression of CSPG4 in BRAF inhibitor-
resistant tumours, claiming that anti-CSPG4 therapy prolongs tumour growth in-
hibition of the clinically approved BRAF inhibitor vemurafenib [Chekenya et al.,
2008, Yu et al., 2011]. This may provide an opportunity to target BRAF-resistant
tumours with anti-CSPG4 therapies, including monoclonal antibodies. (vii) In sev-
eral clinical trials, CSPG4 specific antibodies alone or conjugated to radioisotopes
or toxins were administered [Larson et al., 1985, Schroff et al., 1985, Spitler et al.,
1987], and although there were only modest clinical responses observed, none of the
patients in the trials experienced major adverse events [Ferrone et al., 1993,Reisfeld
and Cheresh, 1987]. Furthermore, in a group of 300 patients that had been enrolled
in an immuno-scintigraphy trial, patients that had received multiple injections of
CSPG4-specific antibody displayed significant survival benefits [Bender et al., 1997].
A study by Hamby et al. investigated the propensity of sera from different human
melanoma patients, immunized monkey or immunized rabbits to inhibit the binding
of anti-CSPG4 antibodies to melanoma cells expressing CSPG4. While sera from
rabbits as well as from monkeys inhibited binding of some antibody clones, human
sera did not inhibit binding of the CSPG4 antibodies to the cell line. This indicated
that immunogenicity of human CSPG4 in rodents is different from that in human
patients [Hamby et al., 1987].
1.6.5.2 Strategies using CSPG4 as a therapeutic target
Several studies in patients and in animal models have evaluated treatment with ei-
ther monoclonal antibodies coupled to toxins, or anti-idotype antibodies to mount
an immune response against CSPG4. A clinical trial reported that patients treated
with anti-idiotypic antibodies and who subsequently developed an adaptive im-
mune response against CSPG4 including anti-CSPG4 antibodies, had statistically
significant survival benefits [Mittelman et al., 1992]. These suggested the poten-
tial of anti-CSPG4 antibodies to mediate tumour cell death and anti-tumoural im-
mune responses. Likewise, several preclinical studies show that antibodies isolated
from rodents immunised with CSPG4 mimotopes and injected into recipient tumour
xenograft-challenged mice conferred protection against growth of the xenograft tu-
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Figure 1.11: CSPG4: schematic representation of chondroitin sulphate proteoglycyan 4.
Adapted from [Campoli et al., 2010]
mours [Luo et al., 2005, Wagner et al., 2005, Wagner et al., 2008]. Moreover, anti-
idiotypic antibodies mimicking the epitope defined by the anti-CSPG4 antibody clone
225.28s were reported to induce HLA class 1-restricted CSPG4-specific cytotoxic T
cells [Murray et al., 2004]. This study infers that immunotherapy against CSPG4
can result in T cell activation and protection from melanoma tumours. Further
supporting this hypothesis is the finding that adoptive transfer of cytotoxic T cells
engineered to express receptors against CD20 and CSPG4 can block tumour growth
and promote regression in animal models of CSPG4-expressing melanoma [Schmidt
et al., 2011]. More recent reports show that monoclonal antibodies against CSPG4
inhibit constitutive activation of the MAPK/ ERK 1,2, signalling pathway and en-
hance the effects of BRAFV 600E -specific inhibitors [Wang et al., 2010b,Yang et al.,
2009,Yu et al., 2011]. All these attributes and preliminary findings make CSPG4 an
attractive target for antibody-mediated immunotherapy.
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1.6.5.3 The anti-CSPG4 antibody clone 225.28s
The monoclonal antibody 225.28s was initially generated from mice immunized with
the human melanoma cell line M21 COLO38 by hybridizing mouse splenocytes with
murine myeloma cells and developing a mouse hybridoma [Ng et al., 1982]. The
specific mouse clone was originally used as part of a panel of antibodies to help
identify CSPG4 in histological sections with the aim of enabling better diagnosis of
melanoma. It was considered necessary to use a variety of antibodies for the de-
tection of melanoma, as CSPG4 was reported to have different determinants with
variable expressions during tumour development [Giacomini et al., 1984, Ziai et al.,
1987,Neri et al., 1996]. Multiple dosing with the mouse 225.28s antibody conjugated
to methotrexate (MTX) showed efficacy at 5 mg/kg doses in a M21 xenograft nude
mouse model. Interestingly, isolated tumours from these animals did not show any
refractory against the antibody or MTX indicating that this therapy could overcome
tumour evasion [Ghose et al., 1991]. The 225.28s antibody was also used in several
anti-idiotypic studies to analyse whether the induced antibody response in human
sera was CSPG4 specific and could therefore inhibit the binding of the antibody
to the antigen [Mittelman et al., 1990, Chattopadhyay et al., 1991]. Likewise the
antibodies were used to select mimotopes for vaccination against melanoma since
the induced antibodies restrict growth and induce lysis of the melanoma cell line
in vitro [Wagner et al., 2005]. Mouse anti-CSPG4 225.28s furthermore was shown
to inhibit the constitutive activation of MAPK/ ERK 1,2, signalling pathway and
to enhance the effects of BRAFV 600E -specific inhibitors [Wang et al., 2010a, Yang
et al., 2009,Yu et al., 2011]. In a recent study reporting CSPG4 to be an antigen ex-
pressed by triple-negative breast cancer, the 225.28s antibody induced growth arrest
by restricting colony formation in vitro and partly inhibited tumour cell migration of
MDA-MB-231 triple negative breast cancer cells in vitro [Wang et al., 2010a]. These
studies imply that the 225.28s clone recognises an epitope on CSPG4 that is involved
in promoting tumour growth, motility and metastasis. The above pre-clinical and
clinical studies for clone 225.28s demonstrate promise for this and potentially other
antibody therapies that directly target antigens such as CSPG4 on the surface of
melanoma cells. However none of these have conclusively demonstrated immune ac-
tivation. Thus engineering an antibody of this specificity with human Fc regions to
also perform effector functions may improve efficacy and clinical translation.
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1.7 Using IgE antibodies to target tumours
1.7.1 Rationale for examining the relationship between anti-
body class and efficacy
Solid tumours such as melanoma are frequently highly refractory to treatment with
IgG antibodies. Possible explanations for the partial success of IgG antibodies may
be their low affinity for its receptors, resulting in circumscribed capacity to recruit,
focus and activate effector cells against cancer cells. Other reasons may include
inhibitory mechanisms employed by tumours such as the expression of inhibitory
and decoy receptors such as FcγRIIb on effector cells and expression of FcγRIIb
receptors by melanoma tumour cells [Andreu et al., 2010]. Efforts to design more
efficacious antibodies for cancer have so far either focused on developing conjugates
to toxins, cytokines and radioisotopes or concentrated on structural modifications
of antibody Fc regions to render them more potent against tumours. The latter
involves for instance glycoengineering of antibodies, which has been reported to en-
hance effector functions [Woof, 2012, Okazaki et al., 2004, Kircheis et al., 2012] and
to extend their half-life in the circulation and improve their bioavailability [Kaneko
and Niwa, 2011]. A concrete example is the drug-conjugated antibody trastuzumab
emtansine-1 (T-DM1) that improved survival of trastuzumab-resistant tumours in
a phase III trial [Verma et al., 2012], thus demonstrating not only its efficacy but
also superiority to the native antibody. In contrast, an alternative modification uses
natural immune surveillance and immune activatory properties of the constant re-
gions of different classes and subclasses of antibodies. This approach potentially
leads to a significant enhancement in the abilities of antibodies to function in the
context of cancer at different anatomical sites. The human immune system employs
nine classes and subclasses of antibodies that differ in Fc regions to combat disease.
At present, only IgG (most often IgG1) is used in immunotherapy of cancers, while
antibodies belonging to non-IgG antibody classes such as IgE and IgA have yet not
been tested in patients [Woof, 2012]. The use of alternative antibody classes could
be of potential benefit as each antibody class operates in different anatomic com-
partments and functions through unique Fc-receptors and immune effector cells with
diverse capabilities to target specific antigens in the body [Reali et al., 2001,Vange-
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lista et al., 2005,Karagiannis et al., 2012]. In humans, IgA antibodies comprise two
subclasses, IgA1 and IgA2 [Woof, 2011]. IgA is the most hydrophilic antibody class
(a characteristic it gains most likely from its glycosylation pattern), thus offering a
highly useful and efficacious alternative to IgG immunotherapy for the treatment of
mucosal cancers. Studies examining IgA-mediated effector functions, report a role of
IgA in maintenance of the mucosal barrier by opsonising pathogens or by inducing im-
mune cell mediated responses in the context of against microbes and parasites [Balu
et al., 2011, Bakema et al., 2011]. Likewise, initial investigations demonstrate that
IgA mediates efficient tumour cell killing [Bakema et al., 2011, Lohse et al., 2011].
These promising findings need to be further investigated in order to elucidate the full
potential of IgA class antibodies in the context of cancer therapy. A number of dis-
parate studies suggest that antibodies of the IgE class can activate immune effector
cells to target and kill tumour cells more effectively than the equivalent IgG anti-
bodies [Karagiannis et al., 2009, Karagiannis et al., 2009, Karagiannis et al., 2007].
Antibodies of the IgE class are known for their role in the allergic response and in
protection against parasites, naturally residing in tissues where they exert immuno-
logical surveillance. Comparative studies examining the efficacy of IgE antibodies
include research conducted at King’s College London on the chimaeric monoclonal
antibody MOv18 IgE [Gould et al., 1999,Karagiannis et al., 2008,Karagiannis et al.,
2007, Karagiannis et al., 2009]. MOv18 IgE recognises the tumour-associated anti-
gen Folate Receptor α (FRα) that is expressed by ovarian cancers, mesotheliomas
and other solid tumours. In these studies the IgE antibody demonstrated superior
efficacy compared to the corresponding IgG1 in two in vivo models of cancer [Gould
et al., 1999,Karagiannis et al., 2007]. Thus, the mechanisms by which antibodies of
different isotypes influence the nature of the immune response harnessed to combat
cancer cells informs and may potentially benefit the design of future effective thera-
pies [Kershaw et al., 1998,Turner et al., 2006,Jensen-Jarolim et al., 2008]. Antibodies
of the IgE class primarily mediate allergic responses; thus, in an effort to understand
whether IgE antibodies play a role in natural immune surveillance against cancer,
researchers have for a number of years explored epidemiological associations between
allergy and cancer.
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1.7.2 Epidemiological associations between IgE allergy and
cancer
Several associations between allergic conditions and cancers have been reported. In
the late 1960s, Ure and MacKay described a negative correlation between atopy
and cancer in studies based on patient history records [Ure, 1969]. Subsequently,
a study by Jacobs et al., conducted in a larger population measuring IgE by two
independent techniques, confirmed prior findings of an association between low IgE
titres and neoplasms [Jacobs et al., 1972], thus increasing the credibility of prior find-
ings. Following the described studies and further epidemiologic observations, recent
meta-analyses indicate a more complex association between allergy and cancer and
reported segregation between cancers with strong inverse correlations with cancers
like glioma [Van Hemelrijck et al., 2010]. Yet all these studies have limitations, one
being that they investigate overall levels of IgE irrespective of any specificity, and do
not measure specific IgE reactivity to tumour cells. It may therefore be more rele-
vant to evaluate tumour antigen-specific IgE for tumour cell reactivity rather than
to measure total IgE levels.
1.7.3 Why design IgE antibodies for cancer therapy
A number of attributes of the IgE antibody class may support its potential study as
an anti-cancer modality. Unlike IgG, IgE antibodies lack an inhibitory receptor. An-
dreau et al. reported that the IgG inhibitory receptor FcγRIIb is overexpressed on
tumour cells indicating a potential mechanism of tumour cell evasion from immune
attack. The absence of such a receptor for IgE suggests that this potential escape
mechanism can be overcome if IgE antibodies are used as a therapeutic tool [Gould
et al., 2003,Gould and Sutton, 2008]. In addition, the difference in serum and tissue
half-lives of IgE antibodies compared to IgG might also confer an advantage to IgE in
the treatment of solid tumours. IgE has 1.5 days clearance from the serum [Ravetch
and Kinet, 1991, Gould et al., 2003, Gould and Sutton, 2008], while the half-life of
IgE antibodies in tissues can exceed two weeks [Hellman, 2007]. The opposite is
true for IgG. IgE is mainly bound with exceedingly high affinity to FcRI bearing
cells assuring longer tissue immune surveillance, which can be beneficial in the con-
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text of tissue-resident cancer cells. It is therefore possible that tumour-specific IgE
immunotherapy can overcome immune suppression by triggering long-lived powerful
effector functions in tissues, and, unlike IgG, it is not subject to inhibitory signals in
tumours. The following section elaborates on the mechanism of immune suppression
and FcR bearing cells which may reveal the ”hidden” potential of the IgE antibody
subclass. In order to eradicate tumour cells IgE mediates effector cell activation
through its receptors FcRI and CD23 [Karagiannis et al., 2008]. Activation of this
signalling cascade can result in 1) degranulation of pro-inflammatory mediators and
cytokines, 2) antibody dependent cytotoxicity (ADCC) induced by mediators such
as nitric oxid that results in target cell lysis, and 3) antibody dependent phagocy-
tosis (ADCP) by natural phagocytes such as macrophages naturally residing in the
tumour microenvironment. However, cytokine signalling is subject to influences from
the tumour microenvironment composed of stromal cells (e.g. fibroblasts, endothe-
lial cells) and immune cell infiltrates. The latter group includes cells that express
Fc receptors such as macrophages, DCs, mast cells, B cells and eosinophils; these
cells are thought to provide a tumour promoting environment through tissue remod-
elling, suppressing effective immune responses and promoting metastasis by release
of inflammatory cytokines and chemokines. The main hypothesis in the field of
Allergo-Oncology, the emerging discipline advocating that IgE-mediated functions
may be harnessed against cancers, is that treatment with a tumour antigen-specific
IgE antibody either directly administered or triggered by vaccination, can stimulate
Fc receptor-expressing cells enabling the cells to overcome the immune suppression
and to mount a response against the tumour. Three key Fc receptor bearing cells,
mast cells, eosinophils and macrophages have been proposed to play a major role as
described below.
1.7.3.1 Mast cells
The early presence of mast cells in a variety of solid tissues and in tumours like
melanoma, characterises their role as tissue-resident ”sentinels” prone to initiate a
rapid response to pathogens and immunogenic antigens [Galli et al., 1999, Ribatti
et al., 2003,Molin et al., 2002]. However, mast cells have also been described to ex-
ert immune suppression by secreting modulatory cytokines such as IL-10 and TNF-α;
while their presence in tumours has been associated with poor prognosis [Gulubova
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Figure 1.12: IgE cross-linking of FcRI induced degranulation.
and Vlaykova, 2009, Cai et al., 2011]. Investigating the biological mechanisms of
mast cells revealed that they contribute to tumour invasion and angiogenesis by
secreting VEGF [Coussens et al., 1999, Soucek et al., 2007, Gounaris et al., 2007],
and by promoting Tregs development. VEGF and Tregs can in turn suppress im-
mune response and impair cross-presentation by dendritic cells, thereby mediating
tolerance [de Vries et al., 2011]. Using a mouse allograft model, Noelle and col-
leagues demonstrated that triggering intra-graft or systemic mast cell degranulation
by cross-linking of IgE resulted in the transient loss of the suppressive activities of
Tregs [de Vries et al., 2009]. This model illustrates the transient breakdown of pe-
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ripheral tolerance induced by IgE thus proposing a therapeutic mechanism against
tumours directly based on specific IgE immunotherapy.
1.7.3.2 Eosinophils
Eosinophils were long regarded as Fc receptor-expressing cells in allergic diseases
and parasitic infections. In 1981 eosinophils were first observed in peri-tumoural
infiltrates of several types of cancers including solid tumours, and thereafter termed
tumour-associated tissue eosinophilia (TATE) [Lowe et al., 1981, Munitz and Levi-
Schaffer, 2004]. Traditionally referred to as effector cells, eosinophils are now recog-
nised as multifunctional cells capable of initiating and regulating inflammatory re-
sponses as well as activating the adaptive immune response by antigen presenta-
tion to T cells [Gatault et al., 2012]. Several studies have reported TATE to be
a positive prognostic indicator in solid tumours such as bladder cancer, colorectal
cancer, laryngeal carcinoma and squamous cell carcinoma [Ferna´ndez-Acen˜ero et al.,
2000,Dorta et al., 2002, Ishibashi et al., 2006]; with the exception of Hodgkin’s lym-
phoma [Gatault et al., 2012,vonWasielewski et al., 2000]. Despite TATE’s heightened
prognostic capacity, the exact mechanisms underlying this anti-tumour immune re-
sponse are not yet elucidated. Studying the presence and status of eosinophils during
IL-2 therapy in renal cancer and melanoma showed that systemic IL-2 treatment in-
duced eosinophil degranulation and the subsequent tumour cell death [Huland and
Huland, 1992, Cormier et al., 2006, Simson et al., 2007]. In several in vivo studies
eosinophil infiltration into tumours of wild-type mice was shown to induce an early
and persistent response [Cormier et al., 2006]. Analysis of the role of eosinophils
in IL-5 transgenic mice demonstrated a significant increase of eosinophils into the
tumour resulting in reduction of tumour establishment and growth [Simson et al.,
2007]. The common IL-5-rich environments found in allergy and also in this can-
cer model may suggest that an ”allergic-like” response involving activated eosinophils
can induce eradication of tumours. This concept was further investigated by Legrand
et al. analysing the cytotoxic potential of eosinophils from allergic donor (n=4) and
non-allergic donors (n=6) against the colon cancer cell line Colo-205 [Legrand et al.,
2010].
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1.7.3.3 Macrophages
Macrophages are the major Fc-bearing cell type in tissues. They express all three
classes of Fcγ receptors and also both Fc receptors. Therefore these cells can be
potentially activated by either immunoglobulin class. Most observations of tumour-
associated macrophages (TAMs) described TAMs to foster tumour progression [Qian
and Pollard, 2010]. TAMs were reported to mediate a pro-tumour microenvironment
by: 1) producing VEGF [Lin et al., 2007]; 2) remodelling the tissue matrix via MMPs;
3) supporting tumour cell proliferation, survival and invasion by secreting chemokines
and cytokines such as CXCL3, TNF-α, TGF-β, EGFR ligand or IL-6 [Mantovani
et al., 2008]; and 4) maintaining immunosuppressive microenvironments that inhibit
cytotoxic T cell activities by secreting IL-10 and promoting Tregs [Ojalvo et al.,
2009](Ojalvo 2009; Deodens 2010). Monocytes/macrophages can be differentially
polarised under different stimuli: M1 macrophages are inducible via lipopolysaccha-
ride and produce IFNγ, IL-2 and TNFα; and M2 macrophages secrete mediators
such as IL-4, IL-13 and IL-10 [Biswas and Mantovani, 2010] thought to have sup-
pressive effects. High plasticity of those cells in the tumour microenvironment allows
for both phenotypes to co-exist. This model may provide new attractive therapeutic
opportunities such as strategies to block the immunosuppressive functions, or limit
their recruitment in tumours, or reprogram TAMs or prevent their polarisation to-
wards M2. In this context, DeNardo et al. showed in a murine model that inhibition
of macrophage colony-stimulating factor 1 or its receptor diminished macrophages
and promoted cytotoxic therapies in a CD8+ T cell-dependent manner [DeNardo
et al., 2011]. Furthermore, repolarisation of macrophages through the TNF-α recep-
tor superfamily member, CD40, leads to anti-tumour effects and depletes tumour
stroma, thus enabling access of other immune cells resulting in pancreatic tumour
regression [Beatty et al., 2011]. This thesis puts forward the hypothesis that tumour-
specific IgE antibodies activate TAMs triggering their activation and repolarisation,
leading to anti-tumoural functions (Chapter 5).
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1.7.4 Immunotherapeutic approaches aimed at activating IgE-
mediated immunity against tumours
Different attempts have been made to harness allergic and IgE reactions against
cancer and to investigate their potential benefits. These studies have utilised im-
munological strategies such as the deployment of IgE as an adjuvant [Reali et al.,
2001], development of IgE-coated cellular vaccines [Reali et al., 2001, Nigro et al.,
2009, Nigro et al., 2012], production of oral mimotope vaccination strategies with
the aim of inducing tumour-specific IgE antibodies [Riemer et al., 2007], or the pro-
duction of recombinant IgE antibodies targeting tumour-associated antigens [Nagy
et al., 1991,Daniels et al., 2012,Kershaw et al., 1996,Kershaw et al., 1998,Teo et al.,
2012,Karagiannis et al., 2012].
1.7.4.1 IgE adjuvant model
In the IgE adjuvant model, aimed at inducing specific tumour responses, IgE is cou-
pled to the surface of tumour cells through a three-step biotin-avidin bridge strategy,
these IgE coated tumour cells are then used to immunise immunocompetent mice. In
these experimental models tumour growth was significantly reduced in IgE treated
animals and they show prolonged survival compared with controls and also with IgG
treated animals. Interestingly, disintegration of the antibody-Fc regions as well as
depletion of eosinophils, CD8+, or CD4+ cells abolishes the anti-cancer effects of the
treatment [Reali et al., 2001] implying the importance of IgE effector cells and also of
adaptive immunity in this process. Experiments in either FcRI or CD23 knockout
mice were conducted to further explore the properties of IgE as an adjuvant [Ni-
gro et al., 2009]. These showed that IgE-coated tumour cells in FcRI knockout
animals did not restrict tumour growth, whereas those in CD23 knockout animals
retained the anti-tumour effect, thus linking efficacy to FcRI [Nigro et al., 2009].
Human FcRIα transgenic mice immunised with a different alternatively developed
IgE adjuvant vaccine (from the above explained) also showed significant anti-tumour
properties, thereby confirming the key role of human FcRI in IgE anti-tumour ad-
juvanticity [Nigro et al., 2012].
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1.7.4.2 Mimotope vaccine model inducing IgE antibodies
An independent study made use of the phage display technology to define peptide
structures mimicking natural epitopes of HER2/neu recognised by trastuzumab (mi-
motopes). Selected mimotopes were used to induce an immune response consisting
of tumour antigen-specific IgE antibodies, by immunising BALB/c mice via the oral
route under simultaneous neutralisation of gastric acid [Riemer et al., 2007]. This ap-
plied immunisation regime resulted in serum IgE antibodies recognising HER2/neu
which were capable of mediating cytotoxicity of the HER2/neu overexpressing cell
line SKBR3 in vitro. Although these results suggest that oral administration of mi-
motopes can lead to the production of cytotoxic IgE antibodies, it remains unclear
whether these antibodies mediated these anti-tumour effects in vivo [Riemer et al.,
2007].
1.7.4.3 Passive IgE immunotherapy
Advances in the production of recombinant antibodies have allowed for quick de-
velopment, assessment and evaluation of passive IgE immunotherapy. Two decades
ago, Nagy et al. conducted a study showing that a murine IgE antibody specific
to the major envelope glycoprotein (gp36) of the mouse mammary tumour virus
(MMTV) overexpressed in syngeneic H2712 cells improved the survival of immuno-
competent mice [Nagy et al., 1991]. Further development of this model used both a
murine anti-Ly-2 IgE in an immunocompetent mouse populated with murine cyto-
toxic T cells (CTLs), which expressed a chimeric FcRI-ζ receptor (human FcRIα
and the human CD3ζ) and immunosuppressed animals utilising primary human T
cells retrovirally-transduced with a chimeric FcRI receptor linked to the cytoplas-
mic domains of the human co-stimulatory molecule CD28. This resulted in improved
survival of mice when compared to controls [Kershaw et al., 1996]. Moreover, testing
a murine IgE antibody specific to the 30.6 antigen, expressed by human colorectal
carcinomas (COLO205) in an immunosuppressed mouse model showed superior effi-
cacy at a lower concentration than its IgG1 counterpart. It is however noteworthy
that these antibodies were never tested simultaneously [Kershaw et al., 1998,Mount
et al., 1994]. Furthermore, the efficacy of the first mouse/human chimeric IgE anti-
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body was demonstrated in immunosupressed animals populated by human immune
cells. This was the ovarian cancer-associated anti-folate receptor α (FRα) antibody
termed MOv18 IgE. In order to allow for comparison of the IgE antibody to its IgG1
counterpart, MOv18 IgE was engineered using chimeric MOv18 IgG1 by exchang-
ing first the Fc of the heavy chain and subsequently the κ-light chain [Gould et al.,
1999]. After a series of comparison experiments in vitro, both antibodies were tested
in immunodeficient mice (in vivo) using two separate human xenograft models. One
model was an ovarian carcinoma model using the human FRα-overexpressing cell line
IGROV-1 grown subcutaneously in SCID mice. The second model was an orthotopic
human ovarian carcinoma ascites model grown intraperitoneally in nude mice which
expressed moderate levels of FRα. Since the human IgE Fc regions are not recog-
nised by mouse Fc receptors, and unlike in humans, mouse FcRI is only expressed
on mast cells and basophils, both of these mouse model systems entailed antibody
administration together with human PBMCs in order to provide the relevant effector
cells [Gould et al., 1999,Karagiannis et al., 2003,Karagiannis et al., 2007,Karagiannis
et al., 2008]. In both of these model systems, MOv18 IgE was shown to be superior
to its IgG1 counterpart in restricting tumour growth over time and in enhancing sur-
vival of IgE treated mice, respectively. Histological analysis of the cell line derived
tumours revealed large areas of tumour necrosis in mice treated with MOv18 IgE
compared to controls, further suggesting that anti-tumour effector cell functions are
activated in response to MOv18 IgE treatment [Karagiannis et al., 2003,Karagiannis
et al., 2007, Karagiannis et al., 2008]. These studies also demonstrated that mono-
cytes/macrophages are important immune effector cells in the context of tumour
antigen-specific IgE immunotherapy, since depletion of monocytes from the human
PBMCs administered in the orthotopic patient-derived ovarian carcinoma model
abolished the anti-tumoural effects of IgE; and reconstitution of depleted PBMCs
with monocytes restored the survival advantage conferred by IgE immunotherapy.
Furthermore, human macrophages infiltrated tumours from the IgE-treated animal
cohort in the orthotopic patient-derived xenograft model, further supporting a role
for monocytes/macrophages in IgE immunotherapy. In support of the findings with
MOv18 IgE, two separate studies by Daniels-Wells et al. showed that in immunocom-
petent human FcRIα transgenic mice, an anti-HER2/neu IgE and an anti-PSA IgE
antibody did not display any toxicity, while each antibody conferred survival benefits,
in each model system. In the anti-PSA IgE study, the IgE antibody was compared
to its IgG1 counterpart and displayed superior efficacy [Daniels et al., 2012,Daniels-
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Wells et al., 2013]. All of the above-mentioned mechanisms of IgE antibodies are
described in protection from parasitic infections, further supporting the possibility
that they may also be harnessed against tumour cells [Jensen-Jarolim et al., 2008].
Furthermore, Fc receptors are also present on antigen presenting cells such as DCs,
B cells and macrophages, and may also trigger possible cross-presentation, poten-
tially inducing adaptive immune responses against tumours. This could increase the
potent as well as longevity of protection against tumours conferred by IgE antibod-
ies. Mounting evidence thus supports the notion that the potent immune responses
of IgE can be harnessed against cancer and this may include developing recombinant
IgE antibodies recognising tumour antigens. The IgE concept as a therapy has not
been examined in melanoma and merits investigation.
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Figure 1.13: Interaction of IgE with Fc receptors mediate effector cell functions in re-
sponse to cancer cells. Schematic of IgE binding to FcRI tetrameric (αβγ2) (left) and
FcRI trimeric (αγ2)(middle) through extracellular alpha (α) chain and interaction with
the low-affinity receptor CD23 trimer is through recognition of the lectin domain (right).
Expression affinities for IgE and expression densities of IgE receptors of key effector cells
and immune mechanisms each mediates.The presence of the β chain on the FcRI tetramer
is responsible for high cell surface expression densities on mast cells and basophils and is as-
sociated with induction of degranulation. In the presence of IgE, FcRI trimers are known
to induce ADCC, while CD23 expression on monocytes and macrophages can trigger ADCP
of parasites. Figure reproduced from [Karagiannis et al., 2012]
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1.8 Biomarkers in melanoma
The quest for disease-relevant biomarkers for many disease pathologies including
malignant diseases is receiving great attention with the advent of novel screening
technologies and our enhanced understanding of disease pathways. In the context of
cancer, molecules associated with tumour inflammation and possibly with tumour-
promoting or tumour-eradicating mechanisms locally and systemically could be can-
didate biomarkers. New reliable biomarkers are indeed needed in the growing field
of oncology to assist with diagnosis, early detection, staging of patients, prognosis
of disease progression and also to stratify patients for particular treatments or to
help predict responses to specific therapies. One can foresee that the discovery of
specific disease-relevant biomarkers could potentially help us harness the full thera-
peutic benefits of drug interventions before terminal endpoints. Clinically validated
biomarkers could for example be used to evaluate a therapy in phase III trials before
the terminal endpoint is reached, thus allowing for quicker assessment and better
health care provision.
1.8.1 Definition of a clinically relevant biomarker
Several definitions and guidelines have been proposed to define biomarkers. These
include specifications that a biomarker should be objectively measured and eval-
uated as an indicator of a pathological process, or of a pharmacological response
to a therapeutic intervention. Henry and Hayes were among the first to propose
criteria that a candidate biomarker must fulfil in order to qualify for clinical applica-
tion: 1) there must be a clear difference between readouts from each of the analysed
groups; 2) the rationale and utility of the test used to measure the biomarker must
be well-defined; 3) the results measured must be reliable and reproducible. Following
these guidelines, Hunter et al. distinguished between different ”validation steps” for
biomarkers: 1) validity of the test; 2) clinical validity and 3) clinical utility [Henry
and Hayes, 2012]. In 2000, at the First International Meeting on Cancer Diagnos-
tics (NCI-EORTC) the ”Reporting Recommendations for Tumour Marker Prognostic
Studies” (REMARK) was developed. This guideline was implemented to overcome
the widespread deficiencies in the reporting of putative biomarkers during prospec-
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tive trials. The guideline consists of a checklist of 20 items including full description
of the research and hypotheses, patient sample selection and recruitment, marker
evaluation and measurement techniques, statistical design and analysis of study re-
sults [McShane et al., 2005, Altman et al., 2012]. This collaborative effort among
clinicians, laboratory scientists, statisticians and journal editors has the potential
to drastically improve the implementation of novel biomarkers into common clinical
practice. There have been extensive efforts in the field to define biomarkers in patient
blood and melanoma lesions and the most commonly examined are discussed below.
1.8.2 Serological biomarkers in cancer
1.8.2.1 LDH
The enzyme Lactate dehydrogenase (LDH) is the most used serological biomarker in
melanoma. It remains to date the strongest prognostic biomarker found to increase
with tumour burden [Solassol et al., 2011]. LDH is mostly released upon cell damage
or death with both phenomena indicating higher tumour burden and disease progres-
sion. It is however noteworthy that release of LDH in the sera does not exclusively
occur in neoplasia but also in other disease settings such as hemolysis, hepatitis,
myocardial infarction and infectious diseases. Therefore LDH presence in the blood
of patients with melanoma may result in false-positive readouts. Recent studies have
shown that LDH is less sensitive in early stage disease with low predictive value
for metastatic relapse [Hofmann et al., 2009]. It is nonetheless at present a useful
and clinically-available tool for indication of tumour progression in patients at later
disease stages.
1.8.2.2 Tyrosinase
Tyrosinase is part of the biosynthesis process of melanin and constitutively expressed
in melanocytes and melanoma cells. Tyrosinase mRNA levels are detectable in the
blood of melanoma patients with advanced metastatic disease detected by nested
RT-PCR [Quaglino et al., 2007,Visu´s et al., 2007]. Initial evaluations revealed that
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tyrosinase is an independent prognostic marker for tumour progression [Schmidt
et al., 2005,Visu´s et al., 2007,Quaglino et al., 2007]. Samija et al demonstrated that
tyrosine mRNA is associated with a decrease in overall survival [Samija et al., 2010].
However, high variability in the readouts of serum tyrosinase have been reported,
most likely due to difficulties in sample processing and the transient presence of
metastasising tumour cells in the blood [Visu´s et al., 2007]. Therefore it is not
surprising that several studies could not confirm a significant prognostic utility of
tyrosinase [Garbe et al., 2003, ?]. This includes a recent study that showed no
differences in tyrosinase serum levels when comparing patient to healthy volunteer
blood [Zhang et al., 2011].
1.8.2.3 VEGF
Growth factors in combination with interleukins are major regulators of inflammatory
conditions in the tumour microenvironment. VEGF is known to support tumour-
associated angiogenesis, and to contribute to inflammatory conditions which promote
immunosuppression and redirection of effective anti-tumoural immunity. Ugurel et
al. reported that vascular endothelial growth factor was an independent prognos-
tic marker for overall and progression-free survival in their cohort (125 stage I-IV
patients) [Ugurel et al., 2001]. Unfortunately, several subsequent studies could not
confirm this finding. Although associations between VEGF and the disease were
found, no correlation with disease progression was attained [Osella-Abate et al.,
2002,Pelletier et al., 2005,Vihinen et al., 2007].
1.8.2.4 Osteopontin
Osteopontin, a secreted integrin-binding glycophosphoprotein, has been described
to reduce apoptosis, enhance tumour growth and be a major component for the
recruitment of tumour promoting stromal cells from the bone marrow [Perrotta et al.,
2011, McAllister et al., 2008]. In a recent study, Maier et al. demonstrated that
osteopontin in combination with S100B can help to differentiate patients who are
likely to subsequently relapse and develop metastatic disease from those who do not
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. Yet, the presence of osteopontin is also associated with other medical conditions
such as autoimmune diseases and might therefore be associated with increased false-
positive readouts in patients with melanoma [Maier et al., 2012].
1.8.2.5 YKL-40
YKL-40 is a glycoprotein secreted by many cells including cancer cells and by immune
cells such as macrophages and activated neutrophils [Volck et al., 1998, Johansen,
2006]. The physiological functions of YKL-40 are yet not fully understood and
reports of its functionality as an independent prognostic marker vary [Schmidt et al.,
2006, Dı´az-Lagares et al., 2011, Egberts et al., 2012]. More importantly, YKL-40
expression is influenced by immunomodulatory drugs such as IL-2 and IFN-α2b and
therefore its use as a biomarker can yield in false-negative readouts during treatment
[Krogh, 2013].
1.8.2.6 Melanoma inhibitory activity
The small protein Melanoma inhibitory activity (MIA) is secreted by melanoma cells
and is involved in cell-cell contact by interacting with the extracellular matrix. It
is also thought that MIA promotes tumour cell invasion and metastasis [Palmer
et al., 2011]. Equally it was reported that MIA has a high sensitivity and speci-
ficity compared to other clinically-relevant biomarkers such as LDH [Hofmann et al.,
2009, Dı´az-Lagares et al., 2011]. Elevated levels of MIA correlated with more ad-
vanced disease stages, poorer prognosis and decreased disease-free survival [Hofmann
et al., 2009, Dı´az-Lagares et al., 2011, Perrotta et al., 2011, Juergensen et al., 2001].
However, different studies using multivariate analysis demonstrated higher rates of
false positive readouts in women, suggesting an alternative source of MIA may exist
and that this protein may participate in and be influenced by other biological pro-
cesses unrelated to malignancy [Essler et al., 2011, Bosserhoff et al., 2004, Hofmann
et al., 2009].
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1.8.2.7 Cell adhesion molecules
Cancer associated cell adhesion proteins are proteins that adhere to different cells,
show altered expression levels in cancer, and impact cell tumour migration, im-
mune cell evasion and angiogenesis [Sapoznik et al., 2012]. Past studies have as-
sociated serum levels of cell adhesion molecules with the development of metasta-
sis [Ebrahimnejad et al., 2004, Franzke et al., 1998, Hirai et al., 1997]. An exam-
ple from this group of proteins is carcino-embryonic antigen-related cell adhesion
molecule 1 (CEACAM1), which is recognised as an independent predictive maker for
the risk of metastasis [Thies et al., 2002]. Moreover, it was shown that CEACAM
expression correlates with disease stage and with overall survival (OS) [Sivan et al.,
2012].
1.8.2.8 S100
The family of S100 proteins has been of special interest as diagnostic markers in
melanoma over the last decade since the expression and secretion of these proteins
is much higher in malignant compared to healthy tissues [Davey et al., 2000, Hsieh
et al., 2002, Petersson et al., 2009]. S100 proteins and in particular S100B were
recently found to be elevated in the serum of melanoma patients with these elevated
levels being associated with poorer prognosis [Beyeler et al., 2006,Oberholzer et al.,
2008], disease free-survival and overall survival [Kruijff et al., 2009]. In a more recent
prognostic study of patients treated with IFN-α2b versus observation in stage II and
III patients, investigators showed that S100B is associated with worse OS and distant
metastasis free survival (DMFS). Interestingly, S100B in patients’ sera correlated over
time with disease progression, increasing further in parallel to increases in disease
burden [Bouwhuis et al., 2011]. False positive results can occur during brain, liver
or renal injuries as well as infectious diseases [Molina et al., 2002, Tsoporis et al.,
2011, Michetti et al., 2012]. However, data acquired, to date point to the merits of
further evaluations of S100 as a potential clinical tool.
1.8. Biomarkers in melanoma 71
1.8.3 Tissue specific biomarkers for melanoma
Tissue specific biomarkers are molecules demonstrated to be over-represented in can-
cer lesions, and may facilitate diagnosis, early detection, prognosis of disease pro-
gression and patient stratification.
1.8.3.1 BRAF
Approximately 50% of all melanoma patients have an activating mutation in the
BRAFV 600 gene on the long arm of chromosome 7 [Davies et al., 2002, Long et al.,
2011]. This change results in the constitutive activation of BRAF kinase, which is
likely to promote the RAS—RAF—MEK—ERK pathway-induced proliferation and
extensive tumour cell growth. Recently two type I RAF inhibitors, vemurafenib and
dabrafenib, have shown to improve survival in phase III clinical trials in patients with
advanced-stage disease. These drugs are now standard of care [Hauschild et al., 2012,
Chapman et al., 2011,Flaherty et al., 2014]. Although progression—free survival with
each drug is only 5—7 months, this treatment option are far superior from historical
agents [Chapman et al., 2011, Flaherty et al., 2010, Sosman et al., 2012, Falchook
et al., 2012]. The disease recurrence during BRAF kinase inhibtor treatment may be
induced by different mechanisms such as the alternative splice variants of BRAF or
de novo mutations in the NRAS or MEK kinases [Mao et al., 2013]. Taken together,
screening of the BRAF mutation in melanoma patients allows for the stratification
of treatment with effective agents and is therefore a curial biomarker in melanoma.
1.8.3.2 Cyclooxygenase-2
Cyclooxygenases (COX1-3) are a group of proteins that are important modulators
in the human body, affecting essential pathways such as the catabolic metabolism.
COX1-3 also converts arachidonic acid into prostaglandin. Of this group COX-2
can be induced in tumour cells [Meyer et al., 2009, Bosserhoff, 2006]. Becker et
al. showed a correlation between COX-2 staining intensity and Breslow thickness
in melanoma [Becker et al., 2009]. Furthermore, Kuzbicki et al. reported a higher
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COX-2 staining intensity in melanoma lesions compared to benign nevi [Kuzbicki
et al., 2012].
1.8.3.3 Galectin-3
The Galectin-3 molecule is mainly secreted by inflammatory cells and is associated
with both tumour progression and metastasis in melanoma [Buljan et al., 2011].
However, using a multifactorial Cox regression analysis, Brown et al. showed an
inverse association between galectin-3 with tumour size (thin tumours had more
galectin-3) and improved OS [Brown et al., 2012].
1.8.4 Matrix Metalloproteinases
Matrix metalloproteinases play an important role in remodelling the tumour tissue
microenvironment as they are responsible for proteolytically breaking components of
the local tissue architecture, promoting tissue remodelling and facilitating tumour
cell migration (reviewed in [Stamenkovic, 2003]). For these reasons the proteins
are over-represented in tumour tissues. Nikkola and colleagues showed that MMP-
1 and MMP-3 positive melanoma metastases correlate with decreased disease-free
survival (DFS) [Nikkola et al., 2002]. Furthermore, Rotte et al. confirmed a higher
expression of MMP-2 in melanoma when compared to normal and dysplastic nevi.
In this study, the levels of MMP-2 expression positively correlated with tumour
progression and worse survival [Rotte et al., 2012]. It is however noteworthy that
this study was conducted using tumour tissue microarrays through the application of
peroxidase developed with 3,3’-Diaminobenzidine (DAB - a brown substrate), making
the assessment of MMP-2 difficult to distinguish from melanoma cells in pigmented
lesions.
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1.8.4.1 Cell adhesion molecules
Cell adhesion molecules are linker proteins that connect cells. Some among them,such
as the carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM-1), fos-
ter interactions between somatic cells and immune cells. It was demonstrated that
expression of CEACAM on tumour cells inhibits immune responses and leads to
tumour progression (reviewed in Clin and Develop Immunol 2012). Investigation
of CEACAM1 expression suggested it to be an independent factor for the risk of
metastasis [Thies et al., 2002].
1.8.4.2 The Chondroitin sulphate proteoglycan 4 (CSPG4) as a biomarker
The Chondroitin sulphate proteoglycan 4 (CSPG4), also known as the High Molecu-
lar Weight Melanoma Associated Antigen (HMW-MAA) or the Melanoma-associated
chondroitin sulphate proteoglycan (MCSP) is a glycoprotein-proteoglycan complex
expressed on the surface of melanoma, glioma, neuroblastoma, certain breast canci-
nomas and acute leukaemias [Ross et al., 1983]. CSPG4 is thought to play crucial
roles in cell adhesion, melanoma migration and metastasis (see Section 1.6.5.1) (re-
viewed in [Campoli et al., 2010]). Although CSPG4 is over-expressed in over 80%
of all melanomas, it is found at all disease stages and data so far have not yielded
any correlations with disease progression [Vergilis et al., 2005]. However, a recent
study reported that a cytoplasmic form of the protein appears to correspond with
response to therapy of a melanoma vaccine, indicating that CSPG4 may potentially
be evaluated as a marker of disease progression [Reynolds et al., 2006].
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1.8.5 Statistical methods to evaluate the importance and pre-
dictive value of a biomarker including combination anal-
ysis
The identification and development of novel biomarkers is very important in evidence-
based medicine. Not only could early disease detection or patient stratification guide
the selection of therapies for individual patients and patient subpopulations, but also
it could permit defining new endpoints during prospective drug studies that would
allow quicker access to novel beneficial treatments. Due to natural variability of
different measured substances, it has proven difficult to identify single biomarkers
that provide such information with high accuracy. Choosing threshold points for
binary markers has multiple dimensions such as detecting cases and detecting con-
trols. Any threshold proposing reduction to a single (dimensional) decision involves
making a value judgment about the relative importance of these two dimensions (i.e.
detecting cases and controls). William John Youden has suggested the use of the
following calculation to make this judgement call: Y (Youden Index) = sensitivity +
specificity - 1. The Youden Index still implies a judgement, albeit a conscious one.
While in some contexts it is more important to detect cases with high probability
(defined as sensitivity), in others, it is more important to detect controls with high
probability (defined as specificity). In the example of population screening, only
small percentages of people constitute cases, while prediction of the cases depends
on the threshold value picked. Thus, an incorrect threshold value based on high sen-
sitivity in the Youden Index may detect too many cases in the population. On the
other hand, in clinical studies one might elect to replace the existing gold standard
test since it is very important to detect as many cases as practically possible by
choosing a threshold of high sensitivity at the expense of low specificity. As an alter-
native to single biomarker analysis, it has been suggested that a strategy entailing
multiple measurements could be adopted to increase the diagnostic accuracy by com-
bining biomarkers that are already clinically-validated. For this improved approach,
quantitative measures of performance (accuracy) for various collections of diagnostic
tests need to be compared with different combinations of available diagnostic tests
or techniques. For this purpose, adaptive mathematical methods are required to be
operationalized. In the past, various statistical methods were used to identify mark-
ers with diagnostic or prognostic capability; some of the most important ones are
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linear discriminant analysis, regression trees, binary regression and artificial neural
networks [Lin et al., 2012]. All of these methods are designed to calculate hazard
ratios or (in other words) likelihoods, assuming linear effects across one of the vari-
ables in the logistic regression. However, in cases with a curvilinear relationship,
a quadratic term in the marker over and above the linear term would provide an
improved fit and ultimately yield a better analysis. McIntosh and Pepe suggest that
modification of linear binary regression in terms of optimising the function through
maximisation of the receiver operating characteristic curve (ROC) [McIntosh and
Pepe, 2002] would lead to a better analysis and prediction. A more recent report by
Lin et al. compares likelihood approaches for the evaluation of medical diagnostic
systems by applying a multiple binary test. The authors conclude that modification
and further development of the method published by Pepe and colleagues leads to
an improvement in accuracy [Lin et al., 2012]. Taken together, the validity of a
biomarker does not only depend on its biological function and measurement but also
on the subsequent calculation and evaluation of it.
1.8.6 Immunoglobulins: promising biomarkers for early dis-
ease
The development of novel biomarkers capable of diagnosis at early stages of the
disease would improve therapy. From the 100,000 biomarkers reported in the liter-
ature [Amur et al., 2008] only 43 are approved by the FDA [FDA, 2013] in clinical
settings. In the context of cancer, one of the biggest challenges is the undetectable
levels of potential biomarkers at early disease stages. Early stages are character-
ized by mostly minimal disease manifestation with no more than 1x106 tumour
cells that release approximately 1,000 molecules into five litres of blood volume at
steady state. Therefore, the concentrations of the biomarker would only amount to
3x10−14 M, which would make the detection of relevant biomarkers quite challeng-
ing. Delectability, sensitivity and specificity in the circulation are all important and
desirable for assessing the potential clinical utility of a biomarker. High concentra-
tion of antibodies and thus vast amplification of a specific signal is achieved through
the activation of B cells. Each B cell can produce 5,000-20,000 antibodies/minute
and B cells can go through mitosis every 3 days, which may maintain or enhance
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antibody production [Sulzer et al., 1994,Cenci and Sitia, 2007,Forster and Rajewsky,
1990,Cooperman et al., 2004]. These features might render the study of B cells and
antibody responses in cancer an attractive proposition. A new technologies termed
”immunosignaturing” features protein-coated chips which are used to screen for reac-
tive antibodies against specific proteins. The ”signatures” resulting from this process
allow for the identification and prediction of the course of the disease. This relatively
new method was described to have a diagnostic utility in Alzheimer’s disease [Re-
strepo et al., 2013] and in brain cancers [Hughes et al., 2012]. Preliminary evaluations
suggest that IgG4, subclass antibodies, known to be associated with ”alternative”
Th2 immune environments (discussed in sections 1.3.5.1, 1.4 and 1.5.3 above) may be
used in the diagnosis of pancreatic cancer to help distinguish between autoimmune
pancreatitis and pancreatic cancer. This finding indicates that higher levels of IgG4
may be present in autoimmune diseases compared to cancer [Kawa et al., 2012]. The
presence of IgG4 in relation to pathologies has been examined in the context of al-
lergies and chronic exposure to antigens or allergens. Increased serum levels of IgG4
antibodies were observed in bee keepers associated with chronic occupational expo-
sure to bee venom. Furthermore, numerous studies point to elevated levels of IgG4
antibodies associated with allergic individuals undergoing allergen immunotherapies.
Patients are exposed to melanoma-associated antigens in the context of long-lived
IL-10-driven inflammatory conditions that may favour IgG4 antibodies and the lat-
ter is supported by an early report of dysregulated levels of IgG4 in patients with
melanoma. For the above reasons, the IgG4 antibody subclass is of interest as a
component of melanoma-associated inflammation (Chapter 3). By extension, and
based on reports evaluating IgG4 as an indicator of pathology or response to stimuli
in different disease settings, including some malignancies, Chapter 4 is focusing on
examining the presence of circulating and tissue-associated IgG4
+ B cells and IgG4
antibodies and their significance in disease pathology and prognosis.
1.9 Aims and Hypothesis
In light of the importance of understanding the complexity of the immune response
in melanoma and to inform the design of effective immunotherapies, the overarching
goal of this thesis is to dissect the humoral responses in melanoma and to derive and
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evaluate an immunotherapeutic approach using an antibody agent recognising the
melanoma surface antigen CSPG4. The primary objectives are threefold:
1) To dissect the humoral response by analysing antibody B cell infiltration, antibody
subclasses expression, and antibody class and subclass modulation of the humoral
immune response in melanoma and eventually to examine the functional implications
of these findings (i.e. impairment of the immunological reaction); 2) To evaluate the
propensity of antibodies and components of the redirected humoral immune compart-
ment in melanoma as putative biomarkers; 3) To explore efficacy and mechanisms
of a class of antibodies that may be less prone to tumour-induced humoral immune
blockade in melanoma, namely antibodies of the IgE class. In this thesis, an IgE
antibody recognising the tumour cell surface antigen, CSPG4 was engineered and
compared to its IgG counterpart in vitro and in two independent humanised mouse
models of melanoma.
Chapter 3 describes findings relating the modulation of humoral immunity, specifi-
cally of B cell and antibody responses, by immunosuppressive cytokines such as IL-
10, secreted in the tumour microenvironment. This Th2-biased microenvironment
in melanoma may trigger altered immune responses [Satoguina et al., 2005, Jeannin
et al., 1998], inducing antibodies of the less activatory IgG4 subclass. This impairing
mechanism was evaluated in vitro and in a humanised mouse model, by develop-
ing and implementing a range of new and improved functional assays. Based on
the relevance of redirected humoral responses in melanoma, Chapter 4 reports on
the investigation into the use of immunoglobulin IgG4 as a putative biomarker in
melanoma. Antibodies of the IgG4 subclass are produced at elevated levels in dif-
ferent cancers (section 1.4) and in Chapter 3, it is demonstrated that they exert
functional immunomodulatory roles in melanoma (Chapter 3). Therefore, the po-
tential of IgG4 to predict the risk of disease progression was investigated. Chapter
5 examines the activity and efficacy of the engineered anti-CSPG4 IgE class anti-
body. Using established in vitro techniques and novel in vivo models, anti-CSPG4
antibodies (IgG1 and IgE) were compared. Experiments investigate tumour antigen
epitope recognition on patient specimens, confirming the relevance of this agent in
the treatment of many patient lesions. Experiments reported here also evaluated the
potency and mechanisms of action of the novel anti-CSPG4 IgE confirming its func-
tional activity and its capacity to mediate tumour cell death. The anti-CSPG4 IgE
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was examined in two independent humanised mouse models, comparing its efficacy
against its IgG1 counterpart and against isotype control antibodies. Ultimately, gene
expression analysis from xenograft tumours demonstrated IgE specific gene expres-
sion patterns providing insights into the antibody’s mechanisms of action.
2 MATERIAL & METHODS
2.1 Human sample collection
All human samples, including healthy skin, tumour samples, lymph nodes and blood,
were collected with written informed consent. The study was approved by the Guy’s
Research Ethics Committee, Guy’s and St. Thomas’ NHS Trust for all experiments
described (Title: ”Molecular and Immunopathogenesis of Melanoma”, REC reference
number 08/H0804/139, approval date 15/10/2008).
2.2 Sterile culture of cell lines
All cells were maintained in a 5% CO2 humidified incubator at 37
◦C. All tissue cul-
ture reagents were from Gibco, unless otherwise indicated. The human monocytic
cell line U937 [Sundstro¨m and Nilsson, 1976] and the melanoma cell line A2058 (CRL-
1593.2; CRL-11147, ATCC, Manassas, USA) were grown in RPMI 1640 medium, 10%
(FCS), 2 mM L-glutamine, penicillin (5000 U/ml) and streptomycin (100 µg/ml).
The melanoma cell lines A375 (CRL-1619, ATCC, Manassas, VA), SK-MEL28 (HTB-
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72, ATCC) and MALM-3M (CCL-185, ATCC) naturally expressing Chondroitin
sulfate proteoglycan 4 (CSPG4) also known as High Molecular Weight Melanoma
Associated Antigen (HMW-MAA) were grown in Dulbecco’s Modified Eagles Me-
dia (DMEM) (Gibco, Eugene, USA), 10% FCS, 2 mM L-glutamine, penicillin (5000
U/ml) and streptomycin (100 µg/ml). The melanoma cell lines wm-115 (CRL.1675,
ATCC) and SK-MEL2 (HTB-68, ATCC) naturally expressing CSPG4 were grown in
Modified Eagles Media (MEM) (Gibco, Eugene, USA), 10% FCS, 2 mM L-glutamine,
penicillin (5000 U/ml) and streptomycin (100 µg/ml). The melanoma cell line G-
361 (CRL-1424, ATCC) naturally expressing CSPG4 was grown in Modified Ea-
gles Media (MEM) (Gibco, Eugene, USA), 10% FCS, 2 mM L-glutamine, penicillin
(5000 U/ml) and streptomycin (100 µg/ml). Primary human melanocytes (ATCC,
PCS-2000-012, ATCC) were grown in Dermal Cell Basal Medium (ATCC) and sup-
plemented with the Melanocyte Growth Kit (ATCC). The rat basophilic leukemia
mast cell line, RBL SX-38 (Wiegand et al., 1996) (a gift by Prof. JP Kinet, Har-
vard University, USA) is transfected to express the tetrameric form of the human
FcRI receptor (αβγ2) and was maintained in DMEM supplemented with 10% FCS,
500 µg/ml with 1.2 mg/ml G418, 2 mM L-glutamine, penicillin (5000 U/ml) and
streptomycin (100 µg/ml) (all by Gibco).
2.3 Biotinylation of anti-CSPG4 IgE antibody
The amount of biotin used to biotinylate a protein is dependent on its size and
distribution of amino groups on the protein. For antibodies one can use a 20-fold
molar excess of biotin reagent to label 1-10mg/ml of antibody, which would lead to
binding of 4-6 biotin groups/ antibody. Calculation for the use of Sulfo-NHS-LC-
Biotin were performed according to the instructions provided by Thermo Scientific
using the EZ-Link Sulfo-NHS-LC-Biotinylation kit (Thermo Scientific). Following
the calculation, the vial containing Sulfo-NHS-LC-Biotin (Biotin) was allowed to
equilibrate to room temperature and subsequently dissolved in PBS according to
calculation. Subsequently, biotin was mixed to CSPG4 IgE antibody and incubated
at 4 ◦C for two hours. Shortly before the incubation period ended Thermo Scientific
Zebra Spin Desalting Column were prepared by washing (spin columns at 1,000g for
2 minutes) the column 3x with 2.5 ml of PBS. The antibody biotin mix was pipetted
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onto the resin and allowed to be absorbed. 100 µl of ultrapure water were added and
the column was subsequently spun at 1,000g for 2 minutes to collect the biotinylated
antibody.
2.4 Immunohistochemistry
Paraffin sections were cut at 6 µm thickness on a microtome (Leica) and dried
overnight at 37 ◦C. Prior to staining, sections were deparaffinised with a 20 min
incubation in Xylene and then re-hydrated by serial incubations in alcohol (95%
→ 70% → 50% → 30% ethanol). Heat-induced antigen retrieval was performed
in a 95 ◦C water bath, using Citric Acid (10mM Citric Acid, 0.05% Tween 20, pH
6.0). Section were then blocked with blocking buffer containing 2.5% goat serum
and 0.1% bovine serum albumin (BSA) in PBS 0.05% Tween (PBST) for 35 minutes
at room temperature. Subsequently, sections were stained overnight at 4 ◦C us-
ing the following commercial antibodies: mouse anti-human CD22 (Abcam; 1:200);
rabbit anti-human FoxP3 (eBioscience; 1:50); mouse anti-humanCD45 (eBioscience;
1:250); and mouse anti-human IgG4 (BD Bioscience; 1:50-1:100). On the following
morning slides were washed 3x with PBST. Primary antibodies were then detected
using biotinylated goat anti-rabbit IgG (1:400, Vector labs, USA) (incubating for 1
hour at room temperature). Sections were subsequently washed 3x in PBST and
incubated for 30 minutes with VECTASTAIN© ABC-AP Reagent containing Lev-
amisole (Vector Labs) to block endogenous alkaline phosphatase. Following another
wash, slides were incubated in alkaline phosphatase substrate buffer and left to de-
velop for a maximum of 30 minutes at room temperature. Washing the slides in tap
water stopped the reaction. Hematoxylin counterstaining was performed by dipping
the slides into Mayer’s hematoxylin solution (Sigma Aldrich). After a final wash
in tap water, slides were de-hydrated by serial incubations in alcohol and xylene
(30%→50%→70%→95%→xylene) and mounted using DPX mounting media. All
components used to visualise the biotinylated antibodies are part of the VECTOR
Red Alkaline Phosphatase Substrate Kit (Vector Labs). Analysis was performed on
a Zeiss Axiophot microscope using 10x and 20x magnification lenses (Carl Zeiss) and
NIS-Elements imaging software (Nikon) or a tissue image analyser (Hamamatsu).
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2.4.1 Immunohistochemistry assessment
Expression of CSPG4 on tissue microarray sections was evaluated analysing high
power fields (7.5x) using the following criteria: ”negative” = no intensity; ”low”= low
intensity; ”intermediate”= intermediate intensity; ”high”= high intensity. Cell den-
sity of sections stained for IgG4+ cell infiltration was evaluated analysing high power
fields (10x) using the following criteria: ”negative”=0% infiltration; ”low”<25% in-
filtration; ”high”>25% infiltration.
2.5 Immunofluoresence
Freshly-frozen tissue sections embedded in OCT were cut at 4 µm-8 µm thickness
using a cryostat (Leica, Wetzlar, Germany), sections were air-dried and stored at
−80 ◦C until further use. Prior to staining, slides were equilibrated at room tem-
perature for 10 minutes, followed by fixation in acetone for 20 minutes. Section
were then blocked with blocking buffer containing 2.5% goat serum and 0.1% bovine
serum albumin (BSA) in PBS 0.05% Tween (PBST) for 35 minutes at room tem-
perature. Subsequently, sections were stained overnight at 4 ◦C using the following
commercial antibodies: mouse anti-human CD22 mAb (eBioscience; 1:200); goat
anti-human IgG (DakoGlostrup; 1:500); mouse anti-human IgG4 (BD Bioscience;
1:50-1:100); mouse anti-human CD64 (Biolegend; 1:250); mouse anti-human CD32
(Abcam; 1:250); mouse anti-human CD16 (Abcam; 1:200); goat anti-mouse IgG,
biotinylated (DAKO); rabbit anti-human S100. Alkaline phosphatase staining was
conducted as described in immunohistochemistry section. Fluorescent staining was
performed as followed: donkey anti-mouse Alexa 555 and donkey anti-goat Alexa
488 (both Life Technologies; 1:250) were incubated for 45 minutes and slides were
then subsequently washed 3x in PBST. Following the wash slides were mounted with
ProlongGold antifade containing DAPI (LifeTechnologies). Images were captured
using a Zeiss Axio Observer.Z1/ Axiophot microscope using AxioVision (10x, 20x
and 63x magnification lenses (Carl Zeiss)).
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2.6 Gene expression analysis
2.6.1 Specimen collection for mRNA analysis
Primary melanoma tumour lesions, melanoma skin metastases, lymph nodes and
healthy skin were collected with informed written consent. For gene expression stud-
ies, all primers and all probes used are listed in the Appendix (Supplements). Sam-
ples were freshly placed in RNAlater solution (Qiagen, Crawley, UK) and stored at
−70 ◦C until use.
2.6.2 RNA isolation form patient-derived samples
RNA isolation was performed using a Qiagen Homogenizer II and an RNeasy kit.
All reagents were from Qiagen unless otherwise indicated. Tissues were removed
from RNAlater and placed in a 2 ml microfuge tube. Tissues were immersed in
600 µl lysis buffer, placed in Qiagen Homogenizer II and blended until liquidised.
After homogenisation, the sample was spun at 14000 rpm for 3 min. Following
centrifugation, supernatants were aspirated and pipetted into gDNA Eliminator spin
columns and spun for 30 sec at ≥ 10,000 rpm. To each flow-through, 600 µl (1
volume) of 70% ethanol was added and samples were mixed immediately by pipetting,
transferred to RNeasy spin columns and spun for 30 sec at 14,000 rpm. Spin columns
were then washed with 700 µl of buffer RW1 and 500 µl buffer RPE (centrifuged for
15 sec at 14,000 rpm). After columns were air dried by centrifugation (2 min at
14,000 rpm), RNA was eluted with 50 µl of RNAase-free water into RNAse-free
microfuge tubes. The quality of the RNA was assessed by recording absorbance at
A260/A280 using a NanoDrop ND-1000 Spectrophotometer, and the Agilent 2100
RNA kit and Bioanalyser platform (Agilent Technologies, Wokingham, UK). Samples
with A260/A280 ratios >1.8 or a RNA Integrity Number (RIN) >5.0 were used.
2.6. Gene expression analysis 85
2.6.3 cDNA production
For production of cDNA, 500 ng RNA per reaction was used as a template for reverse
transcription as follows: 12 µl reactions containing 0.5 µg/µl OLIGO dT primer and
1 µl RNA in nuclease free water were prepared and denatured at 70 ◦C for 10 min.
The reverse transcription reaction was performed using 1 µl SuperScript II Reverse
Transcriptase (Invitrogen), 4 µl 5x 1st strand buffer, 2 µl 0.1M DTT, 1 µl 10 mM
dNTPs and 12 µl RNA OLIGO dT primer mix. The cDNA was amplified by the
following thermal cycling steps: 42 ◦C for 5 min, 45 ◦C for 50 min, 70 ◦C for 10 min.
For reverse transcription of flow cytometically-sorted cells, High Capacity cDNA
Reverse Transcription Kit (Life Technologies) was used as follows: a master mix
consisting of 2µl of 10x RT Buffer, 0.8 µl of 25x dNTP Mix, 2 µl of 10x RT random
primers was prepared. Subsequently, 14.2 µl of isolated RNA was added to 9 µl of
master mix. Finally 1 µl of MultiScribe Reverse Transcriptase was added and placed
into a BioRad thermal cycler (Biorad). cDNA was produced using the following
thermal cycling steps: 37 ◦C for 30 min, 95 ◦C for 5 min, 4 ◦C on hold.
2.6.4 cDNA quality control
Successful production of cDNA was analysed by a PCR reaction to detect the
ubiquitously-expressed gene GAPDH. Briefly, 30 µl of PCR reaction per sample
was prepared with 2 µl cDNA, 3 µl 10x PCR buffer, 3 µl 25 mM MgCl2, 1 µl 10 mM
dNTPs, 0.5 µl 20 µM GAPDH forward primer, 0.5 µl 20 µM GAPDH reverse primer,
0.5 µl Taq DNA polymerase (2.5 U/rxn) and 19.5 µl H2O. Reaction mixtures were
denatured at 95 ◦C for 5 mins followed by 32 thermal cycles of: 94 ◦C 1 min; 59 ◦C, 1
min; and 72 ◦C, 1 min; additional final extension at 72 ◦C for 4 min. PCR products
were analysed by gel electrophoresis (1.5% agarose gel with 1x TBE plus Ethidium
Bromide (EthBr), voltage of 125V) and DNA bands were visualized using UV light.
PCR products showing a band at 400 kB were selected for further assessments.
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2.6.5 Immunoglobulin and cytokine mRNA analysis of patient
specimens/ Real-time gene expression Taqman assays
CD22, mature IgG, IL-4, IL-10, IFNγ and VEGF mRNA expression were assessed by
multiplex real-time quantitative RT-PCR using TaqMan® Gene Expression Assays
(primers and probes from Life Technologies) according to the manufacturers’ in-
structions. Primers and probes for the quantification of mature IgG mRNA were de-
signed in-house using Primer Express (Life Technologies) as follows: Probe: 5’ FAM
CATCGGTCTTCCCC-MGB 3’; J segment primer: 5’ACCCTGGTCACCGTCTC-
CTCA 3’; Mature IgG reverse primer: 5’ TGCAGCAGCGGGTCAAG 3’. For each
sample, mRNA abundance was normalized against the amount of human GAPDH
mRNA (VIC) for the cytokine TaqMan® Gene Expression Assays or against β2-
microglobulin mRNA (VIC) for CD22 and mature IgG mRNA. Data analysis was
performed using either a ∆Ct method and subsequently, comparing it to an arbi-
trary number, or a ∆∆Ct method comparing it to freshly isolated cells from blood.
Results were expressed as relative mRNA expression units or ∆∆Ct.
2.7 Antibody and cytokine analysis
2.7.1 Isolation of primary human cells from peripheral blood
B cells or monocytes from human peripheral blood were isolated by negative selec-
tion using RosetteSep enrichments kits (StemCell) according to the manufacturer’s
instruction. Briefly, human blood was incubated with RosetteSep for 20 minutes
at room temperature, then mixed with an equal amount of PBS containing 2%
FCS and layered carefully on a 15 ml Ficoll-PaquePLUS (GE Healthcare) gradient.
Following a centrifugation at 1200g for 20 minutes (increase 3; break 0) at room
temperature, enriched cells were removed with a Pasteur pipette from the density
media and washed (1400rpm for 6 minutes at room temperature) in PBS 2% FCS to
remove any remaining contaminating Ficoll-PaquePLUS. Where necessary, an addi-
tional red blood cell lysis was performed using Red Cell Lysis buffer (Biosciences).
Subsequently cells were counted on a Haemocytometer and resuspended in appropri-
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ate buffers or media as needed for down stream applications. Monocytes were kept
in PBS 2% FCS with the addition of 1mM EDTA to prevent aggregation.
2.7.2 Ex vivo cultures of B cells from melanoma lesions
Single cell suspensions were derived from patient tissues (lymph nodes or melanoma
skin lesions) using a GentleMACs tissue dissociator (Miltenyi, Bergisch Gladbach,
Germany) and filtered through a 100 µm strainer. Subsequently, cell were grown
ex vivo in RPMI 1640 media supplemented with 10% FCS, 2 mM L-glutamine,
penicillin (5000 U/ml) and streptomycin (100 µg/ml), Epstein Bar Virus and CpG
(as described in the PhD thesis of Dr. Amy Gilbert, King’s College London, 2013).
2.7.3 Ex vivo co-cultures with allogeneic tumour cell and pe-
ripheral blood mononuclear cell enriched with B cells
In ex vivo culture and stimulation experiments, human peripheral blood B cells were
co-cultured in 96-well plates for 5 days together with irradiated peripheral blood
mononuclear cells (PBMCs) and tumor cells at 1:5:10 ratios in RPMI 1640 medium,
10% FCS, 2 mM L-glutamine, penicillin (5000 U/mL), streptomycin (100 µg/mL)
(all Life Technologies) and 2.5 ng/ml CpG 2006 ODN (InVivogen, California, USA)
in a 5% CO2 humidified incubator at 37
◦C.
2.7.4 Co-cultures of allogeneic human melanoma cells or
melanocytes with human peripheral blood B cells
B lymphocytes freshly isolated from human blood using RosetteSep (StemCell) and
Ficoll-PaquePlus (GE Healthcare) were plated at 2 x 103 cells/well on U-bottom
microplates (Nunc) along with 1 x 104 irradiated A375 (48 Gy) melanoma cells or
primary human melanocytes. Co-cultures were incubated in RPMI 1640 medium,
10% FCS, 1% penicillin-streptomycin. After 5 days, total IgG secreted or cytokines
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in B cell culture supernatants were measured using a sandwich ELISA or Milliplex
for cytokines assay kit. Cells were also harvested and stained for cell sorting using
the anti-MCSP-APC (Miltenyi) and anti-CD45-PeCy7 (BD Bioscience) antibodies.
2.8 Quantification of Immunoglobulins in patient sera
Luminex bead array assay kits, Milliplex for cytokines (Millipore) or Bioplex for
IgG subclasses (Biorad), were used according to the manufacturers’ instructions and
data were acquired and analyzed using a FlexMap3D or Bio-Plex200, luminex bead
analyser, respectively. Serum and isotyping standards were thawed and diluted in
serum matrix (provided by supplier) and left on ice 30 min prior to each assay.
Anti-isotype conjugated beads were vortexed for 3 minutes and then diluted in assay
buffer to adjust to a final volume of 50 µl. 96-well plates were pre-wetted with 100
µl of assay buffer/well, vacuumed using a Vacuum manifold (Millipore), and 50 µl
multiplex bead working solution was added per single well. Subsequently, wells were
vacuumed, washed using 100 µl wash buffer per well, and standards or samples were
added to the appropriate wells (resuspending the beads), before a further 30 minutes
incubation at room temperature on an orbital shaker. Following 3 washes with 100
µl wash buffer, 25 µl of detection antibodies mix were added to the wells and samples
were incubated for 30 minutes. This step was then followed by 3 washes with 100 µl
wash buffer and treatment with 50 µl Strepavidin-PE for 15 minutes. After a final 3
washes with wash buffer (3x 100 µl), the wells were resuspended in 125 µl PBS and
analysed on a Bioplex200 or FlexMap3D.
2.8.1 Evaluation of IgG4/IgGtotal levels
Elevated serum levels of IgG4 antibody in patient compared to healthy volunteer
sera correlate with risk of disease progression and survival. Blood samples were cen-
trifuged for 15 minutes at 1500x g (4 ◦C) and subsequently stored at −80 ◦C prior to
analysis. Milliplex IgG subclass luminex bead array assay kits (Millipore) were used
as described above. Data were acquired and analyzed using a FlexMap3 (Luminex
2.9. Flow cytometric cell sorting 89
Cooperation). IgG4/IgGtotal was calculated by dividing the concentration of IgG4
by the total concentration of IgG measured (concentration in pg/ml). LDH serum
levels were measured at the central laboratories of the associated hospital. Patients
were segregated into those with stable disease (SD, neither progressive disease nor
subsequent relapse during study period) and those with progressive disease (PD, ei-
ther active progressing disease or subsequent relapse patients being up-staged during
study period). Patients with co-morbidities that may have influenced IgG4/IgGtotal
(IgG4 levels) (e.g. lymphoma), or patients who missed their follow-up appointments,
were excluded.
2.9 Flow cytometric cell sorting
Cells for downstream mRNA or protein analysis were sorted on a FACSAriaIITM or
a FACSAriaIITM (special order) cytometer (Figure 2.1). Briefly, cells were prepared
as described in the appropriate sections of this Chapter. Cytometer settings were
optimized for the specific sample and drop delay was calculated using AccuDropTM
(BD Bioscience) technology. A sorting layout, defining cell number and position was
generated. Sorting strategies for each cell type are depicted in the Supplementary
Figures of Chapters 3 and 5.
Figure 2.1: Flow cytometric sorting strategy to isolate A375 tumor cells and PBMCs from
co-culture experiments.
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2.10 Western blot assays to examine signalling path-
ways
Protein lysates were separated by SDS-PAGE using 4-15% polyacrylamide minigels
(Bio-Rad) and transferred onto 0.2 µm PVDF membranes (BioRad Trans-Blot Turbo
single use packages) using a BioRad Trans-Blot Turbo Transfer system (Bio-Rad).
Membranes were blocked with 5% skimmed milk in PBS-Tween for 1.5 hours on an
orbital shaker at room temperature. Subsequently, blots were incubated overnight on
an orbital shaker with the primary antibodies against unphosphorylated and phos-
phorylated forms of Src, Akt, MEK(1/2) and SHIP-1 (all from Cell Signaling) diluted
in 1% skimmed milk-PBS-Tween (PBST) according to manufacturer’s recommenda-
tions. On the following day, membranes were washed 3x in 5 ml PBST and then
incubated with goat anti-rabbit-HRP (Cell Signaling, 1:5000) for 1.5 hours at room
temperature on an orbital shaker. After three washes in PBST, antibodies were vi-
sualized with an ECL detection kit (GE Healthcare) on a Hyperfilm (Amersham)
using a film developer.
2.11 Cell-based ELISA detection subclass antibod-
ies
Tumour cell-reactive antibodies were detected using cell-based ELISA as previously
described [Gilbert et al., 2011]. Briefly, A375 tumor cells were plated at 3-6 x 105
cells on 96-well flat-bottom tissue culture plates (Corning). Cells were lightly fixed
in 0.5% formaldehyde / Hank’s Buffered Salt Solution. Plates were then wrapped in
foil and placed in a −80 ◦C freezer until the day of the assay. On the day of the assay,
plates were thawed for 30 minutes, washed 3 times with PBS and then blocked with
a 5% non-fat milk/PBS solution for 2 hours. After removal of the blocking solution,
100 µl of supernatants from ex vivo B cell cultures, or non-specific IgG control (125
µg / 100 µl) or tumour-specific IgG1 or IgG4 antibodies (0.05 µg / 100 µl) were added,
and plates were incubated for 90 minutes at room temperature on an orbital shaker.
Plates were subsequently washed, and bound tumour cell-reactive antibodies from B
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cell culture supernatants were detected using a mouse anti-human IgG1 (AbSerotec,
1:400) or mouse anti-human IgG4 (BD Bioscience, 1:50) antibody. This was followed
by a 45 minute incubation with a goat anti-mouse IgG PE-labelled F(ab)2 Fc-specific
antibody (Jackson ImmunoResearch, 1:350). After a final wash in PBS, fluorescence
intensities, describing the tumour cell reactivity for each sample, were measured on
an ELISA reader (BMG Labtech, excitation 488, emission 540). All samples were
measured in duplicates and median fluorescence intensities (MFI) were corrected
against background and normalized against the MFI of the equivalent non-tumour
cell reactive isotype control antibody. Antibodies were defined as reactive against
tumor cells when the measured MFI was two standard deviations above the MFI of
the non-specific isotype control antibody.
Figure 2.2: Experimental design depicting a cell-based ELISA to detect tumour-reactive
antibodies of different IgG subclasses
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2.12 In vitro analysis of anti-CSPG4 antibodies
2.12.1 Flow cytometric assessments of antibody binding to
antigen/ cell surface receptors
To assess antibody binding to the tumour associated antigen CSPG4 on tumour cells
or to Fc receptors on monocytic U937 and on human primary immune effector cells,
cells were incubated with 10 µg/ml of mAb for 30 minutes at 4 ◦C and washed twice
in PBS, 5% normal goat serum (FACS buffer). Cells were then incubated with mouse
anti-human IgG-FITC or IgE-FITC antibodies (Jackson ImmunoResearch, Suffolk,
UK) (10 µg/ml) for 30 minutes at 4 ◦C. Cells were finally washed again in FACS
buffer prior to acquisition and analysis on a FACSCantoTM (BD Biosciences San
Diego, California, USA).
2.12.2 In vitro assays of antibody mechanisms of action/Flow
cytometric ADCC/ADCP assay
We adapted a modified three-colour flow cytometric assay to simultaneously measure
tumour cell cytotoxicity (ADCC) and phagocytosis (ADCP) (Bracher et al., 2007;
Karagiannis et al., 2007; Karagiannis et al., 2008a; Karagiannis et al., 2008b) to
assess killing of CSPG4 expressing cells by human effector cells. Prior to assays,
A375 cells were labelled with 5.0 µM CFSE (5-(and-6-) carboxyfluoresceindiacetate-
succinimidyl ester, (Molecular Probes, Eugene, Oregon, USA) in PBS for 10 min at
37 ◦C. Cells were then washed in DMEM medium, 10% FCS, 2 mM L-glutamine
and returned to normal culture conditions overnight (5% CO2 humidified incubator
at 4 ◦C). The following day, CFSE-labelled tumour cells were washed, mixed with
effector cells at E:T ratio of 3:1 with or without antibodies, and incubated for 3 h at
37 ◦C (all antibodies were tested at a concentration of 10 µg/ml). Subsequently, cells
were washed in PBS supplemented with 5% BSA (FACS buffer) and incubated for
20 min at 4 ◦C with an anti-CD89-PE (BD Bioscience, San Diego, California, USA)
(10 µg/ml) (BD Bioscience). Following a further wash, dead cells were labelled for
2 min at 4 ◦C with DAPI (LifeTechnologies 1:10000). After a final wash, cells were
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mixed thoroughly to interrupt cell-cell contact, re-suspended in 300 µl FACSbuffer
and acquired on a FACS Canto (BD Biosciences). CFSE-labelled tumour cells were
detected in the FITC channel (530/30 nm band pass filter and a 502 long pass filter),
CD89-PE-labelled monocytic effector cells in the PE channel (585/42 nm band pass
filter and a 556 long pass filter) and DAPI+ dead cells in the PacificBlue channel
(345/20 nm band pass filter), while single fluorochrome-labelled control samples were
included in each experiment for compensation adjustments between channels. Two
dual colour flow cytometric dot plots were generated to calculate ADCC and ADCP
as previously described [Bracher et al., 2007, Karagiannis et al., 2009]. Briefly, one
dot plot depicted CFSE+ tumour cells on the x-axis and DAPI+ cells on the y-axis,
allowing quantification of % double positive events (CFSE+/DAPI+ cells) indicating
tumour targets killed by effector cells by antibody-dependent cell mediated cytotoxi-
city (ADCC, cytotoxicity). The second dot plot depicted CFSE+ tumour cells on the
x-axis and CD89-PE+ effector cells on the y-axis in order to quantify total CFSE+
tumour cell events for each experimental condition and the % of tumour cells present
within PE+ effector cells, indicating antibody-dependent cell mediated phagocytosis
(ADCP, phagocytosis) by effector cells (CFSE+/PE+ cells) (Figure 2.3).
The proportions of tumour cells killed by cytotoxicity and phagocytosis were derived
using the following formulas:
Percentage of tumour cells killed by cytotoxicity (ADCC):
R1 SL control - R1 = X; [(X + R3)/R1 SL Control] x 100
Percentage of tumour cells phagocytosed (ADCP): [R2/R1 SL Control] x 100
Control samples were either given no antibody, or incubated with chimaeric MOv18
(IgE and IgG1) antibodies against the tumour antigen Folate Receptor α, which is
not expressed on A375 tumour cells, and is therefore not expected to mediate tumour
cell death. Each assay condition was tested in triplicate.
2.12.3 In vitro flow cytometric ADCC/ADCP assay using kinase
inhibitors to block IgE mediated mechanism
The previously described ADCC/ADCP assay was performed with the addition of
an incubation step. Prior to the co-incubation of effector and target cells, primary
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Figure 2.3: Diagram of ADCC/ADCP mechanisms. Below are two examples of flow cy-
tometic dot plots to quantify ADCP and/or ADCC. ADCP was calculated from dot plot
with cancer cells stained by CFSE and immune cells stained in PE (Left). Phagocytosed
cells are double positive CFSE-PE depicted in R2. Cytotoxicity was calculated using dot
plots with DAPI and CFSE (right). Double positve cells R3 along with loss of total number
in R1 compared to control allows for the calculation of total ADCC.
monocytes were incubated with the kinase inhibitor PF-431396 (Sigma Aldrich) for
20 minutes to inhibit PTK2 activity. Subsequently monocytes were washed in RPMI
1640 medium, 10% FCS, 2 mM L-glutamine (1200rpm for 5 minutes at room tem-
perature) and co-incubation with A375 melanoma cells at a 3:1 ratio. Following
a 3 hour incubation cells were handled as previously described and analysed on a
FACSCantoTM.
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2.12.4 Imagestream analysis of receptor binding
For assessments of antibody binding to CSPG4 on a panel of human melanoma cell
lines A375 primary human melanocytes, U937 monocytes or human primary mono-
cytes, cells were incubated with 10 µg/mL CSPG4-IgG1 or CSPG4-IgG4 for 30 min-
utes at 4 ◦C, followed by two washes in FACSbuffer. Cells were then treated with goat
anti-human IgG (Fab’)2-FITC antibody on an ImageStreamX (Amnis Corporation,
Seattle, WA). ImageStreamX quantitative analyses were based on the acquisition
of 20,000 cell events, and median fluorescence intensities (MFI) were measured and
calculated using an object mask to detect surface staining only (method described
in ImageStreamX users manual).
2.12.5 Imagestream analysis of IgG1 and IgG4 binding compe-
tition assay
To investigate the competition between IgG4 and IgG1 in binding to the cells surface
Fcγ receptors on primary monocytes, increasing concentrations of IgG4 were added
together with a defined concentration of IgG1. Specifically, CSPG4-IgG1 (10 µg/ml)
was co-incubated with increasing concentrations of CSPG4-IgG4 (at 1:1; 1:3; 1:6, 1:10
ratios of IgG1 to IgG4). Each incubation was performed for 30 minutes at room tem-
perature, followed by two washes in PBS with 5% normal goat serum (FACS buffer).
Cells were then treated with goat anti-human IgG1-PE (10 µg/mL) (MiltenyiBiotec)
to detect IgG1 binding only for 30 minutes at 4
◦C, and cells were washed in FACS
buffer prior to acquisition and analysis on an ImageStreamX (Amnis Corporation,
Seattle, WA). As above, ImageStreamX quantitative analyses constituted acquisition
of 20,000 cell events and median fluorescence intensity (MFI) measurements using
an object mask to detect cell surface staining only.
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2.12.6 Cell viability assay (MTS)
The direct effects of antibodies on cell viability were measured by the MTS assay
(tetrazolium compound 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxyphenyl)-2-(4-sulfo-
phenyl)-2H-tetrazolium inner salt) using phenazinemethosulfate (PMS) as a reduc-
ing agent (CellTiter 96© Aqueous One Solution Cell Proliferation Assay, Promega
Southampton, UK). During the experiment, MTS/PMS tetrazolium compound is
bioreduced by cells into a colored formazan (orange) product that is soluble in tissue
culture medium and can be measured on an absorbance plate reader. The absorbance
does then correlate directly with proliferation. To assess the anti-proliferative po-
tential of the CSPG4-IgE antibody, cells were seeded on 96-well plates in grown in
DMEM, 10% FCS, 2 mM L-glutamine, penicillin (5000 U/ml) and streptomycin (100
µg/ml) and allowed to adhere before treatment with 10 µg/ml of anti-CSPG4-IgE,
trastuzumab IgG1, anti-NIP-IgE control antibody (final concentration 10 µg/ml, 200
µl per well) or no additives. Cells were returned to culture, and cell viability was
assessed at 24 hours and 72 hours. Following cell cultures, MTS/PMS reagent was
added at 20 µl per well to cell cultures, and cells were incubated for 2 hours be-
fore analysis on a absorbance plate reader (all components for these assay were from
the CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay kit (Promega,
Wisconsin, USA)). The quantity of formazan product (as measured by recording ab-
sorbance at 490 nm, and following subtraction of background absorbance at 650nm)
was considered directly proportional to the number of live cells in culture.
2.12.7 in vitro mast cell degranulation assays
The engineered IgE antibody against the melanoma-associated antigen CSPG4-IgE
was evaluated in a potency assay for its capacity to engage its congnate Fc recep-
tors and activate effector cells to degranulate in vitro. The rat basophilic leukemia
mast cell line RBL SX-38 expresses the human form of the FcRI receptor as a
αβγ2 tetramer, which is naturally expressed on the surface of human mast cells and
basophils. RBL SX-38 [Linko-Lopponen and Makinen, 1985, Bodinier et al., 2008]
cells were seeded at a concentration of 2 x 104 cells/well in 100 µl media onto 96-
well round bottom plates (Nunc, Roskilde, Denmark) and incubated in a 5% CO2
2.12. In vitro analysis of anti-CSPG4 antibodies 97
humidified incubator at 37 ◦C overnight. The following day, cells were sensitized
with 100 ng/ml of CSPG4- IgE or control hapten specific IgE (NIP) antibody for 2
hrs at 37 ◦C in a humidified incubator. Cells were then washed twice with stimula-
tion buffer (Hank’s Buffered Salt Solution, HBSS supplemented with 1% BSA) and
stimulated with either 1 x 105 A375 tumour cells per well, 100 ng/ml of polyclonal
rabbit anti human-IgE (Dako, Ely, UK) antibody, or stimulation buffer alone for 30
mins at 37 ◦C in a humidified incubator. Controls were: untreated wells, to measure
background degranulation; or HBSS containing 0.1% Triton-X100 (Sigma), to mea-
sure total mediator release. Degranulation was terminated by placing samples on ice
and 50 µl of supernatant was transferred to 96-well polystyrene black MicroWellTM
Plates (Nunc). Degranulation was quantified by measuring release of the media-
tor β-hexosaminidase using a fluorogenic substrate (4-methylumbelliferyl-N-acetyl-
β-D-glucosaminide) prepared according to a standard protocol (Linko-Lopponen and
Makinen, 1985; Casal et al., 2003). Supernatants were incubated with an equal
amount of fluorogenic substrate at 37 ◦C in the dark for 2 hrs and then quenched
using 0.5M tris (hydroxymethyl) aminomethane buffer (Tris) (pH=9.0) (Sigma, St.
Louis, Missouri, USA). Fluorescence was measured on an Omega micro-plate reader
(BMG Labtech, Aylesbury, UK), using excitation and emission filters at 360nm and
405nm. Degranulation was calculated as % relative to that measured with addition
of Triton X-100, and compared with unstimulated cells (< 10%).
2.12.8 FcγR inhibition assays and functional analysis of IgG1
and IgG4
To investigate which FcγR family on the surface of monocytes is responsible for
the tumouricidal functions of the engineered anti-CSPG4 IgG1 antibody, an in vitro
ADCC/ADCP tumour killing experiment was conducted using either anti-CSPG4
antibodies alone or in combination with antibodies that are known to block indi-
vidual Fcγ receptor families. The above-mentioned ADCC/ADCP assay was uti-
lized for this purpose. The cells were incubated simultaneously with the appropri-
ate CSPG4-IgG1/IgG4 antibodies alone or in combination with mouse anti-human
FcγRI (Biolegend, used at 5µg per test; [Bruhns et al., 2009]; mouse anti-human
FcγRII (Abcam, used at 10µg per test); and mouse anti-human FcγRIII (Abcam,
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used at 5µg per test), which have been previously described to block the antibody
Fc-mediated functions of different FcγR family members [Bruhns et al., 2009,Bunk
et al., 2010]. Blocking experiments with specific or non-specific IgG4 antibodies were
conducted using a 3:1 (IgG4:IgG1) ratio and the appropriate concentrations of the
blocking antibodies were used as reported.
2.12.9 Cell sorting of human monocytes and protein isolation
Primary monocytes were isolated by flow cytometric cell sorting following ADCC/-
ADCP assays in order to assess the downstream signalling signatures associated with
specific antibody treatments. Following ADCC/ADCP assays, cells were incubated
with mouse anti-human CD14-PECy7 (Miltenyi) for 30 min at 4 ◦C, followed by
two washes in PBS, 1% BSA/DAPI (Sigma; LifeTechnologies). Cells were then
filtered and sorted on a FACSAriaII (BD Biosciences) for CD14+ viable cells into a
mammalian cell lysis buffer (Cell Signaling) containing PMSF (Sigma Aldrich).
2.13 Antibody analysis in vivo
2.13.1 Animal models
Male and female NOD/scid/ IL-2Rγ-/- mice (NOD.cg-Prkdcscid Il2rg tm1Wjl /SzJ
[NSG]; The Jackson Laboratory, Bar Harbor MA) were used between 6 and 10 weeks
of age. Mice were maintained under specific pathogen-free conditions and handled in
accordance with the Institutional Committees on Animal Welfare of the UK Home
Office (The Home Office Animals Scientific Procedures Act, 1986).
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2.13.2 Allo-immunity xenograft model
NSG mice were injected subcutaneously with 5 x 105 A375 melanoma cells in 150 µl
PBS. On day 5, mice received intravenous injections of 10 x 106 human peripheral
blood lymphocytes (PBL, derived from whole human blood by lysis of red blood cells)
and 10 mg/kg of appropriate antibody. Subsequent injections of antibody treatments
were given either three more times (on days 12, 18 and 25) or once more (on day 13)
at doses of 10 mg/kg each in 150 µl PBS each. A control group was treated with
10 x 106 human PBLs on day 5 and injected with 150 µl of PBS on treatment days.
Tumor growth was monitored and measured using calipers. Tumor size (mm3) was
calculated using the following formula: mm3 = d2 x (D/2) [d= small diameter of
tumor; D= large diameter of tumor]. Experiments were terminated once the first
animal was measured with a subcutaneous tumour size no greater than 750 mm3.
Spleen engraftment of 40-70% human CD45+ cells was confirmed by flow cytometry
for each animal and in all experiments.
2.13.3 Humanized mouse model of an orthotropic patient tu-
mour with autologous PBMCs
NSG mice were transplanted with equal sizes of original patient-derived skin melanoma
tumour obtained by surgical procedure. In brief, mice were anaesthetised with
Isoflurane (Baxter, 2%-0.5%) using a routine vaporiser. Subsequently, the surgical
area was cleared of hair and disinfected with Povidon-Iodide solution (Betaisodona,
Mundipharm). A 1 cm incision above the abdomen was performed. Whilst avoiding
perforating the peritoneum, the subcutis was explored and the tumour was placed
between the dermis and peritoneum. The incision was then closed using Vetbond
tissue adhesive (3M) and bandaged. At the same time, mice were injected intra-
venously with 10 x 106 human peripheral blood lymphocytes (PBL, derived from
whole human blood by lysis of red blood cells) and 10 mg/kg of antibody or control
saline. Subsequent injections of antibody were given every 7 days. Tumour growth
was monitored and measured using calipers. Tumor size (mm3) was calculated using
the following formula: mm3 = d2 x (D/2) [d= small diameter of tumor; D= large
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diameter of tumor]. Mice were sacrificed when their tumour reached a size no greater
than 750 mm3.
2.14 Quality control and quantification for cRNA pro-
duction
The agilent 2100 bioanlyser is a microfluidics-based platform used of the sizing, quan-
tification and quality control of nucleic acids, protein and cells. The RNA Nano kit
(Agilent Technology) allowed for the quantification and analysis of the integrity of
total RNA as to detect possible rRNA impurities. The RNA Integrity Number (RIN)
was set at 9 and any sample that showed a value below was excluded from further
analyses. RNA that was of good enough quality was further processed using the
IlluminaTotalPrep RNA Amplification kit (Ambion) as following: RT-PCR with T7
oligodT primers was used to produce first strand cDNA. The cDNA then underwent
second strand synthesis using DNA polymerase and enzymatic RNA degradation.
in vitro transcription technology, along with biotin UTP, was employed to gener-
ate multiple copies of biotinylated cRNA. The labelled cRNA was purified via filter
cartridges and quantified using a Qubit RNA assay kit (LifeTechnolgy) on a Qubitflu-
orometer (LifeTechnolgy). The KCL Genomics Centre performed the hybridization
and microarray data acquisition. Chrysanthi Ainali (PhD student, KCL) in collab-
oration with Jananan S. Pathmanathan (MSc student, KCL) conducted subsequent
data analysis.
2.15 Statistical analyses
All statistical test where performed using GraphPad Prism Version 6 with the ex-
ception of cross-table calculations, Fisher Exact Test and binary logistic regressions
which were performed using IBM SPSS software. Results were initially assessed for
Gaussian distribution. Subsequent statistical analysis was chosen according to the
distribution.
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2.15.1 In vitro and in vivo data statistical evaluations
All statistical analyses were performed using GraphPad Prism software (version 5
or 6 GraphPad). Comparative quantitative RT-PCR analyses in human skin speci-
mens were conducted using a Kruskal-Wallis analysis with a Dunn post-test. Com-
parative analyses of immunohistochemical staining were performed using a Mann-
Whitney-U-test. One-way ANOVA with Bonferoni post-test was employed to com-
pare ADCC/ADCP of tumor cells by human monocytes, triggered by antibodies.
Two-way ANOVA with Bonferoni post-test was employed to compare restriction
of tumor cell growth in vivo. Prior to any analysis data points in each cohort were
tested for normal distribution using the D’Agostino-Pearson normality test. P values
were indicated as follows: * P<0.05, ** P<0.01, *** P<0.001; ns = not significant
P>0.05. Box plots in real-time RT-PCR expression experiments represent mean
and whiskers indicate Min/Max values. Error bars in all in vitro figures represent
standard deviation (SD). Error bars in all in vivo figures and histological analyses
represent standard error of mean (SEM).
2.15.2 Statistical tests used for IgG4 biomarker evaluation
Significant increases between the IgG4 fraction (IgG4/IgGtotal) measurements in healthy
volunteer sera and breast cancer sera were calculated using the Kruskal-Wallis one-
way analysis of variance with post-hoc Dunn’s test. ROC analysis was performed
using the build-in method in GraphPad Prism Version 6. The Youden Index (speci-
ficity + sensitivity -1) was used to calculate the cut-off point for IgG4 used to evaluate
differences in overall survival and disease-free progression between groups. The sen-
sitivity and specificity was calculated via the ROC analysis. Significant differences
in progression free survival and overall survival for IgG4 levels and LDH were calcu-
lated using Mantel-Cox analysis. Statistical differences in circulating B cells between
healthy volunteer blood and blood form patients with melanoma were calculated us-
ing a Mann-Whitney-U-test.
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Product name Catalogue No. Supplier
BupH Carbonate-Bicarbonate Buffer Packs, 0.2M carbonate-bicarbonate,
pH 9.4
28382 Pierce
Maxisorp 96 Well Plates 442404 Nunc
O-Phenylene Diamine Dihydrochloride (OPD) Tablet P6912 Sigma Aldrich
Stable Peroxidase Substrate Buffer 10x 34062 Pierce
Streptavidin-Horseradish Peroxidase (HRP) Conjugate 21130 Pierce
Tween® 20 P1379 Sigma Aldrich
Phosphate Buffered Saline 1x pH 7.2, Non-sterile 20-7400-10 Severn Biotech
Phosphate Buffered Saline 1x pH 7.2, sterile 20012 LifeTechnologies
Dimethyl Sulfoxide (DMSO) 472301 Sigma Aldrich
FluoroNunc Black 96 Well Plates MPA-560-040A Fisher Scientific
Hanks’ Balanced Salt Solution (HBSS) with Calcium, Magnesium, no Phenol
Red
14025050 LifeTechnologies
Triton X-100 X100 Sigma Aldrich
4-methylumbelliferyl-N-acetyl-D-glucosaminide
(β-N-acetylhexosaminidase substrate) C18H21NO8 M2133 Sigma Aldrich
HCl 1 M H1758 Sigma Aldrich
6 Well Tissue Culture Plates 3516 Corning
CellTracker Blue Dye (7-Amino-4-Chloromethylcoumarin) C211 LifeTechnologies
LIVE/DEAD Viability/Cytotoxicity Kit for mammalian cells containing
Calcein AM and Ethidium homodimer-1
L3224 LifeTechnologies
MatTek 12 Well Glass Bottomed Culture Plates P12G-1.0-10 MatTek Corporation
Carboxy Fluorescein Diacetate Succinimidyl Ester (CFSE) 21888 Sigma Aldrich
Vacuum Stericup® Filter Units (0.22 µm pore size) FDR-120-090W Millipore
Sodium Azide S-2002 Sigma Aldrich
β-mercaptoethanol 50 mM M6250 Sigma Aldrich
TaqMan® Universal PCR Master Mix 4326708 Applied Biosystems
Oligo dT AM5730G LifeTechnology
Superscript II 18064022 LifeTechnology
10x Lysis Buffer 9803 BioLabs
PMSF P7626 Sigma
HBSS 14025050 LifeTechnology
Ficoll Paque Plus 17144003 GE Healthcare
TBE 10x T8935 Sigma Aldrich
Agarose A4679 Sigma Aldrich
Ethanol 45-986-6 Sigma Aldrich
Neutral Buffered Formalin (10%) PRC/R/4/200ml Pioneer Research Chem.
MicroAmp® Optical 96 Well Reaction Plate N8010560 LifeTechnologies
MicroAmp® Optical Adhesive 4311971 LifeTechnologies
% (v/v) formaldehyde in PBS 361367L Pioneer Research Chem.
ProLong® Gold antifade reagent with DAPI P36931 LifeTechnologies
4–15% Mini-PROTEAN® TGX Precast Gel 456-1083 BioRad
Trans-Blot® Turbo Midi PVDF Transfer Packs 170-4157 BioRad
Precision Plus Protein Kaleidoscope Standards 161-0375 BioRad
LDS Sample Buffer, Non-Reducing (4X) 84788 Pierce
RNAlater AM7021 LifeTechnologies
O-Phenylene Diamine Dihydrochloride (OPD) Tablet P6912 Sigma Aldrich
Stable Peroxidase Substrate Buffer 10x 34062 Pierce
Streptavidin-Horseradish Peroxidase (HRP) Conjugate 21130 Pierce
Tween® 20 P1379 Sigma Aldrich
Phosphate Buffered Saline 1x pH 7.2, Non-sterile 20-7400-10 Severn Biotech
Phosphate Buffered Saline 1x pH 7.2, sterile 20012 LifeTechnologies
Dimethyl Sulfoxide (DMSO) 472301 Sigma Aldrich
FluoroNunc Black 96 Well Plates MPA-560-040A Fisher Scientific
Hanks’ Balanced Salt Solution (HBSS) with Calcium, Magnesium, no Phenol
Red
14025050 LifeTechnologies
Triton X-100 X100 Sigma Aldrich
4-methylumbelliferyl-N-acetyl-D-glucosaminide
(β-N-acetylhexosaminidase substrate) C18H21NO8 M2133 Sigma Aldrich
HCl 1 M H1758 Sigma Aldrich
6 Well Tissue Culture Plates 3516 Corning
CellTracker Blue Dye (7-Amino-4-Chloromethylcoumarin) C211 LifeTechnologies
LIVE/DEAD Viability/Cytotoxicity Kit for mammalian cells containing
Calcein AM and Ethidium homodimer-1
L3224 LifeTechnologies
MatTek 12 Well Glass Bottomed Culture Plates P12G-1.0-10 MatTek Corporation
Carboxy Fluorescein Diacetate Succinimidyl Ester (CFSE) 21888 Sigma Aldrich
Vacuum Stericup® Filter Units (0.22 µm pore size) FDR-120-090W Millipore
Sodium Azide S-2002 Sigma Aldrich
β-mercaptoethanol 50 mM M6250 Sigma Aldrich
TaqMan® Universal PCR Master Mix 4326708 Applied Biosystems
Oligo dT AM5730G LifeTechnology
Superscript II 18064022 LifeTechnology
10x Lysis Buffer 9803 BioLabs
PMSF P7626 Sigma
HBSS 14025050 LifeTechnology
Ficoll Paque Plus 17144003 GE Healthcare
TBE 10x T8935 Sigma Aldrich
Agarose A4679 Sigma Aldrich
Ethanol 45-986-6 Sigma Aldrich
Neutral Buffered Formalin (10%) PRC/R/4/200ml Pioneer Research Chem.
MicroAmp® Optical 96 Well Reaction Plate N8010560 LifeTechnologies
MicroAmp® Optical Adhesive 4311971 LifeTechnologies
4% (v/v) formaldehyde in PBS 361367L Pioneer Research Chem.
ProLong® Gold antifade reagent with DAPI P36931 LifeTechnologies
4–15% Mini-PROTEAN® TGX Precast Gel 456-1083 BioRad
Trans-Blot® Turbo Midi PVDF Transfer Packs 170-4157 BioRad
Precision Plus Protein Kaleidoscope Standards 161-0375 BioRad
LDS Sample Buffer, Non-Reducing (4X) 84788 Pierce
RNAlater AM7021 LifeTechnologies
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Antibody Supplier Host Species Conjugate Catalogue No.
anti-human CD14 Biolegend mouse PE-Cy7 325618
anti-human CD22 BD Bioscience mouse APC 333145
anti-human CD19 BD Bioscience mouse FITC 555412
anti-human IgG Jackson Immuno-
Research
goat FITC 109-095-098
anti-human IgG AbDSerotec goat unconjugated 204001
anti-human CD89 BD Bioscience mouse PE 555686
Anti-human HER2/neu Trastuzumab (Her-
ceptin®)
Roche human unconjugated
anti-mouse IgG Invitrogen goat Alexa 488 A11017
anti-human IgE Vector goat FITC FI-3040
anti-human CD3 DAKO mouse PE R0910
anti-human CSPG4 IgG1 (high-molecular
weight melanoma associated antigen)
In house human chimaeric unconjugated Clone:
225.28s
anti-human CSPG4 IgG4 (high-molecular
weight melanoma associated antigen)
In house human chimaeric unconjugated Clone:
225.28s
anti-human CSPG4 IgE (high-molecular
weight melanoma associated antigen)
In house human chimaeric unconjugated Clone:
225.28s
anti-human FRα (Folate Receptor α) IgG In house human chimaeric unconjugated Clone:
MOv18
anti-human FRα (Folate Receptor α) IgE In house human chimaeric unconjugated Clone:
MOv18
isotype control DAKO mouse unconjugated X0931
anti-rabbit IgG Invitrogen goat Alexa 647 A21245
anti-human IgG Fc-specific antibody Sigma goat HRP A0293
anti-human IgG Fc-specific F(ab)’2 antibody Jackson Immuno-
Research
goat HRP 109-036-098
anti-human CD27 eBioscience mouse PE 12-0279-73
anti-human CD27 BD Bioscience mouse APC 337169
anti-human CD20 BD Bioscience mouse APC 340908
anti-human CD20 BD Bioscience mouse PerCP-Cy5.5 332781
anti-human CD3 Invitrogen mouse Pe-Cy5.5 MHCD0318
anti-NIP IgE AbDSerotec human chimaeric unconjugated MCA3335
anti-human IgE Dako rabbit unconjugated A0094
anti-human MCSP (high-molecular weight
melanoma associated antigen)
Invitrogen mouse unconjugated 412000
anti-goat IgG Invitrogen donkey Alexa 555 A21432
anti-human CD22 eBioscience rabbit unconjugated 14-0229-80
anti-human CD64 Biolegend mouse unconjugated 305015
anti-human CD32 Abcam mouse unconjugated ab41899
anti-human CD16 Abcam mouse unconjugated ab46679
anti-human CD27 BD Bioscience mouse V450 560448
anti-human CD19 BD Bioscience mouse BV605 562653
anti-human CLA BD Bioscience rat FITC 555947
anti-human CD14 BD Bioscience mouse AlexaFluor
700
557923
anti-human CD45 BD Bioscience mouse V500 560777
anti-human CD3 BD Bioscience mouse APC-H7 641397
anti-human IgG1 Miltenyi Biotec mouse PE 130-093-188
anti-human IgG4 BD Bioscience mouse unconjugated 555881
human IgG4 Sigma human unconjugated I4639
human IgG3 Sigma human unconjugated I5654
IgG, F(ab’)2 fragment Fcγ Jackson Immuno-
Research
goat unconjugated 109-036-098
anti-mouse CD45 eBioscience rat APC-Fluor
700
47-0451
anti-human CD68 DAKO unconjugated
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Product Name Catalogue No. Supplier
Dermal Cell Basal Medium PCS-200-030 ATCC
Dimethylsulfoxide (DMSO) 472301 Sigma
Ethanol; CH3OH 45-983-6 Sigma
EDTA dissodium salt C10H14N2ONa2O82xH20 E0399 Sigma
RPMI 1640 31870-025 LifeTechnology
Dulbecc’s Modified Eagle’s Medium (DMEM) 21980-032 LifeTechnology
Dimethylsulfoxide (DMSO) D2650 Sigma
Eagle’s Minimum Essential Medium with Earle’s Salts E15-825 PAA
Foetal Calf Serum (FCS) 10106-169 LifeTechnology
Penicillin; Streptomycin; Glutamine (PSG) 10378-016 LifeTechnology
Geneticin (G418) 10131-027 LifeTechnology
Goat Serum (non specific) 16210-072 LifeTechnology
Phosphate buffered saline sterile 14190-094 LifeTechnology
recombinant human IL-4 204-IL R&D Systems
Trypsin EDTA Solution 35400-027 LifeTechnology
Trypan Blue Solution T8154 Sigma
Bovine Serum Albumin 5497 Sigma
HBSS with Phenol 24020-133 LifeTechnology
IgG from human I2511 Sigma
RosetteSep CD14 monocyte enrichment 15068 StemCell Technologies
RosetteSep HLA B cell enrichment 15064HLA StemCell Technologies
Trizma T1503 Sigma
Ficoll Paque Plus 17144003 GE Healthcare
TBE 10x T8935 Sigma
Agarose A4679 Sigma
Corning® cell culture flasks (175cm) CLS431079 Corning
Corning® cell culture flasks (75cm) CLS430720 Corning
U 96 well plate; Cell Culture; clear with lid; Sterile 168136 Thermo Fischer
Table 2.3: Cell culture material
Name Supplier Catalogue No.
High Capacity RNA-to-cDNA Kit LifeTechnologies 4387406
RNeasyPLUS Mini Kit Qaigen 74104
Illumina® TotalPrep RNA Amplification Kit LifeTechnologies AMIL1791
MILLIPLEX® MAP Human Isotyping Magnetic Bead Panel Millipore HGAMMAG-301K
Bio-Plex Pro Human Isotyping Assays BioRad 171-A3100M
MILLIPLEX MAP Human Cytokine/Chemokine Magnetic
Bead Panel
Millipore HCYTOMAG-60K
Table 2.4: List of kits
3 IGG4 SUBCLASS ANTIBODIES
IMPAIR ANTITUMOR IMMUNITY IN
MELANOMA
Chapter 3 Paper 1: IgG4 subclass antibodies impair antitumour immunity in melanoma
The following figures from paper 1 were contributed by myself:
Figure 1: All data
Figure 2: 2A in collaboration with Dr. Amy E. Gilbert, the rest of Figure 2 all data
Figure 3: 3A in collaboration with Dr. Amy E. Gilbert, the rest of Figure 3 all data
Figure 4: All data
Figure 5: All data
Figure 6: All data
Figure 7: 3B in collaboration with Mr Alexander Koers, the rest of Figure 3 all data
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Host-induced antibodies and their contributions to cancer inflammation are largely unexplored. IgG4 sub-
class antibodies are present in IL-10–driven Th2 immune responses in some inflammatory conditions. Since 
Th2-biased inflammation is a hallmark of tumor microenvironments, we investigated the presence and func-
tional implications of IgG4 in malignant melanoma. Consistent with Th2 inflammation, CD22+ B cells and 
IgG4+-infiltrating cells accumulated in tumors, and IL-10, IL-4, and tumor-reactive IgG4 were expressed in 
situ. When compared with B cells from patient lymph nodes and blood, tumor-associated B cells were polar-
ized to produce IgG4. Secreted B cells increased VEGF and IgG4, and tumor cells enhanced IL-10 secretion in 
cocultures. Unlike IgG1, an engineered tumor antigen-specific IgG4 was ineffective in triggering effector cell–
mediated tumor killing in vitro. Antigen-specific and nonspecific IgG4 inhibited IgG1-mediated tumoricidal 
functions. IgG4 blockade was mediated through reduction of FcγRI activation. Additionally, IgG4 significantly 
impaired the potency of tumoricidal IgG1 in a human melanoma xenograft mouse model. Furthermore, serum 
IgG4 was inversely correlated with patient survival. These findings suggest that IgG4 promoted by tumor-in-
duced Th2-biased inflammation may restrict effector cell functions against tumors, providing a previously 
unexplored aspect of tumor-induced immune escape and a basis for biomarker development and patient- 
specific therapeutic approaches.
Introduction
Despite numerous reports investigating the clinical significance of 
immune cells in the circulation and in tumor lesions, the nature of 
local B cell responses and functional contributions of antibodies 
produced in cancer are largely unexplored (1–4). Recent studies 
have mainly focused on the immunoregulatory roles of B cells in 
mouse models of cancer through mechanisms such as effector cell 
engagement of Fcγ receptors and production of cytokines such as 
TNF-α and IL-10 (5, 6).
B cells respond to a variety of local stimuli to differentiate, 
undergo class switching, and produce antibodies of specific classes 
and subclasses. Human B cells are known to produce 4 subclasses 
of IgG (IgG1, IgG2, IgG3, IgG4), with each subclass having differ-
ent biological functions (7, 8). These antibody types vary in their 
ability to activate immune system components, including the 
formation of the complement complex or the engagement of Fc 
receptors on the surface of effector cells (9). However, whether IgG 
subclasses and their effector functions are of significance in cancer 
inflammation is relatively unknown.
IgG4 is considered a “weak” subclass due to its poor ability 
to bind complement and Fc receptors and to activate effector 
cells. IgG4 production is normally associated with prolonged 
exposure to antigens and has been reported to interact with 
antibodies of the IgG and IgE classes through their Fc domains, 
potentially influencing antibody-mediated functions (10, 11). 
In healthy adult serum, IgG1, IgG2, IgG3, and IgG4 represent 
65%, 25%, 6%, and 4% of the total IgG pool, respectively, but 
these proportions may be altered in certain disease contexts 
(8, 12). Associations of IgG4 antibodies are reported in a range 
of chronic inflammatory and autoimmune conditions that 
feature infiltration of target organs by IgG4-expressing cells 
(13, 14). Despite association with inflammatory pathologies, 
in allergy, elevated serum IgG4 antibody titers correlate with a 
reduction of allergic symptoms and successful allergen immu-
notherapy (15, 16). In this context, IgG4 antibodies are thought 
to interfere with IgE-mediated effector cell activation. This indi-
rectly implies a functional significance of IgG4 in modulating 
antigen-specific antibody-mediated effector mechanisms and in 
inducing clinical tolerance (17, 18).
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The relationship between IgG4 and malignancy is largely unex-
plored. Infiltrating IgG4+ cells in lesions of patients with extrahe-
patic cholangiocarcinomas and pancreatic cancers were recently 
reported (19, 20), and early studies have indicated abnormalities 
in serum titers of IgG4 in patients with melanoma (21). Both 
the presence and potential biological role of IgG4 subclass anti-
bodies in melanoma tumor lesions remain largely unknown. 
Th2-mediated immune responses represent the classical hallmarks 
of local inflammation in solid tumors such as melanomas (22). 
The immunoregulatory cytokine IL-10 has been shown to trigger 
“a modified Th2 response” by inducing differentiation of IgG4+ 
B cells and, in the presence of IL-4, to direct antibody class switch-
ing of B cells to secrete IgG4 (23, 24).
The association between induction of IL-10 and production of 
IgG4 antibodies has been shown in IgG4-related diseases and also 
in allergic individuals undergoing allergen immunotherapy (25). 
Th2-type inflammation in tumor tissues is dominated by IL-10–
producing cells, such as Tregs and M2-type macrophages (26, 27). 
We therefore reasoned that these Th2-type tumor inflammatory 
microenvironments may favor “alternatively activated” humoral 
immunity and local expression of IgG4 antibodies.
In this study, we show mature B cells and IgG4 antibodies in 
melanoma lesions in the presence of key Th2-type cytokines that 
may trigger IgG4 production. Using engineered IgG1 and IgG4 
antibodies of the same specificity against a tumor-associated anti-
gen, we demonstrate the capacity of IgG4 to counteract antitumor 
immunity in vivo.
Results
CD22+ B cells infiltrate melanoma lesions and IgG antibodies are expressed 
in situ. The presence of mature CD22+ B cells was observed in mel-
anoma lesions by immunohistochemistry (Figure 1A). CD22+ cell 
infiltrates were found both within tumor lesions and in surround-
ing stroma areas rich in CD45+ cells, indicating that this popula-
tion is part of the immune inflammatory infiltrate in tumors. Fur-
thermore, CD22+ cells were also seen in close proximity to FoxP3+ 
Figure 1
B cells (CD22+) infiltrate melanoma lesions and produce 
IgG. (A) Immunohistochemistry showing the presence of 
lymphocytes (CD45+), mature B cells (CD22+), activated 
lymphocytes (FoxP3+) (alkaline phosphatase [red], hema-
toxylin [blue]), and colocalization of all 3 within cutaneous 
metastases (scale bar: 100 μm; original magnification, 
×10). CD22+ cells in melanoma are shown at higher mag-
nification (original magnification, ×40). (B) Significantly 
increased CD22+ B cell infiltration was measured in pri-
mary (n = 6) and metastatic (n = 7) melanoma lesions 
compared with healthy skin (n = 8). HPF, high-powered 
microscope field. (C) Comparative real-time PCR showed 
significantly elevated CD22 expression in primary (n = 10) 
and metastatic (n = 10) melanomas compared with 
healthy skin (n = 9). (D) Increased expression of mature 
IgG mRNA in metastatic melanoma lesions (n = 10) com-
pared with primary melanomas (n = 10) and healthy skin 
(n = 9) measured by comparative real-time PCR analysis. 
(E) IgG expression (by comparative real-time RT-PCR) is 
elevated in melanoma lesions of stage IV patients com-
pared with lesions of stage I–III patients. (F) Immunoflu-
orescent evaluations of IgG+ B cells in human metastatic 
melanoma lesions (CD22+ B cells in red; left) (IgG+ cells 
in green; middle) and CD22+IgG+ B cell infiltrates (right). 
Scale bar: 10 μm; original magnification, ×63. (B and 
E) *P < 0.01, **P < 0.01, ***P < 0.001, Mann-Whitney 
U test. (C and D) *P < 0.05, **P < 0.01, ***P < 0.001, 
Kruskal-Wallis 1-way ANOVA with Dunn’s post-hoc test. 
Horizontal lines in box plots represent the mean, and 
whiskers indicate minimum and maximum values
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cells, which may imply associations between regulatory elements 
and B cells in tumors, as reported in the context of cholangiocar-
cinoma (19). CD22+ cell infiltrates were found in 8 out of 9 mel-
anoma lesions examined, and 6 of these CD22+ tumors were also 
positive for FoxP3 (Table 1). Quantitative immunohistochemical 
evaluations also confirmed infiltration of CD22+ B cells, asso-
ciated with 6 out of 6 primary and 5 out of 7 metastatic tumor 
lesions, while we detected sporadic CD22+ infiltrates in 2 out of 
8 healthy skin specimens (Figure 1B and Supplemental Figure 1, 
left panel; supplemental material available online with this article; 
doi:10.1172/JCI65579DS1). Primary and metastatic melanoma 
tumors had ≥7 CD22+ B cells per high-powered microscope field, 
compared with very low or absent CD22+ B cell infiltration in 
healthy skin (P < 0.05 and P < 0.001, respectively; Figure 1B).
The presence of CD22+ B cells in melanoma lesions was also 
confirmed by quantitative RT-PCR analyses. CD22 mRNA expres-
sion was determined in healthy skin (n = 9), primary melanoma 
lesions (n = 10), and melanoma skin metastases (n = 10) (Figure 
1C). We detected low to no expression of CD22 mRNA in healthy 
skin samples and significantly elevated levels in primary and meta-
static melanoma skin lesions (P < 0.01 and P < 0.001, respectively), 
suggesting recruitment of mature B cells to tumors (Figure 1C). 
Levels of mature IgG mRNA were elevated in metastatic melanoma 
lesions (n = 10) compared with those in both primary melanomas 
(n = 10) (P < 0.05) and healthy skin samples (n = 9) (P < 0.001), in 
which there was little to no expression (Figure 1D and Table 2). 
When we analyzed IgG4 expression by disease stage, we found sig-
nificantly higher expression of IgG mRNA in lesions from patients 
with stage IV disease (n = 6) compared with expression in lesions 
from patients at stages I–III (n = 14) (Figure 1E). Local expres-
sion of CD22+IgG+ B cell infiltrates was detected in melanoma 
lesions, as determined by dual-color immunofluorescence (Figure 
1F). These data confirm that mature antibody-expressing B cells 
infiltrate melanoma lesions and that IgG antibodies are expressed 
locally in metastatic melanoma.
Tumor-associated B cells are polarized to produce IgG4 antibodies in Th2-
biased inflammatory melanoma microenvironments. To examine the 
proportions of IgG subclasses produced in melanoma, B cells from 
melanoma skin lesions (n = 2, stages III and IV), patient lymph 
nodes (n = 3, stage III), patient blood (n = 6, stages III and IV), 
and healthy volunteer blood (n = 4) were cultured ex vivo (Tables 2 
and 3 and Supplemental Table 1). IgG subclass titers (IgG1, IgG2, 
IgG3, IgG4) in culture supernatants were then measured by ELISA. 
Proportional IgG subclass expression and IgG4/IgGtotal ratios from 
healthy volunteer peripheral blood B cells (IgG1: 79.5% ± 8.5%; 
IgG2: 14.3% ± 7.9%; IgG3: 4.3% ± 1.5%; IgG4: 1.5% ± 1%), patient 
peripheral blood B cells (IgG1: 76.4% ± 14.3%; IgG2: 15.8% ± 10.2%; 
IgG3: 4.1% ± 3.2%; IgG4: 3.9% ± 2.2%), and B cells from patient 
lymph nodes (IgG1: 83.2% ± 3.6%; IgG2: 6.5% ± 0.5%; IgG3: 
3.3% ± 1.0%; IgG4: 7.0% ± 2.1%) were consistent with those 
commonly detected in human sera (IgG4/IgGtotal ratio range: 
0.01–0.083, each condition tested in triplicate) (Figure 2A and ref. 
12). However, B cells derived from metastatic melanoma lesions 
exhibited higher proportional IgG4 subclass production (IgG4/
IgGtotal ratio range: 0.209–0.334) (IgG1: 43.2% ± 1.7%; IgG2: 
4.1% ± 1.4%; IgG3: 24.8% ± 3.5%; IgG4: 27.5% ± 5.3%) (Figure 2A).
Using immunohistochemical evaluations, we also detected sub-
stantial levels of IgG4-immunopositive cells infiltrating tumor 
areas in primary and metastatic melanoma lesions, while IgG4+ 
cells were rarely observed in healthy skin (Figure 2B, left, and Sup-
plemental Figure 1, right panels). These observations were con-
firmed with quantitative assessments of sections, which showed 
IgG4 positivity in 9 out of 12 melanomas and sporadic expres-
sion in 2 out of 10 healthy skin specimens (P < 0.001; Figure 2B, 
right). Furthermore, immunohistochemical evaluations of IgG4+ 
infiltrates were examined in relation to clinical parameters for a 
cohort of 9 patients. Although these observations are limited by 
the small number of patients, it is noteworthy that 3 patients who 
are deceased demonstrated IgG4 positivity in the lesions tested 
(Table 1). Expression of IgG4 was also confirmed by RT-PCR 
sequence alignments of patient specimens (representative clone in 
Supplemental Figure 2). These data suggest that IgG4 production 
occurs in situ in the melanoma microenvironment.
We then asked whether IgG4 antibodies in the tumor microenvi-
ronment and in patient circulation may recognize tumor cells. For 
this, we examined the reactivities against tumor cells of IgG1 and 
IgG4 antibodies produced by B cells derived from patient blood 
(n = 2, patients in stage III and IV), cutaneous metastases (n = 3, 
2 patients in stage III and 1 patient in stage IV), and a lymph node 
metastasis (n = 1, a patient in stage III) and cultured ex vivo for 
5 days. Tumor cell reactivity evaluations were conducted using 
a previously described cell-based ELISA (28). We found detect-
able levels of IgG4 reactivity against A375 metastatic melanoma 
cells, above background set by human IgG4 antibody controls, in 
Table 1
Pathological evaluations of IgG4, CD22, and FoxP3 of melanoma lesions, with corresponding clinical parameters
Patient  Gender Breslow Stage Date of  Date of  Infiltrating  Infiltrating  Infiltrating  Status 
ID    diagnosis biopsy CD22 IgG4 FoxP3
M72 F 3.12 IV 12/12/2003 01/26/2011 – – – Alive
M78 M 1.07 IV 03/02/2009 05/14/2009 + + – Deceased
M109 M 1.86 IV 02/19/2007 09/13/2009 + + – Deceased
M141 M 9.7 IV 10/23/2006 11/27/2009 + – + Alive
M173 F 2.2 IIIB 10/23/1998 02/12/2010 ++ + + Deceased
M248 F NA IIIB 06/01/2004 07/30/2010 + – +/– Alive
M430 F 6.75 IIC 11/29/2011 01/27/2012 ++ – ++ Alive
M525 F 2.2 IIC 06/29/2012 08/02/2012 ++ ++ + Alive
M549 F 0.45 III 07/02/2010 09/29/2012 + +/– ++ Alive
Evaluation criteria were as follows: –, 0% infiltration; +/–, <25% infiltration; +, >25% < 50% infiltration; ++, >50% infiltration; +++, >75% infiltration. See also 
Figures 1 and 2. n = 9. NA, not available.
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1 blood sample and 1 cutaneous metastasis (Figure 2C). In the same 
specimens, we found no equivalent detectable reactivity of IgG1 
antibodies against these tumor cells. In contrast, we detected IgG1 
antibody reactivity to melanoma cells in the lymph node sample 
without detectable equivalent IgG4 reactivity. Additionally, using 
2-color immunofluorescence on a cutaneous melanoma lesion, 
we demonstrated colocalization of IgG4 with the melanoma-as-
sociated antigen S100, further supporting the presence of tumor 
reactive IgG4 antibodies in situ (Figure 2D). These experiments, 
together with detected IgG4 expression in melanoma lesions by 
RT-PCR analysis (Supplemental Figure 2), suggest that tumor- 
reactive antibodies of the IgG4 subclass are expressed by patient 
B cells situated in both melanoma lesions and the circulation. We 
reasoned that the polarization of IgG4 in situ may be influenced by 
local factors, such as production of IL-10 in combination with IL-4, 
which is known to induce differentiation of IgG4+ B cells, drive 
class switching, and to maintain polarization of humoral immune 
responses in favor of IgG4 (29). Accordingly, we found significantly 
elevated mRNA expression of the Th2 cytokines IL4 and IL10 and 
of the inflammatory cytokine IFNG, reported to be involved in 
tumorigenesis, by quantitative RT-PCR in both primary (n = 10) 
and metastatic (n = 10) melanoma skin specimens when compared 
with healthy skin samples (n = 9) (P < 0.05; Figure 2E and ref. 30). 
Secretion of these cytokines was also confirmed in ex vivo cultures 
of tumor lesions (Figure 2F). These findings indicate a potential 
association of Th2-biased local expression of IL-10 and IL-4 with 
IgG4 production at inflammatory tumor sites.
Melanoma tumor cells trigger Th2-driven polarization, inducing B cells 
to secrete IgG4. To elucidate whether melanoma cells can influence 
polarized expression of IgG4 by B cells, we attempted to recre-
ate the proximity between B cells and tumor cells in an ex vivo 
stimulation assay. We cocultured melanoma patient peripheral 
blood B cells with autologous irradiated PBMCs in the presence 
or absence of A375 metastatic melanoma cells or human primary 
melanocytes. Similarly to that in B cells isolated from melanoma 
lesions, we detected increased IgG4/IgGtotal ratios from blood 
B cells cultured with PBMCs in the presence of melanoma cells 
(IgG1: 35.0% ± 5.6%; IgG2: 23.1% ± 0.9%; IgG3: 30.3% ± 4.6%; 
IgG4: 20.0% ± 1.1%), while IgG4/IgGtotal ratios remained low 
when B cells were cultured with PBMCs in the absence of mel-
anoma cells (IgG1: 54.8% ± 3.5%; IgG2: 29.3% ± 8.6%; IgG3: 
9.2% ± 1.3%; IgG4: 6.7% ± 1.2%) (n = 9, Figure 3A, left). When we 
compared IgG4 polarization of B cells plus PBMCs in the absence 
or presence of melanocytes (IgG1: 51.9% ± 2.9%; IgG2: 21.5% ± 4.2%; 
Table 2
Clinical parameters, pathological evaluations, and IgG expression levels for melanoma lesions
Patient  Gender Age Stage IgG  Breslow Clark Ulceration Tumor inf.  Classification TNM  
ID    expression    lymphocytes  classification
M123 M 76 IV 0.5 5.85 IV Absent Absent Primary T4a;N3;M1a
M125 F 62 IB 0 1.65 III Absent Present Primary T2a;N0;M0
M127 F 36 IIIC 4.006 N/A N/A N/A N/A In transit metastasis T3a;N3;M0
M128 F 82 IB 0 1.08 III Absent Present Primary T2a;N0;M0
M129 M 63 IV 22 N/A N/A N/A N/A In transit metastasis T3a;N3;M1c
M133 M 75 IIC 0.0234 3.3 IV Absent Absent Primary T4b;N0;M0
M147 F 46 IIIA 1.456 2.1 Unknown Absent Unknown Primary T3a;N1a;M0
M171 M 48 IIIC 0.00032 N/A N/A N/A N/A In transit metastasis T2a;N3;M0
M173 F 87 IIIB 0.00041 N/A N/A N/A N/A In transit metastasis T3b;N2c;M0
M192 F 88 IV 4.006 N/A N/A N/A N/A Dist. subcutaneous metastasis T4b;N0;M1a
M294 M 80 IIC 0.0041 6.36 IV Present Absent Primary T4b;N0;M0
M72 F 77 IV 17 N/A N/A N/A N/A In transit metastasis T3a;N3;M1c
M80 M 70 IIA 0.0056 2.85 IV Absent Absent Primary T3a;N0;M0
M172 M 73 IIIB 1.78 N/A N/A N/A N/A In transit metastasis T3b;N2c;M0
M141 M 64 IV 0.861 N/A N/A N/A N/A Dist. skin metastasis T4a;N3;M1a
M245 M 79 IIB 1.61 3 III Present Unknown Primary T3b;N0;M0
M284 F 65 IIIC 0.0202 N/A N/A N/A N/A In transit metastasis Tx;N3;M0
M149 M 60 IB 1.4 1.11 IV Absent Absent Primary T2a;NxMx
M269 F 73 IIA 0 2.32 IV Absent Present Primary T3a;N0;M0
M221 M 52 IV 25 N/A N/A N/A N/A In transit metastasis Tx;N0;M1c
See also Figures 1 and 2. n = 20. N/A, not assessed; inf., infiltrating; Dist., distant. Numbers in the “Breslow” column indicate the thickness (mm) of the pri-
mary melanoma. Values in the “Clark” column (I–V) indicate the level of anatomical invasion of the skin into different skin compartments
Table 3
Clinical parameters and pathological evaluations for lymph node specimens
Patient ID Gender Age Stage Nodes sampled Nodes involved Metastasis TNM
M488 F 53 IIIA 2 1 Yes T2a;N1a;M0
M36 M 69 IIIC 9 1 Yes T4b;N3;M0
M490 F 54 IIIB 14 2 Yes T4b;N2a;M0
See also Figures 1 and 2. n = 3.
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Figure 2
B cells in melanoma lesions are polarized to produce IgG4 antibodies with reactivity against tumor cells. (A) Polarization of IgG subclasses in 
B cells derived from metastatic melanoma skin tumor lesions (n = 2), patient lymph nodes (n = 3), peripheral blood from patients with melanoma 
(n = 6), and from healthy volunteers (n = 4). Cells were cultured ex vivo, and IgG subclass expression profiles were analyzed from culture superna-
tants by ELISA (mean ± SD; each sample condition tested in triplicate). (B) Immunohistological evaluations confirm significantly increased IgG4+ 
cell infiltration in melanoma lesions (n = 10) but not healthy skin (n = 10) (***P < 0.001), and representative metastatic melanoma depicts IgG4+ 
cells (red; hematoxylin [blue]) (scale bar: 20 μm; original magnification, ×10). (C) Reactivity of patient B cell–derived IgG1 and IgG4 antibodies 
to A375 tumor cells evaluated using a cell-based ELISA. Dashed black and gray lines indicate cut-off points for IgG1 and IgG4 tumor-reactive 
antibodies, respectively (lines defined as 2 SDs above isotype control antibodies). (D) Immunofluorescent staining of IgG4+ (red) colocalized 
with S100+ (green) cells in metastatic melanoma (scale bar: 50 μm; original magnification, ×40). (E) Increased expression of IL4, IL10 and IFNG 
in metastatic melanomas (n = 10) compared with primary melanomas (n = 10) and healthy skin (n = 9) by comparative real-time PCR. Horizontal 
lines in box plots represent mean, and whiskers indicate minimum and maximum values. *P < 0.05, **P < 0.01, Kruskal-Wallis 1-way ANOVA with 
Dunn’s post-hoc test. (F) Cytokines IL-4, IL-10 and IFN-γ are secreted in metastatic melanoma lesion ex vivo cultures.
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Figure 3
Ex vivo stimulation assays demonstrate that tumor cells polarize B cells to produce IgG4. (A) IgG subclass production by patient peripheral 
blood B cells. Cells were cocultured with irradiated PBMCs with or without metastatic melanoma cells or primary melanocytes for 5 days. Culture 
supernatants were harvested, and IgG subclass expression profiles were analyzed by IgG subclass ELISA. IgG subclass fractions and total IgG 
concentrations were illustrated for each sample as mean ± SD of 3 independent experiments (all conditions performed in triplicates). *P < 0.01. 
Secretion of Th2 cytokines IL-10 and IL-4 from B cell cultures treated with or without (B) tumor cells or (C) primary melanocytes were analyzed by 
cytokine multiplex assay analysis. Both cytokines were significantly increased in cultures containing tumor cells but not in cocultures with mela-
nocytes (*P < 0.01; **P < 0.01, Mann-Whitney U test; n = 9 replicates per coculture condition). Horizontal lines in box plots represent mean, and 
whiskers indicate minimum and maximum values. Comparative real-time PCR analysis of IL-4, IL-10, and VEGF expression by A375 melanoma 
cells isolated by flow cytometric sorting before (–) and after (+) cocultures with B cells and PBMCs shows (D) increased IL-10 expression by 
cocultured melanoma cells and (E) confirmation that A375 cells secrete IL-10 but not IL-4 in culture. ND, not detected. (F) Comparative real-time 
PCR analysis of IL-4, IL-10, and VEGF expression by B lymphocytes isolated by flow cytometric sorting from monocultures or from cultures with 
tumor cells, showing increased expression of VEGF expression by B cells when cocultured with tumor cells.
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IgG3: 14.0% ± 1.5%; IgG4: 12.6% ± 2.8%), we observed a small, 
but not statistically significant, difference in IgG4/IgGtotal ratios 
with the addition of melanocytes, indicating that IgG4 polariza-
tion may be partly due to an allogeneic HLA mismatch effect in 
these assays. We demonstrated significant changes in IgG4 polar-
ization (higher IgG4/IgGtotal ratios) when comparing B cells, 
PBMCs, and melanocytes with samples of B cells, PBMCs, and 
melanoma cells (P < 0.05). The overall titers of IgG antibodies 
produced in the presence or absence of melanoma cells in these 
assays were comparable (Figure 3A, right).
Figure 4
Biological properties of engineered IgG1 and IgG4 antibodies recognizing the melanoma-associated antigen CSPG4. Anti-CSPG4 IgG1 and 
anti-CSPG4 IgG4 antibodies bind to receptors on the cell surface of (A) U937 monocytic cells, (B) primary monocytes, and (C) tumor cells. 
ImageStream and flow cytometric evaluations confirm IgG1 and IgG4 antibody binding to Fcγ receptors (top and middle panels) and also to the 
antigen CSPG4 (bottom panel) expressed on the surface of SK-MEL-28 melanoma cells. ImageStream images are shown on the left. IgG FITC, 
cell surface (area indicated by circle on top left of each panel) binding of antibodies on cells; BF, bright-field image of cells; IgG FITC/BF, composite 
image of antibody and bright-field images, confirming anti-CSPG4 antibody binding to the cell surface. Quantitative analyses are based on the 
acquisition of 20,000 cells. Control samples for U937 and monocytes were incubated with goat anti-human IgG (Fab′)2-FITC antibody. Control 
samples for antibody binding to tumor cells were human IgG1 and IgG4 isotype antibodies of irrelevant specificity. (D) Flow cytometric analysis 
of CSPG4 IgG1 or CSPG4 IgG4 antibody binding to a panel of tumor cell lines or primary human melanocytes. Antibody binding was detected 
with an anti-human IgG (Fab′)2-FITC, and specific binding was depicted by MFI values above isotype control antibody binding.
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We next asked whether ex vivo production of IgG4 in the pres-
ence of melanoma cells is associated with Th2-biased inflam-
matory cytokines. Consistent with our findings in metastatic 
melanoma lesions, ex vivo stimulation of B cells with metastatic 
melanoma cells triggered enhanced IL-4 and IL-10 levels, as 
compared with B cell cultures in the absence of melanoma cells 
(P < 0.01 and P < 0.05, respectively) (Figure 3B). We also detected 
increased titers of VEGF, IL-6, and MCP-1, but not IFN-γ, in cocul-
tures with melanoma cells (Supplemental Figure 3A). In contrast, 
when we compared IL-4 and IL-10 titers in cultures of B cells and 
PBMCs in the presence or absence of melanocytes, we did not 
observe any significant increases (Figure 3C). These findings indi-
cate that melanoma cells drive Th2-biased inflammatory environ-
ments favoring increased IgG4/IgGtotal production ratios.
To further investigate the origin of Th2 cytokine production, 
we harvested A375 melanoma cells before and after coculture 
assays by flow cytometric cell sorting (strategy for flow cytomet-
ric sorting shown in Supplemental Figure 3B). We demonstrated 
increased expression of IL-10 by these cells following coculture 
with B cells and PBMCs. Message for IL-4 was not detected, and 
VEGF mRNA was present but was not upregulated following 
coculture (Figure 3D). When cultured alone under normal culture 
conditions, melanoma cells did not express or secrete IL-4, but the 
cells secreted detectable levels of IL-10 (Figure 3E). These assays 
point at enhanced expression of IL-10 by melanoma cells in these 
coculture assays. Neither B cells nor tumor cells expressed IL-4 
message under these culture conditions, and therefore, IL-4 may 
be contributed by another cell type in PBMCs (Supplemental Fig-
ure 3C) or possibly stromal cells in the tumor microenvironment.
Having shown that tumor cells produce IL-10 in culture, next we 
investigated the cytokines produced by sorted B cells in these cul-
ture conditions (strategy for flow cytometric sorting shown in Sup-
plemental Figure 3D). B cells in coculture experiments upregulated 
VEGF expression, while expression of IL-10 by these cells was 
detected but not upregulated following coculture with tumor cells 
(Figure 3F). These experiments suggest that B cells may contribute 
to polarized humoral immunity by enhancing production of VEGF.
IgG4 subclass antibodies lack antitumoral effector functions and block 
IgG1-mediated tumor cell killing by patient monocytes. To explore 
potential mechanisms by which IgG4 may impact on antitumoral 
responses, we engineered 2 antibodies, with IgG1 and IgG4 Fc 
regions, that share identical variable regions recognizing the mel-
anoma-associated antigen CSPG4. With these, we attempted to 
mimic a clinically relevant situation, in which IgG1 and IgG4 were 
found alone or together in the presence of tumor antigen-express-
ing cancer cells and FcγR-expressing immune effector cells, such as 
patient monocytes/macrophages (5, 19). Both antibodies bound to 
FcγR-expressing U937 monocytes, to patient monocytes (Figure 4, 
A–C), and to a panel of melanoma cells (Figure 4D).
First, we examined the ability of each antibody to activate 
patient-derived monocytes to kill tumor cells in vitro. Patient 
monocytes incubated with anti-CSPG4 IgG4 and A375 melanoma 
cells mediated nonsignificant tumor cell killing compared with 
a nonspecific IgG4 (antibody clone SP211-IgG4) after 3 hours 
(n = 6). In contrast, the corresponding anti-CSPG4 IgG1 of the 
same specificity triggered statistically significant increases in 
phagocytosis (antibody-dependent cellular phagocytosis [ADCP]) 
(21.1% ± 2.5%) of melanoma tumor cells by monocytes compared 
with anti-CSPG4 IgG4 (3.2% ± 0.3%) and controls (2.6% ± 0.1%) 
(P < 0.001; Figure 5, A and B). Consistent with reduced IgG4 anti-
tumor activity, we detected lower levels of IFN-γ (P < 0.01), IL-1β 
(P < 0.01), and TNF-α (P < 0.05) in supernatants from cultures 
treated with anti-CSPG4 IgG4 compared with those treated with 
anti-CSPG4 IgG1 (n = 6) (Figure 5C).
When anti-CSPG4 IgG1 and anti-CSPG4 IgG4 were combined 
with patient-derived monocytes and melanoma cells, the tumori-
cidal capacity of anti-CSPG4 IgG1, previously observed in the 
antibody-dependent cellular cytotoxicity/ADCP (ADCC/ADCP) 
assays, was significantly reduced in the presence of anti-CSPG4 
IgG4 (P < 0.001, Figure 5D). This suggested that anti-CSPG4 IgG4 
is not only incapable of triggering effector cell–mediated tumor 
killing but may additionally suppress tumor cell killing capacity 
of tumor-specific IgG1. To evaluate whether specificity for the 
tumor antigen was necessary for an IgG4 antibody to block IgG1 
effector cell functions against tumor cells, we performed ADCC/
ADCP (cytotoxicity/phagocytosis) assays, incubating tumor cells 
and patient-derived monocytes with anti-CSPG4 IgG1 in combina-
tion with a human IgG4 antibody of irrelevant specificity. Nonspe-
cific IgG4 partly hindered tumor-specific IgG1 tumor cell killing 
(P < 0.001; Figure 5E), suggesting that tumor cell specificity may 
only be partly responsible for the antibody modulatory properties 
of IgG4. These data are in line with known properties of IgG4 inter-
actions with Fc regions of immunoglobulins, and they are also con-
sistent with reports that only a small fraction of IgG4 antibodies are 
allergen specific in allergic subjects following immunotherapy (31). 
In summary, IgG4 antibodies lack antitumoral effector functions 
and impair IgG1-mediated tumor cell killing by patient monocytes.
IgG4 blocks IgG1 tumor cell killing by inhibiting IgG1 binding and acti-
vation through FcγRI. In order to elucidate whether IgG4 antibodies 
could hinder binding of IgG1 on the surface of effector cells, we 
performed a competition binding assay using monocytic cells. 
This showed decreased IgG1 binding on the surface of human 
monocytes with increasing concentrations of IgG4 (Figure 6A), 
suggesting that IgG4 competes with IgG1 for FcγR binding on 
the surface of effector cells.
Figure 5
IgG4 irrespective of tumor specificity is ineffective in triggering anti-mel-
anoma effector functions in vitro and prevents IgG1 from mediating 
tumor cell killing. (A) Dot plots depicting CFSE+ tumor cells and CD89-
PE+ monocytes (effector cells) were used to quantify CFSE+ tumor 
cells present within PE+ effector cells, indicating phagocytosis (ADCP) 
(CFSE+/PE+ cells) (top panel). CFSE+/DAPI+ double-positive tumor 
cell events indicate tumor targets killed by cytotoxicity (ADCC, bottom 
panel) by IgG1 but not IgG4. (B) Quantification of tumor antigen-spe-
cific IgG1 and IgG4 antibody induced ADCC/ADCP by monocytes. 
Tumor antigen-specific IgG1 mediated tumor cell killing compared 
with an unspecific control antibody or cells alone. The corresponding 
anti-CSPG4 IgG4 antibody induced no tumor cell killing above iso-
type control levels. (C) Titers of secreted IFN-γ, IL-1β, and TNF-α, but 
not of IL-10, were higher in culture supernatants of monocytes and 
tumor cells stimulated with anti-CSPG4 IgG1 antibodies compared with 
those stimulated with anti-CSPG4 IgG4 or controls. All samples were 
tested in duplicates; mean ± SD (n = 6). (D) Tumor antigen-specific 
IgG1 against the melanoma antigen CSPG4 can induce monocytes to 
kill tumor cells, but addition of anti-CSPG4 IgG4 blocks the antitumor 
functions of the same concentrations of IgG1. (E) Similar blocking of 
IgG1-mediated tumor cell killing can be observed when CSPG4 IgG1 is 
coincubated with a nonspecific human IgG4 antibody. (B, D, and E) All 
assays were performed in triplicates. Data represent percentage tumor 
cell killing (mean ± SD) (n = 6). *P < 0.05, **P < 0.01; ***P < 0.001.
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In order to investigate which FcγR is predominantly responsi-
ble for the induction of tumor cell killing via IgG1, we conducted 
tumor killing assays during which individual FcγR families were 
blocked with antibodies described in the literature to have an 
inhibitory capacity for these specific receptor families. We demon-
strate that, in this experimental system, blockade of FcγRI, but 
not of the other 2 receptor families, was responsible for the IgG1-
mediated tumor cell killing (Figure 6B). We confirmed the wide-
spread distribution of FcγRI along with the other 2 FcγRs (FcγRII 
and FcγRIII) in melanoma lesions (1 representative of 4 patient 
specimens shown in Supplemental Figure 4). Since FcγRs such as 
FcγRIIb are known to play immunomodulatory roles, we investi-
gated whether specific inhibition of IgG binding to each of these 
receptor families had any bearing on the killing inhibition medi-
ated by IgG4. In these experiments, we found that inhibition of 
CD32 is not involved in IgG1 blocking by IgG4 (Figure 6C).
Next, at different time points during in vitro tumor cell killing 
assays, we harvested monocytes by flow cytometric sorting and 
assessed phosphorylation of downstream signaling events trig-
gered through engagement of FcγR engagement and activation 
(32). We observed increased phosphorylation of known mem-
bers of the FcγR activatory signaling cascades (Src, MEK, and 
AKT) in the presence of IgG1 compared with the presence of 
both IgG1 and IgG4 antibodies (33). On the contrary, there were 
no differences in the levels of phosphorylated SHIP1 in relation 
to CSPG4 IgG1 or in relation to coincubation with IgG1 and 
IgG4 antibodies together at any of the time points tested (Fig-
ure 6D). These data suggest that inhibition of IgG1-mediated 
tumor cell killing by IgG4 is attributed to lack of effector cell 
activation rather than induction of inhibitory signals via FcγRs 
such as FcγRIIb. We conclude that in this experimental system 
IgG4 functions by competing with IgG1 for FcγRI binding and 
therefore blocking the activatory cascades through reduced 
phosphorylation of Src, MEK, and AKT.
IgG4 impairs antitumor immunity in a human melanoma xenograft 
model. Next, we compared the efficacies of anti-CSPG4 IgG1 and 
IgG4 in vivo in a subcutaneous human melanoma xenograft mouse 
model engrafted with human immune effector cells (Supplemen-
tal Figure 5 and ref. 34). Intravenous treatment with anti-CSPG4 
IgG1 (3 × 10 mg/kg weekly doses) significantly reduced tumor 
size compared with treatments with nonspecific mAb or vehicle 
controls (n = 6, P < 0.05; Figure 7A). However, tumor size in anti- 
CSPG4 IgG4–treated mice increased in line with that in controls, 
suggesting that IgG4 was significantly less effective than IgG1 at 
restricting tumor growth in vivo (P < 0.001). Furthermore, when 
anti-CSPG4 IgG1 and IgG4 were administered together, tumors 
grew similarly to vehicle-treated controls (n = 6, P < 0.001 for IgG1/
IgG4 combinations compared with IgG1 treatment alone; Figure 
7A), indicating that anti-CSPG4 IgG4 might counteract IgG1 anti-
tumor functions in vivo.
To ascertain that impaired antitumoral functions of anti- 
CSPG4 IgG4 were not due to inability of IgG4 to localize in 
CSPG4-expressing tumors in the mice, 111In radio-labeled anti- 
CSPG4 IgG4 biodistribution was monitored by PET/SPECT 
imaging of human xenografts (n = 3). Accumulation in tumors 
was observed within 24 hours following antibody treatment (Fig-
ure 7B). Furthermore, we observed that subcutaneous human 
melanoma xenografts from mice treated with anti-CSPG4 IgG1 
attracted higher levels of human CD68+ cells (macrophages) 
compared with mice treated with IgG4 or combinations of IgG1 
and IgG4 antibodies (Figure 7, C and D). These findings indicate 
that macrophages may be recruited and potentially play a role in 
restricting tumor growth when engaged by CSPG4 IgG1 in situ.
Serum IgG4 antibodies may be predictive of clinical outcomes in mela-
noma. Having investigated the immunomodulatory potential of 
IgG4 in melanoma in vitro and in vivo, we then evaluated whether 
the presence of IgG4 in patient circulation could be used as a pos-
sible biomarker. We performed IgG1–IgG4 subclass Luminex bead 
array assays using sera from 33 patients with stage III and IV mel-
anoma (Figure 8 and Table 4). Spearman correlation analyses were 
performed to examine any significance among IgG subclass titers 
in sera in relation to patient survival. We demonstrated a negative 
correlation only between IgG4 serum titers and patient survival 
(r = –0.31, P < 0.05), while no significant correlations were found 
in relation to the other IgG subclasses (Figure 8A).
Normal IgG4/IgGtotal ratios in human sera have been reported 
around 0.025 (35). In this study, we confirmed this (Figure 2A) 
and additionally found that IgG4/IgGtotal ratios in patient sera 
had a median of 0.034 (95% CI of mean, 0.024–0.044). We there-
fore reasoned that serum IgG4/IgGtotal ratios above the 75% per-
centile (IgG4/IgGtotal = 0.04) may be considered high in patient 
sera (Supplemental Figure 6). To gain an insight into the signif-
icance of IgG4/IgGtotal ratios in patient sera, we analyzed cumu-
lative survival on a Kaplan-Meier survival plot in our 33 patient 
cohort. We found that patients with higher serum IgG4/IgGtotal 
ratios (>0.04, n = 13) had significantly lower survival rates (median 
survival 8 months; hazard ratio, 0.19; 95% CI, 0.0635–0.5685) 
compared with patients whose IgG4/IgGtotal serum ratios were 
<0.04 (n = 20) (P < 0.01) (Figure 8B).
Overall, we have shown that IgG4 subclass antibodies are pres-
ent in tumor lesions and that they are inefficient in restricting 
melanoma tumor cell growth. In addition, IgG4 suppressed IgG1-
mediated melanoma cell killing in vitro and in a clinically relevant 
humanized mouse engrafted with human melanoma. When exam-
ined in relation to clinical outcomes, data presented here suggest 
that IgG4 is associated with reduced survival and may be evaluated 
as a prognostic biomarker in melanoma.
Figure 6
IgG4 blocks IgG1 antibody-dependent tumor cell killing by inhibiting 
IgG1 binding and activation through FcγRI. (A) Competition assay 
of IgG1 binding on the surface of monocytic cells displaced by addi-
tion of increasing concentrations of IgG4 antibody. Proportion of 
cells binding IgG1 is decreased with increasing concentrations of 
IgG4, demonstrated by flow cytometric evaluations and represen-
tative confocal images (yellow, by ImageStream). (B) Anti-CSPG-4 
IgG1-mediated tumor cell killing (by flow cytometry) is inhibited by 
addition of an antibody known to block IgG Fc binding to FcγRI but 
not with addition of blocking antibodies to FcγRII or to FcγRIII. (C) 
Inhibitory functions of anti-CSPG-4 IgG4 are not lost by blocking 
FcγRII or FcγRIII with previously described specific FcγR blocking 
antibodies in flow cytometric antibody-dependent tumor cell killing 
assays. (D) Protein extracts of primary human monocytes isolated by 
flow cytometric sorting at different times during the antibody-mediated 
tumor cell killing assay were examined for phosphorylated products of 
the FcγR signaling pathway. Western blots of phospho-proteins and 
band density quantifications relative to freshly isolated monocytes 
demonstrate that IgG4 inhibits the activatory signaling cascades of 
FcγR (Src, AKT, MEK), while lack of pSHIP implies that FcγRII signal-
ing is not involved in the IgG4 blockade. (B and C) Data are represen-
tative figures of 3 independent experiments.
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Despite the fact that B lymphocytes constitute important senti-
nels of adaptive immunity and the antibody-mediated immune 
response, the mechanisms by which they participate in tumor 
immunity remain only partially understood (2–4, 36–39). We 
described a hitherto undiscovered aspect of local humoral 
immunity in melanoma, characterized by B cell infiltration and 
local expression of IgG4 antibodies, in the context of prominent 
expression of IgG4 polarizing cytokines IL-10, IL-4, and VEGF. We 
demonstrated that, in the presence of melanoma cells, production 
of these cytokines is enhanced and B cells are polarized to produce 
IgG4 ex vivo. Importantly, we showed that IgG4 antagonizes IgG1-
mediated human anti-melanoma immunity in vitro and in vivo 
and that IgG4 blockade is mediated through competition with 
IgG1 for FcγR binding and therefore inhibits downstream signal-
ing activation of effector cells (i.e., monocytes).
Previous studies have reported the presence of CD20+ cells 
in melanoma lesions (2, 3), but this pan–B cell marker is also 
expressed by melanoma stem cells (40, 41). We selected the B cell 
marker CD22 to differentiate B cells from melanoma stem cells 
and to study mature B cells that may express class-switched anti-
bodies. We detected CD22 at the mRNA and protein levels in mela-
noma lesions but at very low levels in normal skin (Figure 1). These 
cells were observed within tumor lesions and also surrounding 
stroma areas rich in CD45+ cells, indicating that B cells form part 
of the immune inflammatory infiltrate; however, the significance 
of CD22+ B cell infiltrates in cancer remains unclear. B cell and 
plasma cell (CD138) infiltration in melanoma have been associ-
ated with favorable clinical outcomes, and lymphoid structures 
containing B cells (CD20) and also plasma cells (CD138) were 
recently reported (4, 42). Other reports highlight immunomod-
ulatory roles for B cells in cancer, suggesting that their contribu-
tion may reflect a balance between effective immunity and tumor- 
induced inflammation (20, 43).
The presence of mature IgG mRNA in metastatic melanoma 
lesions and CD22+IgG+ and IgG4+ cells infiltrating tumor cell areas 
Figure 7
IgG4 has no antitumoral effector functions in vivo and blocks tumor-specific IgG1 function. (A) Anti-CSPG4 IgG1 antibody is capable of restrict-
ing the growth of subcutaneous melanoma lesions in NSG mice engrafted with human immune effector cells, while tumors in mice treated with 
an anti-CSPG-4 IgG4 antibody or coadministered with anti-CSPG4 IgG1 and IgG4 antibodies grow similarly to those from mice treated with 
nonspecific antibody or vehicle alone (n = 7 mice per group; mean ± SEM tumor volume in mm3). *P < 0.05, ***P < 0.001, 2-way ANOVA with 
Bonferroni post-hoc test. Data are representative of 2 experiments. (B) Representative NanoSPECT/CT images of Indium-111–labeled anti- 
CSPG4 IgG4 antibody (red), demonstrating accumulation of antibody in subcutaneous melanoma lesions at 20 minutes, 8 hours, and 24 hours 
following intravenous administration (n = 3). (C) Representative immunohistological images and (D) quantitative analyses of sections from human 
melanoma tumors grown in NSG mice treated with vehicle alone, anti-CSPG4 IgG1, anti-CSPG4 IgG4, or a combination of anti-CSPG4 IgG1 
plus anti-CSPG4 IgG4 antibody, demonstrating elevated levels of human CD68+ (brown) immune cell infiltration in human xenograft tumors in 
animals treated with anti-CSPG4 IgG1 antibody. Horizontal bar indicate the mean, and individual symbols indicate individual tumors. Scale bar: 
50 μm; original magnification ×20. ***P < 0.001.
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suggest that B cells may participate in local tumor surveillance 
through production of antibodies. This study demonstrates the 
expression of IgG antibodies in situ rather than being sequestered 
or diffused into tumors from the circulation. This was shown by 
the detection of mature IgG mRNA, IgG4 clone expression, and 
IgG4+ infiltrates in melanoma lesions as well as by the produc-
tion of tumor-reactive IgG4 antibodies by tumor-resident B cells 
(Figure 2). Recent findings implicate increased IgG4 serum titers 
and IgG4+ tissue infiltrates in a range of inflammatory conditions 
triggered by chronic exposure to nonmicrobial antigens (14, 18, 
31). Our findings demonstrating increased expression of IgG, the 
presence of IgG4+ infiltrates in tumors, and tumor-reactive B cells 
in lesions are consistent with exposure to tumor antigens, as this 
might allow for antibody class switch recombination (44).
We found a striking polarization in IgG subclass distribution 
produced by tumor-derived B cells in favor of IgG4 (Figure 2). We 
directly showed a role for tumor cells in influencing IgG4 pro-
duction by B cells (Figure 3). Furthermore, ex vivo stimulation 
of human B cells with melanoma cells also resulted in a similar 
proportional increase in IgG4/IgGtotal 
ratios compared with unstimulated 
B cells, and we demonstrated that mel-
anoma tumor cells, but not normal 
human melanocytes, are capable of 
polarizing B cell responses in favor of 
IgG4 production. In melanoma tumor 
lesions, these increased IgG4/IgGtotal 
ratios were accompanied by expression 
of Th2-biased inflammatory cytokines 
known to drive production of IgG4 by 
B cells. Tumors circumvent immune-
mediated clearance by triggering 
inflammatory cells with immunoreg-
ulatory properties and immunosup-
pressive mediators (e.g., IL-10, VEGF, 
TGF-β) in situ (34, 45, 46). The immu-
noregulatory cytokine, IL-10, can direct 
“a modified Th2 response” favoring B 
cell production of IgG4 (23, 25, 47). In 
support of this, we have found induc-
tion of increased IL-10 production 
by tumor cells cultured with B cells 
ex vivo. IL-10 has been implicated in 
modified Th2 responses in the con-
text of IgG4-related diseases (48, 49). 
Although IgE and IgG4 are triggered 
by similar Th2-biased signals, IL-10 is 
thought to divert a classical Th2-type 
immunity, bypassing IL-4–induced 
IgE responses in favor of IgG4 (23, 29). 
Classically, high IgG4/IgGtotal ratios 
are considered a natural effort by the 
immune system to contain immune 
activation. These alterations, how-
ever, have also been documented in 
individuals chronically exposed to 
occupational or environmental anti-
gens and are not normally accompa-
nied by development of IgE (50, 51). 
Consistent with this, we detected IgE 
mRNA in only 2 out of 10 patient lesions that we examined (data 
not shown), which also points to the involvement of altered Th2 
responses in tumor microenvironments (52).
As reported by others in the context of IgG4-related diseases, 
we detected local expression of tissue-resident IgG4 together with 
enhanced expression of IL-10 and IL-4 cytokines in tumors (Figure 3 
and ref. 49). We also demonstrated that tumor cells are capable of 
stimulating such modified Th2 responses, featuring production 
of IL-10 and IL-4 and secretion of IgG4 by B cells. Also consis-
tent with a tumor-associated inflammatory environment, VEGF, 
known to polarize Th2-biased cytokine production by PBMCs 
through induction of IL-10–secreting cells such as Tregs (53), 
along with well-described tumor-induced inflammatory media-
tors IL-6 and MCP-1 (53–56), was found at significantly increased 
levels (P < 0.001; Supplemental Figure 3A), upregulated by B cells 
in cultures of B cells with melanoma cells compared with cultures 
without tumor cells. While tumor cells contributed enhanced 
expression of IL-10 in coculture assays, neither B cells nor tumor 
cells expressed IL-4 under these coculture conditions, and it is pos-
Table 4
Clinical parameters and disease staging at the time of sampling for peripheral blood donor 
cohort used for serum detection of IgG subclass and correlations
Patient Gender Breslow Date of sample Age at date  Date of death Stage 
    of sample (yr)
M31 F 3.5 03/05/2009 45 01/20/2010 IV
M42 F 4.29 03/19/2009 80 07/20/2009 IIIc
M70 M 9.3 04/23/2009 43 10/05/2009 IV
M72 F 3.12 04/16/2009 76 Alive IV
M85 M NA 06/18/2009 53 Alive IV
M95 F 2.77 12/10/2009 65 06/28/2011 IV
M107 M 6 08/06/2009 63 09/10/2011 IIIC
M109 M 1.86 08/13/2009 74 02/23/2010 IV
M110 F 2.42 08/21/2009 48 Alive IIIB
M111 M 1.21 08/21/2009 66 12/19/2010 IIIB
M114 F 2.37 09/10/2009 52 Alive IIIC
M123 M 2.04 10/08/2009 76 05/05/2010 IV
M130 M 3.6 11/05/2009 66 12/31/2009 IV
M137 F NA 11/26/2009 69 03/18/2010 IV
M138 F 2 11/26/2009 60 Alive IV
M139 F 2.3 11/26/2009 55 Alive IV
M146 F 4.2 12/03/2009 80 11/11/2010 IIIC
M147 F 2.3 01/07/2010 46 Alive IIIA
M150 F 1.6 01/07/2010 32 Alive IIIA
M154 M NA 01/14/2010 80 Alive IIIB
M158 M NA 02/11/2010 53 Alive IIIA
M161 F 1.1 02/11/2010 52 Alive III
M163 M NA 01/28/2010 75 11/14/2010 IV
M199 M 6.7 04/15/2010 62 04/26/2012 IV
M247 F 2.16 07/29/2010 35 Alive IV
M122 M NA 10/15/2009 78 05/05/2010 IV
M134 M 3.45 11/12/2009 81 02/05/2010 IV
M214 M 2.2 05/13/2010 70 Alive III
M235 F 5.25 06/03/2010 60 Alive III
M244 M NA 07/15/2010 34 Alive IV
M251 M 2.1 08/05/2010 70 Alive III
M268 M 3.1 10/21/2010 83 12/11/2011 III
M399 M 3.7 10/20/2011 41 Alive IV
Numbers in the “Breslow” column indicate the thickness (mm) of the primary melanoma. See also 
Figure 8. n = 33.
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antigen recognition, and, in support of this, we found tumor-re-
active IgG4 antibodies associated with melanoma lesions. Second, 
IgG4 could bind to Fcγ receptors, preventing IgG1 interactions on 
the surface of effector cells. The implications of the latter mecha-
nism would be that IgG4 of any specificity could neutralize IgG1-
FcR–mediated effector functions against tumors through engage-
ment of the main Fcγ receptor families (58). In agreement with this 
possibility, a nonspecific IgG4 also blocked IgG1-mediated tumor 
cell ADCP by patient monocytes almost as effectively as the tumor 
antigen-specific IgG4 (Figure 5). This suggested that antigen spec-
ificity may only partly account for the IgG4 antibody-neutralizing 
properties (31, 59, 60). Furthermore, here we demonstrated that 
tumor antigen-specific IgG4 inhibited IgG1-dependent tumor cell 
killing by blocking activatory signal cascades associated with FcγRI 
effector mechanisms, which would normally lead to functions such 
as ADCP (Figure 6). One can therefore envisage that if IgG4 anti-
bodies are abundant in tumor microenvironments, their proxim-
ity to tumor cells may not only inhibit the effector functions of 
naturally expressed antibodies, but IgG4 could also impair thera-
peutic antibody effector functions in situ by one or more mecha-
nisms, as has already been reported following antibody treatments 
for rheumatoid arthritis (61, 62). Our findings are also consistent 
with similar reported functional roles of IgG4 in blocking immune 
responses in atopic individuals receiving allergen immunotherapy 
(18, 31). While these effects signal the relief of symptoms and suc-
cessful allergen immunotherapy, the presence of IgG4 in tumor 
microenvironments and its antibody-neutralizing functions may 
contribute to evasion of the humoral immune response to cancer.
Further supporting the potential significance of IgG4 in mela-
noma growth are our findings that elevated levels of IgG4 in patient 
sible that IL-4 production may be contributed by other stromal or 
immune cells in tumor microenvironments. Our findings there-
fore identify melanoma tumor cells as potential inducers of IgG4 
in tumor microenvironments via B cell–produced VEGF, trigger-
ing enhanced IL-10 production by tumor cells.
Insights into how IgG4 antibodies contribute to immune homeo-
stasis and to different disease pathologies are starting to emerge. 
IgG4 is considered a “nonactivating” subclass associated with 
chronic inflammation and limited immune activating functions 
(57). Links between IgG4 and tissue inflammation (14), in the 
context of well-characterized inflammatory mechanisms at play 
in tumors, raise the possibility of a key role for this antibody sub-
class in tumor inflammation. In support of this concept, we have 
shown the local presence of IgG4 antibodies in melanoma and their 
contributions to tumor inflammatory responses. In addition, we 
found that tumor antigen-specific IgG1, but not the corresponding 
IgG4, could activate patient-derived monocytes to kill tumor cells 
in vitro (Figure 5). These findings were confirmed by in vivo exper-
iments, since tumor antigen-specific IgG4 was unable to restrict 
tumor growth, despite accumulating in tumor lesions (Figure 7). 
Polarizing humoral responses in favor of IgG subclasses with low or 
no potency in activating effector cells against tumors may therefore 
represent a mechanism of tumor escape.
Another potential mechanism relates to IgG4 interactions with 
other IgG antibodies and its capacity to impede IgG functions that 
would otherwise activate effector cells to eradicate tumors. We 
observed that a tumor antigen-specific IgG4 antibody hindered the 
ability of the corresponding IgG1 to induce ADCP of tumor cells 
by patient monocytes. This may be the outcome of one or more 
potential scenarios. First, IgG4 may compete with IgG1 for tumor 
Figure 8
Elevated levels of IgG4 antibodies in patient sera correlate 
with patient survival. (A) IgG subclass ELISA evaluations of 
sera from 33 patients with stage III and IV melanoma were 
evaluated using Spearman correlation analyses for IgGsubclass/
IgGtotal, fractions in relation to patient survival (months), show-
ing a statistically significant negative correlation between IgG4 
fraction only (r = –0.32; P = 0.00353). (B) Kaplan-Meier cumu-
lative survival analysis of overall patient survival was compared 
with respect to IgG4/IgGtotal fractions (stratified according to 
fractions above (blue) or below (black) the 75 percentile of the 
IgG4/IgGtotal fractions measured from the 33 metastatic mela-
noma patient cohort), indicating that high IgG4/IgGtotal ratios in 
sera are associated with a significantly lower overall survival 
(P = 0.003; hazard ratio 0.19; 95% CI 0.0635–0.5685).
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012) were grown in Dermal Cell Basal Medium (ATCC) and supplemented 
with the Melanocyte Growth Kit (ATCC). The monocytic cell line U937 
(CRL-1593.2) was grown in DMEM, 10% FCS. Cells were grown in 2 mM 
l-glutamine, penicillin (5,000 U/ml), and streptomycin (100 μg/ml). The 
B95-8 marmoset blood leukocyte cell line secreting Epstein-Barr virus was 
grown in RPMI 1640 medium, 10% FCS, 2 mM l-glutamine, penicillin 
(5,000 U/ml), and streptomycin (100 μg/ml). All cells were maintained in a 
5% CO2 humidified incubator at 37°C.
RNA isolation from patient samples. Specimens placed in RNAlater solution 
(Life Technologies) were stored at –70°C prior to RNA extraction. RNA 
isolation was performed using a Qiagen Homogenizer II and an RNeasy Kit 
(Qiagen). Reagents were from Qiagen unless otherwise indicated. Tissue 
was removed from RNAlater, placed in a 2-ml microfuge tube with lysis 
buffer, and homogenized. Total RNA was prepared using the RNeasy Plus 
Mini Kit (Qiagen) according to the manufacturer’s protocol. A total 500 
ng of RNA was reverse transcribed into complementary DNA, using Super-
Script II Reverse Transcriptase and OLIGO(dT) primer mix (Life Technol-
ogies) according to the manufacturers’ instructions.
RNA and protein isolation from in vitro assays. Cells used in coculture exper-
iments were labeled either with CSPG4-IgG-APC (Miltenyi) and CD45-PE-
Cy7 (BD Biosciences) or with CSPG4-IgG-APC, CD45-PE-Cy7, and B cell 
lineage (CD19, CD22)-FITC and sorted using an Aria II (BD Biosciences). 
Cells from the ADCC/ADCP assay were labeled with anti-CD14-PE-Cy7 
or CD89-PE. Sorted cells were resuspended either in RLT buffer for RNA 
isolation following the RNeasy Kit (Qiagen) or in Cell Lysis buffer (Cell 
Signaling) supplemented with 5 mM PMSF for protein isolation.
Western blot. Protein lysates were separated by SDS-PAGE using 4%–15% 
polyacrylamide minigels (Bio-Rad) and transferred onto PVDF mem-
branes using a Bio-Rad Trans-Blot Turbo Transfer system (Bio-Rad). 
Membranes were blocked with 5% skimmed milk in PBS-Tween 20 and 
incubated with rabbit antibodies specific for the unphosphorylated and 
phosphorylated forms of Src, Akt, MEK(1/2), and SHIP-1 (all from Cell 
Signaling) in 1% skimmed milk-PBS-Tween 20 according to manufacturer 
recommendations. Rabbit antibodies were detected with goat anti-rab-
bit-HRP (Cell Signaling) and visualized with the ECL Detection Kit (GE 
Healthcare) on a Hyperfilm (Amersham).
Cell-based ELISA. Tumor cell–reactive antibodies were detected using cell-
based ELISA, as previously described (28). Briefly, A375 tumor cells were 
plated at 3 × 105 to 6 × 105 cells on 96-well flat-bottom tissue culture plates, 
fixed in 0.5% formaldehyde, and stored at –80°C. On the day of the assay, 
plates were thawed, blocked with a 5% skimmed milk/PBS solution for 
2 hours, and incubated with 100 μl of ex vivo culture supernatants, nonspe-
cific IgG (125 μg/100 μl), or tumor-specific IgG1 or IgG4 antibodies (0.05 
μg/100 μl) for 90 minutes at room temperature. Bound tumor cell–reac-
tive antibodies were detected using a mouse anti-human IgG1 (AbD Sero-
tec, 1:400) or mouse anti-human IgG4 (BD Biosciences, 1:250) antibody. 
This was followed by a 45-minute incubation with a goat anti-mouse IgG 
PE-labeled F(ab)′2 Fc-specific antibody (Jackson ImmunoResearch, 1:350). 
Fluorescence intensity depicting tumor cell reactivity was measured on an 
ELISA reader (BMG Labtech; excitation 488 nm, emission 540 nm). All 
samples were in duplicates, and MFIs were corrected against background 
and normalized against the MFI of the isotype control antibody. Antibod-
ies were defined as reactive against tumor cells when the measured MFI was 
2 SDs above the MFI of the specific isotype control antibody.
Quantitative real-time RT-PCR analysis. CD22, mature IgG, IL4, IL10, IFNG, 
and VEGF mRNA expression were assessed by multiplex real-time quanti-
tative RT-PCR using TaqMan Gene Expression Assays (primers and probes, 
Life Technologies) according to the manufacturers’ instructions. Primers 
and probes for the quantification of mature IgG mRNA were designed 
in-house using Primer Express (Life Technologies) as follows: probe, 
sera are associated with poorer survival (Figure 8). Data presented 
here mandate a closer examination of IgG4 antibodies but also of 
IgG3 antibodies, which are also proportionally elevated in tumors 
and possess lower effector cell activatory properties compared with 
IgG1 antibodies (63), as potentially useful biomarkers in tumor 
lesions and/or in the circulation. Additionally, data demonstrat-
ing VEGF and IgG4 production by B cells in the presence of tumor 
cells imply that B cells may be “reeducated” through cross-talk with 
tumor cells and highlight the need to further dissect the mecha-
nisms by which tumors escape humoral immune responses.
In conclusion, we present the first evidence of local IgG4 expres-
sion in melanoma, associated with the IgG4-polarizing cytokines 
IL-10, VEGF, and IL-4. Our data suggest that IgG4 antibodies trig-
gered in the presence of tumor cells participate in local inflam-
mation and may represent one regulatory mechanism by which 
tumors evade immune attack. Studies in larger cohorts of patients 
are required to elucidate associations of IgG4 with immunologi-
cal, molecular, and clinical parameters and patient responses to 
treatments, paving the way for biomarker development and design 
of personalized medicine approaches. Future strategies to coun-
teract IgG4 immunoregulatory pathways or to design antibody 
treatments and derivatives less prone to IgG4 blockade will be 
of potential therapeutic value.
Methods
Patient data and specimen collection. Melanoma tumor skin lesions, lymph 
nodes, and blood were collected from a total of 57 patients diagnosed with 
stage I–IV malignant melanoma (Tables 1–3 and Supplemental Table 1). 
Patients were staged and classified according to the American Joint Com-
mittee on Cancer Melanoma Staging and Classification criteria (64). Sam-
ples were used fresh, or placed in OCT for cryosectioning or in RNAlater 
solution (Life Technologies) and stored at –70°C for subsequent RNA 
extraction, or fixed in formal saline and embedded in paraffin. Discarded 
human skin samples were obtained from 18 volunteers undergoing routine 
plastic surgery. Human peripheral blood lymphocytes (PBLs) and B cells 
were isolated from a cohort of 8 healthy volunteers. Human samples were 
collected with informed written consent, in accordance with the Helsinki 
Declaration, and study design was approved by the Guy’s Research Ethics 
Committee, Guy’s and St. Thomas’ NHS Foundation Trust.
Human cell isolation and ex vivo stimulation assays. Peripheral blood B cells 
from patients with melanoma and healthy volunteers were isolated using 
the B cell enrichment cocktail (Stemcell Technologies) and cultured at a 
density of 500 cells per well (in 96-well plates) in combination with (3,010 
cGy) irradiated autologous PBMCs, Epstein-Barr virus, and the TLR9 ago-
nist CpG 2006, as previously described (28). Single cell suspensions were 
derived from patient tissues (lymph nodes or melanoma skin lesions) 
using a Gentle MACs Tissue Dissociator (Miltenyi) and filtered through a 
100-μm strainer. In ex vivo stimulation experiments, human peripheral 
blood B cells were cocultured for 5 days together with irradiated PBMCs 
and tumor cells at 1:5:10 ratios in RPMI 1640 medium, 10% FCS, 2 mM 
l-glutamine, penicillin (5,000 U/ml), and streptomycin (100 μg/ml) (all 
Life Technologies) (65). Primary human monocytes from patients with 
melanoma were obtained using the monocyte enrichment cocktail (Stem-
cell Technologies) according to the manufacturer’s instructions (66).
Cell culture and reagents. Cell lines were obtained from ATCC. Media for 
maintaining the melanoma cell lines were as follows: DMEM, 10% FCS 
for A375 (CRL-1619) and A-2058 (CRL-11147); McCoy’s medium, 10% 
FCS for G-361 (CRL-1424); MEM, 10% FCS for WM-115 (CRL-1675) and 
SK-MEL-28 (HTB-72); and Iscove’s modified Dulbecco’s medium, 20% 
FCS for Malme-3M (HTB-64). Primary human melanocytes (PCS-2000-
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Luminex bead array analysis. Luminex Bead Array Assay Kits, Milliplex for 
cytokines (Millipore) or Bioplex for IgG subclasses (Bio-Rad), were used 
according to the manufactures instructions, and data were acquired and 
analyzed using a FlexMap3 (Luminex Cooperation) or Bio-Plex200 (Lumi-
nex Cooperation), respectively.
Production of human anti-CSPG4 antibodies. The cDNA of the heavy and 
light chain variable regions directed against the human CSPG4, a cell sur-
face antigen expressed by >80% of malignant melanomas, were derived 
from previously published variable region sequences of the murine mAb 
225.28S (68–70), and antibodies were subsequently cloned and produced 
in an method analogous to that previously described (71).
Flow cytometric and ImageStream evaluations of antibody binding. For assess-
ment of antibody binding to CSPG4 on a panel of human melanoma cell 
lines (A375, A-2058, G-361, WM-115, SK-MEL-28, Malme-3M), primary 
human melanocytes, U937 monocytes, or human primary monocytes, cells 
were incubated with 10 μg/ml mAbs for 30 minutes at 4°C, followed by 
2 washes in PBS with 5% normal goat serum (FACS buffer). Cells were then 
treated with goat anti-human IgG (Fab′)2-FITC antibody or goat anti-hu-
man IgG1-PE (10 μg/ml) (Jackson ImmunoResearch) for 30 minutes at 
4°C and washed in FACS buffer prior to acquisition and analysis on a 
FACSCanto flow cytometer (BD Biosciences) or ImageStreamX (Amnis 
Corporation). For ImageStreamX, quantitative analyses are based on the 
acquisition of 20,000 cell events, and MFIs were measured and calculated 
using an object mask to detect surface staining only.
Cytotoxicity/phagocytosis (ADCC/ADCP) assays. Antibody-dependent cell-
mediated killing of CSPG4-expressing cells by anti-CSPG4 antibodies was 
quantified by a 3-color flow cytometric ADCC/ADCP assay, as previously 
described (72). Briefly, A375 melanoma cells were stained 24 hours prior 
to assays with 5.0 μM CFSE (5-[and 6-] carboxyfluorescein diacetate suc-
cinimidyl ester, Life Technologies) in PBS for 10 minutes at 37°C; washed 
in DMEM medium, 10% FCS, 2 mM l-glutamine; and returned to stan-
dard culture conditions. The following day, CFSE-labeled tumor cells were 
washed and then mixed with human monocytes at an E/T cell ratio of 2:1, 
with or without (5 μg/ml) antibodies, followed by a 3 hours incubation at 
37°C. Cells were then washed in PBS with 2% normal goat serum (FACS 
buffer), incubated for 30 minutes with a mouse anti-human CD89 PE (BD 
Biosciences), washed again in FACS buffer, and resuspended in PBS sup-
plemented with DAPI (Life Technologies). All assay conditions were tested 
in triplicates and replicated in 6 independent experiments using peripheral 
blood monocytes derived from 6 patients with stage II melanoma.
Assessments of receptor function were conducted using blocking anti-
bodies: mouse anti-human FcγRI (Biolegend); mouse anti-human FcγRII 
(Abcam); and mouse anti-human FcγRIII (Abcam), which have been pre-
viously described to block the antibody Fc-mediated functions of differ-
ent FcγR family members (73–75). Blocking experiments with specific or 
nonspecific IgG4 antibodies were conducted using a 3:1 (IgG4/IgG1) ratio.
Samples were acquired immediately using a FACSCanto flow cytometer 
(BD Biosciences). For event acquisition and analysis, CFSE-labeled tumor 
cells were detected in FITC (530/30-nm band-pass filter and a 502-nm 
long-pass filter), CD89-PE-labeled primary monocytes were detected in 
PE (585/42-nm band-pass filter and a 556-nm long-pass filter), and DAPI+ 
dead cells were detected in Pacific Blue (345/20-nm band-pass filter) 
channels, while control samples were set for compensation adjustments 
between CFSE and PE. Two dual-color flow cytometric dot plots were gen-
erated to calculate ADCC and ADCP, as previously described (66, 72, 76).
Assessments of antibodies in a subcutaneous human melanoma model in NOD/
SCID/Il2rg–/– mice engrafted with human immune cells. Male and female NOD/
SCID/Il2rg–/– mice (NOD.cg-Prkdc SCID Il2rg tm1Wjl /SzJ [NSG]; The 
Jackson Laboratory) were used at between 6 and 10 weeks of age. Mice were 
maintained under specific pathogen–free conditions and handled in accor-
5′ FAM-CATCGGTCTTCCCC-MGB 3′; J segment primer, 5′ ACCCTGGT-
CACCGTCTCCTCA 3′; mature IgG reverse primer, TGCAGCAGCGGGT-
CAAG). For each sample, mRNA abundance was normalized against the 
amount of human GAPDH mRNA (VIC) for the cytokine TaqMan Gene 
Expression Assays or against β2-microglobulin mRNA (VIC) for CD22 
and mature IgG mRNA. Data analysis was performed using either a ΔCt 
method, comparing it to an arbitrary number, or a ΔΔCt method, compar-
ing it to freshly isolated cells from blood. Results were expressed as relative 
mRNA expression units or ΔΔCt.
Immunohistochemical evaluations of frozen tissue specimens. Freshly frozen tis-
sue sections embedded in OCT were cut at 4-μm to 8-μm thickness using 
a cryostat (Leica), and sections were air dried and stored at –80°C until 
further use. Prior to staining, slides were equilibrated at room temperature 
for 10 minutes, followed by fixation in acetone for 20 minutes. Sections 
were then air dried and stained using standard operation procedures for 
immunohistochemistry and immunofluorescence using the following 
commercial antibodies: mouse anti-human CD22 mAb (eBioscience); goat 
anti-human IgG (DakoGlostrup); mouse anti-human IgG4 (BD Biosci-
ences); mouse anti-human CD64 (Biolegend); mouse anti-human CD32 
(Abcam); mouse anti-human CD16 (Abcam); goat anti-mouse IgG, biotiny-
lated (DAKO); and rabbit anti-human S100. Subsequently, antibodies were 
detected with the VECTOR Red Alkaline Phosphatase Substrate Kit (Vec-
tor Labs) or with donkey anti-mouse Alexa Fluor 555 and donkey anti-goat 
Alexa Fluor 488 (both Life Technologies). Images were captured using a 
Zeiss Axio Observer.Z1/ Axiophot microscope using AxioVision (×10, ×20, 
and ×63 magnification lenses, Carl Zeiss).
Immunohistochemical evaluations of paraffin-embedded tissue specimens. Paraf-
fin sections were cut at 6-μm thickness on a microtome (Leica) and dried 
overnight at 60°C. Prior to staining, sections were deparaffinized with a 
20-minute incubation in Xylene and then rehydrated by serial incubations 
in alcohol. Heat-induced antigen retrieval was performed in a 95°C water 
bath, using citric acid. Subsequently, sections were stained using standard 
operation procedures for immunohistochemistry with the following com-
mercial antibodies: mouse anti-human CD22 (Abcam); rabbit anti-human 
FoxP3 (eBioscience); mouse anti-human CD45 (eBioscience); and mouse 
anti-human IgG4 (BD Biosciences). Antibodies were detected with goat/
rabbit anti-mouse IgG-biotinylated (DAKO) and visualized using the 
VECTOR Red Alkaline Phosphatase Substrate Kit, including Levamisole 
(Vector Labs). All sections were mounted in DPX mounting solution and 
analyzed on a Zeiss Axiophot microscope using ×10 and ×20 magnification 
lenses (Carl Zeiss) and NIS-Elements imaging software (Nikon).
IgG subclass ELISA. Immunoglobulin subclasses produced in cell culture 
supernatants were measured using an IgG1-, IgG2-, IgG3-, and IgG4- 
specific ELISA. Capture antibodies were from AbD Serotec (IgG1 and IgG3) 
and BD Biosciences (IgG2 and IgG4). Certified Reference Material 470 
(67) (ERM-DA470, Institute for Reference Materials and Measurements) 
was used as the standard to quantify Ig subclass. Maxisorp 96-well plates 
were coated with mouse anti-human IgG1, IgG2, IgG3, or IgG4 antibodies 
in carbonate-bi-carbonate buffer (0.2 M, pH 9.4) overnight, and plates 
were blocked for 1 hour with 2% nonfat milk and PBS-Tween 20. Plates 
were incubated with culture supernatants diluted 1:1 in 50% RPMI media, 
50% PBS, 0.025% Tween 20 for 3 hours, and subclass antibody binding 
was detected with goat anti-human IgG F(ab′)2-HRP incubated for 2 hours 
(Jackson ImmunoResearch), followed by a color reaction with 0.5 mg/ml 
o-phenylenediamine dihydrochloride substrate (Sigma-Aldrich) in perox-
ide substrate buffer (Pierce). Reactions were stopped with the addition of 
1 M HCl. Optical density values were measured at 492 nm (reference wave-
length: 650 nm). Standard curve fitting was performed using Graphpad 
Prism software (Graphpad) with a 4-parameter curve fit using a minimum 
of 6 points on the standard curve.
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dance with the Institutional Committees on Animal Welfare of the UK 
Home Office (The Home Office Animals Scientific Procedures Act, 1986). 
NSG mice were injected subcutaneously with 5 × 105 A375 melanoma cells 
in 150 μl PBS. On day 5, mice received intravenous injections of 10 × 106 
human PBLs (derived from whole human blood by lysis of red blood cells) 
and 10 mg/kg of antibody. Subsequent injections of antibody treatments 
were given 3 times on days 12, 18, and 25 at doses of 10 mg/kg each in 150 μl 
PBS. A control group was treated with 10 × 106 human PBLs on day 5 and 
injected with 150 μl of PBS on days 12, 18, and 25. Tumor growth was 
monitored and measured using calipers. Tumor size (mm3) was calculated 
using the following formula: mm3 = d2 × (D/2), where d stands for the small 
diameter of tumor and D stands for the large diameter of tumor.
Experiments were terminated once the first animal was measured with 
a subcutaneous tumor size no greater than 750 mm3. Spleen engraftment 
of 40%–70% human CD45+ cells was confirmed by flow cytometry for all 
experiments (Supplemental Figure 5).
NanoSPECT/CT imaging of anti-CSPG4 antibody in vivo. NSG mice were 
injected subcutaneously with 5 × 105 A375 tumor cells on day 0. On day 5 
mice were injected intravenously with 10 × 106 human PBLs. Spleen 
engraftment was analyzed as above (Supplemental Figure 5). Anti-CSPG4 
IgG4 (7 mg) was conjugated with the bifunctional chelator CHX-A”-DTPA 
prior to experiments, and on day 24, the antibody was radiolabeled with 20 
MBq of Indium-111 (St. Thomas’ and Guy’s Trust, KCL, London, Radio-
pharmacy) and administered intravenously at 10 mg/kg as above. Images 
were captured under anesthesia after 20 minutes, 8 hours, and 24 hours 
using a NanoSPECT/CT preclinical imager (Bioscan) equipped with a 
multipinhole (9 pinholes; aperture 1.0 mm) collimator and reconstructed 
using the Invivoscope software (Bioscan).
Statistics. Comparative quantitative PCR analyses in human skin specimens 
were conducted using a Kruskal-Wallis analysis with a Dunn post-hoc test. 
Comparative analyses of immunohistochemical staining were performed 
using a Mann-Whitney U test. One-way ANOVA with Bonferroni post-hoc 
test was used to compare ADCC/ADCP of tumor cells by human monocytes, 
triggered by antibodies. Two-way ANOVA with Bonferroni post-hoc test was 
used to compare restriction of tumor cell growth in vivo. For correlation and 
patient survival analyses, Spearman and Mantel-Cox analyses were applied. 
All statistical analyses were performed using GraphPad Prism software (ver-
sion 5.03, GraphPad). Error bars in all in vitro figures represent SD. Error 
bars in all in vivo figures and histological analyses represent SEM.
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Supplementary Figure 1: Immunohisochemical analysis of CD22+ (left) and IgG4 (right), cells (shown 
in red and indicated by arrows) in healthy skin, primary and metastatic melanoma lesions. 
Counterstaining in hematoxylin (blue; Scale bar: 100 μm, magnification 10x). 
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Supplementary Figure 3: (A) Cytokines secreted in culture supernatants of B cells and PBMCs 
stimulated with or without A375 melanoma tumour cells were analysed by Luminex bead array 
analysis. Titres of VEGF, IL-6 and MCP-1, but not of IFN, were significantly increased in cultures 
treated with tumour cells (*** P<0.001; ns = not significant P>0.05, analysed by using Mann-Withney-U-
test, n=9). (B) Flow cytometric sorting strategy to isolate A375 tumor cells and PBMCs from co-culture 
experiments; purified cells were used to examine cytokine expression in Figure 3D and expression of 
cytokines by PBMC in these cultures is depicted in (C). (D) Flow cytometric sorting strategy to isolate B 
cells from co-culture experiments described in Figure 3F. 




Supplementary Figure 4 
Supplementary Figure 4: Immunohistochemical analysis of FcγR distribution was conducted using 
fresh-frozen sections of human melanoma lesions and visualized using AP (in red). Representative 
images demonstrate all three families of FcγRs, i.e. FcγRI (CD64), FcγRII (CD32) and FcγRIII (CD16) 
widely expressed in melanoma lesions. Main images were captured at 10x magnification (scale bars: 
100 mm); magnified images were captured at 20x (scale bars: 50 mm). 
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Supplementary Figure 5: (A) Design of in vivo model in NOD/scid/ IL-2Rγ-/- mice to determine 
antibody-mediated effector functions. (B) Engraftment of human CD45+ immune cells in mouse 
spleens, evaluated by flow cytometry showed no significant difference in human CD45+ engraftment 
across treatment groups. (C) Representative flow cytometric gating strategies to identify immune cell 
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Supplementary  Figure 6 
Supplementary Figure 6: Patient distribution based on % IgG4\IgGtotal; black dashed line indicates the 
75 percentile, used as cut off point for cumulative survival analysis (Figure 8).   
Downloaded on June 22, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/65579
Patient ID Gender Age Stage TNM 
M282 F 43 IB T2a;N0;M0 
M285 M 82 IIA T2b;N0;M0 
M286 F 68 IIB T4a;N0;M0 
M287 F 62 IIIA T2a;N1a;M0 
M338 M 72 IIIB Tx;N2c;M0 
M385 M 67 IIIC Tx;N3;M0 
M380 M 41 IIB T4a;N0;M0 
M381 M 57 IB T1b;N0;M0 
M386 F 64 IIIB Tx;N2c;M0 
M394 M 56 IIB T4a;N0;M0 
M396 M 73 IIC T4b;N0;M0 
M397 F 70 IIB T3b;N0;M0 
M401 F 60 IIIA T2a;N1a;M0 
M402 M 50 IIIB Tx;N1b;M0 
M404 F 65 IB T2b;N0;M0 
M405 M 51 IIC T4b;N0;M0 
M408 F 71 IB T1a;N0;M0 
M409 F 78 IIA T3a;N0;M0 
M430 F 78 IIC T4b;N0;M0 
M433 F 48 IIIB T3b;N2c;M0 
M435 M 45 IB T2a;N0;M0 
M437 M 46 IIA T3a;N0;M0 
M438 F 62 IIA T2b;N0;M0 
M443 M 69 IB T2a;N0;M0 
M318 M 60 IB T2a;N0;M0 
M320 F 71 IIB T3b;N0;M0 
M247 F 37 IV T3b;N0;M1c 
M224 F 76 IIB T3b;N0;M0 
M223 M 35 IB T2a;N0;M0 
Supplementary Table 1: Clinical parameters and disease staging of 
peripheral blood donors used for ex vivo B cell cultures at the time of 
sampling (Figures 2 and 3). 
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Approximately 20% of individuals diagnosed with malignant melanoma at early stage
go on to develop metastases, yet current serum and histopathological evaluators can-
not predict the risk of disease recurrence. Presently, it is difficult to predict which
patients will develop metastatic disease and this contributes to malignant melanoma
still remaining a lethal skin cancer despite emerging targeted therapies [Hodi et al.,
2010, Chapman et al., 2011, Wolchok et al., 2013]. Prognosis still relies on histo-
logical evaluation of the primary lesion including Breslow thickness, ulceration and
mitotic rate, together with sentinel node involvement, all requiring surgical interven-
tions [de Vries et al., 2011]. Whilst sentinel node biopsy has been demonstrated to
provide valuable prognostic information, around 80% of patients have a negative test
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and may develop complications of as a result of surgery [de Vries et al., 2006,Morton
et al., 2006]. Hence, alternative non-invasive biomarkers would be highly valuable
for early disease. Serum readouts such as S-100B and melanoma-inhibitory activity
(MIA) have demonstrated some value in predicting poor outcomes; yet, the only
serological marker recommended in the American Joint Committee on Cancer guide-
lines is lactate dehydrogenase (LDH). LDH is the only serum marker routinely used
in the clinical management of patients with melanoma [Balch et al., 2009]. Elevated
LDH levels indicate active cell necrosis, normally associated with increased disease
burden occurring in advanced stages [Tandler et al., 2012]. Hence, novel early dis-
ease prognostic serum biomarkers are needed to stratify patients who are most likely
to recur and who may benefit from early interventions [Gogas et al., 2009]. More-
over, as emerging immune checkpoint blockade therapies may depend on patients’
immunological status, identification of biomarkers associated with immunosuppres-
sion could inform treatments. Insights into pathogenic roles of IgG4 in inflammatory
diseases and also in cancers, such as pancreatic cancer, extrahepatic cholangiocarci-
nomas, squamous cell carcinomas and melanomas [Daveau et al., 1977,Harada et al.,
2012, Strehl et al., 2011], include the presence of IgG4
+ immune cell infiltrates, ele-
vated or dysregulated IgG4 serum levels and associations with regulatory elements
in tumour microenvironments. Additionally, findings presented in Chapter 3 demon-
strate not only the presence of IgG4 infiltrating cells in melanoma tumours, but
also functional contributions of IgG4 in promoting tumour progression by impairing
anti-tumoural immunity. Importantly, preliminary assessments of IgG4 in sera from
patients with melanoma reported in Chapter 3 reveal correlations of higher IgG4
serum levels with less favorable patient survival. Taken together, these data man-
date a closer examination of the clinical significance of this antibody subclass and
its relevance to prognosis in melanoma, ultimately leading to an assessment of IgG4
as a disease biomarker.
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4.2 IgG4 serum levels predict the risk of disease pro-
gression
Collection of melanoma patient sera and healthy volunteer sera was conducted at a
South London melanoma clinic between 2000 and 2012. Samples were anonymised
prior to handling and examined for IgG4 levels (IgG4/IgGtotal). Additionally, 80 sera
previously collected from patients with stage I-II breast cancer were kindly provided
by Prof. Ian S. Fentiman (Guy’s Hospital), Prof. Joyce Taylor-Papadimitriou and
Prof. Joy Burchell (KCL) and were included in this study. Subsequently collected
samples were assayed for IgG4 levels using a Luminex bead array assay. Collected
data were linked to patient information and analysed (Figure 4.1).
Melanoma Breast Cancer Healthy Volunteer
Mean age
(SD)
60 (17) 59 (8) 55 (19)
Sex
Male (%) 85 (49.70) 0 (0) 42 (40.40)
Female (%) 86 (50.30) 80 (100) 62 (59.60)
Disease Stage
I 36 46 NA
II 48 34 NA
III 49 0 NA
IV 38 0 NA
Table 4.1: Baseline characteristics of patients and healthy volunteer cohort. SD: standard
deviation; NA: not applicable
The analysis of 265 cancer patient (171 melanomas; 80 breast cancers) and 104
healthy volunteer sera (patient baseline characteristics described in Table 4.1), re-
vealed statistically significantly elevated serum IgG4 levels in melanoma (median
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Figure 4.1: Flow diagram depicting study and experimental design as well as collection
and processing of clinical samples(*:Researchers working on this study were blinded to
prevent bias; **: Two independent medical professionals not involved in the quantification
of IgG4 or LDH evaluated patient information; ***: Patients with co-morbidities that may
influence IgG4 levels were excluded from the analysis)
0.031; 95%[CI] 0.036-0.051) compared with IgG4 levels in healthy sera (median 0.017;
95%[CI] 0.026-0.042; P<0.05), (Figure 4.2). In contrast, serum IgG4 levels in breast
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cancer (median 0.013; 95%[CI] 0.012-0.030) were not significantly elevated compared
to those in healthy sera (P<0.05).
Figure 4.2: Sera from patients with melanoma (n=171) and breast cancer (n=80) were
analyzed for circulating IgG4 serum levels and compared to sera from healthy volunteers
(n=104). IgG4 levels in the melanoma patient cohort were statistically significantly in-
creased compared to IgG4 levels in healthy volunteer sera, whilst IgG4 levels in breast
carcinoma sera were not elevated in comparison to those in healthy sera, indicating that
IgG4 may be relevant in melanoma but not in breast carcinomas (Kruskal-Wallis one-way
analysis of variance with post-hoc Dunn’s test; lines represent medians and error bars
indicate interquartile range; *P<0.05).
In order to evaluate IgG4 as a prognostic tool, sera from 162 patients with melanoma
were further analysed. From the original cohort of 171, 6 patients were excluded as
they did not attend follow-up appointments and 3 patients were excluded due to
subsequent diagnosis of other carcinomas which may have affected IgG4 serum lev-
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els. Patients were segregated into those with stable disease (SD, neither progressive
disease nor subsequent relapse during study period) and those with progressive dis-
ease (PD, either active progressing disease or subsequent relapse patients who were
up-staged during study period). Here, receiver operating characteristic (ROC) and
area under the curve (AUC) analyses were performed [Baker, 2003]. Patients with
stable disease (SD) (median 0.023; 95%[CI] 0.026-0.040) displayed significantly lower
serum IgG4 levels (median 0.023; 95%[CI] 0.026-0.040) compared with those who de-
veloped progressive disease (PD) (median 0.039; 95%[CI] 0.039-0.066) (P<0.01). A
mean AUC of 0.64 (P=0.0021), 57.14% sensitivity (95%[CI] 45.35-68.37) and 67.78%
specificity (95%[CI] 57.10-77.25), demonstrated the value of IgG4 as a prognostic
marker (Figure 4.3).
Since LDH is the only clinically-used serum biomarker to predict metastatic disease,
the potential of IgG4 and LDH to predict the risk of progression-free survival (PFS)
and overall survival (OS) was next evaluated in the same patient serum samples.
Based on ROC analysis, a threshold of 0.034 for IgG4 levels was calculated via the
Youden’s Index [YOUDEN, 1950] (n=90 in IgG4low, <0.034; n=72 in IgG4high,
≥0.034). For LDH, samples were segregated into normal (240-480 mmol/l, n=137)
and abnormal (>480 mmol/l, n=19) concentrations. These cutoffs were subsequently
used to compare patient serum IgG4 and LDH hazard ratios (HR) for the risk of
progression-free survival (PFS) and overall survival (OS). Kaplan-Meier Curve eval-
uations revealed statistically significantly worse PFS (HR 95%[CI] 2.56 (1.58-4.17);
log-rank P=0.0001) and lower OS (HR 95%[CI] 2.54 (1.43-4.54); log-rank P=0.0015)
in the IgG4high group compared to the IgG4low group (Figure 4.4, left). The age-
and sex-adjusted HR to predict the risk for PD in the IgG4high group of patients
across all disease stages (I-IV) was 2.23 (95%[CI] 1.36-3.64) (Table 4.2). Patients with
abnormal LDH levels (n=19) had lower PFS (HR 95%[CI] 5.60 (15.19-106.2); log-
rank P<0.0001) and lower OS (HR 95%[CI] 5.34 (11.11-101.50); log-rank P<0.0001)
compared to those in the LDH normal group (Figure 4.4, right). The adjusted HR
for PD across all stages in the abnormal LDH group was 6.48 (95%[CI] 3.68-11.37)
(Table 4.2). These data support the value of serum LDH and IgG4 in prognosis of
disease outcomes in melanoma.
In stages I-III, each serum marker, IgG4high and abnormal LDH, independently
predicted the risk for PD (IgG4: HR 95%[CI] 4.01 (1.98-8.11); LDH: HR 95%[CI]
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6.65 (2.49-17.72)). However, in regional disease (stages I-II) IgG4 had a statistically
significant (HR 95%[CI] 4.60 (1.73-12.23) for predicting PD, whereas serum LDH was
not statistically significant (Table 4.2; ; patient baseline clinical characteristics and
correlations with serum IgG4 and LDH levels are described in Table 4.3 and Table
4.4, respectively). Thus, while these data confirms the prognostic value of LDH
in metastatic disease stages only, IgG4 serum levels provide significant prognostic
information in earlier stages (I-II).
Stage I–II Stage I–III Stage I–IV




<0.034 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
≥0.034 4.60 (1.73–12.23) 4.01 (1.90–8.11) 2.23 (1.36–3.64)
AUC (95% [CI]) 0.68 (0.55–0.81) 0.68 (0.58–0.77) 0.64 (0.66–0.72)
P-Value 0.01 0.001 0.002
LDH (mmol/L) n=74 n=119 n=156
240–480 1.00 (Ref) 1.00 (Ref) 1.00 (Ref)
≥480 non significant∗ 6.65 (2.49–17.72) 6.48 (3.68–11.37)
ˆ: Age and sex adjusted Hazard Ratio (HR) and 95% Confidence Intervals (CI) for risk of
disease progression. Ref: reference value; * non significant as no HR could be calculated
due to sample size distribution; calculated values: 13.61 95% [CI] 1.22–151.61
Table 4.2: IgG4 hazard ratio prediction calculation. IgG4 had a significant HR to predict
the risk of disease progression overall (combined stages I–IV) as well as in subgroups
(stages I–II; stages I–III) (P<0.01). In contrast, LDH had a more significant HR to predict
the risk of disease progression overall (combined stages I–IV) as well as in the subgroup
including patients with lymph node metastasis (stages I–III), but failed to show statistical
significance in the early disease patient group (stagesI-II). The analysis of this data was
performed by Dr. Mieke Van Hemelrijck (KCL)
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Figure 4.3: Comparative IgG4 serum level analysis among melanoma patients with subse-
quent stable (SD; n=90) or progressive disease (PD; n=72) demonstrates increased IgG4
levels in patients with subsequent PD compared to patients with SD during the study
(as D’Agostino’s K-square test for normality did not pass, statistical significance was cal-
culated using the Mann-Whitney-U-test (**P<0.01))(upper panel). Receiver Operating
Characteristic (ROC) analysis was performed to assess the potential of IgG4 serum levels
to predict the risk for disease progression. The calculated mean AUC= 0.64 and P=0.0021
indicate that IgG4 can predict the risk of melanoma progression (lower panel).
4.2. IgG4 serum levels predict the risk of disease progression 141
Figure 4.4: Evaluatation of progression free survival (PFS) and overall survival (OS) in a
melanoma cohort. Based on ROC analysis, a threshold value of 0.034 for IgG4 (calculated
via the Youden’s Index) was used to compare patient serum IgG4 and LDH (hazard ratios
(HR) for the risk of progression free survival (PFS) and overall survival (OS)). The cohort
was analyzed using multivariate analysis. For LDH, samples were segregated into normal
(240-480 mmol/l) and abnormal (>480 mmol/l) concentrations. Top row: Kaplan-Meier
Curve evaluations of progression free survival (PFS) for IgG4 (HR 95%[CI] 2.56 (1.58-
4.17); log-rank P=0.0001) and PFS for LDH (HR 95%[CI] 5.60 (15.19-106.20); log-rank
P<0.0001) (n=154 patient sera) confirm that patients with low IgG4 serum levels have an
increased PFS compared to patients with high IgG4 levels. Bottom row: Kaplan-Meier
Curves of (OS) for IgG4 (HR 95%[CI] 2.54 (1.43-4.54); log-rank P=0.0015) and OS for
LDH (HR 95%[CI] 5.34 (11.11-101.50); log-rank P<0.0001) (n=154 patients in both IgG4
and LDH cohorts), demonstrating that elevated IgG4 levels are associated with worse OS
and could predict the risk of disease progression.
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4.3 Circulating IgG4+ B cells predict the risk of dis-
ease progression in early stages of melanoma
Since serum IgG4 levels were predictive of the risk of disease progression in ear-
lier stages of melanoma, the presence of corresponding circulating IgG4
+ B cells
in patients and healthy volunteers was next examined. Increased frequencies of
IgG4
+ B cells in peripheral blood mononuclear cells (PBMC) of melanoma pa-
tients compared to those from healthy volunteers were investigated by flow cy-
tometry (Figure 4.5).Flow cytometric analyses were performed using an antibody
cocktail to the markers CD45, CD22, CD19, CD3, CD14 and IgG4 (Figure 4.5). Af-
ter dead cells were excluded, the frequencies of circulating IgG4
+ peripheral blood
B cells (IgG4
+CD45+CD22+CD19+CD3−CD14−) in peripheral blood mononuclear
cells (PBMC) of melanoma patients were compared to those from healthy volunteers
(Figure 4.5, bottom panel for representative flow cytometric dot plots used to draw
comparisons between a healthy volunteer and a patient sample).
The proportion of IgG4
+ cells in the peripheral blood B cell (CD45+CD22+CD19+
CD3−CD14−) compartment of melanoma patients (n=47) (median 0.50; 95%[CI]
0.47-0.73) was significantly elevated, (median 0.50; 95%[CI] 0.47-0.73) compared to
that of healthy volunteers’ (n=24) (median 0.2; 95%[CI] 0.13-0.37) (Mann-Whitney-
U-test; P<0.001) (Figure 4.6, top). Furthermore, statistically significantly higher
circulating IgG4
+ B cell frequencies in stage I-II (median 0.50; 95%[CI] 0.44-0.72)
(P<0.001) (n=24) and stage III-IV (median 0.40; 95%[CI] 0.41-0.89) (P<0.01) (n=23)
disease were measured when compared with IgG4
+ B cell frequencies in healthy vol-
unteer bloods (median 0.2; 95%[CI] 0.13-0.37) (n=24) (Kruskal-Wallis one-way anal-
ysis of variance with post-hoc Dunn’s test) (Figure 4.6, bottom). These data are
consistent with previous reports of dysregulated humoral immunity in melanoma,
IgG4-mediated immune suppression reported in Chapter 3 and also with the serum
IgG4 findings described Section 4.2 above. The frequencies of circulating IgG4
+ B
cells from patients with melanoma diagnosed at different disease stages were fur-
ther analyzed to examine whether they can predict the risk of disease progression
(Mann-Whitney-U-test; significance was indicated where appropriate; lines represent
medians and error bars indicate interquartile range) (Figure 4.7) along with corre-
sponding ROC analysis. As with circulating IgG4 levels, increased IgG4
+ B cells
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Figure 4.5: Representative flow cytometric dot plots and gating strategy for evaluation of
the circulating IgG4
+ B cell compartment. Lymphoid cells were gated according to their
FSC-A and SSC-A properties, viable CD45+ were selected and cell doublets excluded using
FSC-A and FSC-H dot plots. CD3−CD14− cells were selected and subsequently the B cell
compartment was identified as CD19+CD22+ cells (first row). Representative dot plots
depicting IgG4
+ (CD45+CD22+CD19+CD3−CD14−) peripheral B cells from PBMCs of a
healthy volunteer (left) and of a melanoma patient (right) are shown in the lower panel.
were predictive of the risk of disease progression in regional disease. In the stage
I-II patient cohort, patients with stable disease had a statistically significantly lower
frequency of IgG4
+ B cells compared with patients who developed progressive disease
(stages I-II; AUC=0.81; P=0.014; (median of SD 0.30; 95%[CI] 0.17-0.56 vs. median
of PD 0.70; 95%[CI] 0.50-0.95 )). There were no statistically significant differences
between SD and PD patient groups in stages I-III; (AUC=0.54; P=0.64; (median of
SD 0.30; 95%[CI] 0.28-0.66 vs. median of PD 0.50; 95%[CI] 0.29-0.86 ) and in stages
I-IV (; AUC=0.54; P=0.64; (median of SD 0.30; 95%[CI] 0.30-0.69 vs. median of
PD 0.50; 95%[CI] 0.35-0.82 )) (Figure 4.7).
Taken together, these data suggest that, similarly to elevated serum IgG4 levels being
prognostic at early stage (I-II) disease, the IgG4
+ B cell compartment is elevated in
the circulation of patients with melanoma and these elevated IgG4
+ B cell frequencies
are predictive of the risk of disease progression. These findings further support the
value of IgG4 as a promising biomarker in melanoma.
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Figure 4.6: Top: Frequency of the IgG4
+ peripheral B cell
(CD45+CD22+CD19+CD3−CD14−) compartment was compared between 24 healthy
control and 47 melanoma patient samples, showing a statistically significant increase
in the patient group (Mann-Whitney-U-test; *** P<0.001); Bottom: Patient samples
were stratified by disease stage (I-IV) and compared with a healthy volunteer cohort
(Kruskal-Wallis one-way analysis of variance with post-hoc Dunn’s test). IgG4
+ B cell
frequencies were statistically different between stage I-II (n=24; ***P<0.001) or stage
III-IV (n=23; **P<0.01) in comparison to B cells from healthy volunteers. Lines represent
medians and error bars indicate interquartile range.
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Figure 4.7: Frequency of circulating IgG4
+ B cells from patients with melanoma diagnosed
at different disease stages were analyzed to examine whether they can predict the risk
of disease progression (Mann-Whitney-U-test; *P<0.05; lines represent medians and error
bars indicate interquartile range). Corresponding ROC analysis is depicted directly next
to each column graph. In the stage I-II patient cohort, patients with stable disease had
a statistically significantly lower frequency of IgG4
+ B cells compared to patients with
progressive disease (*P<0.05; top panel). For this cohort, a median AUC of 0.81 calculated
by ROC analysis further demonstrating the validity of the marker.
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4.4 IgG4 expression in tumours
In order to evaluate whether elevated serum IgG4 and circulating IgG4
+ B cells in
melanoma were also reflected by tumour IgG4
+ cell infiltration immunohistochemical
analysis of tissue microarrays (n=256) for the presence of IgG4
+ cells was conducted
(Figure 4.8).
IgG4
+ cell infiltration was detected in melanoma tumours and it was higher in
melanoma skin lesions (n=108), melanoma lymph node metastases (n=56) and dis-
tant organ metastases (n=60) when compared to healthy skin (n=32) specimens.
IgG4 expression was detected in 42.60% (19.45% high positivity) of melanoma skin
lesions, 21.40% (8.90% high positivity) of lymph node metastases and 30% (10%
high positivity) of distant metastases. Low-grade positivity was found in 12.25% of
healthy skin specimens (n=32) (Figure 4.9). Similarly, IgG4
+ cells infiltrates were
observed across disease stages (stage I-II: 39.43% (16.90% high; 22.53% low); stage
III-IV: 40% (6.67% high; 33.33% low)) and in skin tumour lesions of different thick-
nesses (T1-T2: 38.88% (33.33% high; 5.55% low); T3: 37.29% (27.29% high; 10%
low); T4: 46.03% (15.87% high; 15.87% low)) (Figure 4.9, bottom panel). These
findings may signify, suggesting that IgG4-attributed immunosuppression may occur
throughout malignant disease and irrespective of skin tumour thickness.
These promising data suggest the merit of further analyses to correlate tissue IgG4
+
infiltrates with disease outcomes to assess the clinical relevance of IgG4 as a histo-
logical biomarker.
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IgG4<0.034 IgG4≥0.034
(n=90) (n=72)
Mean age (SD) 57 (18) 64 (15)
Sex
Male (%) 40 (44.44) 41 (56.94)
Female (%) 50 (55.56) 31 (43.06)
Mean Breslow (SD) 2.68 (2.42) 3.20 (2.10)
Disease Stage (%)
I 27 (30.00) 9 (12.50)
II 19 (21.11) 23 (31.94)
III 23 (25.56) 23 (31.94)
IV 21 (23.33) 17 (23.61)
Ulceration (%)
None 53 (58.89) 28 (38.89)
Present 19 (21.11) 28 (38.89)
Unknown 18 (20.00) 16 (17.78)
SD: Standard deviation
Table 4.3: Baseline clinical characteristics of melanoma patient cohort and correlations
with serum IgG4 levels
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Figure 4.8: Representative images of IgG4 staining on tissue microarray sections (IgG4 is
stained by alkaline phosphatase in red, counterstaining in hematoxylin in blue).
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Figure 4.9: Evaluation of TMA sections showed more frequent IgG4
+ cell infiltration in
melanoma tissues when compared to healthy discarded skin, and infiltration found in early
and metastatic skin lesions (Pie charts represent % of total numbers).
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LDH (240–480) LDH >480
(n=137) (n=19)
Mean age (SD) 60 (17) 62 (14)
Sex
Male (%) 68 (49.64) 11 (57.89)
Female (%) 69 (50.36) 8 (42.11)
Mean Breslow (SD) 2.88 (2.27) 2.73 (2.10)
Disease Stage (%)
I 34 (24.82) 0 (0)
II 39 (28.47) 1 (5.26)
III 41 (29.93) 4 (21.05)
IV 23 (16.79) 14 (73.68)
Ulceration (%)
None 73 (52.90) 5 (26.32)
Present 38 (27.54) 7 (36.84)
Unknown 27 (19.56) 7 (36.84)
SD: Standard deviation
Table 4.4: Baseline clinical characteristics of melanoma patient cohort and correlations
with serum LDH levels
4.5. Conclusions 151
4.5 Conclusions
Taken together, these findings identify the prognostic value of IgG4 in early stage
melanoma (I-II). In agreement with previous reports [Hofmann et al., 2009,Hofmann
et al., 2011, Kluger et al., 2011], the data presented here demonstrate that LDH is
an independent predictor with specificity in metastatic melanoma, but lacks pre-
dictive value in local disease (stage I-II). This may be because LDH serum levels
are proportional to cell necrosis, not commonly present in patients with low disease
burden, and this is supported here by observed baseline LDH readouts at early dis-
ease stages (I-II) (Table 4.2). A drawback for the use of LDH release as a marker of
melanoma progression is the presence of serum LDH as a result of other diseases such
as hemolysis, hepatitis, myocardial infarction or infection. Thus, abnormal serum
LDH levels are not exclusive to neoplasia, but may indicate underlying pathologies
such as hemolysis, hepatitis, myocardial infarction or infection, yielding false-positive
results in melanoma [Vereecken et al., 2012]. Similarly, elevated serum IgG4 is de-
scribed in autoimmune pancreatitis, indicating that IgG4 may also be influenced by
biological mechanisms unrelated to malignancy [Kawa et al., 2012], albeit for a subset
of patients. This issue needs to be further investigated in future studies evaluating
the clinical utility of serum IgG4 as a biomarker in melanoma. Elevated levels of
serum IgG4 in melanoma could predict the risk of disease progression for patients at
early disease stages (I-II), and these data were also supported by the significance of
an elevated IgG+ B cell subset in predicting the risk of disease progression at the
same early stages of disease (I-II). Taken together, these findings not only support
the relevance of serum IgG4 as a promising biomarker in early disease, but may also
signify the presence of an IgG4-biased mature memory B cell compartment in pa-
tient circulation. This suggests that temporal and memory IgG4-biased immunity is
an early indicator of active immunosuppressive mechanisms associated with worse
prognosis and lends support to recent evidence of IgG4 antibodies contributing to
the impairment of effective immunity against melanoma. Additionally, the presence
of a prominent IgG4
+ cell infiltrate in melanoma tumours across patient tumours,
tumour thickness and stages of disease indicates that potential immunosuppressive
mechanisms are present and most likely active in melanoma at the peripheral and
local levels. Although immunohistochemical evaluations demonstrated IgG4
+ cell
infiltration in melanoma tumours, it was not possible to associate these infiltrates
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with patient history or clinical outcome information. However, the findings man-
date further examination of IgG4 as a tissue biomarker in future studies, correlating
these IgG4
+ cell infiltrates with other immunohistochemical parameters such as ul-
ceration, mitotic rate and potentially other known markers such as S-100B as well
as with patient information. In summary, data presented in this Chapter provide
the rationale for future evaluations of IgG4 and potentially other immunoregula-
tory components of the humoral response as prognostic indicators in melanoma and
possibly other malignant diseases. In support of this notion, humoral immune com-
ponents, including circulating antibodies, are emerging biomarkers for autoimmune,
inflammatory, allergic and malignant diseases, strengthened by recent reporting of
”immunosignaturing”’ a method which predicates that monitoring antibodies could
prove more sensitive than screening for specific antigens in early disease [Maecker
et al., 2010, Gilbert et al., 2011, Sykes et al., 2013]. IgG4, here reported to be in-
dicating immunosuppressive mechanisms in melanoma, and to be elevated in the
circulation of patients with worse prognosis, is a promising prognostic factor at early
stages, where standard markers like LDH lack sensitivity. Larger prospective studies
analyzing IgG4 and LDH will ascertain the clinical significance of IgG4 and pave the
way for improved patient stratification and therapy.
5 IGG1 AND IGE ANTIBODIES
AGAINST CSPG4: INVESTIGATING A
NEW THERAPEUTIC APPROACH
5.1 Introduction
Findings presented in this thesis provide evidence that IgG4 can impair the cytotoxic
properties of IgG1 antibodies in melanoma (Chapter 3), suggesting that therapeutic
antibodies of the IgG1 class may be partly prevented from engaging Fcγ receptors on
immune effector cells in tumours and may consequently be less effective in activating
these cells to kill cancer cells. This chapter aims to investigate a strategy to design
a therapeutic antibody of a class other than IgG that may be less prone to IgG4
blockade mechanisms. Previous literature demonstrates that antibodies engineered
with Fc regions of the IgE class may trigger highly effective Fc-mediated functions
against cancer cells and might be superior to those triggered by the equivalent IgG1
antibodies (Chapter 1, Section 1.7). The rationale for designing an antibody of the
IgE class to treat melanoma tumours is also based on a number of reasons:
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a) Melanoma tumours are known to comprise substantial immune cell infiltrating
components, and the recent clinical success of checkpoint blockade antibody strate-
gies such as ipilimumab (Chapter 1, Section 1.6) indicate that immune responses
can be successfully activated against cancer cells by targeted immunotherapies [Hodi
et al., 2010]. Yet, there are presently no antibodies in clinical use that directly tar-
get antigens expressed on melanoma tumour cells. Therefore, designing a tumour
antigen-specific antibody that could direct effective immune responses specifically
against melanoma cells may be highly desirable.
b) IgE mediates effector functions by activating a distinct set of cognate receptors
(FcRI and FcRII) on immune effector cells (monocytes, mast cells, eosinophils etc)
different to those recognised by IgG Fc. Therefore, an antibody with Fc regions of
the IgE class may not be subject to the Fc receptor blockade mechanisms mediated
by IgG4 as IgG4 Fc may compete with IgG1 Fc for FcγRI binding and immune cell
activation (Chapter 3).
c) FcR-bearing immune effector cells naturally reside in the skin and certain types
like monocytes/macrophages and mast cells are also present in melanoma. IgE se-
questered into tissue binds with very high affinity to these Fc receptors on potent
immune effector cells. These cells retain the antibody through strong IgE Fc-FcR
interactions resulting in antibody half-life in tissues longer than that of IgG (Chap-
ter 1, section 1.7) [Gould et al., 2003, Clynes et al., 2000, Geha et al., 1985]. IgE
antibodies naturally exert immune effector functions in tissues, including the skin,
and these functions are reported to occur in Th2-biased inflammatory environments,
normally found in tumours, including melanomas.
d) The rationale for studying antibodies of different classes originates from a number
of studies dating back over two decades that suggest that antibodies of the IgE class
may hold promise for the treatment of solid tumours. This concept has not been
tested in melanoma [Kershaw et al., 1996, Jensen-Jarolim et al., 2008]. Therefore,
designing melanoma-specific antibodies of the IgE class may be of interest for the de-
velopment and testing of potentially more efficacious therapeutics for the treatment
of melanoma. Based on the above, the potency of an IgE antibody directed against a
melanoma associated antigen (the melanoma associated antigen CSPG4 discussed in
Chapter 1, section 1.6.8) is a worthwhile novel endeavour. The melanoma-associated
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antigen CSPG4 was discovered three decades ago. Its expression was initially thought
to be limited to melanocytes, endothelial cells and pericytes. However continuous
evaluation of this antigen revealed that it is also expressed on the interfollicular
epidermis, the basal layer of normal oral mucosa, chondrocytes in normal and os-
teoarthritic adult articular cartilage, smooth muscle cells, angiomyolipomas, differen-
tiated myofibers of the sarcolemma and neuromuscular junction of human postnatal
skeletal muscle, microglial and mesangial cells of the renal glomerulus. The anti-
gen is also over-expressed in a number of other malignancies such as mesotheliomas,
triple negative breast cancer squamous cell carcinomas of the head and neck, and
glioblastomas [Campoli et al., 2010,Wang et al., 2010a,Rivera et al., 2012]. The most
notable expression of CSPG4 has been shown in stem-like cells of the inter-follicular
epidermis of the skin, lower levels of expression by human melanocytes have been
reported. However, loss of CSPG4 was found to be not lethal, as knock-out mice
for the mouse homologue of CSPG4 survived [Price et al., 2011]. Expression of
CSPG4 is also linked to numerous signaling pathways that support tumour growth,
adhesion, migration and which support tumour progression and metastasis (Chapter
1, Section 1.6.8), making it a suitable therapeutic target. Indeed, CSPG4-targeted
therapies and immunotherapies, including those utilising antibodies have been tested
in patients with melanoma, with some success and without overt toxicities [Campoli
et al., 2010, Ferrone et al., 1993, Kang et al., 2000, Siccardi et al., 1986]. Therefore
harnessing the potent immune activatory potential of IgE class antibodies directed
against tumour-associated antigens merits investigation, especially in Th2 biased mi-
croenvironments such as those of melanoma tumours, as this may result in effective
immune responses against this difficult to treat malignancy.
5.2 Generation of chimeric anti-CSPG4-specific an-
tibodies
For this study, the variable region sequences of the mouse monoclonal antibody clone
225.28s were selected, these were originally published in 1996 by Neri et al. [Neri
et al., 1996]. The original 225.28s clone was derived by hybridoma technology in
mice and showed efficacy against tumour growth in a number of in vitro and in vivo
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models [Ferrone et al., 1993,Hafner et al., 2005b]. Furthermore, a toxin-conjugated
F(ab)2 derivative of this clone reached clinical testing [Imai et al., 1983]. However, to
date no molecule of this specificity has been engineered into a chimeric or humanised
recombinant format. This modification is important as the mouse antibody clone
suffers from two obvious disadvantages: a) mouse sequences are expected to induce
HAMA responses in patients, resulting in neutralisation of the antibody and rapid
clearance from the circulation, thereby significantly reducing any efficacy against
tumour cells, and b) an antibody with Fc regions of mouse origin cannot be used in
patients as it will not effectively recognise Fc receptors expressed by human immune
effector cells and therefore it is not expected to effectively recruit these cells to
target and kill tumour cells by mechanisms such as cytotoxicity and/or phagocytosis.
With the exception of an antibody obtained by phage display technology, which
did not progress further than preliminary functional evaluations, there does not
appear to be any human or chimeric antibody specific for CSPG4 in preclinical
or clinical evaluation at present, and therefore the potential therapeutic relevance of
a recombinant antibody (with matched heavy and light chains) against this antigen
has not yet been fully examined.
5.2.1 Engineering IgG and IgE antibodies of known melanoma
antigenic specificity
In order to engineer antibodies using defined variable heavy and light chains of known
melanoma tumour specificity, the matched sequences of heavy and light chains were
cloned into a single vector system designed at KCL. Vector design is reported in the
PhD thesis of Dr. Tihomir Dodev (KCL, 2013). The single vector incorporating the
antibody heavy and kappa light chains is depicted in (Figure 5.1), and features two
different promoters which take into account that at least twice as many light chains
to heavy chains are need for expression and production of recombinant antibodies.
To investigate the role of IgG1 and IgE antibody classes, dedicated vectors with Fc-
and Fcγ constant heavy and light chain regions were designed.
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Figure 5.1: Heavy and light variable region sequences of the melanoma antigen CSPG4-
specific antibody clone 225.28s derived by immunising mice with melanoma tumour cell
lysates, as previously published [Neri et al., 1996]. Murine heavy (VH) and κ (Vκ) regions
cDNA and translated protein sequences are depicted.
5.2.2 Generation and initial testing of anti-CSPG4 IgG and IgE
antibodies
The variable sequences of antibody clone 225.28s were inserted into the human IgG1
and IgE heavy and kappa light chain vectors (Figure 5.2) and these were used to
transfect competent HEK293F cells. Supernatants were collected after 4 weeks and
antibodies were purified using affinity columns as described in the PhD thesis of Dr.
T Dodev; KCL, 2013.
The biophysical properties of the two engineered chimeric antibodies were tested by
SDS polyacrylamide gel electrophoresis under non-reduced and reduced conditions
and by HPLC size-exclusion chromatography analysis (kindly provided by Dr. T.
Dodev). In these assays, the newly engineered antibodies were directly addition-
ally compared to previously produced antibodies engineered as IgG1 and IgE class
molecules with variable domains recognising the tumour-associated antigen FRα,
which is expressed by a number of solid tumours including ovarian cancer. The IgG1
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antibody was also compared to clinical-grade trastuzumab (Herceptin®), a human-
ised IgG1 antibody in clinical use for the treatment of HER2/neu-expressing breast
cancers [Hudis, 2007]. SDS-PAGE chromatography demonstrated that both CPSG4
IgE and IgG1 antibodies were of the same molecular weight as the isotype control.
HPLC analysis confirmed that both antibodies are monomeric of (>95% purity) and
only minimum aggregation was detected for both purified antibodies (Figure 5.3).
5.2.3 Binding of antibodies to tumour cells and FcR-expressing
immune effector cells
The capacity of the engineered antibodies to recognise their target antigens and Fc
receptors on immune effector cells was next examined. Interactions of anti-CSPG4
antibodies with A375 tumour cells were analysed by immunofluorescence and flow cy-
tometry. Both anti-CSPG4 IgE and IgG1 chimeric antibodies recognized the CSPG4
antigen on A375 melanoma cells since each bound to >99. % of melanoma cells
as demonstrated by flow cytometry. The antibodies also bound to Fc receptors on
monocytic cells (Figure 5.4).
The IgE antibody bound to cells of the monocytic cell line U937, which also express
both IgE receptors, FcRI and FcRII (CD23) at low densities and also to FcR-
expressing human primary monocytes (Figure 5.5).
As expected, the IgG1 antibody also bound to U937 cells which are known to express
FcγRI and FcγRII and to FcγR-expressing primary human monocytes (Figure 5.4).
We further confirmed the specific binding of the chimeric CSPG4 IgE and IgG1
antibodies to the surface of the A375 tumour cells by immunofluorescence microscopy,
while a hapten-specific isotype control IgE antibody (NIP IgE) and a human IgG1
antibody isotype control (MOv18 IgG1) for CSPG4 IgG1 did not show binding above
background. Counterstain was performed using DAPI (Figure 5.6).
In conclusion, the two chimeric antibodies of known specificity were engineered with
human Fc regions of the IgE and IgG1 classes, and these antibodies recognised the
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CSPG4 tumour-associated antigen on tumour cells and bound through their Fc re-
gions to immune effector cells.
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Figure 5.2: A) Schematic representations of the heavy and light chain cloned into the
pVitro vector design for cloning and expression of IgG and IgE antibodies. B) Schematic
representation of the design of an IgE antibody: the variable heavy and light chains of
IgG1 (left, regions indicated with stars) were inserted into the epsilon heavy chain regions
of IgE and the epsilon heavy chain was combined with the kappa light chain domains to
produce the corresponding IgE antibody (right). The resulting engineered IgE molecule
should recognise the same antigenic epitope and be bound by IgE receptors. Glycosylation
sites are depicted by black circles (adopted from [Karagiannis et al., 2009]).
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Figure 5.3: Biophysical characterisation of the engineered CSPG4 melanoma antigen-
specific IgG1 (top) and IgE (bottom) antibodies. Nonreduced (left) and reduced (middle)
SDS polyacrylamide gel electrophoresis of CSPG4 IgE (bottom) and IgG1 (top) protein
products, compared with the previously-characterised chimeric antibodies MOv18 IgE and
trastuzumab IgG1. Size-exclusion chromatography analysis of purified CSPG4 IgE and
IgG1 antibodies compared to purified chimeric human MOv18 IgE and trastuzumab IgG1
(right). Figure courtesy of Dr Tihomir Dodev, KCL.
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Figure 5.4: Flow cytometric histograms showing CSPG4-IgE and CSPG4-IgG1 binding. A)
Binding of CSPG4 IgG (left) and CSPG4 IgE (right) to A375 melanoma tumour cells. B)
Binding of CSPG4 IgG1 (left) and CSPG4 IgE (right) to U937 monocytic cells. Detection
of the primary antibody was performed with goat anti-human IgG or goat anti-human IgE
(both in grey), respectively.
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Figure 5.5: Flow cytometric histograms showing CSPG4 IgG1 and CSPG4 IgE binding
on primary monocytes. Detection of the primary antibody was performed with goat anti-
human IgG or goat anti-human IgE (both in grey), respectively.
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Figure 5.6: Immunofluorescence staining confirming binding of CSPG4 IgE and CSPG4
IgG1 antibodies to A375 melanoma tumour cells. The depicted isotype control a hapten
specific IgE antibody (NIP IgE). Antibodies bound to tumour cells were detected using
a goat anti-human IgE-FITC or IgG-FITC antibody. Counterstain was performed using
DAPI. Images were captured using a 63x oil objective. Scale bar = 20 µm.
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5.2.4 Distribution of CSPG4 in human skin and in melanoma
recognised by the engineered antibody
To evaluate the specificity of this engineered antibody clone, a human tissue microar-
ray comprising of 221 melanoma tumour specimens and 16 healthy skin specimens
were stained with purified and directly biotinylated CSPG4 IgE antibody. Reactivity
with specimens was detected by alkaline phosphatase, which produced a pink/red
colour for CSPG4-expressing cells, allowing the distinction between CSPG4 expres-
sion and melanin in pigmented melanoma lesions (Figure 5.7).
Immunohistological evaluations confirmed high levels of expression of CSPG4 in cu-
taneous melanomas, with a total of 93.66% of melanoma lesions testing positive for
CSPG4 (17.72% high; 37.97% intermediate; 37.97% low positivity). Further evalu-
ations of disease-involved lymph nodes demonstrated that 85.72% were positive in
total (25.00% high; 42.86% intermediate; 17.86% low positivity). Moreover, 72.72%
(10.40% high; 25.97% intermediate; 36.36% low positivity) of distant site metastases
specimens, such as those of the colon, oesophagus and liver expressed CSPG4. Ad-
ditionally, CSPG4 expression was detected in different disease stages and also in
cutaneous lesions of different thicknesses (T2-4) (Figure 5.7). These findings indi-
cate that CSPG4 may be considered as a target for therapy for most patients with
melanoma. These data are also in concordance with previous reports, demonstrating
overexpression of CSPG4 across different disease stages [Campoli et al., 2010]. In
contrast to expression by tumour lesions, expression of low level CSPG4 was ob-
served in 6.25% of human skin specimens. Thus, tissue microarray (TMA) data
demonstrates that this engineered antibody clone (CSPG4 IgE) can recognise its
target antigen on patient-derived lesions and that the target epitope is accessible in
tissue metastases and throughout different disease stages in patient tumours. Fur-
thermore, data presented here confirm enhanced expression of CSPG4 in melanoma
compared to healthy skin specimens, confirming previously published reports.
5.3. Functional properties of engineered antibodies 166
Figure 5.7: Evaluation CSPG4 detected by the anti-CSPG4 IgE antibody in patient
melanoma lesions, diseased lymph nodes, distant organ metastases and healthy skin
(n=228). The sections are part of tissue microarrays (BioMax®) and detection was con-
ducted using immunohistochemistry (alkaline phosphatase in red, counterstaining with
hematoxylin in blue). A) Representative images of melanoma skin and lymph node spec-
imens. B) Evaluation of the TMA sections showing that melanoma related samples have
higher expression of CSPG4 compared to healthy skin.
5.3 Functional properties of engineered antibodies
Following engineering and specificity evaluations of the chimeric antibodies, it was
essential to examine whether these antibodies were: a) functionally active once they
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engaged the antigen on tumour cells, and/or b) capable of activating immune effector
cells by signalling through their Fc receptors. Moreover, it was reasonable to ask
whether recognition of the target epitope of the antigen on the surface of tumour
cells contributes or is necessary for any anti-tumoural functions these agents may
confer. The subsequent section discusses the functional properties of the engineered
antibodies using established in vitro functional assays.
5.3.1 Direct anti-CSPG4 antibody-mediated effects on tumour
cells in vitro
A non-immunological mechanism by which therapeutic antibodies work is the direct
induction or inhibition of essential downstream signals related to the specific epi-
tope of this target antigen. Antibody-antigen engagement may trigger downstream
signaling cascades that may eventually lead to tumour cell death. The potential of
anti-CSPG4 antibodies to trigger direct tumour cell death or anti-proliferative events
in the absence of effector cells was investigated by employing a cell viability assay
(MTS). With this assay, the potential of the engineered antibodies to directly me-
diate reduction of A375 melanoma tumour cell proliferation in vitro was examined.
Cell viability of cells cultured with different antibodies was measured after 24 and
72 hours. Neither anti-CSPG4 IgE nor IgG1 appeared to restrict cell proliferation
after 24 hours (CSPG4 IgE: 100.3% (SD: 2.4); CSPG4 IgG1: 102.1% (SD: 10.5)),
compared to equivalent isotype control antibodies of the same classes (MOv18 IgE:
102.8% (SD: 6.5); MOv18 IgG1: 107% (SD: 4.4)) or compared to trastuzumab IgG1
(105% (SD: 5.8)). Decreased cell proliferation was measured after 72 hours in cells
incubated with trastuzumab IgG1 (18% (SD: 3.6)). This confirmed the known func-
tion of trastuzumab in restricting proliferation of HER2/neu-expressing tumour cells
over time, and this was expected since A375 melanoma cells express moderate levels
of the target antigen for this antibody (Figure 5.8).
However, cell viabilities for the anti-CSPG4 IgE (120.0% (SD: 8.3)) anti-CSPG4 IgG1
(114.9% (SD: 7.5)) as well as the isotype controls (MOv18 IgE: 102.4% (SD: 9.2)
and MOv18 IgG1 131% (SD: 11.4)) appeared similar, leading to the conclusion that
under these culture conditions, antibodies recognising CSPG4 did not induce any
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Figure 5.8: A) Light gray: Expression of Her2/neu antigen on A375 tumour cells. Dark
gray: Expression of CSPG4 on A375 tumour cells. Unstained histogram represents isotype
control. B) MTS cell viability assay examining potential direct effects of the anti-CSPG4
antibodies on melanoma tumour cell proliferation. Effects on proliferation were compared
with those of trastuzumab (IgG1), which is known to reduce tumour cell proliferation.
anti-proliferative effects against melanoma tumour cells (Figure 5.8). This shows
that A375 tumour cells were not susceptible to direct anti-proliferative effects by
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anti-CSPG4 antibodies, while trastuzumab IgG1 exerted an anti-proliferative effect
on these cells over a period of 72 hours.
5.3.2 Engaging the FcRI receptors on effector cells by anti-
bodies
5.3.2.1 Ability of IgE to engage FcRI and trigger mast cell degranulation
The functional properties of IgE in engaging FcRI on the surface of mast cells to
trigger effector cell activation and to induce a functional degranulation were firstly
examined. The engineered anti-CSPG4 IgE antibody could trigger functional degran-
ulation through recognition of human high affinity IgE (FcRI) receptors together
with cross-linking of these FcRI receptors on the surface of effector cells, a process
normally not triggered by antibody alone, but which can take place when FcRI
is cross-linked by antibody-multivalent antigen complexes on the surface of effector
cells. These experiments made use of the rat basophilic leukaemia mast cell line RBL
SX-38, which was transfected to express the human FcRI. This assay is normally
used as a functional readout to confirm IgE antibody functional capacity and to
evaluate potency. Degranulation was measured by β-hexosaminidase release, depict-
ing mast cell activation (Figure 5.9). Because degranulation requires cross-linking
of antibody on the surface of mast cells, mast cells alone 0.0% (SD: 3.54) or mast
cells incubated with anti-CSPG4 IgE antibody only (0.6% (SD: 10.03) did not po-
tentiate β-hexosaminidase release. As expected, mast cell lysis yielded high levels
of stored β-hexosaminidase enzyme (Triton-X, 100% (SD: 12.58)). On the contrary,
the CSPG4 IgE antibody induced significant degranulation of RBL SX-38 cells fol-
lowing stimulation with a polyclonal anti-human IgE antibody (25.44% (SD: 3.41))
which could cross-link FcRIs on the cell surface. The CSPG4 IgE antibody could
also activate RBL SX-38 cells in an antigen-dependent manner through cross-linking
of cell surface bound IgEs by the CSPG4-expressing A375 melanoma cells when
added to effector cells in this assay (39.40% (SD: 3.82)). The control antibody NIP
IgE could also activate RBL SX-38 cells when added with a polyclonal anti-human
IgE antibody (21.31% (SD: 5.75) while minimal degranulation was observed with
NIP IgE antibody alone (0.0% (SD: 8.74). These data show that the anti-CSPG4
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IgE can function by cross-linking the Fc-receptor via polyclonal antibodies and via
multivalent antigen engagement, leading to mast cell activation, degranulation, and
potential cytotoxic activity which could be directed against cancer cells in tumours
where mast cells may reside.
Figure 5.9: Effect of CSPG4 IgE cross-linking the human FcRI on RBL SX-38 mast cell
leads to degranulation. CSPG4 IgE was cross-linked with a polyclonal anti-human IgE
antibody to confirm its degranulation activity. Degranulation was detected by measuring
β-hexosaminidase release into the culture supernatant.
5.3.2.2 Antibody-dependent cell-mediated tumour killing mechanisms
To investigate cell-dependent mechanisms (ADCC and ADCP) mediated by anti-
CSPG4 IgE and IgG1 antibodies, a three-colour flow cytometric assay measuring
tumour killing (Chapter 2 Section 2.12.2) was employed. In this set of experi-
ments, U937 monocytic cells or primary monocytes were used as effector cells and
the CSPG4-expressing A375 metastatic melanoma cells as tumour targets. The as-
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say was modified from the one previously published and adapted for the purpose of
this experiment [Bracher et al., 2007]. CFSE, a green fluorescent intracellular dye,
was used to label A375 tumour cells prior to incubation with U937 monocytic cells
or primary monocytes (isolated by RosetteSep Monocytes purification kit) in the
presence or absence of antibodies. After the incubation period (3 hours), U937 cells
or monocytes were labelled with anti-CD89 PE. Before acquisition and analysis by
flow cytometry, these mixed cell cultures were also incubated with DAPI, which was
subsequently used to identify dead cells. Quantification of the flow cytometric data
(as described in Figure 2.3) demonstrated that after 3 hours in culture, the anti-
CSPG4 IgG1 antibody mediated significant levels of tumour cell death, mostly me-
diated through ADCP, against A375 tumour cells by monocytic U937 cells. Tumour
killing was mediated by ADCP (30.93%) for anti-CSPG4 IgG1 compared to tumour
cell death measured for samples incubated with the control FRα-specific chimeric
MOv18 IgG1 antibody (15.40%) or with cells incubated with no antibody (8.26%)
(p<0.001, One-way ANOVA, with modified Bonferroni post-test; Figure 5.10). On
the other hand, anti-CSPG4 IgE triggered significant levels of melanoma cell death,
mostly through ADCC (ADCC: 27.02% for anti-CSPG4 IgE; 5.34% for MOv18 IgE;
6.07% with no antibody (p<0.001 Figure 5.10). Incubation with anti-CSPG4 IgE
induced only minimal tumour cell ADCP compared to those incubated with control
MOv18 IgE (6.65% vs. 7.78%; p<0.001, One-way ANOVA, with modified Bonferroni
post-test; Figure 5.10).
Moreover, employing the ADCP/ADCC assay and using patient-derived (stage II
melanoma, n=9) primary monocytes as effector cells, both anti-CSPG4 IgE (ADCP
20.97% (anti-CSPG4 IgE); 13.50% (MOv18 IgE); 4.42% (no antibody); p<0.01 Fig-
ure 5.10) and anti-CSPG4 IgG1 (ADCP: 42.70% (anti-CSPG4 IgG1); 12.10% (MOv18
IgG1); 5.68% (no antibody); p<0.001 Figure 5.10) antibodies induced tumour cell
killing by monocytes in vitro. These data demonstrate that both anti-CSPG4 anti-
bodies can activate human monocytic cells as well as patient-derived monocytes and
they can direct anti-tumoural functions. The findings suggest that, given appropri-
ate stimuli, patient immune effector cell mechanisms retain the potential to mount
effective responses against cancer cells.
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Figure 5.10: Quantification of ADCC/ADCP assay confirmed that anti-CSPG4 IgG1 and
anti-CSPG4 IgE mediated significant ADCP and ADCC of A375 tumour cells by U937
monocytic cells (top panel, n=4). Quantification of ADCC/ADCP assay confirmed that
anti-CSPG4 IgG1 and anti-CSPG4 IgE mediated significant ADCP and ADCC of A375
tumour cells by primary monocytes (bottom panel, n=9). Cytotoxicity: dark grey bars;
phagocytosis: light grey bars. Results are means ± SD. (*p<0.05; **p<0.01; ***p<0.001;
ns: p>0.05).
5.4 In vivo functional assays to study antibody effi-
cacy for cancer therapy
Ultimately, all potential therapeutics must be tested for their efficacy using relevant
in vivo models. It is therefore desirable to design and validate novel translational
5.4. In vivo functional assays to study antibody efficacy for cancer
therapy 173
assays in order to examine the potential therapeutic efficacy of these agents. In the
context of developing translational strategies to examine immune effector-mediated
functions of antibodies, in vivo models, which can demonstrate these functions are
needed. Hence, developing in vivo systems with human immune system components
can be informative; such as mice humanised for the expression of human Fc recep-
tors; or mouse models amenable to engraftment of human immune cells. Additionally,
in vivo models akin to the patient disease setting, which may feature patient-derived
tumours or patient immune cell components, can provide key information on thera-
peutic benefits in a patient setting and can contribute to the translational significance
of a candidate therapeutic. This section describes the establishment and application
of two humanised mouse models of human melanoma that permit investigations of
IgG and IgE class antibody efficacy.
5.4.1 Establishment of a human melanoma xenograft model
in NOD/SCID γ-/- mice to study efficacy of antibodies for
cancer therapy
An immunodeficient mouse model strain NOD/SCID γ-/- mice (NOD.Cg-Prkdcscid
Il2rgtm1Wjl/SzJ), lacking T-, B- and NK cells was chosen as their immune system
can be reconstituted with human immune cells in spleens and circulation, allowing
the investigation of therapeutics in the context of human immunity [Ali et al., 2012].
A375 human melanoma cells (doses 0, 1x104, 1x105, 5x105, or 1x106 tumour cells per
challenge) were injected subcutaneously in the flank of the mice, and tumour growth
was monitored over time (Figure 5.4.1) by calliper measurements as described in
Chapter 2 (Section 2.13.2).
Tumours were measured until they reached a maximum of 750mm3 in size. In pilot
experiments, tumours grew exponentially up to 750mm3 over a period of 4 weeks in
a reproducible manner (Figure 5.4.1), two representative experiments, n=4 and n=5
mice per tumour challenge dose). A tumour cell challenge of 5x105 melanoma cells
per mouse resulted in reproducible tumour growth over a period of 4 weeks and this
dose was used in subsequent experiments. Moreover, introduction of peripheral blood
mononuclear (PBL) cell into this system did naturally result in significant tumour
5.4. In vivo functional assays to study antibody efficacy for cancer
therapy 174
Figure 5.11: Establishment of a subcutaneous melanoma tumour model using A375
metastatic melanoma cells injected on day 0 into NOD/SCID γ-/- mice. Top left: n=4
mice per condition (tumour cells only); Top right: confirmation of initial experiments with
n=5 mice per condition (tumour cells only) Bottom left: Comparison between animals
with/without engraftment of human peripheral blood leukocytes (PBL). Bottom right: il-
lustration of subcutaneous tumour in NOD/SCID γ-/- (**p<0.01). The y-axis respresents
tumour volume in mm3.
growth restriction compared to engraftment of the tumour cells alone. This finding is
expected, as the PBL are not HLA matched with the tumour cells and will therefore
induce, to some extend, an immunological response (Figure 5.4.1). Tumours were ex-
cised and embedded in paraffin for further macroscopic and microscopic observation
of tumour growth and tumour-associated antigen CSPG4 expression by the xenograft
was assessed by immunofluorescence staining. These evaluations confirmed that the
tumour-associated antigen CSPG4 is expressed in subcutaneous melanoma tumours
grown in NOD/SCID γ-/-mice (Figure 5.12).
5.4. In vivo functional assays to study antibody efficacy for cancer
therapy 175
Figure 5.12: Immunofluorescence analysis of subcutaneous tumour model of A375
metastatic melanoma cells. Sections were stained for expression of the melanoma marker
CSPG4 (left) and mouse IgG isotype control antibody (right). Images were captured using
a 10x objective. Scale bar = 150 µm.
Expression of CSPG4 antigen confirms that the A375 melanoma xenograft model may
be used to evaluate the therapeutic potential of monoclonal antibodies recognising
this antigen. Investigation of splenic engraftment in this xenograft model (Day 30)
revealed that the animals reconstituted with human peripheral blood cells (PBLs)
had a detectable human CD45+ compartment distinct from spleen-resident mouse
CD45+ cell populations. The human immune cell compartment comprised a range of
specialised human immune effector cells such CD3 (T cells), CD22 (B cells), CD14
(monocytes) and CD123 (plasmacytoid dendritic cells or basophilis) (Figure 5.13).
5.4.2 in vivo evaluation of anti-CSPG4 antibodies in a subcu-
taneous melanoma xenograft model
The tumour growth restricting capacities of the engineered human/chimeric anti-
bodies recognising CSPG4 (IgG1 and IgE) were investigated in the above estab-
lished subcutaneous human melanoma xenograft model. Following tumour chal-
lenge and engraftment of human PBLs to provide human effector cells in this sys-
tem, antibodies were administered weekly (Figure 5.13) or fortnightly (p<0.001;
Figure 5.14) at 10 mg/kg doses by the intravenous route. Treatment with weekly
doses of CSPG4 IgE resulted in severely-restricted melanoma tumour growth over
a period of 30 days (p<0.01), while tumours in mice treated with the correspond-
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Figure 5.13: Representative flow cytometric dot plots identifying human immune cell
subsets within the live singlet human CD45+, mouse CD45− population engrafted in
NOD/SCID γ-/- mouse spleens. Top panel: Lymphoid cells were gated according to their
FSC-A and SSC-A properties, viable CD45+ were selected and cell doublets excluded us-
ing FSC-A and FSC-H dot plots, subsequently mouse CD45+ were excluded from human
CD45+. Bottom panels are representative dot blots of engrafted lymphoid cells including
CD3, CD22, CD14, CD27 and CD123 cells indicating that the immune system is partially
present after PBL engraftment.
ing CSPG4 IgG1 antibody were growing significantly larger compared with those
in the IgE antibody-treated animals (p<0.05). The growth of tumours from ani-
mals treated with CSPG4 IgG1 antibody was significantly restricted compared with
those from animals treated with isotype control antibodies MOv18 IgE and IgG1
against the tumour antigen FRα, which is not expressed on A375 melanoma cells
(p<0.05; Figure 5.14). Xenografts given vehicile alone grew exponentially up to
750mm3 over the same time period (data from 2 independent experiments (2 human
PBL donors); n=7 animals per group). These experiments suggest that the tumour
antigen-specific chimeric antibody CSPG4 IgE and to a lesser extent, the antibody
CSPG4 IgG1, demonstrated tumour growth restricting functions in vivo. Moreover,
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dosing fortnightly with CSPG4 IgE resulted in severely restricted melanoma tumour
growth over a period of 30 days compared to controls (p<0.001; Figure 5.14), while
tumours in mice treated with the corresponding CSPG4 IgG1 antibody grew in a
fashion similar to control antibody-treated animals (p<0.05). These findings im-
ply that IgE antibodies retain their tumour growth-restricting properties even when
dosed less frequently than their IgG1 antibody counterparts (Figure 5.14).
Immunohistochemical analysis of the extracted tumours revealed that all groups fea-
tured human CD45 infiltration into tumours, suggesting that human immune cell
engraftment extended beyond the spleen and into the human xenografts, rendering
this model more relevant in the context of studying antibody therapeutic efficacy for
cancer. Interestingly, tumours from CSPG4 IgE-treated animals had statistically sig-
nificantly increased CD45 infiltration (*p<0.05) and CD68 (***p<0.001) infiltration
compared to those treated with PBS alone. Furthermore, localization and distribu-
tion of human immune cell infiltrates appears disparate between controls and IgE:
tumour-associated human CD68+ (macrophage) infiltrates from IgE-treated animals
appeared to be located in cell clusters, potentially indicating differences in chemo-
taxis and function of these cells in response to treatment with IgE. These data are
in line with a previous report of human CD68+ infiltrating cells in a patient-derived
orthotopic model of ovarian carcinoma in mice treated with the chimeric MOv18 IgE
antibody [Karagiannis et al., 2003] (Figures 5.15 and 5.16).
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Figure 5.14: Anti-CSPG4 IgE is restricting tumour growth in subcutaneous melanoma tu-
mour model. A) Design of dosing regime in in vivo model to determine antibody-mediated
effector function. B) Anti-CSPG4 IgE restricts growth of A375 s.c. human melanoma in
the humanised mouse compared to anti-CSPG4 IgG1 (*p<0.05) and non-specific antibody
controls (***p<0.001) when administered intravenously every 7 days following tumour chal-
lenge (4x10 mg/kg doses, n=7). C) Anti-CSPG4 IgE restricts s.c. tumour growth when
administered every 14 days following tumour challenge (2x10 mg/kg doses) while anti-
CSPG4 IgG1 and control antibodies display no tumour-restricting functions (***p<0.001,
n=7).
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Figure 5.16: Evaluation of immune cells infiltration in subcutaneous melanoma tumour
model. A) Human leukocytes (CD45) infiltration is observed in all treatment groups.
Anti-CSPG4 IgE treated animals have a statistically significantly increase of CD45 cells
compared to PBS treated animals. B) Human macrophages (CD68) infiltration is observed
in all treatment groups. Anti-CSPG4 IgE and anti-CSPG4 IgG1 treated animals have
a statistically significant increase compared to PBS treated animals (average number of
3 independent high power fields magnification 10x (HPF); *p<0.05; ***p<0.001; lines
represent mean and error bars standard error).
Analysis of human immune cell populations in the spleens demonstrated comparable
engraftment levels in animals treated with PBS (36.66%), CSPG4 IgE (39.67%),
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CSPG4 IgG (40.96%), MOv18 IgE (37.58%) and MOv18 IgG1 (44.35%) antibodies
(Figure 5.17.
Figure 5.17: Engraftment of human CD45+ immune cells in mouse spleens of NOD/SCID
γ-/- mice, showing no significant difference in human CD45+ engraftment across treatment
groups.
Since immune responses in this model may be partly due to alloimmunity (human
PBLs are not HLA-matched with A375 tumour cells), a novel disease-relevant human
skin tumour engraftment model was developed which featured a human patient-
derived melanoma tumour engrafted with autologous PBLs.
5.4.3 In vivo evaluation of anti-CSPG4 antibodies in a human
tumour transplantation model with autologous PBLs
Human metastatic melanoma lesions (n=3 in independent experiments) derived from
patients with stage III or IV melanoma were transplanted intraperitoneally into
NOD/SCID γ-/- mice and simultaneously engrafted with autologous human lym-
phocytes (PBLs). Quintana and colleagues have recently reported a similar patient-
derived model, and demonstrated correlations between disease progression in animals
with disease outcome of the patient. This might indicate that intrinsic differences
5.4. In vivo functional assays to study antibody efficacy for cancer
therapy 182
in metastatic efficiency among melanoma patient-derived tumours are important de-
terminants of clinical outcome in patients and may be used to mimic natural disease
in animal recipients [Quintana et al., 2012]. An advantage of the patient tumour
xenograft model developed herein lies with the additional reconstitution of the pa-
tient’s immune system component, which was not the case in the study by Quintana
et al. This additional feature permits examination of immunotherapies and antibody
therapeutic candidates in the background of the patient’s immune system which may
include immunoregulatory components; this may provide a better prediction of this
agent’s efficacy as a treatment in patients. Transplanted tumours triggered multiple
disseminated metastases in the lung, liver and spleen of the animals within seven to
nine weeks following tumour implantation in the PBS treated group (Figure 5.18).
Figure 5.18: Human metastatic melanoma lesion derived from a patient with stage III/IV
melanoma was established subcutaneously in NOD/scid/IL-2Rγ-/- mice engrafted with
human lymphocytes (A), which triggers multiple disseminated metastases six weeks follow-
ing tumour implantation (B-E). Treatment with anti-CSPG4 IgE mAb (weekly 10 mg/kg
doses) singificantly prolongs survival compared to untreated controls (Mantel-Cox: p<0.05;
(F)).
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Treatment with CSPG4 IgE at 10 mg/kg weekly doses significantly prolonged survival
of tumour-bearing animals (median survival 57.5 days; hazard ratio 0.35 confidence
interval 0.11-0.90; n=8) compared with those animals treated with PBS (median
survival 42 days; hazard ratio 2.79 confidence interval 1.12-9.46; n=9) (Mantel-Cox:
p<0.05). These data suggest that IgE can prolong survival of mice bearing human
melanomas in the context of patients‘ immune system components.
5.5 Gene expression arrays analysis of tumours
from animals treated with antibodies
To gain early insights into active immune pathways associated with improved ef-
ficacy of IgE antibody treatments, gene expression analyses were performed us-
ing the human melanoma xenografts derived from the different treatment groups
(CSPG4 IgE n=5; CSPG4 IgG1 n=4; PBS n=4). The xenograft samples were re-
trieved at the end of experiments described in section 5.4.2. After assessing for
RNA integrity, Human Ref-6 and Ref-12 BeadChips (Illumina, Ambion) were used
to generate RNA expression data from tumours. Each array contains over 50000
probe sets representing approximately 40000 human genes. Data were background-
subtracted then log-transformed and quantile-normalized. The expression levels were
compared by the limma method (Limma package from the R software), an empir-
ical Bayesian method with a moderated t- statistic implemented in Bioconductor
and the Benjamini-Hochberg method was used to correct for multiple testing. A
gene was considered as differentially expressed if the q-value (false discoveries) was
below 0.02 and fold change (FC) more than 1.2 and less than -1.2 (analysis was
performed by Dr. Chrysanthi Ainali and Mr. Jananan S. Pathmanathan). When
comparing gene expression between tumours from the PBS group versus those from
the CSPG4 IgE-treated group, 797 genes were identified as differentially expressed.
For the PBS versus CSPG4 IgG1-treated group comparisons, 681 genes were found
to be differentially expressed. Interestingly, 665 gene signatures were found to be
common between the CSPG4 IgE and CSPG4 IgG1 treatment groups, but differen-
tially expressed in these tumours when compared to the PBS only treatment group.
Furthermore, 132 genes were differentially expressed in the CSPG4 IgE cohort com-
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pared to all the other groups including the CSPG4 IgG1, but only 16 genes were
specifically differentially expressed in the CSPG4 IgG1 cohort compared to the oth-
ers, including the CSPG4 IgE group (these results were generated by Mr. Jananan
S. Pathmanathan; Figure 5.19). These findings may indicate a notable impact of
CSPG4 IgE when compared to CSPG4 IgG1 and the other treatments in eliciting
immune responses, and these are in line with the improved anti-tumoural functions
of the tumour antigen-specific IgE antibody obsereved in these xenograft models.
Figure 5.19: Gene expression microarrays from melanoma xenografts indicate differential
gene expression profiles associated with anti anti-CSPG4 IgE-treated tumours compared
to those treated with anti-CSPG4 IgG1.
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5.6 Signalling pathway evaluation in vitro expression
and functional validation of differentially expressed
genes
Knowledge of all direct and indirect interactions between proteins in a biological sys-
tem could facilitate the description of cellular mechanisms and functions. Especially
gene expression profiles allow us to detect the activation of distinct genes and to pro-
vide hints into their biological activities by placing their interactions in the context
of larger known networks and signalling pathways in human cells. These evaluations
can lead to the discovery of novel signalling pathways, and importantly, they can
point at the key signalling cascades involved in biological processes or associated
with specific treatments. One useful tool for these analyses, the STRING database,
provides available data on protein-protein interactions, also including lower-quality
data or computational predictions [Franceschini et al., 2013]. The STRING database
was employed in the present study to annotate the differentially expressed genes
identified in the experiments and analyses described in section 5.5. For this pur-
pose, the genes identified as uniquely differentially expressed in tumour specimens
from the CSPG4 IgE treated group compared to others were plotted against one of
the best characterised published downstream IgE signalling pathway cascades (these
gene expression analysis results were generated by Mr. Jananan S. Pathmanathan;
Figure 5.20). From the transcriptomic analyses, it was clear that a number of sig-
nalling molecules which are mapped through STRING analyses as part of the FcR
downstream signalling pathways were also upregulated in the CSPG4 IgE-treated tu-
mours. From the previously-identified group of differentially upregulated genes and
consequential enhanced signalling pathway analyses, the kinase PTK2 (p-value=0.01)
which is connected to FcR signalling is up-regulated in IgE-treated mice and accord-
ingly, it is connected with GSK3B, which is thought to directly interacting with
NFκB1. Therefore, this kinase is indirectly connected with NFκB1 and can regulate
the IgE mediated tumour killing in vitro. It is important to note, that PTK2 is
also indirectly connected with SOS1 (which is under-expressed in our experiments
and involved in FcRI signalling pathway) via NCK2, CRK and FYN. The kinase
was previously described to be involved in the FcRI signalling cascade [Vial et al.,
2000]. To study the validity of the transcriptomic findings, the functional roles of
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PTK2 were then further evaluated in relation to CSPG4 IgE antibody treatment, in
order to confirm not only its role as an important component of IgE-FcRI activatory
cascades in IgE-treated tumours, but also as a step to validate the activation of the
downstream network it belongs to. These data would support that engagement of
tumour antigen-specific IgE antibodies with their FcRs on the surface of immune
effector cells may be part of the activatory network that contributes to IgE-mediated
anti-tumoural function. The role of PTK2 in antibody-mediated anti-tumoural ef-
fects conferred by CSPG4 IgE was then examined using functional in vitro assays.
Firstly, an ADCC/ADCP assay was conducted using human monocytic cells as effec-
tor cells and A375 melanoma cells as targets. As previously demonstrated, CSPG4
IgE in the presence of human monocytic cells triggered 58.5% tumour cell death,
higher than the non-specific isotype control antibody MOv18 IgE (22.15%), or no
antibody (22.32%). In the same experiments, when PTK2 activity was blocked in
human monocytes with the kinase inhibitor PF-431396 prior to the ADCC/ADCP
assay incubations, CSPG4 IgE-mediated tumour cell killing was statistically signif-
icantly inhibited (21.85%) down to levels similar to controls (Figure 5.20). These
findings indicate that treatment with a tumour antigen specific IgE antibody is cru-
cially associated with enhanced downstream signaling through FcRI, which triggers
cell activation and it is directly linked to the tumour killing properties conferred
by this IgE antibody. These data support the findings of the transcriptomic analy-
ses presented in section 5.5, and point to the importance of IgE-FcRI engagement
and the downstream FcRI activatory cascades all participating in triggering IgE
effector functions of monocytes/macrophages by in vitro and in vivo. In addition to
enhanced gene expression, activation of protein kinases such as PTK2 can be ex-
amined by their phosphorylation state. In order to examine PTK2 phosphorylation
in effector cells when engaged with anti-CSPG4 IgE and tumour cells, monocytes
used as effector cells in the ADCC/ADCP assays were isolated by flow cytometric
sorting at the end of assays and phosphorylation of PTK2 in primary monocyte
lysates was studied by western blotting. These experiments indicated that mono-
cytes isolated after incubation with tumour cells and CSPG4 IgE were associated
with higher levels of phosphorylated PTK2 compared to monocytes incubated with
the no antibody. These experiments suggested that phosphorylation of PTK2 was
associated with increased levels of IgE antibody-mediated tumour cell death in a
tumour antigen-specific manner (Figure 5.20).
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Figure 5.20: A) Integrated signalling pathways for Fc receptor designed by data mining
from KEGG and publications including genes that were differentially expressed in the
NSG tumour environment. (in red over-expressed genes while yellow genes correspond
to hypothetical connectors. B) ADCC/ADCP assay measurements confirmed that anti-
gE mediated significant levels of tumour cells killing by U937 monocytic cells. The killing
mediated by IgE was inhibited by the specific PTK2 kinase inhibitor PF-431396, indicating
the relevance of this kinase in the downstream singalling of IgE. C) Protein extracts from
U937 monocytic cells isolated by flow cytometric sorting at the end of a ADCC/ADCP
assay. Examination of phophorylated PTK2 by western blot indicated that monocytic cells
incubated with anti-CSPG4 IgE had enhanced amounts of phosphorylated PTK2 compared
to cell incubated with no antibody.
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5.7 Conclusions
Previous studies have presented substantial in vitro and in vivo evidence that IgE
immunotherapy against cancer may be comparable or even superior to that of IgG1
antibodies and new independent preclinical evidence supports the original findings for
the superior efficacy of IgE cancer immunotherapy in a variety of cancers and model
systems [Daniels et al., 2012,Daniels-Wells et al., 2013,Gould et al., 1999,Karagiannis
et al., 2003,Karagiannis et al., 2007]. However the number of the IgE class candidates
for passive immunotherapy, which are suitable for further clinical translation is lim-
ited, and the concept remains widely unexplored for a number of solid cancers. Up
to now only the anti-folate receptor α specific antibody MOv18-IgE has been tested
in several mouse and rat models for its efficacy and safety ( [Karagiannis et al.,
2007, Karagiannis et al., 2008, Karagiannis et al., 2012]; Josephs KCL PhD thesis).
The data in this chapter show for the first time the relevance of the IgE therapeutic
concept in the context of melanoma using another engineered chimeric IgE antibody
an indication not previously explored with IgE immunotherapy. Anti-CSPG4 IgE
antibody is shown to induce melanoma tumour death in vitro and in two highly-
translational xenograft-bearing humanised mouse models. The anti-CSPG4 IgE a)
could be produced under serum-free conditions at high purity, and these characteris-
tics can help its translation for cancer therapy; b) recognised its target antigen on the
surface of tumour cells and in different melanoma tumour tissues, illustrating that the
epitope is accessible regardless of anatomic location of the tumour and throughout
disease stages; c) the antibody could activate mast cells (RBL-SX38) through cross-
linking of the Fc-receptor by multivalent antigen, triggering mast cell degranulation;
d) the antibody was active in recruiting monocytes to mediate ADCC and ADCP
against tumour cells; and e) IgE showed superiority in humanised animal models
compared to isotype controls and its IgG1 counterpart. Analysis of lesions from dif-
ferent treatment groups revealed that tumour lesions from anti-CSPG4 IgE-treated
animals had enhanced human CD68+ and CD45+ immune cell infiltrates compared to
animals treated with PBS alone. This observation may indicate that macrophages
(CD68+), normally reported in the literature to be alternatively activated in the
context of cancers, including melanoma, are potentially functionally-active or could
be activated in tumours treated with IgE antibodies. This is supported by previous
findings with the anti-FRα IgE antibody. Indeed, the activation of the protein kinase
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PTK2 demonstrated in this chapter to be associated with the anti-tumoural functions
of IgE antibody treatment in vitro and in vivo is known to be involved in effector cell
downstream activation cascades triggered by engagement of IgE receptors (FcRs) on
immune effector cells such as macrophages and monocytes. These data support the
notion that effector cells, and in particular monocytes/macrophages, are important
and key effector cells which may be redirected against tumour cells by IgE thera-
peutics and that these cells participate in anti-tumoural responses. Furthermore, in
concordance with these findings several reports indicate that the micro-anatomical
location and activation profile of macrophages influences clinical outcomes in certain
tumour types [Dai et al., 2010, Movahedi et al., 2010]. Moreover, gene expression
analysis of the extracted xenograft tumours from animals treated with anti-CSPG4
antibodies or PBS alone revealed a high number of differentially-expressed genes in
anti-CSPG4 IgE-treated animals that allowed for subsequent identification of sig-
nalling molecules involved in the Fc signalling cascade. Further in vitro phospho-
protein analysis targeting these genes confirmed that the kinase PTK2 is essential
for the activation of human monocytes by IgE antibodies in the presence of tumour
cells. Although the in vitro experiments in this chapter as well as published data
demonstrate that PTK2 (also known as FAK1) is phosphorylated in IgE-activated
monocytes and mast cells, the functional involvement of PTK2 requires further in-
vestigation, since there are reports that expression and functions of this protein can
be modulated by anti-CSPG4 antibodies in cancer cells and therefore engagement
with CSPG4 IgE with tumour cells may trigger downstream events activating tu-
mour cells with unknown consequences [Vial et al., 2000,Campoli et al., 2010]. The
initial work presented in this chapter finally illustrates the promise of interrogat-
ing protein-protein interaction networks in translational research. The use of tools
such as the STRING database, benefiting from increased coverage and integration
by also including lower-quality data and computational predictions, will help gen-
erate novel hypotheses to guide research. With regards to anti-cancer immunity,
a protein-protein landscape illustrating the potential interactions between tumours
and components of immunity can be designed through an immune-scoring system
for all human genes, based on literature mining and information theory principles.
In summary, this chapter contributes a set of data confirming the promise of an IgE
therapeutic candidate in a number of in vitro and in vivo model systems and provides
a combination of transcriptomic, computational and functional analyses which point
to activatory mechanisms associated with IgE antibody-mediated activation of key
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effector cells such as monocytes/macrophages against tumours. These findings sup-
port further research on immunotherapeutic strategies focusing immune responses
directly against tumours such as those employing antibodies of the IgE class.
6 DISCUSSION
6.1 Impaired antibody responses against tumours:
IgG4
6.1.1 Immunoediting of antibody responses in melanoma
Monoclonal antibodies form a significant addition to the therapies against cancer,
with 17 antibodies already approved for oncology indications [Reichert and Dhi-
molea, 2012]. Although monoclonal antibodies function by a multitude of mecha-
nisms against tumour cells, the Fc-mediated mechanisms by which antibodies engage
and activate immune cells play important roles [Woof, 2012, Moore et al., 2010]. In
this context, Fc-mediated functions have been observed to have a substantial effect
on the efficacy of clinically-applied antibodies and are already associated with on-
cology treatments such as trastuzumab [Karagiannis et al., 2009,Nahta and Esteva,
2007, Lazar et al., 2006], cetuximab [Jonker et al., 2007] and ipilimumab [Lipson
and Drake, 2011]. Whether administered as therapeutics or expressed by host B
cells in response to tumour growth, antibodies have the potential to trigger potent
anti-tumoural responses by activating effector cells to destroy tumour cells. How-
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ever, tumour-induced immunoediting in the tumour microenvironment is known to
suppress the anti-tumoural functions of T cells and it would be reasonable to hypoth-
esize that those tumour-induced inflammatory conditions triggering suppression of T
cell functions can also lead to immunoediting of humoral responses and substantially
impair the potency of B cell and antibody functions against cancer. Until recently,
the nature and functional significance of the humoral response in cancer and par-
ticularly in melanoma have been insufficiently studied, understood or appreciated.
Moreover, whether and how the humoral response is immunoedited or suppressed by
the presence of tumours have also remained great unknowns. Our group previously
reported the presence of a tumour-reactive mature memory B cell compartment in
the circulation of patients with melanoma. By isolating tumour-reactive antibody
clones from patients’ mature memory B cells, we found that patient-derived antibod-
ies can activate effector cells to destroy tumour cells ex vivo in an antigen-specific
manner [Gilbert et al., 2011]. These findings suggest that patient humoral immunity
is not oblivious to the presence of cancer and additionally harbours the potential to
be triggered against tumour cells. However, hints that immune escape mechanisms
may operate to suppress tumour-reactive humoral responses came from our findings
that this tumour-reactive memory B cell compartment appears more prominent at
earlier disease stages and is substantially reduced with disease progression. Findings
reported by others and us also demonstrate that both the broad and the tumour-
reactive mature memory B cell compartments are reduced in patients with advanced
disease [Carpenter et al., 2009]. Taken together, these reports suggest that like T
cells, B cells may also be subject to tumour-induced suppressive signals.
6.1.2 Redirection of humoral immunity by tumour-induced Th2
inflammation
Insights into one immune escape mechanism are provided with findings presented in
this thesis which demonstrate that in tumour microenvironments and in the pres-
ence of melanoma tumours, B cells are polarized to favour production of IgG4, an
antibody subclass with substantially-restricted effector functions compared to well-
known potent IgG1 antibodies; this can translate to severely-impaired anti-tumoural
effector cell activation. The biological relevance of IgG4 subclass antibodies in cancer
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disease pathogenesis is a novel discovery and adds to the relatively newly-described
roles of IgG4 subclass in some inflammatory diseases (IgG4-related disease) [Stone
et al., 2012]. In melanoma, early studies have indicated polarization of IgG antibody
subclasses in the serum of patients with melanoma, but the biological relevance and
functional implications of these findings remained unexplored until recently [Daveau
et al., 1977]. The presence of infiltrating IgG4
+ plasma cells in cholangiocarcino-
mas [Harada et al., 2012] was also recently reported, sparking new interest in the
roles different components of humoral immunity play in cancer. However, beyond
this small number of reports, the effects of IgG4 in cancer have been largely unex-
plored. Immunohistological analysis of patient specimens demonstrated an increase
in IgG4 positive cell infiltrates in melanoma. Following this observation of IgG4
polarization, the impact of Th2 cytokines on the humoral immunity were explored.
Mechanisms by which antibody immune responses are influenced by Th2 cytokine
environments have been previously described. In these reports, it was shown that
IL-4 could induce class switching to IgE and IgG4 and that IL-10 could enhance
IgG4 production by switched B cells [Satoguina et al., 2005, Jeannin et al., 1998].
Increased production of Th2 cytokines such as IL-4 and IL-10 has been described in
melanoma and other cancers [Sheu et al., 2001, Agarwal et al., 2006, Nevala et al.,
2009]; and IgG4, rather than IgE antibodies, have been described to be elevated in
individuals chronically exposed to known allergic triggers such as bee venom and an-
imal fur [van de Veen et al., 2013]. However until recently, the combination of these
conditions, (i.e. IL-10-driven Th2 inflammatory conditions and chronic exposure to
antigens) in relation to their potential to redirect antibody production by B cells was
not investigated in the context of cancer. Using tumour specimen and ex vivo culture
studies, Chapter 3 reports a substantial CD22+ and IgG4
+ cell infiltrate detected in
melanoma tumours and the presence of Th2 cytokine conditions which can alter IgG
subclass production in the tumour microenvironment. When cultured ex vivo, B
cells from tumours produced a greater proportion of IgG4 subclass antibodies than
B cells in the circulation, hinting at a considerable tumour-associated polarisation
of B cells in favour of IgG4. Additionally, ex vivo stimulation experiments showed
that IgG4 levels were increased only in culture conditions that included melanoma
cells in combination with peripheral immune cells, and these cultures featured in-
creased levels of inflammatory Th2-biased mediators IL-4, VEGF and IL-10, which
are known to favour polarisation of B cells to produce IgG4. This skewing of anti-
body subclasses was not observed in culture conditions where melanoma cells were
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absent or substituted with human melanocytes. These latter cultures lacked sub-
stantial levels of the key IgG4-promoting cytokines IL-10 and VEGF [Chen et al.,
1994, Sumimoto et al., 2006]. This suggests that key Th2 mediators such as IL-10,
VEGF and IL-4 contribute to IgG4 polarisation and that melanoma cells could be
an important source or trigger of at least some of these inflammatory cytokines.
Our additional finding that only a small fraction of patient derived tumours tested
positive for IgE antibody expression is consistent with chronic exposure to antigens
(possibly tumour antigens) and the alternative (or IL-10-driven) rather than classic
(or IL-4-dominant) Th2-driven inflammatory conditions in tumours, both of which
are expected to favour class switching to and enhanced production of IgG4 rather
than IgE. The additional data presented in Chapter 3 demonstrating that IgG4 an-
tibodies in tumours and patient circulation can also recognise tumour cells, further
suggest that humoral immunity recognising cancer cells triggered in patients may be
biased towards IgG4, and not IgE or IgG1. These findings may explain why in the
presence of Th2-biased inflammatory conditions, IgE-driven anti-tumoural responses
are not commonly observed in patients. These may support the case that perhaps
a ”classic”, IgE-biased, rather than an ”alternative”, IgG4-biased, immunity may
tip the balance in favour of anti-tumoural immunity, and they need further consid-
eration and investigation. Thus, findings reported in this thesis reveal for the first
time a hitherto undiscovered feature of humoral immunity in melanoma tumours,
characterized by B cell infiltration and local expression of IgG4 antibodies, polar-
ized by cytokines such as IL-10, IL-4 and VEGF. These findings link the presence
of melanoma cells with the secretion of these cytokines and with B cell polarization,
contributing to enhanced production of IgG4 subclass antibodies in the presence of
tumours.
6.1.3 Impairing antibody effector functions: the roles of IgG4
Insights into the functional significance of IgG4 polarisation in tumours come from
findings presented in this thesis which demonstrate that not only is IgG4 itself shown
to be ineffective in activating effector cells to destroy tumours, it also antagonizes
otherwise cytotoxic IgG1-mediated human anti-melanoma immunity in vitro and in
vivo. An interesting mechanistic insight is provided by evidence that IgG4 blockade
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is mediated through competing with IgG1 for FcγR binding and therefore inhibiting
downstream signalling activation of effector cells (i.e. monocytes), rather than by
potentiating suppressive triggers through engagement with FcγRIIb. This inhibi-
tion of anti-tumoural functions of IgG1, the antibody subclass thought to have the
most potent immune effector functional capacity among IgGs, accompanied by the
proportional increase in IgG4, generally thought to have the least potent Fc effector
functions among the four IgG subclasses [van der Zee et al., 1986,Bru¨ggemann et al.,
1987, Aalberse et al., 2009]. This translates into weakened anti-tumour antibody
responses. An obvious consequence would be impairing the capacity of host-induced
and therapeutic antibodies to mediate antibody dependent-mechanisms including
CDC, ADCC and ADCP. Additional in depth studies are required to dissect the full
immunomodulatory mechanisms influencing antibody functions of different classes
and subclasses in melanoma and to elucidate whether and how these mechanisms
might apply in different cancers. A number of conclusions may be derived from
these findings:
1. the importance of activating effector cells against cancer highlighted by data
presented in Chapter 3 are in concordance with a growing appreciation for the
clinical significance of immune cell infiltrates in tumour microenvironments,
their roles in immune surveillance and their utility in predicting disease out-
comes and response to treatments;
2. the plastid nature of effector cells to either become activated or suppressed
under different conditions in the context of host-induced and therapy-triggered
anti-tumoural immunity and in the presence of diverse immunosuppressive con-
ditions;
3. the potential merit of designing targeted therapeutic strategies to sequester
and activate these effector functions against cancer cells, and
4. the need to further elucidate mechanisms of immune suppression of humoral
immunity is evident and can potentially translate into better-designed thera-
peutic strategies that perhaps may be less prone to or capable of reversing or
overcoming tumour-induced immune blockade mechanisms.
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The work presented in this thesis presents the first evidence of local and systemic
enhancement of IgG4 in melanoma. The associated IgG4-polarization driven by key
cytokines such as IL-10 and VEGF suggests that IgG4 antibodies triggered in the
presence of melanoma cells contribute to local inflammation and may represent a
regulatory mechanism by which tumours evade clearance by the immune system.
6.1.4 Future directions in dissecting the mechanisms of hu-
moral immune responses by tumours
Data in this thesis demonstrate that IgG4 promoted by tumour-induced Th2-biased
inflammation restricts anti-tumoural immunity. These insights provide a novel per-
spective on tumour-induced immune escape, a rationale for further dissecting the
cross-talk between different components of humoral immunity with tumours and for
studying the implications of these associations on clinical outcomes. Importantly,
the present and also future findings will continue to provide translational opportu-
nities by informing the search for better treatments. The humoral response remains
only partly investigated in the context of immunoediting [Tan and Coussens, 2007].
Therefore, future work dissecting the role of tumour-specific IgG4 antibodies, and
perhaps also other antibody classes in cancer, may lead to a better understanding of
immune impairment in the tumour microenvironment. For instance:
1. Tumour-specific IgG4 antibodies may both compete for the Fc receptors as well
as for tumour antigens with other host-induced and/or therapeutic antibodies,
thus blocking antibody-mediated mechanisms in a dual manner.
2. One direction for further exploration also lies with understanding the con-
tributions of different cells in Th2-biased inflammation. In this study, when
co-cultured with B cells, tumour cells enhanced IL-10 expression, while B cells
secreted enhanced amounts of VEGF in the presence of tumour cells.
(a) Firstly, exploring the feedback loops of signalling cascades induced by
VEGF in tumour cells and linked events that trigger production of Th2
cytokines such as IL-10 which polarise the humoral response, would lead
to a better understanding of immunoediting. This can inform the design of
6.1. Impaired antibody responses against tumours: IgG4 197
novel therapies aiming to reverse immune escape or help stratify patients
who may benefit from certain therapies such as anti-VEGF treatments.
(b) Secondly, data in this thesis are in concordance with published findings
by Harada and colleagues who report co-localisation of T regulatory cells
(FoxP3+) with B cells and in particular with IgG4 producing cells in tu-
mours. As Tregs are also rich sources of IL-10, it is conceivable that
the presence of these cells can further contribute to ”alternative”, Th2-
polarised conditions that favour IgG4. These findings would also support
the idea that B cells are polarized locally in the tumour microenvironment
to switch to IgG4. Furthermore, for the initiation of IgG4 production, the
cytokine IL-4 was reported to be essential [Robinson et al., 2004] and con-
tinuous IL-4 production is highly dependent on prior expression of IL-4
(auto-feedback) [Le Gros et al., 1990]. T regulatory cells, which can also
produce IL-4, might therefore be of crucial importance to the polarisa-
tion of B cells in tumours. Thus, Tregs may be a source of this crucial
component required to trigger those IgG4-driven suppressive responses.
3. Moreover, analysis of the anatomical compartment in which class switch re-
combination takes place, locally or in adjacent lymph nodes, may improve op-
portunities for interventions aimed at reversing this polarisation. This could be
accomplished by repolarising or directing potent immune cells against the tu-
mour and may lead to tumour eradication rather than evasion. Pre-clinical
studies reporting that blocking the migratory potential of antigen present-
ing cells could lead to more potent anti-CD8 effects directed against tumour
cells hint towards the potential involvement of antigen presenting cells in im-
munomodulatory mechanisms through perhaps production of cytokines such as
IL-10 that may suppress T cell but also, as presented in this thesis, humoural
responses. For example, CD141+ dermal dendritic cells, known for their im-
munoregulatory roles in immunity may regulate the humoral response through
production of IL-10 and prevent tumour eradication [Chu et al., 2012].
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6.1.5 IgG4 blockade mechanisms informing future novel ther-
apeutic approaches
Future strategies to counteract IgG4 immunoregulatory pathways such as IL-10
blockade or anti-CD25+ antibodies might lead to an advanced clinical improvement
in patients who do not respond to treatments with immune checkpoint blockade an-
tibodies. Curran et al. reported that the combination of anti-CTLA-4 antibodies
and anti-PD1 antibodies lead to a proportional increase in T effector cells (such as
CTLs), as the antibodies decrease the T regulatory cell compartment by inducing
ADCC against them. These data suggest that checkpoint blockade antibodies of
the IgG1 class have a bivalent mechanism, namely unblocking CD8 T cell activation
and also targeting suppressive T regulatory cells. Therefore, combining checkpoint
blockade antibodies with Treg specific antibodies such as anti-CD25 may translate
into higher efficacy. In future studies, it may be worth investigating if IgG4 levels
in the serum of cancer patients correlate with clinical responses to antibody im-
munotherapy. Furthermore, longitudinal studies in phase III trials monitoring not
only IgG4 protein levels but also IgG4
+ cells and their abilities to recognise tumour
cells may lead to a better understanding of the systemic memory B cell response in
the disease. This may then lead to the development of new therapeutics targeting
these cells to counteract IgG4 impairment in melanoma. An alternative approach is
to design antibody treatments with engineered Fc regions and antibodies of differ-
ent classes and derivatives less prone to IgG4 blockade; this may have an increased
therapeutic value.
6.2 IgG4: a novel promising biomarker in melanoma
6.2.1 The search for disease-relevant biomarkers for melanoma
and the promise of humoral responses
Despite the rise of numerous biomarkers for many malignancies including melanoma,
there remains an unmet clinical need in this field. Although currently most biomark-
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Figure 6.1: IgG1 induces ADCC while IgG4 impairs effector cell function in the tumour
microenviroment. A) Tumour cells, aided by immune inflammatory and stromal cells
in the tumour microenvironment, can polarise B cells to secrete IgG4 subclass antibod-
ies by secreting Th2 cytokines such as IL-10 and IL-4, and via B cell-produced VEGF,
which may favour further production of IL-10 by tumour cells and inflammatory infil-
trates. IL-10-VEGF-IL-10 induction may be part of a feedback loop mechanism resulting
in class-switching and activation signals for IgG4
+ B cells in tumours. IgG4 antibodies
(red) are poor activators of anti-tumoural effector cell functions, while IgG1 antibodies
(blue) are effective activators of immune cells. B) Tumour specific IgG1 antibodies can
mediate effective antibody-dependent tumour cell killing by immune effector cells (e.g.
monocytes/macrophages) through activation of FcγRI (CD64) signalling. C) IgG4 does
not activate effector cells to kill tumour cells (through ineffective induction of FcγR sig-
nalling upon effector cell engagement). D) IgG4 antibodies can impair IgG1-mediated
tumour cell killing by competing for recognition of FcγRI receptors on effector cells.
ers lack sufficient combined sensitivity and specificity, there is wide scope for po-
tential applications for clinically-validated biomarkers [Tandler et al., 2012]. Novel
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biomarkers are needed for many applications, such as aiding diagnosis, early detec-
tion, staging of patients, prognosis of disease progression, patient stratification for
particular treatments or to help predict responses to specific therapies. For instance,
a biomarker could in principle be used to assess the superiority of a therapy in phase
III trials before the terminal endpoint is reached, thus allowing for quicker assess-
ment and better health care provision. One can foresee that the discovery of specific
disease-relevant biomarkers could potentially help us harness the full therapeutic
benefits of drug interventions before terminal endpoints. Importantly, markers that
are directly linked to the pathogenesis or progression of the disease are desirable. The
only serum biomarker in clinical practice for melanoma is LDH. Elevated LDH serum
levels are found in patients with progressive disease at later stages of melanoma. The
presence of LDH indicates active cell necrosis, which occurs during disease progres-
sion in melanoma [Balch et al., 2009]. In this context, it is important to highlight that
LDH only indicates enhanced cell death, which normally occurs in advanced disease
when patients have high tumour burden, thus this marker is generally useful in late
but not in early disease stages [Hofmann et al., 2011]. Furthermore, serum LDH is
not exclusively elevated as a result of tumour burden and can be influenced by other
conditions such as myocardial infarction. Another promising serum biomarker candi-
date is S-100B; it has demonstrated high sensitivity and specificity higher than that
of LDH in advanced disease, but it is still not applied in clinical routine as the data
reported indicate a large variation between patient samples [Tandler et al., 2012].
This latter feature of variation among patients is a common problem in the search
for clinically-useful serum biomarkers and generally represents a limitation that has
prevented a number of clinically available biomarkers to reach clinical utility. Detec-
tion of circulating tumour cells (CTCs) represents an alternative biomarker approach
to the analysis of protein and DNA in patient sera. CTCs should be relevant to dis-
ease progression, as their presence is expected in the circulation of patients with
advancing and metastatic tumours and may signify a worse clinical prognosis. This
approach is however limited due to the large inter- and intra-patient variabilities in
the cancer cell markers for those cells and large variations in CTC counts between
blood draws [Karakousis et al., 2013]. Humoral immune components, including cir-
culating antibodies, are emerging as biomarkers for autoimmune, inflammatory, al-
lergic and malignant diseases. This concept is strengthened by the recent reports
on ”immunosignaturing”, a method which lends merit to the notion that monitoring
antibodies could prove more sensitive than screening for specific antigens in early dis-
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ease stages (Chapter 1, Section 1.4). Immunosignaturing is conducted using protein
arrays to determine whether specific antibody patterns correlate to disease [Hughes
et al., 2012]. This technique has two unique advantages: a) antibody responses are
occurring at early points of pathogenesis and could be used as a sign of disease oc-
currence; and b) antibody production is naturally amplified upon B cell activation
by antigen recognition and can be measured. The merits of immunosignaturing have
been demonstrated in Alzheimer’s disease by comparing different cohorts of patients
and one can also foresee potential applications in cancer [Restrepo et al., 2013].
6.2.2 The merits of evaluating IgG4 as a biomarker in melanoma
In support to the above principle that antibodies could be useful indicators of dis-
ease pathology and outcomes even at early stages, data presented in this thesis
indicate that the presence of IgG4 in melanoma is indicative of active immunosup-
pressive mechanisms. Importantly, preliminary evidence conducted in a 33 patient
cohort demonstrates that higher IgG4 serum levels are associated with worse prog-
nosis (Chapter 3). These findings were further dissected in Chapter 4, using a larger
cohort of patient sera and blood PBMCs, and it is concluded that circulating IgG4
can be a promising prognostic readout at early stages of melanoma, where standard
markers like LDH lack sensitivity. Elucidating the association of IgG4 with clini-
cal outcome can pave the way for biomarker development and implementation for
more sensitive markers at early disease stages. Although IgG4 may be a promising
candidate marker in prognosis of early disease patients, the important question of
whether it could help inform decisions along with or instead of sentinel lymph node
biopsy (SNB) still remains. Presently, 80% of SNB samples are histologically tumour
cell-negative, and it may be useful to develop novel less intrusive readouts that can
provide similar information for patients with local disease whilst avoiding or reduc-
ing the risk of potential long-term complications associated with SNB interventions.
Further studies must be conducted to compare the predictive values of SNB and
serum IgG4 readouts; these evaluations may yield better and less intrusive clinical
tools along with improved patient management. Furthermore, the increased num-
bers of IgG4
+ B cells in the circulation of melanoma patients compared to healthy
volunteers may pave the way for a more personalised medicine approach involving
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monitoring circulating B cell subsets such as memory class-switched cells. Monitor-
ing B cell subsets associated with immune modulation such as IgG4
+ B cells may
provide useful information with regards to the nature of long-lived memory responses
rather than relying on the temporal immune signals through detecting serum proteins
and antibodies. Data reported in this thesis (Chapters 3 and 4) also demonstrate
IgG4
+ cell infiltration is enhanced in melanoma tumours compared to healthy skin;
although it was not possible with available patient data to correlate these infiltrates
with patient outcomes or history; this finding could lead to further studies specifi-
cally focused on evaluating IgG4 positivity in melanoma as a tissue marker, perhaps
useful in predicting disease burden or metastatic potential. In summary, findings
reported in Chapters 3 and 4 of this thesis demonstrate the potential of IgG4 as an
immunological and serological biomarker, mandating the need for larger longitudinal
studies analyzing IgG4 to ascertain its clinical significance and utility.
6.2.3 Future investigations of IgG4 as a biomarker and poten-
tial clinical benefits
Analysing IgG4 in the serum of patients has shown to predict the risk of progression
in melanoma. The advantages of this minimally invasive test would not only benefit
the patient, but could also have positive financial implications for the health ser-
vice. To date, sentinel lymph node biopsies (SNB) is a tool for staging patients and
for predicting the risk of progressive disease in melanoma. However, SNB require
a specialized team to conduct the procedure, sterile facilities and instrumentation,
which inevitably involves higher costs in comparison to a serological test that can be
conducted after a single blood draw. IgG4 has shown efficacy in predicting the risk
of disease progression at early stage of melanoma. In future, it could be assessed
whether IgG4 serum level, together with histopathological assessments such as Bres-
low thickness, may help to pre-screen patients prior to SNB in order to identify those
who may benefit from undergoing this procedure. This pre-screening could not only
lower the cost of treatment but, if applied, may also be of benefit since the post-
operative complications of SNB such as lymphedema would be avoided for a large
majority of patients who gain no benefit from undergoing SNB. However, extensive
longitudinal studies comparing simultaneously SNB and IgG4 will need to investi-
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gate any correlations or predictive potential of IgG4. In the future, monitoring IgG4
could also help assessment of treatments and treatment-related responses. Including
IgG4 serum level measurements as a surrogate maker to investigate the efficacy of a
drug in a randomized clinical trial may prove effective, as this marker might be able
to help assess the outcome before the primary endpoint. Moreover, evaluating IgG4
in immunotherapy with treatments such as ipilimumab may be considered [Downey
et al., 2007]. The acquired data could reflect the effects of the tumour environment
on the patient immune system and its capacity to respond to specific immune ac-
tivatory therapies. The reported titres of IgG4 correlate with the risk of disease
progression and support the data demonstrating the immune suppressive functions
of IgG4 in melanoma described in this thesis. Therefore, as IgG4 is a part of the
pathological process in this disease it can be used to monitor changes in the course
of the disease. It is noteworthy that similar elevated IgG4 levels were also observed
in pancreatic cancer, extrahepatic cholangiocarcinoma and squamous cell carcinoma,
providing evidence that this phenomenon might not be limited to melanoma [Kawa
et al., 2012, Harada et al., 2012, Strehl et al., 2011]. On another note, IgG4 might
also be further studied as a biomarker in breast cancer; although in this thesis IgG4
did not show any potential to predict progression, it is important to point out that
the patients involved in this study had only stage I-II disease. In future, assessment
of a more heterogeneous population of breast cancer patients should be conducted.
Another interesting consideration would be combining serological and immunological
markers. As is partially the case in immunosignaturing (the protein array shows data
from a variety of antibody reactivities), the use of multiple markers each with differ-
ent sensitivity and specificity could result in an algorithm with improved combined
diagnostic or prognostic potential; this could be successful assuming that decisions
about priority, (e.g. which marker to consider more valid), mathematic methods and
operational feasibility are in place. Larger clinical studies including more patients at
different disease stages are required to identify and validate more reliable biomarkers
in melanoma; these markers may include IgG4. The effort to acquire such markers
could improve the diagnosis, predict the risk of disease progression and guide the ap-
propriate therapy decisions; these concepts fit into the frequently discussed model of
personalised medicine and may help optimise the potential value of many therapies.
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6.3 Extending the translational concept of Allergo-
Oncology towards treating skin cancer
6.3.1 Rationale for improving effector functions by employing
antibodies of the IgE class against tumours
Since the Fc domain of an antibody determines its interaction not only with com-
plement, but also with relevant cell surface Fc receptors, it is evident that the class
or subclass of an antibody critically influences its effector functions and efficacy.
This discovery has stimulated the development of several antibody modifications,
all aspiring to optimise the antibody-immune system interactions by enhancing Fc-
mediated antibody functions and consequently the efficacy of the antibody as a ther-
apeutic agent [Griggs and Zinkewich-Peotti, 2009, Jefferis, 2009]. The nascent field
of Allergo-Oncology aims to harness the inflammatory response observed in allergy
against cancer. The design of IgE passive immunotherapies is only one domain of
the translational scope of this multidisciplinary field, which includes a wide range
of methodologies utilising IgE against cancer: a) the utilisation of IgE as an adju-
vant [Reali et al., 2001], b) the development of oral mimotope vaccination programs
and IgE-coated cellular vaccines [Reali et al., 2001, Nigro et al., 2009, Nigro et al.,
2012, Riemer et al., 2007], c) elucidating the roles of IgE effector cells in promoting
tumour growth and strategies to deploy these cells against cancer [Dalton and Noelle,
2012, Gatault et al., 2012], d) IgE-mediated antigen uptake and cross-presentation
to trigger immunoactivatory responses in cancer [Platzer et al., 2012], e) modula-
tion of host IgE responses utilizing biological therapies [Bluth, 2012], f) induction
of a more inflammatory Th2 biased environment recruiting NKG2D cells to target
tumours [Strid et al., 2008, Strid et al., 2011, Jensen-Jarolim and Pawelec, 2012], g)
understanding differential associations between IgE, allergies and the incidence of a
variety of cancer types and the immunological and pathological mechanisms behind
these diverse findings, h) engineering therapeutic antibodies with IgE Fc regions
to target cancer antigens. Moreover, investigating the presence of IgE antibodies
against tumour antigens in healthy individuals and possibly in patients with can-
cer at different disease stages would provide evidence of the role of IgE in natural
immune surveillance and improve our understanding of host immunity. The unique
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features of IgE antibodies such as stimulating local immune activation in allergy and
parasitic infections, include potent effector cell activation and target cell clearance
-as in the case of protection from parasitic infections- and prolonged immune reaction
at the site of antigen provocation, as in the case of allergen challenge. These proper-
ties provide the basis for the long-standing hypothesis that these mechanisms can be
employed to reject cancer. Based on the above proposed advantages of IgE therapy
in solid cancers, a few research groups developed techniques to produce recombinant
IgE antibodies directed against tumour associated antigens aiming to elucidate the
potency of IgE therapies against cancer [Nagy et al., 1991,Daniels et al., 2012,Kara-
giannis et al., 2012, Kershaw et al., 1996, Kershaw et al., 1998]. Several pre-clinical
models propose that passive IgE immunotherapy is able to recruit Fc receptor-
bearing effector cells and to effectively direct their inflammatory immune reactions
against solid tumours. [Karagiannis et al., 2012]. It is noteworthy that although IgE
is present in the skin, the concept of IgE immunotherapy for solid tumours of the
skin has not been tested until now. Melanoma with its large number of FcR bear-
ing immune cells such as mast cells and macrophages and its origin in the skin may
serve as an ideal candidate for IgE immunotherapy [Duncan et al., 1998,Erdag et al.,
2012, Tth-Jakatics et al., 2000] and this research stream was conducted as part of
this thesis. Investigating immune responses in cancer depends highly on the choice
of antigen. CSPG4 represents an ideal target for a monoclonal antibody therapy
since it is over-expressed on the surface of melanoma and other cancer cells [Campoli
et al., 2010]. It was described that CSPG4 enhances the metastatic potential of
tumour cells and that its blockade by the monoclonal antibody clone 225.28s leads
to non-immunological mechanism-led tumour restriction [Price et al., 2011]. Further
reports show that anti-CSPG4 225.28s restricts tumour growth in murine xenograft
models in vivo [Hafner et al., 2005b, Hafner et al., 2005a]. By engineering an anti-
body of this specificity with human Fc regions, this clone derivative is herein armed
with not only direct, but also effector cell-mediated tumour killing properties.
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6.3.2 An anti-CSPG4 IgE antibody restricts tumour growth in
vitro and in vivo
My colleague Amy Gilbert evaluated the chimeric anti-CSPG4 antibodies (IgE and
IgG1) Fab functions and demonstrated that these antibodies block melanoma cell ad-
hesion and migration, thus targeting these known tumour-promoting advantages that
CSPG4 expression provides for melanoma cells. This inhibition may be explained by
the binding site of the antibody which recognises an epitope of the core glycoprotein
component of CSPG4, a region that has been described to contain integrin and colla-
gen binding sites, and it therefore contributes to adhesion and migration stimuli for
melanoma cells [Wilson et al., 1981,Price et al., 2011,Kantor et al., 1986]. In addition
to these findings, I evaluated the capability of the antibodies to restrict cell prolif-
eration and to induce immune cell mediated responses (Chapter 5). IgE responses
have been described against allergens and also as part of protective immunity against
parasitic infections, through performing effector functions such as antibody depen-
dent cell mediated cytotoxicity and antibody dependent cell-mediated phagocytosis.
These effects were examined using the engineered anti-CSPG4 IgG1 and IgE anti-
bodies with human Fc regions, together with effector cells isolated from melanoma
patients. Such Fc receptor mechanisms are described here for the first time with
regards to this antibody clone, since the original clone, 225.28s, bears only murine
Fc regions which are not able to effectively activate human immune cells (Bergman,
Basse et al. 2000). The results of the in vitro studies demonstrate that anti-CSPG4
IgG1 and IgE antibodies mediated tumour cell killing via ADCP or ADCC, triggered
through the engagement of Fc receptors on human monocytes, which are known to
express Fcγ and Fc receptors [Maurer et al., 1994, Karagiannis et al., 2003]. Ad-
ditionally, investigating the effects of antibodies in vivo is important, as several
attributes of antibodies such as bioavailability cannot be mimicked in vitro. The
anti-CSPG4 IgE antibody significantly restricted tumour growth when compared to
its IgG1 counterpart in a humanised mouse model. In this model, anti-CSPG4 IgE
recruited significant CD68+ macrophage infiltration into the tumours, indicating that
these cells might be altered towards an ”activated” phenotype when engaged by a
tumour-specific IgE antibody. This activation in the presence of IgE can result in
anti-tumoural rather than tumour-promoting functions for these cells. Furthermore,
enhanced overall survival of tumour-bearing animals was demonstrated in three tu-
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mour transplants given to immunocompromised mice together with HLA-matched
PBLs. These findings suggest that despite known immunosuppressive mechanisms
at play in the circulation and in tumour microenvironments, the patient immune sys-
tem has the capacity to be reactivated and redirected against autologous tumours by
the use of tumour antigen-specific human/chimeric IgE antibodies. Thus, this latter
model system contributes to the translational significance of this and perhaps other
IgE antibody therapies. These findings complement data of previous investigations,
which elucidate the effector functions of human, humanised and chimeric IgG and IgE
antibodies recognizing different tumour associated antigens. These include research
by our group on a trastuzumab IgE homologue recognising the Her2/neu antigen
expressed on breast cancer cells [Karagiannis et al., 2009] and extensive studies on
the chimeric IgG and IgE antibodies against the Folate Receptor α (FRα), another
tumour-associated antigen expressed on ovarian cancer and mesothelioma tumour
cells [Karagiannis et al., 2003, Karagiannis et al., 2012]. The latter antibody has
shown significantly improved efficacy when directly compared to the corresponding
IgG1 in three in vivo and numerous in vitro models of cancer. Collectively, these
studies pave the way for the progression of CSPG4 IgE towards further pre-clinical
testing and possibly future translation for clinical use.
6.3.3 Future work to extend the translational concept of Allergo-
Oncology
The work presented in this thesis contributes to the nascent field of Allergo-Oncology,
as here the efficacy of IgE antibodies against melanoma is demonstrated using a num-
ber of in vitro functional assays and two highly translational models of cancer in vivo.
This data, together with on-going studies on MOv18 IgE against FRα-expressing tu-
mours and with other IgE antibodies against a number of other tumour markers,
indicate that IgE immunotherapy has a broad applicability across different solid tu-
mours and can therefore be considered as an alternative treatment to IgG antibody
class therapy. The applicability of IgE immunotherapy for cancer has been reported
in a number of pre-clinical models of different malignant disease indications. These
include several humanised xenograft models of ovarian cancer [Karagiannis et al.,
2008, Karagiannis et al., 2007], human FcRIα transgenic mouse models of breast
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Figure 6.2: IgE immunotherapy induces tumour cell killing and may be less prone to
IgG4 effector cell impairment in the tumour microenviroment A) Tumour cells, aided by
immune inflammatory and stromal cells in the tumour microenvironment, can polarise
immune effector cells and inhibit their anti-tumour function. IgE loaded immune cells
can mediate tumour cell death. B) Tumour specific IgE antibodies are directly inducing
antibody-dependent tumour cell killing. C) IgE triggers degraulation upon cross-linking
of FcRI on effector cells in the presence of antigen expressing cancer cells. D) Tumour
specific IgE antibodies can mediate effective antibody-dependent tumour cell killing by
immune effector cells (e.g. monocytes/macrophages) through activation of FcR signalling
(by mechanisms such as ADCC and ADCP.
and prostate cancer [Daniels et al., 2012,Daniels-Wells et al., 2013], and an immuno-
competent sygeneic rat model of colorectal adenocarcinoma grown as lung metas-
tases (Debra H Josephs, PhD thesis, 2013, KCL). All those models have supported
both the safety and efficacy for the applied IgE therapy and several of those models
demonstrated superiority of IgE when compared directly with its IgG1 counterpart.
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Furthermore, key data by Rudman et al. provided evidence that a tumour antigen-
specific IgE (MOv18 IgE) does not induce activation of effector cells that may con-
tribute to the onset of type I hypersensitivity when this antibody is added to human
blood. Two readouts were adopted in this study; these are normally used in the field
of allergy to help predict and diagnose patient hypersensitivity to allergens or medic-
inal drugs. The findings support the prediction that i.v administration of a human
cancer antigen-specific IgE would not be expected to induce early signs of Type I hy-
persensitivity reactions which may potentially lead to anaphylaxis. Additionally, my
fellow PhD student Dr. Debra H. Josephs provided additional supporting evidence
for the future clinical utility of IgE by demonstrating the safety and efficacy of MOv18
IgE in a dose escalating study using an immunocompetent rat model of a syngeneic
FRα-expressing adenocarcinoma that grows as lung metastases in these animals. In
support of IgE antibody therapeutic translation towards clinical use, Daniels and
colleagues have reported administration of a tumour antigen-specific human IgE in
a primate species (cynomolgus monkey) as part of a pharmacokinetic study. Despite
cross-reactivity of human IgE Fc regions with primate Fc receptors (Dr. Louise
Saul, KCL, manuscript in preparation and personal communication), this systemic
IgE administration did not yield any toxic effects in these animals. The combined
efficacy and safety data collected using at least five in vivo models of cancer and
numerous in vitro and ex vivo functional assays by our group alone, together with
work independently conducted by others in a number of diverse model systems, un-
derpin the case for clinical testing and applicability of this novel approach. Although
a number of reports provide confidence that IgE antibodies are not likely to be asso-
ciated with toxicity and might therefore be safe upon clinical application, the issue
of safety should be considered when designing IgE therapeutics. While mediating
potent immune reactions by IgE are well-desired within the tumour microenviron-
ments in order to induce tumour eradication, it will always remain important to
avoid designing an IgE antibody therapeutic that recognises repeat epitopes per tu-
mour antigen and against antigens found at high levels in soluble multivalent form
in patient circulation. This is because Type I hypersensitivity may be triggered by
crosslinking FcRI on the surface of circulating basophils by soluble IgE complexes
with multivalent but not monovalent antigens when found at high concentrations in
blood. This concept is exemplified by ex vivo data which demonstrate no early signs
of basophil or mast cell activation or degranulation in the presence of MOv18 and
patient sera or blood, despite elevated levels of soluble target antigen FRα in the
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circulation, reported by us and others. The antigenic target FRα is known to be
shed in the circulation in a monovalent form, and because of its monovalent nature,
it could not cross-link MOv18 IgE bound on circulating patient basophils. Thus,
designing antibodies against antigens not shed at high levels in multivalent form in
the circulation is expected to minimise the risk of any potential adverse events. In
future, similar studies to those conducted by Rudman et al for MOv18 IgE should
also be conducted for CSPG4 IgE and its target antigen, CSPG4, by interrogating
ex vivo and in vitro functional assays using sera and whole blood specimens from
patients with melanoma. These will provide some confidence that any shed circulat-
ing tumour antigen would not trigger basophil degranulation in patient circulation
with systemic administration of CSPG4 IgE. An important aspect of translating IgE
antibodies in cancer therapy would lie with dissecting the mechanisms associated
with their superior efficacy in comparison to their IgG1 counterparts. For instance:
1. Investigating pro-inflammatory cytokines as well as chemokines such as MCP-1
(Debra H Josephs, PhD thesis, 2013, KCL) released upon cross-linking of FcRs
by IgE receptor-bearing cells in the tumour microenvironment are shown to
correspond to increased macrophage infiltration and tumour clearance. These
findings suggest important roles for IgE antibodies in recruiting and redirecting
potent immune effector cells against cancer, providing novel insights into the
mechanisms through which IgE antibodies may operate to destroy cancer cells.
2. Furthermore, recent findings demonstrated increased IgE secretion in sera of
OVA-immunised mice associated with lymphoid stress. This increase in IgE
antibodies was linked with increased levels of NKG2D-expressing cells such as
NK and γδT cells. Following from these findings, it is possible that tumour
antigen-specific IgE antibodies may trigger immune activation in Th2-biased
environments which may trigger enhanced infiltration of cells bearing the nat-
ural killer cell activation receptor NKG2D, such as NK cells and CD8+ T cells.
Thus, IgE treatment would not only trigger tumour killing through mechanisms
such as ADCC and ADCP directly mediated by the antibody itself, but it may
additionally potentiate the recruitment of NKG2D+ innate immune cells which
can participate in further tumour cell clearance independently of IgE.
3. The possibility that IgE antibodies may or may not be subject to IgG4 block-
ade in patients with melanoma requires further investigation. IgE antibodies
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may be less prone to IgG4 suppressive functions than IgG1 antibodies because
they activate immune effector cells through a different set of Fc receptors to
IgG1, which IgG4 antibodies do not recognise. Thus, IgG4 antibodies may not
compete with IgE for recognition of FcRs in a way they compete with IgG1
antibodies for recognition and activation of FcγRI. However, since Fc and
Fcγ receptors share the β subunit, it is possible that occupancy of FcγRs may
impede FcR cell surface expression and therefore the effector functions of IgE
antibodies. Furthermore, our findings that some IgG4 antibodies in tumours
and patient circulation recognise tumour cells may also constitute a mechanism
by which IgG4 antibodies could block tumour antigen-specific IgE antibodies
from engaging and clearing tumour cells. This has been demonstrated in the
context of allergy, as IgG4 antibodies elevated in patients receiving allergen
immunotherapies have been shown to partly inhibit allergen-specific IgE anti-
bodies from recognising their specific epitopes on allergens [James et al., 2012].
Further mechanistic evaluations will be required to elucidate whether and to
what extend IgE antibodies, either administered as therapeutics or naturally
produced in response to tumour growth in patients, may be subject to IgG4
blockade.
4. Future studies may focus on elucidating the recruitment of innate as well as
adaptive immune cells following IgE treatment, and this could lead to the dis-
covery of novel immune regulatory pathways, possibly including identification
of new molecules which can activate effective anti-tumoural responses in the
host independently of IgE therapeutics.
5. Investigation of the released cytokine-chemokine milieu in tumours might pave
the way for drug-conjugated antibody immunotherapies aiming to modulate the
tumour microenvironment in the context of tumour-induced immunoediting,
making tumours susceptible to immune cell activation and attack.
The ensuing knowledge from explorations such as those mentioned above could lead
to the design of better therapeutics with greater tumour eradication potential and
to better clinical management of cancer patients.
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6.4 Antibodies and Melanoma: Final remarks
Taken together the data presented in this thesis enhance our understanding of the
interactions between the humoral response and tumours and present a translational
interpretation of these findings by examining IgE antibody immunotherapy for can-
cer. The findings pave the way for further exploring novel mechanisms associated
with immunoediting and irreversible immune escape in metastatic disease. Such
knowledge could give rise to the design of novel therapies less prone to immune mod-
ulation which could prevent incurable malignant disease. Furthermore, these data
point out that tumour-induced inflammatory conditions lead to secretion of sero-
logically detectable proteins such as IgG4, which may be directly involved in the
pathogenesis of malignant disease and immune escape. These explorations may yield
more robust disease-relevant biomarkers that can improve patient care at early stages
of melanoma, where an unmet clinical need still exists to aid prognosis, stratification
and early interventions. And finally, the efficacy of IgE as an emerging immunother-
apeutic agent is evaluated and data presented here support previous findings with
other IgE therapeutic approaches in a variety of tumour types, and indicate the supe-
riority of the IgE antibody class compared to the conventional IgG in the treatment
of solid tumours, including melanoma.
7 ABBREVIATIONS
ADCC Antibody Dependent Cellular Cytotoxicity
ADCP Antibody Dependent Cellular Phagocytosis
AKT Protein Kinase B
APC Antigen Presenting Cell
BCR B Cell Receptor
CDC Complement Dependent Cytotoxicity
CDR Complementarity Determining Region
CFSE Carboxy Fluorescein Diacetate Succinimidyl Ester
CSR Class Switch Recombination
CTC Circulating Tumour Cell
CTL Cytotoxic T Lymphocyte
CTLA-4 Cytotoxic Lymphocyte Antigen 4






EGF Epidermal Growth Factor
EGFR Epidermal Growth Factor Receptor
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EMA European Medicines Agency
Fab Fragment of Antigen Binding
FACS Fluorescence-Activated Cell Sorting
Fc Fragment Crystallisable
FcαR Fc Alpha Receptor
FcγR Fc Gamma Receptor
FcR Fc Epsilon Receptor
FcR Fc Receptor
FDA Food and Drug Administration
FDR Framework Determining Region
FRα Folate Receptor Alpha
GPI Glycophosphatidylinositol
HACA Human Anti-Chimeric Antibody
HAHA Human Anti-Human Antibody
HAMA Human Anti-Mouse Antibody
HEK Human Embryonic Kidney
HER2/neu Human Epidermal Growth Factor Receptor 2
HMW High Molecular Weight
HPLC High Performance Liquid Chromatography





iNOS Inducible Nitric Oxide Synthase
ITAM Immunoreceptor Tyrosine-Based Activation Motif
ITIM Immunoreceptor Tyrosine-Based Inhibitory Motif
LMW Low Molecular Weight
LN Lymph Node
mAb Monoclonal Antibody
MFI Median Fluorescence Intensity
MHC Major Histocompatibility Complex







PBL Peripheral Blood Leukocyte
PBMC Peripheral Blood Mononuclear Cell
PD-1 Programmed Death 1
PDL-1 Programmed Death Ligand 1
PI3K Phosphatidylinositide 3-Kinase
PFS Progression Free Survival
PTK2 Protein Tyrosine Kinase 2
PBS Phosphate buffered saline
PMSF phenylmethanesulfonylfluoride
RBL Rat Basophilic Leukaemia
REC Research Ethics Committee
RNA Ribonucleic acid
RT Room temperature
scFv Single-Chain Fragments of the Variable Region
SCID Severe Combined Immunodeficiency
SDS-PAGE Sodium dodecyl sulphate polyacrylamide gel electrophoresis
TAA Tumour-Associated Antigen
TAM Tumour-Associated Macrophage
TATE Tumour-Associated Tissue Eosinophilia
TGF Transforming Growth Factor
Th1 T Helper Cell Subset 1
Th17 T Helper Cell Subset 17
Th2 T Helper Cell Subset 2
TME Tumour Microenvironment
TNFα Tumour Necrosis Factor Alpha
Treg TRegulatory T Cell
UV Ultraviolet
VDJ Variable Diverse and Joining
VEGF Vascular Endothelial Growth Factor
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Brief Definit ive Report
Efficient immunoregulation in peripheral tis-
sues is essential to maintain tissue homeostasis 
(Swamy et al., 2010). This task is of significant 
importance to skin, a major first line immune 
defense organ that protects the body against 
pathogen-derived and environmental challenges 
(Nestle et al., 2009). In mice, several studies 
have highlighted the critical roles of DCs in 
the regulation of skin immunity and tissue 
homeostasis (Steinman et al., 2003; Reis e Sousa, 
2006; Heath and Carbone, 2009; Merad and 
Manz, 2009). In human skin, studies have 
focused on the functional role of immunostim-
ulatory DCs and their role during skin inflam-
mation (Nestle et al., 2009); however, little is 
known about human tissue-resident DCs with 
regulatory properties. Human blood-derived 
immature DCs have been shown to induce 
IL-10–producing regulatory T (Tr1) cells or 
T cell hyporesponsiveness to antigenic stimula-
tion (Jonuleit et al., 2000; Dhodapkar et al., 
2001). It has also been reported that exposure to 
antiinflammatory or immunosuppressive agents 
can induce a regulatory DC phenotype (Adorini 
et al., 2004). Common features of human reg-
ulatory DCs include altered maturation status, 
reduced T cell stimulatory capacity, and induc-
tion of T regulatory cells (Penna et al., 2005).
In human skin, myeloid DCs that reside in 
the dermis represent a major subset of dermal 
DCs (DDCs) during tissue homeostasis (Nestle 
et al., 2009). Subpopulations of DDCs have been 
described under both normal and pathological 
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Resident CD141 (BDCA3)+ dendritic  
cells in human skin produce IL-10  
and induce regulatory T cells that  
suppress skin inflammation
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Human skin immune homeostasis, and its regulation by specialized subsets of tissue-residing 
immune sentinels, is poorly understood. In this study, we identify an immunoregulatory 
tissue-resident dendritic cell (DC) in the dermis of human skin that is characterized by 
surface expression of CD141, CD14, and constitutive IL-10 secretion (CD141+ DDCs). 
CD141+ DDCs possess lymph node migratory capacity, induce T cell hyporesponsiveness, 
cross-present self-antigens to autoreactive T cells, and induce potent regulatory T cells  
that inhibit skin inflammation. Vitamin D3 (VitD3) promotes certain phenotypic and functional 
properties of tissue-resident CD141+ DDCs from human blood DCs. These CD141+ DDC-like 
cells can be generated in vitro and, once transferred in vivo, have the capacity to inhibit 
xeno-graft versus host disease and tumor alloimmunity. These findings suggest that 
CD141+ DDCs play an essential role in the maintenance of skin homeostasis and in the 
regulation of both systemic and tumor alloimmunity. Finally, VitD3-induced CD141+  
DDC-like cells have potential clinical use for their capacity to induce immune tolerance.
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Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
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significant levels of co-stimulatory molecules, CD80 and 
CD86, and MHC class I and class II molecules (Fig. 1 E). This 
phenotype resembled the steady-state migratory (Kissenpfennig 
et al., 2005) and semimature tolerizing DCs (Lutz and Schuler, 
2002) that have been described in mice. To address in vivo 
migratory capacity of CD141+ DDCs, we established a human-
ized skin transplantation mouse model (Sagoo et al., 2011). 
Human CD45+ leukocytes were detected in lymph nodes, 
but not in spleens, of mice that had received skin transplants 
(Fig. 1 F). Immunofluorescent staining showed both human 
CD3+ and CD141+ cells (Fig. 1 G). Detection of human 
CD141+ transcript in skin-draining lymph nodes via PCR 
confirmed active migration of CD141+ DDCs in vivo (Fig. 1 H). 
Together, human skin-resident CD141+ cells express DC 
markers and display hallmarks of DCs, including dendritic 
morphology, nonplastic adherence, and migratory activity 
in vitro and in vivo.
An important aspect of maintaining tissue homeostasis is 
based on DC capacity to capture, process, and present tissue-
derived self-antigens to self-reactive T cells via the MHC class I 
antigen presentation pathway under steady-state conditions 
(Liu et al., 2002). CD141+ DDCs expressed markers associated 
with cross-presentation, including BATF3, Necl2, the C-type 
lectin CLEC9A, and XC chemokine receptor 1 (XCR1), in 
a pattern similar to human blood CD141+ DCs and mouse 
CD8+ DCs (Bachem et al., 2010; Crozat et al., 2010; Jongbloed 
et al., 2010; Poulin et al., 2010; Fig. 1 I and Table S1). In par-
ticular, macrophage mannose receptor (MMR) and CLEC9A 
were selectively expressed by CD141+ DDCs compared with 
CD1c+ DDCs (Fig. 1, E and J), which may play an important 
role in the cross-presentation of soluble and cell-associated 
antigens (Burgdorf et al., 2006; Sancho et al., 2009). A distinctive 
feature of CD141+ DDCs compared with CD141+ blood DCs 
was the expression of Toll-like receptor (TLR) 4, 7, and 9 
(unpublished data). To determine cross-presentation, CD1c+ 
and CD141+ DDCs pulsed with the model self-antigen 
preproinsulin (PPI) or control protein were co-cultured with a 
human autoreactive CD8+ T cell clone specific for PPI 
(Skowera et al., 2008). PPI-pulsed CD141+ DDCs induced 
significantly higher proliferation of the T cell clone than PPI-
pulsed CD1c+ DDCs (Fig. 1 K). Importantly, cross-presentation 
of PPI by CD141+ DDCs occurred in the absence of proin-
flammatory stimuli such as poly(I:C), which was previously 
shown to be required for cross-presentation by CD141+ blood 
DCs (Jongbloed et al., 2010; Poulin et al., 2010). This suggests 
an intrinsic and unique capacity of CD141+ DDCs to cross-
present self-antigens and may allow regulation of autoreactive 
CD8+ T cell response under noninflammatory, steady-state 
conditions (Liu et al., 2002). Cross-presentation of tissue-
associated self-antigens may significantly contribute to the 
maintenance of skin homeostasis.
CD141+ DDCs produce IL-10  
and induce CD25hi T-regulatory cells
We next investigated the immunoregulatory properties of CD141+ 
DDCs. They expressed high levels of the immunoregulatory 
conditions. Classically, DDCs are CD1c+ with a CD1a+ and 
CD14+ subpopulation (Lenz et al., 1993; Nestle et al., 1993). 
The functional roles of DDC subsets are only partly under-
stood. Zaba et al. (2007) showed that CD1a+ DDCs are 
potent inducers of allogeneic CD4+ and CD8+ T cell prolif-
eration, whereas CD14+ DDCs are less immunogenic and 
might have the potential to differentiate into Langerhans cells 
in response to TGF- (Caux et al., 1996; Larregina et al., 
2001; Klechevsky et al., 2008).
A genome-wide expression profiling study suggested 
that human blood CD141+ DCs may correlate to mouse 
CD8+ DCs (Robbins et al., 2008) and are capable of cross-
presentation. Although CD141+ DCs are present only in small 
numbers in circulating blood, they are found in various 
lymphoid and nonlymphoid tissues (Demedts et al., 2005; 
Narbutt et al., 2006; Tsoumakidou et al., 2006; Zaba et al., 
2007; Fiore et al., 2008; Jongbloed et al., 2010; Poulin et al., 
2010). The functional specialization of CD141+ DCs in human 
skin and other peripheral tissues remains elusive.
In this study, we show that CD141+ DDCs are a major 
IL-10–producing skin-resident DC subset. They induce T cell 
hyporesponsiveness and CD25hi regulatory T cells (T reg cells) 
that suppress skin inflammation. Vitamin D3 (VitD3)–induced 
CD141+ cells generated from blood DCs share phenotypic and 
functional features of skin-resident CD141+ DDCs and are 
powerful regulators of alloimmunity. Adoptive transfer of these 
cells inhibits xeno-graft versus host disease (GvHD) and tumor 
alloimmunity in vivo. Collectively, our data suggest that CD141+ 
DDCs are key immunoregulatory antigen-presenting cells play-
ing a potentially important role in tissue homeostasis and for 
the induction of clinical tolerance.
RESULTS AND DISCUSSION
Identification and characterization  
of a skin-resident CD141+ DDC population
Comprehensive profiling of human skin DCs identified a 
significant percentage of CD141+ DDCs (Fig. 1 A) ranging 
from 14.13 to 53.36% (mean = 30%; SD = 12.08) within the 
viable lineage-negative FSChiSSChiCD45+ migratory dermal 
cell population (Fig. S1). CD141+ migratory DDCs expressed 
CD11c and CD1c at low levels, but lacked expression of 
CD1a (Fig. 1, A and B). Importantly, CD141+ DDCs migrat-
ing from dermal explants coexpressed CD14 on the cell sur-
face. They also expressed skin-relevant myeloid markers such 
as Factor XIIIa and CD163, but not CD103 or C-type lectin 
receptors such as CD209 (DC-SIGN), CD205 (DEC205), 
and CD207 (langerin; unpublished data). CD141+HLA-DR+ 
DDCs were located in a perivascular location in the upper 
dermis (Fig. 1 C). In agreement with the literature, CD141 
expression was also detected on keratinocytes (Raife et al., 
1994). Immunofluorescence staining for filamentous actin of 
flow cytometry–sorted CD141+ DDCs demonstrated a typical 
DC morphology with multiple dendritic processes (Fig. 1 D). 
CD141+ DDCs spontaneously migrated out from human 
dermis in tissue cultures and maintained a semimature pheno-
type, indicated by the absence of CD83, but expression of 
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Figure 1. Identification and characterization of skin migratory CD141+ DDCs. (A and B) Healthy human skin DDCs were stained for CD1c, CD11c, 
CD14, and CD1a. (C) CD141+HLA-DR+ DDCs staining in the upper dermis of normal human skin (arrows). Dashed line indicates epidermal–dermal junction. 
(D) Filamentous actin (F-actin) staining of cell-sorted CD141+ DDCs. (E) CD141+ DDCs or CD1c+ DDCs stained for CD83, CD80, CD86, HLA-ABC, HLA-DR, 
and MMR. (F) Human CD45+ staining of lymph nodes and spleens of BALB/c Rag2/c/ mice bearing human skin transplants (Tx). (G) Human CD141+ 
and CD3 staining in lymph nodes of Tx mice. (H) mRNA expression for human CD141, cyclophilin, and mouse GAPDH in spleens and lymph nodes of  
Tx mice. Blood and skin CD141+ DCs expression of BATF3, Necl2, CLEC9A, and XCR1 (I) and CD141+ DDCs expression of CLEC9A (J) as compared with CD1c+ 
DDCs. (K) CD141+ DDCs or CD1c+ DDCs pulsed with PPI were incubated with autoreactive CD8+ T cell clones and analyzed for proliferation. Net CPM  
represents proliferation of the clone in pulsed DDC co-culture minus nonpulsed DDC co-culture. Error bars indicate SEM. Results are representative of at 
least 30 (A), at least three (B–E), and two (F–K) independent experiments. Two-way ANOVA test; *, P < 0.05.
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However, introducing a neutralizing anti–IL-10 receptor 
antibody significantly reversed the suppression of prolifera-
tion mediated by CD141+ DDCs, whereas no effect was 
observed in CD1c+ co-cultures (Fig. 2 D). During DC–T cell 
co-culture, alloreactive T cells became activated and up-
regulated CD25 expression on the cell surface. Both CD141+ 
and CD1c+ DDCs induced a population of T cells that 
expressed high levels of CD25 (CD141 CD25hi T cells and 
CD1c CD25hi T cells, respectively). CD141+ DDCs induced 
higher surface expression of cytotoxic T lymphocyte antigen-4 
(CTLA-4) on CD25hi T cells than CD1c+ DDCs (Fig. 2 E). In 
addition, CD141 CD25hi T cells, but not CD1c CD25hi T cells, 
were unresponsive to secondary alloantigen restimulation 
(Fig. 2 F). Our previous work has demon-
strated correlation of in vitro hyporespon-
siveness and regulatory function of T cells 
(Lombardi et al., 1994). We then expanded 
the cells in the presence of IL-2 to obtain 
sufficient cell numbers for in vivo functional 
studies (Sagoo et al., 2011). After cell expan-
sion, CD141 CD25hi T cells and CD1c 
CD25hi T cells maintained their expression 
of CD25 and Foxp3 (unpublished data). 
CD141 CD25hi T cells were hyporesponsive 
to secondary TCR stimulation (Fig. 2 G) and 
suppressed CD4+CD25 T effector (T eff) cell 
proliferation, whereas CD1c CD25hi T cells 
enhanced T eff cell proliferation in a dose-
dependent manner (Fig. 2 H).
CD141+ DDCs induce CD25hi T reg  
cells that suppress alloimmune  
cell–mediated skin inflammation
We assessed the in vivo immunoregulatory 
function of DDC-induced CD25hi T cells in 
receptor immunoglobulin-like transcript 3 (ILT3; Chang 
et al., 2002) at the protein and mRNA levels in a consistently 
higher fashion than compared with CD1c+ DDCs (Fig. 2 A). 
In keeping with their immunoregulatory phenotype, CD141+ 
DDCs, but not CD1c+ DDCs, constitutively secreted high 
levels of IL-10 that was significantly enhanced after CD40 
cross-linking (P < 0.05; Fig. 2 B). After CD40L stimulation, 
IL-10 production became detectable in CD1c+ DDCs and 
was boosted in CD141+ DDCs. When co-cultured with allo-
geneic CD4+ T cells, CD141+ DDCs were less proficient than 
CD1c+ DDCs in stimulating T cell proliferation (Fig. 2 C). 
This was not explained by significant differences in expression 
levels of MHC or co-stimulatory molecules (unpublished data). 
Figure 2. CD141+ DDCs are immunoregulatory. 
(A) CD141+ DDCs or CD1c+ DDCs expression of ILT3 
and (B) production of IL-10 in the absence or pres-
ence of CD40 ligand-transfected L cells (CD40L Tx). 
(C) CD141+ DDCs or CD1c+ DDCs stimulation of alloge-
neic CD4+ T cell proliferation. (D) CD141+ DDCs or 
CD1c+ DDCs co-cultured with allogeneic CD4+ T cells 
in the presence and absence of anti–IL-10 receptor 
antibody. CD4+CD25hi T cells induced by CD1c+ DDCs 
(CD1c CD25hi T cells) or CD141+ DDCs (CD141 CD25hi 
T cells) stained for surface CTLA-4 (E) and prolifera-
tion in response to alloantigen stimulation (F).  
(G) IL-2–expanded CD25hi T cells proliferative response 
to secondary polyclonal stimulation and (H) suppression 
of CD4+CD25 T eff cell proliferation. Error bars indicate 
SEM. Results are representative of five (A–C, E, and F) 
and two (D, G, and H) independent experiments.  
Wilcoxon matched pairs test (A), one-way ANOVA 
(B), two-way ANOVA (C, F, and H), or unpaired  
Student’s t test (D, G). *, P < 0.05; **, P < 0.01;  
***, P < 0.001; #, P < 0.05.
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inflammatory skin pathology with increased numbers of epider-
mal T cells, proliferating keratinocytes in the basal epidermal layer, 
and loss of intact CD31+ dermal microvasculature (Fig. 3, B–D). 
our recently described model of human alloimmune cell–medi-
ated skin inflammation (Fig. 3 A; Sagoo et al., 2011). Skin grafts 
from animals receiving allogeneic PBMCs showed typical 
Figure 3. CD141+ DDC-induced CD25hi T reg cells inhibit human alloimmune cell–mediated skin inflammation. (A) Experimental strategy to 
assess CD25hi T cell suppression. BALB/c Rag2/c/ mice transplanted with human skin were injected with PBS, allogeneic PBMCs alone, or in combi-
nation with CD141 CD25hi T cells or CD1c CD25hi T cells. Representative fields from stained skin grafts for epidermal CD3+ T cell infiltration (B, arrows), 
epidermal keratinocyte expression of the proliferation marker Ki67 (C, arrows), and intact human CD31 superficial dermal microvasculature (D, arrows). 
Dashed lines indicate epidermal–dermal junction. Nuclei are stained with DAPI (blue). Bars, 100 µm. (E) Quantitative histological analysis of at least three 
independent visual fields per skin graft. Lines represent the mean (n = 5–9 animals per treatment group). Results are combined data from three 
independent experiments. One-way ANOVA test; **, P < 0.01; ***, P < 0.001.
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and were weak stimulators of allogeneic 
CD4+ T cell proliferation (Fig. 4 D). 
VitD3-induced CD141+ DCs and 
CD141+ DDCs have many similari-
ties, including CD14 and ILT3 co-
expression, semimature phenotype, 
IL-10 production, and poor T cell 
stimulatory capacity. Our findings 
provide a potential cellular link be-
tween VitD3 production and skin 
immune regulation.
Adoptively transferred VitD3–induced  
CD141hi DCs suppress alloimmunity in vivo
Establishment of a method to generate large numbers of 
cells with the immunoregulatory properties of CD141+ 
DDCs would allow the development of adoptive regulatory 
DC therapy in in vivo preclinical models and for develop-
ment of therapeutic applications in patients. We thus investi-
gated a source of DCs generated from blood monocytes after 
incubation with IL-4 and GM-CSF (moDCs). Incubation 
with VitD3 up-regulated CD141 expression on moDCs 
(VitD3 moDCs; unpublished data) and induced the expres-
sion of a molecular profile that resembles CD141+ DDCs 
(Table S1). VitD3 moDCs highly expressing CD141 (CD141hi 
VitD3 moDCs) produced high levels of IL-10 after CD40 
cross-linking and demonstrated a reduced T cell stimulatory 
capacity, as compared with CD141dim VitD3 moDC or moDCs 
(unpublished data). PPI cross-presentation in the presence 
of poly(I:C) stimulation was enhanced in VitD3 moDCs 
compared with control moDCs (unpublished data). We 
assessed the in vivo regulatory capacity of CD141hi VitD3 
moDCs in a human xeno-GvHD model (King et al., 2009; 
Fig. 5 A). Injection of human PBMCs induced xeno-GvHD 
in NSG mice (median survival time [MST] = 32). Co-transfer of 
CD141hi VitD3 moDCs with PBMCs significantly prolonged 
survival time (P < 0.001 versus PBMCs alone; MST = 62), 
whereas no significant protection was conferred by transfer 
of CD141dim VitD3 moDCs (MST = 39; Fig. 5 B). We next 
assessed the immunoregulatory role of CD141hi VitD3 
moDCs in an alloimmune cell–dependent human melanoma 
Co-transfer of CD141 CD25hi T cells protected from the in-
duction of skin pathology in a significant manner, restoring 
markers of pathology to levels observed in control grafts (Fig. 3 E), 
whereas no significant protective effect was seen in mice treated 
with CD1c CD25hi T cells. Together, these data show that 
CD141+ DDCs display both phenotypic and functional charac-
teristics of immunoregulatory DCs and induce T reg cells with 
immunosuppressive capability in vitro and in vivo.
VitD3 induces a CD141+ DDC-like phenotype  
and function in blood DCs
VitD3 has been linked to the immunosuppressive capacity of 
UV light, but human cellular effectors are ill defined (Schwarz 
and Schwarz, 2011). We addressed whether VitD3 could 
induce the unique immunoregulatory characteristics of CD141+ 
DDCs in blood DCs. Culture of CD141CD1c+ blood DCs 
with the active form of VitD3, 1,25-dihydroxyvitamin D3 
(1,25[OH]2D3), induced the coexpression of CD141, CD14, 
ILT3, and MMR (Fig. 4 A). A core module of molecular 
markers present in cross-presenting DCs including BATF3, 
CLEC9A, and Necl2 was also induced in CD141+ VitD3 
blood DCs (Table S1). VitD3-induced CD141+ DCs had 
a stable CD83low immature phenotype after exposure to a 
potent DC maturation cocktail consisting of TNF, IL-1, 
IL-6, and prostaglandin E2 (Fig. 4 B; Jonuleit et al., 1997). 
This was in contrast to VitD3-induced CD141 DCs that 
readily up-regulated CD83 (Fig. 4 B). VitD3-induced CD141+ 
DCs produced significantly higher amounts of IL-10 than 
CD141 DCs after CD40 cross-linking (P < 0.01; Fig. 4 C) 
Figure 4. VitD3 induces CD141+ DDC-
like phenotype in blood DCs. (A) VitD3-
treated blood CD1c+ DC expression of CD141 
with CD14, ILT3, and MMR. VitD3-induced 
CD141+ DCs or VitD3-induced CD141 DCs 
were assessed for their expression of CD83 
and HLA-DR in the presence of a cytokine 
maturation cocktail (B), production of IL-10 
in the presence and absence of CD40L Tx 
stimulation (C), and ability to stimulate allo-
geneic CD4+ T cell proliferation (D). Results 
are representative of at least 12 (A) and 3  
(B–D) independent experiments. One-way 
ANOVA (C) or two-way ANOVA (D);  
**, P < 0.01;  ##, P < 0.01.
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role of DCs residing in mouse tissues, their human counterparts 
are less well characterized. In this study, we identify an immuno-
regulatory CD141+ DC population in dermis of healthy human 
skin and establish culture methods to generate sufficient num-
bers of such cells for future regulatory DC therapy.
CD141+ DDCs coexpressed CD14 with low CD1c 
expression, a phenotypically distinct profile from blood 
CD141+ DCs. Although CD14 is expressed on the cells of 
the monocyte/macrophage lineage in the blood, it is also 
considered a marker of skin DC subsets (Nestle et al., 1993; 
Larregina et al., 2001; Klechevsky et al., 2008). In future 
studies, it will be interesting to investigate whether CD141+ 
DDCs activate follicular helper T cells, as has been shown 
for CD14+ interstitial DDCs (Klechevsky et al., 2008). We 
propose that the coexpression of CD141 and CD14 may be 
model (Fig. 5 C). Injection of PBMCs reduced tumor size 
significantly compared with PBS-injected mice. However, 
tumor size was significantly increased in mice co-injected 
with PBMCs and CD141hi VitD3 moDCs, but not with 
CD141dim VitD3 moDCs or moDCs (Fig. 5 D), suggesting 
suppression of tumor alloimmunity. In line with these find-
ings, we observed a significantly reduced human CD45+ 
cell infiltrate in tumors recovered from CD141hi VitD3 
moDC–injected mice (Fig. 5, E and F). These results indi-
cate that VitD3-induced CD141hi blood DCs have the ability 
to suppress alloimmunity in vivo and are possible candidates 
for regulatory DC therapy approaches.
Immunoregulation at tissue sites is tightly regulated and 
involves key immune sentinels, such as DCs. Although major 
progress has been made in understanding the immunoregulatory 
Figure 5. VitD3-induced CD141hi DCs suppress xeno-GvHD and antitumor immunity. (A) Strategy for preclinical assessment of adoptive cell 
therapy in xeno-GvHD. (B) NSG mice were injected with either PBMCs alone or in combination with moDCs, CD141dim VitD3 moDCs, or CD141hi VitD3 
moDCs to induce xeno-GVHD. Survival was monitored over time. (C) Strategy to determine regulation of antitumor alloimmunity. Tumor size (D) and 
CD45+ infiltration (E and F) were assessed in animals injected with PBMCs alone or in combination with moDCs, CD141dim VitD3 moDCs or CD141hi 
VitD3 moDCs to induce antitumor alloimmunity (E) Quantitative histological analysis of tumor CD45+ infiltration from at least three independent 
visual fields per skin graft. Lines represent the mean (n = 3–6 animals per treatment group). (F) Representative pictures of human CD45+ infiltrates in 
tumors. Nuclei are stained with DAPI (blue). Bars, 100 µm. Results are pooled from three independent experiments (n = 3–6 animals per treatment 
group). One-way ANOVA (E), two-way ANOVA (D), or Mantel-Cox (B) test; **, P < 0.01; ***, P < 0.001; ##, P < 0.01.
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approved by the Institutional Review Board of Guy’s Hospital. Informed 
consent was obtained from all patients and healthy controls before enrollment 
into the study.
Isolation of DDCs. DDC isolation was performed as previously de-
scribed (Nestle et al., 1993). Skin was sliced into long strips, followed by 
5 mg/ml dispase digestion (StemCell) for 2 h at 37°C. Epidermis and loose 
connective tissues in the lower dermis was removed, and dermis was sliced 
into 1–2-mm-thick strips and cultured in RPMI 1640 supplemented with 
50 IU/ml penicillin, 50 µg/ml streptomycin, 2 mM l-glutamine (complete 
RPMI medium, all from Invitrogen), and 10% human AB serum (HS; Sigma-
Aldrich). Nonplastic adherent cells that had migrated out of dermis 48–72 h 
after culture were harvested for flow cytometric analysis. Cell sorting of 
DDC subsets was performed by staining dermal cells with CD45-PECy7 
(eBioscience), CD1c/BDCA1-PE (Miltenyi Biotec), CD141/BDCA3-APC 
(Miltenyi Biotec), and DAPI (Invitrogen), followed by sorting with a 
FACSAria II cell sorter (BD).
Immunodeficient mice. Male and female NOD/scid/IL-2R/ mice 
(NOD.cg-PrkdcscidIl2rgtm1Wjl/SzJ [NSG]; The Jackson Laboratory) and BALB/c 
RAG2/c/ mice (provided by A. Hayday, The London Research In-
stitute, Cancer Research UK, London, England, UK; and P. Gorer, Department 
of Immunobiology, King’s College School of Medicine at Guy’s Hospital, 
London, England, UK) were used between 8 and 12 wk of age. Mice were 
maintained under specific pathogen–free conditions and handled in accor-
dance with the Institutional Committees on Animal Welfare of the UK Home 
Office (the Home Office Animals Scientific Procedures Act, 1986)
Humanized mouse model of skin DC lymph node migration. 
Human skin samples were first keratomed using a hand-held air-powered 
dermatome (Zimmer) to obtain 500–700-µm split-thickness explants con-
sisting of the epidermis and superficial dermis. Explants were kept at 4°C 
in complete RPMI medium and subsequently cut into 1–1.5-cm2 pieces 
and transplanted orthotopically onto the backs of BALB/c RAG2/c/ 
mice, as previously described (Sagoo et al., 2011). Spleens and skin-draining 
lymph nodes were harvested 8–12 wk after transplantation for analysis 
of DDC migration. Cell suspensions were obtained by dissociating spleens 
and lymph nodes through 70-µm nylon mesh strainers (BD). Mouse 
spleens and lymph node cell suspensions were preincubated with Mouse 
Fc Block (BD), and then human leukocytes identified by co-staining 
with anti-human CD45-PECy7 (eBioscience) and mouse CD45-APC/
eFluor780 (eBioscience).
Flow cytometry. The following antibodies were used in different combi-
nations: CD1c-PE and CD141-APC (Miltenyi Biotec); CD45-PECy7 
(eBioscience); CD11c-PerCp/Cy5.5 (BioLegend); CD14-FITC, CD80-PE, 
CD83-FITC, CD86-FITC, and HLA-DR-PE (Invitrogen); CD1a-PE, CD25-
PE, CD45RO-PE, CD152/CTLA-4-APC, CD206/MMR-PECy5, and HLA-
ABC-PE (BD); ILT3-PC5 (Beckman Coulter). Samples were acquired with a 
FACSCanto (BD), and data were analyzed by FlowJo (Tree Star) software.
Immunofluorescence staining. Laser confocal microscopy was performed 
(TCS SP2; Leica). The following antibodies were used to stain OCT-embedded 
cryosections: CD141 (AbD Serotec); CD3 (Dako); human CD45 (eBio-
science); Ki-67 (Abcam); CD31 (Abcam); HLA-DR (BD); goat anti–mouse 
IgG Alexa Fluor 555 or 488 and goat anti–rabbit IgG Alexa Fluor 555 or 488 
(Invitrogen). To determine DC morphology, sorted CD141+ DDCs were 
immobilized on poly-l-lysine coated coverslips (BioCoat; BD) and stained 
with Fluorescent phallotoxins (Invitrogen) according to manufacturer’s 
specification. ProLong Gold antifade reagent with DAPI (Invitrogen) was 
used for nuclear staining.
Blood DCs, monocyte-derived DCs (moDCs), T cell isolation, and 
culturing. PBMCs were isolated from buffy coats by density gradient cen-
trifugation over Lymphocyte Separation Medium (PAA). To obtain CD1c+ 
useful markers to define tissue-resident regulatory DC 
populations. DC populations with a similar phenotype have 
been identified in lung (Demedts et al., 2005), suggesting 
that our findings might extend to CD141+ DCs residing in 
other peripheral tissue sites.
A population of CD103+ DCs coexpressing CD207 has 
recently been identified in the dermis of murine skin as the 
primary migratory DDC subset capable of antigen capturing 
and (cross-)presentation (Bedoui et al., 2009; Henri et al., 2010). 
CD103+CD207+ DCs have been shown to mediate T cell tol-
erance, possibly in the context of their cross-presentation capa-
bility (Waithman et al., 2007) and their ability to induce T reg 
cells (Azukizawa et al., 2011). Given the skin origin, migratory 
capacity, cross-presentation ability, and immunoregulatory char-
acteristics of the CD141+ DDC population described here, 
they may be related to this migratory cross-presenting CD103+ 
DC population. A population of CD26+SIRP DCs that 
shares transcriptomic and functional similarities with mouse 
CD8+ DCs has also been identified in sheep skin (Contreras 
et al., 2010). This suggests a unique functional specialization of 
skin DCs across mammalian species for the maintenance of 
skin tissue homeostasis.
One of the most striking findings was the potent in vivo 
regulatory function of CD141+ DDCs and their induced T reg 
cells, as demonstrated in three independent human in vivo mod-
els of disease. A common denominator across these models was 
the efficient regulation of alloimmune-mediated pathology pro-
viding a framework for the future use of CD141+ DDCs or their 
VitD3-induced functional counterparts in the context of GvHD 
in organ transplantation. On the other hand, specific blockade 
of CD141+ DDCs might be beneficial in the cancer setting.
CD141+ DDCs express various TLRs and CD14, which 
is thought to facilitate microbial clearance and to amplify 
cellular responses (Anas et al., 2010). It is possible that CD141+ 
DDCs may exert antimicrobial or antiviral immunity when 
encountering viral/microbial products or under specific 
environmental conditions. TLR9 ligation was reported to 
reverse the regulatory function of CD8+ DCs and pro-
mote T cell immunity in mice (Rizzitelli et al., 2005). Thus, 
our study does not exclude the possibility that CD141+ 
DDCs may be stimulatory in the context of viral/microbial 
infection and inflammatory skin pathology.
We identified VitD3 as a potent inducer of CD141+ DDC 
phenotype and function. This allowed us to generate large 
numbers of CD141+ DDC-like cells for future use in cell ther-
apy applications. Collectively, our data identify a potent regula-
tory DC that is strategically positioned at epithelial tissue 
sites poised to play an important role in maintaining barrier 
immune homeostasis and to serve as a future therapeutic target 
in conditions of alloimmunity.
MATERIALS AND METHODS
Human samples. Human buffy coats were provided by the National Blood 
Transfusion Centre (South Thames, Tooting, England, UK). Discarded skin 
was obtained from routine plastic surgery of healthy individuals. Human 
studies were conducted in accordance with the Helsinki Declaration and 
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Humanized mouse model of melanoma antitumor alloimmunity. 
To establish a xenograft melanoma model, 5 × 105 human A375 melanoma 
cells (American Type Culture Collection) were injected subcutaneously into 
the flank of adult NSG mice. 5 d after tumor xenografting, 10 × 106 human 
PBMCs were transferred intravenously via the tail vein. To determine 
immunoregulatory ability of VitD3 moDCs, human PBMCs were either 
injected alone or co-transferred with 5 × 105 cell sorted CD141hi VitD3 
moDCs, CD141dim VitD3 moDCs, or moDCs. Tumor size was measured at 
day 15 and day 25 after adoptive transfer and calculated using the formula: 
(short diameter)2 × (long diameter)/2.
Determination of IL-10 production. 2 × 104 DCs were cultured in 96-well 
flat-bottom plates with 100 µl of complete RPMI medium containing 10% HS 
for 2 d in the absence or presence of CD40 ligand-transfected cells (CD40L Tx, 
5 × 104 cells/well). IL-10 levels in the supernatant were assayed by using the 
MILLIPLEX MAP Human Cytokine kit (Millipore) and acquired on a 
Luminex 100 flow-based sorting and detection analyzer (Luminex Corporation).
RNA extraction and quantitative RT-PCR (qRT-PCR). RNA ex-
traction was performed using NucleoSpin RNA XS kit (Macherey-Nagel 
GmbH and Co.) according to manufacturer’s instructions and retrotrans-
cribed into cDNA. Human CD141, CLEC9A, ILT3, BATF3, Necl2, and 
TLR9 expression was assessed by multiplex real-time quantitative RT-PCR 
using TaqMan assays (Applied Biosystems) according to manufacturer’s 
instructions. For each sample, mRNA abundance was normalized to the 
amount of human cyclophilin. Data analysis was performed using the Ct 
method: results were expressed as relative mRNA levels in arbitrary units. 
Where indicated, qPCR products from singleplex assays were run on a 2% 
agarose gel followed by ethidium bromide.
Cross-presentation assays. 20 µg/ml of PPI protein, prepared in-house 
(Skowera et al., 2008), or recombinant CMV protein (Miltenyi Biotec) were 
added to the DDC containing dermal culture prepared from a HLA-A2 
donor. After 48 h, CD1c+ and CD141+DDCs were isolated by cell sorting, 
rested overnight, and then co-cultured with PPI15-24-specific CD8+ T cell 
clone, clone 1E6, as previously described (Skowera et al., 2008).
DDCs pulsed with PPI15-24 peptide 1 h before co-culture were used as 
positive control. Proliferation of clone 1E6 was assessed by [H3]thymidine 
incorporation (1 µCi/well) during the last 18 h of 3-d culture.
Statistical analysis. Statistical analysis was performed using GraphPad Prism 
version 4.0 (GraphPad Software). Results were assessed for normal Gaussian 
distribution, and then analyzed by Mann-Whitney nonparametric Student’s 
t test, Wilcoxon matched pairs test, one-way ANOVA test, two-way ANOVA, 
or Mantel-Cox as appropriate. For markers of skin inflammation quantifica-
tion, at least one independent image was acquired from each individual, and 
every image was counted by two independent researchers blinded from treat-
ment groups. Values of P < 0.05 were considered significant.
Online supplemental material. Fig. S1 shows the gating strategy of skin 
DDCs. Table S1 shows the expression of common molecular markers by 
CD141+ DDCs and VitD3 induced blood DCs. Online supplemental material 
is available at http://www.jem.org/cgi/content/full/jem.20112583/DC1.
We thank Dr. Katie Lacy, Dr. Gayathri Perera, Dr. Rose Mak, Angela Clifford, Sharon 
Jones and Mrs. Jenny Geh and Mr. Ciaran Healy from plastic surgery for help 
with collecting clinical samples. In addition we thank Isabella Tosi for excellent 
management and coordination of our tissue bank. This work would not have been 
possible without the generous help of healthy volunteers and of patients from 
Guy’s and St. Thomas’ Hospital, London.
We acknowledge support by the following grant funding bodies: Wellcome 
Trust Program GR078173MA, Medical Research Council UK Program G0601387, 
Department of Health via the National Institute for Health Research (NIHR) 
comprehensive Biomedical Research Centre award to Guy’s & St Thomas’ NHS 
Foundation Trust in partnership with King’s College London and King’s College 
Hospital NHS Foundation Trust. C.C. Chu is supported by St. John’s Institute of 
myeloid DCs, DC populations were enriched using Dynal DC-enrichment 
kit according to the manufacturer’s specification (Invitrogen). CD1c+ DCs 
were further purified by cell sorting of lineage (CD3, CD14, CD19, and 
CD56)-negative and CD1c-positive populations. Monocytes were isolated 
from PBMCs using CD14 microbeads (Miltenyi Biotec) according to the 
manufacturer’s instructions, and cultured in complete RPMI medium sup-
plemented with 1% single-donor plasma (NBS Totting), 500 IU/ml 
GM-CSF (PeproTech), and 500 IU/ml IL-4 (R&D Systems). Fresh GM-CSF 
and IL-4 were added on day 2 and 5 of a culture period of 7 d.
CD141+ DDC-like DCs were induced by treatment of CD1c+ blood 
DCs with 100 nM VitD3 for 2 d or on day 5 of moDC differentiation. In 
some cases, DCs were matured with TNF (10 ng/ml), IL-1 (10 ng/ml), 
IL-6 (1,000 IU/ml; all from R&D Systems), and prostaglandin E2 (1 µg/ml; 
Sigma-Aldrich) 24 h before harvesting. Where indicated, VitD3-induced 
CD141hi and CD141dim DCs were cell sorted by methods described above.
To study the allostimulatory capacity of DCs, allogeneic CD4+ T cells 
were prepared from buffy coats using RosetteSep human CD4+ T cell 
enrichment cocktail (STEMCELL Technologies) according to the manufac-
turers’ instructions. CD4+ T cells were cultured in 96-well round-bottom plates 
(5 × 104 cells/well) with graded numbers of allogeneic CD141+ and CD1c+ 
DDCs, or VitD3-induced CD141hi and CD141dim DCs. Proliferation of 
alloreactive T cells was assessed by [H3]thymidine incorporation (1 µCi/well; 
GE Healthcare) during the last 18 h of a 5-d culture. In some circumstances, 
because of limiting DDC numbers, responder T cells were scaled down ac-
cordingly resulting in lower thymidine counts. In some cultures, anti–IL-10R 
mAb (3F9; R&D Systems) was added. The optimal dose was determined 
to be 10 µg/ml. DDC-induced CD4+CD25hi T cells were isolated by cell 
sorting CD11cCD4+CD25hi T cells from DDC co-cultures, resting over-
night, and restimulation with CD1c+ DDCs derived from the primary al-
logeneic skin donor. To generate CD4+CD25hi lines, CD4+CD25hi T cells 
were cell-sorted directly into 96-well plates containing RPMI 10% HS and 
left to rest overnight. Subsequently, low dose IL-2 (R&D Systems) was 
added at 250 IU/ml and replenished every 2–3 d. After adequate expansion 
for a period of 4–5 wk, CD25hi T cells were harvested by cell sorting. To 
assess in vitro suppressive capacity, titrated numbers of CD25hi T cells were 
co-cultured with 5 × 104 autologous CD4+CD25 effector T cells for 5 d in 
the presence of CD3/CD28 T cell Expander Dynal Beads (Invitrogen). 
Cell proliferation was measured as described above.
Humanized mouse model of alloimmune cell–mediated skin in-
flammation. BALB/c RAG2/c/ mice bearing human skin trans-
plants were allowed to engraft for 5–6 wk before adoptive transfer of 
human cells. For the total duration of these experiments, purified anti–
mouse Gr1 mAb (100 µg; BioXell) was injected intraperitoneally every 
4–5 d to deplete mouse granulocytes. Allogeneic (to the skin) PBMCs 
depleted of CD25+ cells were then adoptively transferred intravenously 
via the tail vein to induce alloimmune skin inflammation, as previously 
described (Sagoo et al., 2011). The in vivo suppressive capacity of DDC 
induced CD25hi T cells was investigated by co-injecting CD141 CD25hi 
T cells or CD1c CD25hi T cells with PBMCs (autologous to the CD25hi 
T cells and allogeneic to the skin) depleted of CD25+ cells at a ratio of 
1:10 (CD25hi T cells:CD3 composition of PBMCs inoculum); typically 
2.5 × 106 human PBMCs alone or in combination with 1.5 × 105 CD25hi 
T cells. Skin grafts were harvested 3–4 wk after transfer of human cells 
and assessed histologically for markers of skin inflammation.
Humanized mouse model of xeno-GvHD. GvHD was induced by in-
travenous transfer of 10 × 106 human PBMCs into adult NSG mice. Animals 
that developed clinical symptoms of GvHD (severe weight loss, hunched 
posture, fur loss, reduced mobility, and tachypnea) were sacrificed, and 
spleens were harvested for flow cytometric analysis of human cell engraft-
ment. To assess the immunoregulatory potential of VitD3 moDCs in GvHD, 
human PBMCs were either injected alone or co-transferred with 5 × 105 
cell-sorted CD141hi VitD3 moDCs, CD141dim VitD3 moDCs, or moDCs 
with an end point of survival recorded in all treatment groups.
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Summary
Background IgE antibodies, sequestered into tissues and retained locally by the high-affinity
IgE receptor, FceRI, on powerful effector cells such as mast cells, macrophages and
eosinophils, may offer improvements in the therapy of solid tumours. The chimeric antibody,
MOv18 IgE, against the human ovarian carcinoma antigen, folate receptor a (FRa), is more
effective than its IgG1 counterpart in xenograft models of ovarian cancer. Although MOv18
IgE binds to a single epitope on FRa and cannot cross-link IgE receptors on basophils, there
remains a risk that components in the circulation of ovarian cancer patients might cross-link
FRa-MOv18-IgE-receptor-FceRI complexes on basophils to cause type I hypersensitivity.
Objective To assess the propensity for MOv18 used in a therapeutic setting to cause FceRI-
mediated type I hypersensitivity.
Methods As validated readouts of the potential for MOv18 to cause FceRI-mediated type I
hypersensitivity we measured release of a granule-stored mediator from a rat basophilic
leukaemia cell line RBL SX-38 stably transfected with human tetrameric (abg2) FceRI, and
induction of CD63 on blood basophils from patients with ovarian carcinoma and healthy
controls ex vivo.
Results Serum FRa levels were increased in ovarian cancer patients compared with healthy
controls. MOv18 IgE alone, or in the presence of its antigen recombinant human FRa, or of
healthy volunteer (n= 14) or ovarian carcinoma patient (n= 32) sera, did not induce RBL SX-
38 cell degranulation. Exposure to FRa-expressing ovarian tumour cells at target-to-effector
ratios expected within tumours induced degranulation. MOv18 IgE did not induce expression
of CD63 in blood basophils from either healthy volunteers (n= 6), or cancer patients, despite
detectable levels of circulating FRa (n= 5).
Conclusion and Clinical Relevance These encouraging data are compatible with the hypothesis
that, when ovarian carcinoma patients are treated with MOv18, FceRI-mediated activation of
effector cells occurs within the tumour mass but not in the circulation mandating, with due
caution, further pre-clinical studies.
Keywords anaphylaxis, basophil, cancer therapy, CD63, degranulation, FRa, tumour antigen-
specific IgE, type I hypersensitivity
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Introduction
Monoclonal antibodies have become an important treat-
ment modality in the clinical management of both hae-
matological and solid malignancies in the last 25 years
[1]. Nevertheless, many solid tumours such as those of the
ovary remain refractory to treatment, indicating a need to
improve antibody therapeutics, with a particular emphasis
on localization of the antibody and initiation of anti-
tumour immunity within the tumour mass itself.
We have previously investigated means of improving
antibody therapies for solid tumours, using antibodies of
the IgE class [2–7]. Exploitation of the superior tissue
bioavailability and higher Fc receptor affinity of IgE,
compared with IgG antibodies may translate to improved
anti-tumour efficacy. IgE-mediated immune responses
play a role in allergic inflammation and in protection
against parasitic infections [8, 9]. Previous studies have
demonstrated that IgE-mediated immune responses may
be harnessed against malignant cells in tissues [7, 10–14].
MOv18 IgE is a chimeric antibody directed against the
tumour-associated antigen folate receptor a (FRa). We
have shown that it has superior efficacy against solid
ovarian tumours compared with its IgG1 counterpart in
vitro and in two in vivo cancer models [2, 7]. This antibody
may represent a novel paradigm for the treatment of solid
malignancies. FRa, a glycosylphosphatidylinositol-an-
chored membrane protein that binds folic acid, is an
emerging therapeutic target for ovarian cancers [15–17].
It is expressed in 90% of epithelial ovarian carcinomas
and in other types of cancer, but has limited expression in
normal tissues [18, 19]. Elevated FRa expression on
ovarian cancer tumour cells correlates with more aggres-
sive disease and a worse prognosis [18]. Thus FRa would
appear to be a prime molecular target for ovarian carci-
noma and this, together with the aforementioned data
supporting the therapeutic efficacy of MOv18 IgE pre-
clinically supports our enthusiasm for development of this
antibody for clinical studies [2–5, 7].
IgE antibodies can exert anti-tumoural effects by acti-
vating potent FceR-expressing effector cells within
tumours. We have previously reported evidence suggest-
ing that MOv18 IgE can direct monocytes and eosinophils
to kill tumour cells by mechanisms such as antibody-
mediated cytotoxicity and/or phagocytosis [2–4]. In gen-
eral, however, the interactions between this IgE and potent
IgE receptor-expressing immune effector cells, such as
basophils (in the circulation and potentially within tu-
mours) and mast cells (focused in tumour microenviron-
ments), have not been extensively examined [5, 20–22].
To date, IgE has never been used as a therapeutic agent
in patients, and the administration of IgE directed against
a tumour antigen raises the theoretical possibility of
induction of type I hypersensitivity through cross-linking
of IgE molecules bound to FceRI on mast cells and
basophils. It is a requirement, however, that antigens
capable of doing this have two or more IgE binding
epitopes [23, 24] whereas MOv18 binds to only one single
epitope on FRa [25, 26]. Consequently FRa, at least free
and in solution, would not be expected to have the
potential to cross-link surface-bound MOv18 bound to
FceRI although this could at least theoretically occur in
the tumour cells expressing multiple surface FRa mole-
cules within tumour islands.
In this study, we set out to investigate the capacity of
FRa both in solution and expressed on ovarian carcinoma
cells to activate basophils through MOv18 bound to
human FceRI. We adopted two assays used in the allergy
field to examine sensitivity to a range of potential aller-
gens in the presence of sera and blood of allergic indivi-
duals. We measured effector cell activation by functional
degranulation with the humanized rat basophilic leukae-
mia (RBL) SX-38 cell line, and used the basophil activa-
tion test (BAT), based on detection of the activation
marker, CD63, on basophils in the blood of healthy
volunteers and ovarian carcinoma patients. With these
experiments we account for any factors in blood that
might recognize the tri-molecular complexes of FRa-
MOv18 IgE-FceRI on basophils, which could contribute
to a risk of type I hypersensitivity in the proposed
immunotherapy.
Methods
Human subjects and sera
Following written informed consent, sera from the per-
ipheral blood of patients with stage III and IV ovarian
cancer or healthy volunteers were collected and isolated
by centrifugation of clotted blood at 1800 g for 15min at
room temperature. Sera were also collected from ovarian
cancer patient peripheral blood as part of baseline studies
before a clinical trial [27]. For the basophil activation
assay (BAT), whole blood specimens of patients with stage
III and IV ovarian cancer or healthy volunteers were
freshly collected in 1.8mg/mL K2EDTA and assayed im-
mediately.
Cell culture
Cells of the RBL SX-38 RBL cell line stably expressing the
human tetrameric (abg2) high-affinity IgE receptor, FceRI
[28], (a kind gift from Prof. J-P. Kinet, Harvard University,
Boston, MA) were cultured in EMEM, 10% FCS, 1.2mg/mL
Geneticin G418 (Gibco, Invitrogen, Paisley, UK). Human
ovarian carcinoma IGROV-1 cells [3, 7], naturally over-
expressing the human FRa, were cultured in RPMI 1640,
10% FCS and murine colon adenocarcinoma cells CT26 [6]
in IMDM, 5% FCS. Cultures were maintained in a humidi-
fied incubator at 37 1C.
c 2011 Blackwell Publishing Ltd, Clinical & Experimental Allergy, 41 : 1400–1413
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Flow cytometric assessments of MOv18 immunoglobulin
E and antigen binding to effector cells
RBL SX-38 cells (2105 cells per sample) were incubated
with 0.5 mg/mL MOv18 IgE in 0.2mL FACS buffer (PBS,
5% FCS, Invitrogen), followed by 3mg/mL goat anti-
human IgE-FITC (Vector Labs, Peterborough, UK) or
200ng/mL human recombinant FRa [25], 3mg/mL goat
anti-human FRa (R&D Systems, Abingdon, UK) and donkey
anti-goat-Ig-Alexa Fluors 448, (all in FACS buffer). For
MOv18 IgE binding to human basophils in unfractionated
blood, 100mL blood diluted 1 : 1 with FACS buffer was
incubated with MOv18 IgE, anti-IgE-FITC and mouse anti-
CD123-RPE-Cy5 (BD Biosciences, Oxford, UK) or isotypic
control IgG1/RPE-Cy5 (1mg/mL, Dako, Stockport, UK) for
30min at 4 1C. Red blood cells were removed with 2mL lysis
buffer (155mM NH4Cl, 10mM KHCO3, 100mM EDTA) for
10min at room temperature. Cells were acquired on a dual
laser FACSCanto (BD Biosciences) until at least 500 basophil
(SSClowCD123high) events were recorded per sample.
Rat basophilic leukaemia SX-38 degranulation assays
We assessed degranulation of RBL SX-38 cells bymeasuring
b-hexosaminidase release, as before [6, 28, 29]. Controls
were: unstimulated cells; Triton X-100 lysed cells (to
quantify 100% granule release); chimeric NIP IgE against
the hapten 5-iodo-4-hydroxy-3-nitrophenyl (AbD Serotec,
Kidlington, UK) with or without polyclonal antigen NIP-
bovine serum albumin (BSA) [30]; NIP IgE plus polyclonal
rabbit anti-IgE (Dako). Cells were seeded at 1104 cells per
well in culture medium overnight and sensitized with IgE
(200ng/mL), control antibody or medium alone. Samples
were incubated at 37 1C for 1h, washed 3 in stimulation
buffer (HBSS, 1% BSA; Invitrogen) and stimulated for
30min at 37 1C with 100mL FRa [25], human sera (1 : 100
dilution), NIP-BSA, or rabbit anti-IgE (200ng/mL). To detect
b-hexosaminidase, 50mL culture supernatants diluted 1 : 1
in stimulation buffer, were transferred onto black 96-well
plates with 50mL fluorogenic substrate per well (1mM 4-
nethylumbelliferyl N-acetyl-b-D-glucosaminide 0.1%
DMSO, 0.1% Triton X-100, 200mM citrate, pH 4.5) and
incubated for 2 h in the dark. Reactions were quenched with
100mL per well 0.5 M Tris and plates read with a Fluostar
Omega microplate reader (350nm excitation, 450nm emis-
sion) (BMG Labtech, Offenburg, Germany). Degranulation
was expressed as a percentage of Triton X-100 release, and
compared with unstimulated cells (o10%).
Enzyme-linked immunosorbent assay to detect circulating
folate receptor a
To quantify circulating FRa in human sera, 96-well plates
were coated overnight at 4 1C with 2 mg/mL mouse anti-
human FRa (IgG1, R&D Systems) in 0.2 M carbonate-bicar-
bonate buffer, pH 9.4. Plates were given blocking buffer
(SuperBlock buffer, 0.05% Tween-20; Perbio Science UK
Ltd, Cramlington, UK) for 2 h at room temperature, washed
4 with PBS, 0.05% Tween-20 (washing buffer) and given
recombinant FRa [25] or sera (1 : 5 in blocking buffer) and
incubated for 2 h at room temperature. All conditions were
tested in triplicate. Plates were washed 4, incubated with
50ng/mL goat anti-FRa-biotin in blocking buffer (R&D
Systems) for 2 h at room temperature, washed again 4,
and given 50ng/mL streptavidin-HRP (Pierce, Thermo Fish-
er Scientific, Cramlington, UK) in blocking buffer for 30min
at room temperature. Following five washes, samples were
treated with 0.5mg/mL o-phenylenediamine dihydrochlor-
ide substrate (Sigma-Aldrich, Gillingham, UK) in peroxide
substrate buffer (Pierce) for 5min at room temperature.
Following addition of 50mL per well stop solution (1M
HCl), plates were read at 492nm (reference wavelength
650nm) on a Fluostar Omega microplate reader. The lower
limit of quantification of FRa in this assay was 1.25 ng/mL.
Enzyme-linked immunosorbent assay to detect circulating
anti-folate receptor a immunoglobulin G autoantibodies
To quantify anti-FRa IgG autoantibodies in human sera, 96-
well plates were coated overnight at 4 1C with 1mg/mL
recombinant human FRa (R&D Systems) in 0.2M carbo-
nate-bicarbonate buffer, pH 9.4. Plates were incubated in
blocking buffer (SuperBlock buffer, 0.05% Tween-20; Perbio
Science UK Ltd) for 2 h at room temperature, washed 4x with
PBS, 0.05% Tween-20 (washing buffer) and incubated with
MOv18 IgG or human sera (1 : 5 in blocking buffer) for 2 h at
room temperature. All conditions were tested in triplicate.
Plates were washed 4, and incubated with 160ng/mL
F(ab0)2 goat anti-human Fcg-HRP (Jackson ImmunoRe-
search, Stratech, Newmarket, UK) in blocking buffer (Stra-
tech) for 45min at room temperature. Following five washes,
samples were treated with 0.5mg/mL o-phenylenediamine
dihydrochloride substrate (Sigma-Aldrich) in peroxide sub-
strate buffer (Pierce) for 5min at room temperature. Follow-
ing addition of 50mL per well stop solution (1M HCl), plates
were read at 492nm (reference wavelength 540nm) on a
Fluostar Omega microplate reader. The lower limit of quan-
tification of anti-FRa IgG in this assay was 2.5 ng/mL.
Whole blood basophil activation test
Activation of human basophils ex vivo was measured
using a standard BAT, which measures up-regulation of
CD63 on (CCR3highSSClow) basophils in whole human
blood as described previously [31, 32]. Briefly, blood
collected in 1.8mg/mL K2EDTAwas assayed using a FLOW
2 CAST basophil activation kit (Bu¨hlmann, Scho¨nenbuch,
Switzerland) and acquired within 4h on a dual laser
FACSCanto (BD Biosciences, Oxford, UK). To 100mL blood
were added 150mL of stimulation buffer alone
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(background), or 100mL ‘stimulus’ with 50mL stimulation
buffer. Stimuli included positive controls, e.g. 1mg/mL anti-
human FceR1 polyclonal or anti-human IgE polyclonal
antibodies, or MOv18 IgE (ranges from 0.03 to –10mg/mL).
Some blood samples pre-incubated with MOv18 IgE were
given 100mL human recombinant FRa solution (8–333ng/
mL) and incubation continued for a further 10min. Samples
were finally incubated with staining reagent (0.1mg/mL
mouse anti-human CCR3-PE and CD63-FITC antibodies) at
37 1C for 10min before acquisition of at least 500 basophil
(CCR3highSSClow) events per sample.
Live cell imaging
IGROV-1 tumour cells were seeded at 2104 cells/well onto
12-well glass-bottomed plates (MatTek, Ashland, MA, USA)
and labelled with 500mL of 2mM Calcein AM per well
(Molecular Probes, Invitrogen) for 30min, washed and resus-
pended in RPMI 1640 medium, with 10% FCS. RBL SX-38
cells (2105/mL) were labelled for 30min at 37 1C with 2mg/
mL Cholera Toxin B subunit Alexa Fluors 647 (Invitrogen),
which binds ganglioside 1 (GM1), and is a marker of granule
cycling [33, 34]. Cells were washed and treated with MOv18
IgE or NIP IgE in medium for 30min. The adherent labelled
tumour cells and 4104 RBL SX-38 cells/well were incubated
for 30min at 37 1C in a humidified chamber. Images were
captured using a Zeiss AxiovertZ.1 microscope (Welwyn
Garden City, UK) (with incorporated Calibri System) equipped
with a Plan-Apochromat 63/1.4 oil DIC objective, Axio
CamMR3 camera and AxioVision software system (Carl
Zeiss). Measurements of mean fluorescence intensity per cell
(MFISD, five image fields per condition) were conducted
using ImageJ version 1.4 image processing and analysis
software (http://rsbweb.nih.gov/ij/index.html).
Statistical methods
A two-tailed Student’s t-test was used to compare % RBL
SX-38 cell degranulation and FRa concentrations in patient
and healthy control sera (values Po0.05, were considered
statistically significant). Linear regression analysis was used
to assess correlation between degranulation with MOv18 IgE
and FRa titres in patient serum samples. Statistical analyses
were performed using GraphPad Prism version 5.03.
Results
MOv18 immunoglobulin E and soluble antigen do not
trigger effector cell degranulation
We explored whether MOv18 IgE triggers FceRI-mediated
degranulation of RBL SX-38 cells, a validated model of
human FceRI cross-linking in the presence of specific IgE
and polyvalent allergens (Fig. 1a) [28, 35, 36]. Flow
cytometric analysis confirmed that MOv18 IgE bound to
almost 100% of the human FceRI-bearing cells, and that
FRa in turn bound to virtually all of the IgE-primed cells
(Fig. 1b). Cellular degranulation was measured by b-
hexosaminidase release expressed as a percentage of that
measured with Triton X-100 detergent (complete cell
lysis). Unstimulated and NIP IgE-stimulated cells triggered
background degranulation (o10% of Triton X-100, Fig.
1c). NIP IgE with its multivalent antigen NIP BSA or with
polyclonal anti-IgE cross-linking FceRI-bound IgE, trig-
gered detectable degranulation (meanSD, 34.54.1%,
25.42.9%, respectively, n= 3) [37].
We then investigated whether MOv18 IgE alone or in
the presence of soluble FRa can trigger degranulation. As
with NIP IgE, MOv18 IgE alone did not induce degranula-
tion (1.51.1%), but MOv18 IgE cross-linked by polyclo-
nal anti-IgE antibody induced appreciable degranulation
(37.66.7%). Degranulation was also triggered through
cross-linking of cell surface MOv18 IgE-bound FRa by an
anti-FRa polyclonal antibody (15.40.7%) to mimick the
effect of a multimeric antigen or of tumour cells bearing
multiple copies of the antigen. When cells were incubated
with MOv18 IgE and increasing concentrations of recom-
binant FRa (1.9–1000 ng/mL) we measured background
degranulation, even at supra-physiological concentra-
tions (4100 ng/mL) and concentrations 410-fold
(400–1000 ng/mL) in excess of those reported in ovarian
cancer patient blood [39] (Fig. 1d).
MOv18 immunoglobulin E does not stimulate
degranulation in the presence of sera from ovarian
carcinoma patients or healthy volunteers, despite
detectable circulating folate receptor a
We examined whether MOv18 IgE-primed RBL cells showed
evidence of FceRI-dependent activation in the presence of
naturally shed, circulating FRa in sera from patients with
ovarian carcinoma. Sera from 32 patients with stage III or
IV disease caused minimal degranulation which was not
statistically different to that observed in the presence of 14
normal control sera (2.451.53% vs. 3.052.40%, P40.05;
Table 1, Fig. 2a) despite the fact that the median FRa
concentration in the patients’ sera was clearly and signifi-
cantly elevated compared with that measured in the normal
sera (P= 0.006, Fig. 2b). No significant differences in
degranulation were measured in relation to disease stage:
sera from patients with stage III disease (n= 20) compared
with sera from patients with stage IV ovarian carcinoma
(n= 12, P40.05). We measured very low FRa levels in 14
healthy volunteer sera (1.73 ng/mL) and FRa titres above
the mean in the healthy volunteer cohort in 19 out of 30
ovarian carcinoma patient sera (5.48 for stage III, 9.59ng/
mL for stage IV groups; total mean 7.1 ng/mL, Table 1).
What little degranulation was observed in the presence of
patient sera did not correlate with the disease stage or
absolute serum concentration of FRa (Fig. 2c).
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Immunoglobulin E and tumour cells trigger degranulation
in an antigen-dependent manner
A large proportion of ovarian carcinoma cells over-
express FRa on their cell surface. MOv18 IgE may bridge
effector and tumour cells, triggering FceRI cross-linking
through multiple copies of cell surface FRa (Fig. 3a). To
explore the consequences of this interaction, RBL SX-38
cells were sensitized with MOv18 IgE and incubated with
serially increasing numbers of FRa-expressing IGROV-1
ovarian carcinoma cells (Fig. 3b). We were able to detect
significant degranulation at higher IGROV-1 : RBL SX-38
cell ratios (415 : 10), but not at the lower ratios (o8 : 10)


































































MOv18 IgE + FRα
Fig. 1. MOv18 IgE and soluble FRa bind to RBL SX-38 cells and do not stimulate degranulation. (a) Schematic diagram of the monovalent interaction
between shed FRa and MOv18 IgE on the surface of effector cells. (b) Flow cytometric assay demonstrating MOv18 IgE binding to RBL SX-38 cells (solid
line histogram: MOv18 IgE; grey histogram: goat anti-IgE-FITC antibody control); and FRa binding to MOv18 IgE-primed RBL SX-38 cells (solid line
histogram: MOv18 IgE1FRa1goat anti-human FRa1donkey anti-goat-Alexa Fluors 448 antibodies; grey histogram: MOv18 IgE1goat anti-human
FRa1donkey anti-goat-Alexa Fluors 448 antibodies). (c) b-hexosaminidase release showing % degranulation relative to Triton X-100. Minimal
degranulation was seen with cells alone, control antibody NIP IgE, its polyclonal ligand NIP-BSA, or polyclonal anti-IgE antibody alone. Significant
degranulation is observed with samples given NIP IgE1NIP-BSA or NIP IgE1anti-IgE. (d) Degranulation with MOv18 IgE plus anti-IgE and minimal
degranulation with MOv18 IgE alone and MOv18 IgE plus recombinant FRa (1.9–1000 ng/mL). Scale bars indicate mean valuesstandard deviation [38]
of n=3 experiments, all conditions were tested in triplicate. FRa, folate receptor a; RBL, rat basophilic leukaemia; BSA, bovine serum albumin.
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Table 1. Percent RBL SX-38 cell degranulation in the presence of MOv18 IgE and measurement of serum FRa levels in human sera from (A) healthy
volunteers and (B) ovarian carcinoma patients
Volunteer no. Serum origin % Degranulation [FRa] (ng/mL)
(A) Healthy volunteers
1 Healthy 2.68 ND
2 Healthy 0.99 2.30
3 Healthy 1.10 ND
4 Healthy 0.97 ND
5 Healthy 2.78 10.01
6 Healthy 1.66 ND
7 Healthy 2.13 2.74
8 Healthy 3.34 ND
9 Healthy N/A ND
10 Healthy 3.65 ND
11 Healthy 1.91 ND
12 Healthy 2.64 9.15
13 Healthy 9.43 ND
14 Healthy 6.38 ND
MeanSD Mean [FRa]SD
3.052.40 1.733.45
Volunteer no. Serum origin Stage Histological subtype Primary treatment/relapse % Degranulation [FRa] (ng/mL)
(B) Ovarian carcinoma patients
15 Patient 3 PD serous Primary 1.44 5.18
16 Patient 3 Serous Primary 3.27 ND
17 Patient 3 Serous Primary 3.17 21.01
18 Patient 3 Papillary serous Primary 3.92 N/A
19 Patient 3 Serous Primary 1.27 8.27
20 Patient 3 PD serous 1st relapse 1.38 ND
21 Patient 3 Serous adeno 1st relapse 1.66 2.58
22 Patient 3 PD serous 1st relapse 1.40 5.62
23 Patient 3 Papillary serous 1st relapse 3.22 ND
24 Patient 3 Serous adeno 1st relapse 3.55 6.82
25 Patient 3 PD serous 1st relapse 1.29 5.50
26 Patient 3 WD serous 1st relapse 3.01 14.90
27 Patient 3 Serous adeno 1st relapse 3.14 1.60
28 Patient 3 Serous fallopian 1st relapse 1.85 15.85
29 Patient 3 Not known 1st relapse 1.68 ND
30 Patient 3 Primary Peritoneal 1st relapse 1.24 6.30
31 Patient 3 Not known 1st relapse 1.40 ND
32 Patient 3 Not known 1st relapse 2.24 1.53
33 Patient 3 PD serous 1st relapse 2.57 3.45
34 Patient 3 PD serous 1st relapse 2.41 N/A
MeanSD Mean [FRa]SD
2.260.90 5.486.14
35 Patient 4 Clear cell 5th relapse 2.47 12.67
36 Patient 4 Serous 4th relapse 4.04 1.59
37 Patient 4 MD serous 1st relapse 0.0 14.26
38 Patient 4 PD adeno 5th relapse 8.70 ND
39 Patient 4 Adeno 2nd relapse 2.50 21.01
40 Patient 4 PD adeno 3rd relapse 2.40 2.50
41 Patient 4 Pap serous Primary 1.60 ND
42 Patient 4 Serous Primary 3.70 5.64
43 Patient 4 Clear cell 1st relapse 2.76 34.45
44 Patient 4 Serous 1st relapse 2.85 11.84
45 Patient 4 Adeno 2nd relapse 2.14 9.67
46 Patient 4 Clear cell 1st relapse 0.0 1.49
c 2011 Blackwell Publishing Ltd, Clinical & Experimental Allergy, 41 : 1400–1413
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patients with ovarian cancer (equivalent too8103 tumour
cells/104 effector cells, typical basophil counts per mL
blood) (Fig. 3b; supporting information Table S1) [34,
40–45]. Tumour cells that did not express FRa did not
induce degranulation, even at high tumour : effector cell
ratios (6 : 1), suggesting that the phenomenon is antigen-
specific.
We confirmed that RBL SX-38 cells (red) were activated
in the presence of MOv18 IgE and tumour cells using live
cell imaging (Fig. 3c) to monitor membrane motility and
exocytosis after labelling of cell membranes with cholera
toxin B subunit [33, 34]. We observed enhanced mobiliza-
tion of cytoplasmic granules (reduction of red cytoplasmic
fluorescence) by RBL SX-38 cells incubated with MOv18
IgE after 15 and 30min in culture (depicted by reduction
in mean fluorescence intensity per cell, MFISD, mea-
sured at 58.326.4% and 36.617.2% of original after 15
and 30min respectively, n= 5) compared with samples
treated with control NIP IgE antibody (91.415.5% and
77.514.9%, n= 5, P = 0.028).
Examination of early signals of blood basophil activation
ex vivo following administration of MOv18
immunoglobulin E by the basophil activation test assay
To determine whether MOv18 IgE activates blood baso-
phils from patients with ovarian carcinoma directly ex
vivo we used the BAT using CD63 as a readout of basophil
activation [31, 46]. Figure 4 summarizes a typical set of
experiments in a healthy control. Human basophils
(CD123highSSClow) bound MOv18 IgE (CD123highIgE1),
and basophils (CCR3highSSClow) expressing CD63
(CCR3highCD631) were detected in the presence of stimuli
(Figs 4a and b). Only 2.3% of unstimulated basophils
expressed CD63, in agreement with previous reports [32].
This increased to 81.48% and 89.58% following cross-
linking of FceRI with either polyclonal anti-FceRI (Fig. 4b)
or anti-IgE (Figs 4c and d) antibodies respectively. In
contrast a range of concentrations of MOv18 alone
(0.03–3.5 mg/mL) did not augment CD63 expression (Figs
4c and d).
We further investigated whether MOv18 IgE and soluble
FRa can trigger basophil activation in whole human blood
from healthy volunteers. In the presence of MOv18 IgE,
addition of exogenous FRa even at concentrations 10-fold
higher than those observed in patients (333 ng/mL, n= 6)
did not augment CD63 expression (Figs 5a and b). Simi-
larly, addition of MOv18 IgE to blood of five patients with
ovarian carcinoma did not result in detectable augmenta-
tion of CD63 expression (Figs 5c and d) despite the fact
that all five patients had detectable circulating concentra-
tions of FRa (Table 1). In contrast, cross-linking with anti-
FceRI or anti-IgE polyclonal antibodies clearly augmented
CD63 expression (supporting information Figure S1).
We also examined sera from 24 patients in which we had
detected the presence of circulating FRa antigen (Table 1)
for the presence of anti-FRa IgG autoantibodies that might
crosslink sFRa bound to MOv18 IgE-sensitized basophils.
We found no detectable increase above background in sera
from 18 of these patients. In the remaining six patients and
we detected concentrations in the range of 3.23–42.64ng/
mL (supporting information Table S2). When tested in the
RBL SX-38 assay, sera from these patients did not trigger
any functional degranulation in the presence of MOv18
IgE. Further, in two patients with detectable autoantibo-
dies, we could detect no increase in CD63 expression by
the patients’ blood basophils using the BAT.
Discussion
The human immune system uses five classes of antibodies
to combat disease. Each antibody class operates in differ-
ent anatomical compartments, and functions through
unique Fc-receptors and immune effector cells. Under-
standing how antibody class influences the nature of the
immune response harnessed against cancer cells may be
key in the design of future effective antibody therapeutics.
Research to-date has mostly focused on developing IgG
antibodies, the most abundant circulating antibody class,
and all antibodies currently licensed for cancer therapy
are IgG. We have previously shown, using ovarian xeno-
graft models in immunodeficient mice, that survival
following treatment with the anti-FRa chimeric antibody
MOv18 IgE with human PBMC as effector cells is superior
to that with MOv18 IgG1 [2–5, 7]. This suggests that
harnessing IgE as a therapy for human cancer may
Table 1. continued
Volunteer no. Serum origin Stage Histological subtype Primary treatment/relapse % Degranulation [FRa] (ng/mL)
MeanSD Mean [FRa]SD
2.762.24 9.5910.29
Overall meanSD Overall mean [FRa]SD
2.451.53 7.128.15
Patients tested in whole blood basophil activation assay (Fig. 5).
ND, not detected, depicting [FRa] values below 1.5 ng/mL; N/A, not analysed; PD, poorly differentiated; WD, well differentiated; MD, moderately
differentiated; FRa, folate receptor a.
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provide increased efficacy compared with IgG-based
therapies. However, before this hypothesis can be tested
in patients, it is important to demonstrate that this
approach is not likely to trigger type I hypersensitivity.
In the present study we made use of the RBL SX-38 cell
line to examine human FceRI-mediated effector activity
through recognition of MOv18 IgE and its antigen FRa,
excluding variability associated with the use of human
mast cells and basophils. These are difficult to obtain in
sufficient purity and numbers and have to be stripped of
bound endogenous IgE, an aggressive procedure. In con-
trast, RBL cells express pristine, unoccupied, human
tetrameric FceRI which can be saturated with IgE anti-
bodies of interest. While in theory RBL cells may differ
physiologically from human cells, in practise they have
shown high sensitivity and specificity for detecting the
capacity of various allergens to induce type I hypersensi-
tivity after sensitization by IgE from the serum of allergic
human subjects using release of the granule protein b-
hexosaminidase as a readout [28, 35, 48, 49].
We have shown that MOv18 IgE in the presence of
recombinant FRa antigen does not trigger degranulation
in this system, whereas cross-linking of FceRI with an
anti-FceRI antibody or an antibody recognizing MOv18
IgE-bound FRa on the surface of RBL SX-38 cells does
trigger degranulation. These data suggest that once cross-
linked, MOv18 IgE-FRa complexes can mediate effector
cell activation, while FRa is inactive in its monomeric
form. To account for any effects on effector cell activation
mediated by circulating FRa antigen released from tu-
mour cells of patients, we measured serum concentrations
of FRa by ELISA. In agreement with previous studies [39],
we measured increased circulating antigen in patients
compared with healthy volunteers. Nevertheless, MOv18
IgE did not trigger degranulation of the readout cells in
the presence of sera from either cohort. These findings are
consistent with the hypothesis that soluble FRa antigen
binds to, but does not cross-link surface-bound MOv18
IgE. The presence of patient serum also takes some
account of effects of other circulating agents that may
potentially cross-link FceRI such as endogenous anti-FRa
autoantibodies, which we detected in sera of a subset of
patients. Nevertheless, our admittedly somewhat limited
data so far showed no evidence that these antibodies
triggered activation of the relevant readout cells.
In an ex vivo setting, MOv18 IgE similarly did not
induce early signs of basophil activation in the blood of
patients with ovarian carcinoma, even at concentrations
of 10 mg/mL, which we estimate as equivalent to a clinical
therapeutic dose of 1mg/kg. Here, we used the BAT tool,
an emerging assay which has demonstrated sensitivity
and specificity in the clinical diagnosis of type I hyper-
sensitivity to a range of allergens including venom, latex,
food allergens and drugs [31]. A caveat with these experi-
ments is that the responder basophil FceRI receptors are
likely to be partly occupied with endogenous IgE ex vivo,
allowing only partial occupancy by MOv18 IgE. On the
other hand, these experiments take further account of any
additional factors found in whole blood (but removed in
the isolation of serum), that could trigger IgE-mediated
basophil activation, such as circulating immune effector
cells and, in cancer patients’ blood, circulating tumour
cells or fragments.
Although quantification of circulating tumour cells in
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Fig. 2. Sera from ovarian carcinoma patients do not stimulate MOv18
IgE-primed RBL SX-38 cell degranulation despite elevated FRa concen-
trations. (a) b-hexosaminidase release assays performed with 14 healthy
volunteer and 32 ovarian carcinoma patient sera; degranulation was
minimal in both groups with no significant differences observed between
groups (P40.05). (b) Serum samples from the above cohort were
quantified by ELISA: [FRa] increased in ovarian carcinoma patients
compared with healthy volunteers (P= 0.006). (c) No correlation
(r2 = 0.008) is seen between % degranulation and serum [FRa] in the
ovarian carcinoma patient cohort. NS, not significant; FRa, folate
receptor a; RBL, rat basophilic leukaemia.
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the range of 0–566 cells/mL have been reported [40, 41,
43–45], except for one report of a patient with as many as
3118 tumour cells/mL [42]. Our data show that even at a
tumour cell burden of 4000 cells/mL (a density above any
reported in cancer patient blood), MOv18 IgE induced
minimal FceRI-mediated activation of readout cells
(Fig. 3), and did not augment CD63 expression on baso-



















Target : effector ratio
(c)
Fig. 3. MOv18 IgE stimulates RBL SX-38 cell degranulation in the presence of increasing numbers of IGROV-1 tumour cells. (a) Schematic diagram of
FRa-expressing tumour cell cross-linking FceRI-bound MOv18 IgE on mast cells. (b) Degranulation of RBL SX-38 mast cells treated with MOv18 IgE in
the presence of increasing numbers of IGROV-1 tumour cells. Significant degranulation was detected with increasing Target:Effector cell ratios
(415 : 10). Minimal degranulation is seen with non-FRa-expressing tumour cells (CT26). Scale bars indicate mean valuesstandard deviation [38] of
n=3 experiments, all conditions were tested in triplicate. (c) Left: Representative images of RBL SX-38 cell (labelled with Cholera Toxin subunit B, red)
membrane mobilization in the presence of IGROV-1 tumour cells (labelled with Calcein AM, green) with MOv18 IgE (top panel) or control NIP IgE
antibody (bottom panel) following 0, 15 and 30min at 37 1C (magnification 63/1.4 oil DIC objective, scale bars: 20 mm). Right: Quantitative
assessments of % mean fluorescence intensity (MFISD) per cell for Cholera Toxin subunit B-labelled RBL SX-38 cells (red fluorescently labelled cells
from left), measured after 15 and 30min with either MOv18 IgE or control NIP IgE antibodies (n= 5), showing reduced % MFI for MOv18 IgE cells
(P=0.028), which depicts enhanced membrane mobilization in the presence of antigen-specific antibody and tumour cells. FRa, folate receptor a; RBL,
rat basophilic leukaemia.
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that, in some MOv18-treated patients antibody-induced
tumour cell death could release fragments of tumour cells
from lesions that might activate basophils in the periph-
ery. On the other hand our previous studies [2–4] suggest
that MOv18 IgE triggers not only cytotoxicity, but also
substantial tumour cell infiltration and phago‘cytosis by
monocytes/macrophages that may limit their escape into
the circulation. We will monitor this in patients treated
with MOv18 IgE by repeated skin prick and intradermal
testing with the antibody before each dosage by monitor-
ing serum concentrations of FRa, b-tryptase and by
repeated basophil activation testing with MOv18 in the
patient’s own whole blood.
At high tumour cell concentrations, where the density
of epitope arrayed on the tumour cell surface may
stimulate effector cells through IgE cross-linking, we did
observe significant FceRI-mediated activation of readout
cells (Fig. 3). We speculate that this may resemble the
situation where tumour deposits are infiltrated by effector
cells. Infiltration of some tumours by mast cells is well
described [20, 21]. This may trigger IgE-specific anti-
tumour immune mechanisms in the resident mast cells
and possibly infiltrating basophils, as we have previously
observed for monocytes and eosinophils [2, 3, 6, 7]. We are
aware that a number of studies with other cancers have
































Fig. 4. MOv18 IgE does not trigger CD63 expression in whole human blood. (a) Flow cytometric dot plots identify basophils in whole blood
(CD123highSSClow, left), and basophils bind MOv18 IgE (CD123highIgE1, right). Basophil activation assessments with representative two-colour dot plots
of: (b) % CCR3highSSClow basophils (gated, left) expressing CD63 in unstimulated blood (CCR3highCD631, middle), and with anti-FceRI polyclonal
antibody [47]; (c) Increased % CCR3highCD631 basophils with anti-IgE polyclonal antibody (left), but not with MOv18 IgE (0.7mg/mL, right). (d) %
CCR3highCD631 basophils in whole blood titrated with either MOv18 IgE or anti-IgE polyclonal antibody (0.03–3.5 mg/mL). Scale bars indicate mean
valuesstandard deviation [38] of n=5 experiments, all conditions were tested in triplicate.
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immune effector cells, such as monocytes, in tumours has
been correlated with tumour progression [20, 21], and that
activation of mast cells within a tumour mass may at least
in theory trigger hypersensitivity in situ. Nevertheless the
data we have so far concerning the effects of MOv18 IgE
on tumour killing and progression in animal models
suggest added benefits of MOv18 IgE over IgG antibodies
and have not so far produced any evidence whatsoever of
systemic adverse effects [2–4, 7].
Although we here report that circulating FRa in patients
with ovarian cancer did not activate our readouts of
hypersensitivity, another potentially detrimental effect of
circulating FRa is that it might bind to MOv18 IgE bound
to cytotoxic effector cells, blocking the ability of these
cells to recognize tumour cell-associated FRa antigen. Our
in vitro assays suggest that soluble FRa at 200 ng/mL may
saturate cell surface-bound MOv18 IgE on cytotoxic
effector cells, but this greatly exceeds concentrations we
have so far observed in patients with advanced ovarian
carcinoma (Fig. 2). Thus, we would expect that most of the
cell-bound MOv18 IgE will be unoccupied and able to
bind tumour cell surface-bound FRa in most, but perhaps
not in all of the patients. This concern has been examined
in the context of treatment with trastuzumab, where some
patients with HER2/neu1 carcinomas have circulating
serum soluble HER2 receptor concentrations exceeding
15 ng/mL, which was postulated potentially to reduce the
efficacy of trastuzumab. Clinical experience with trastu-
zumab has however uncovered no clear correlation be-
tween serum HER2 concentrations and clinical
responsiveness [50]. We will examine this question in
future clinical studies with MOv18 IgE by measuring
FceRI-MOv18 IgE occupancy by circulating FRa on
immune effector cells and by correlating serum FRa
concentrations with clinical efficacy in dose escalation
studies.
Despite being reassured by the fact that patient sera and
whole blood did not activate our hypersensitivity readouts
in the presence of MOv18 IgE we were intrigued by the
possibility that these patients might make IgG autoanti-
bodies against FRa and therefore developed an ELISA
assay to measure these. We did indeed detect low concen-
trations of these autoantibodies in a small subset of our
patients. Given, however that blood and sera from a
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Fig. 5. MOv18 IgE does not trigger CD63 expression by blood basophils in the presence of soluble monomeric antigen or in the blood of patients with
ovarian carcinoma. (a) Representative two-colour flow cytometric dot plot of % CCR3highCD631 basophils exposed to MOv18 IgE and human FRa
(17 ng/mL) showing background CD63 expression. (b) Basophil activation did not increase in blood from healthy volunteers treated with MOv18 IgE and
increasing concentrations of FRa, but efficient activation occurs with anti-FceRI control. Scale bars indicate mean valuesstandard deviation [38] of
n=6 experiments, all conditions were tested in triplicate. (c) Representative two-colour flow cytometric dot plots of % CCR3highCD631 basophils in
patient blood given MOv18 IgE (0.7 and 10mg/mL). (d) % CCR3highCD631 basophils in blood of a patient cohort (n=5) with detectable serum FRa titre
(indicated in Table 1), illustrating background expression with addition of MOv18 IgE compared with anti-FceRI and no stimulation controls. Scale bars
indicate mean valuesstandard deviation [38] of n= 5 experiments, all conditions were tested in triplicate. FRa, folate receptor a.
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selection of these same patients did not activate our
hypersensitivity readouts, and also the fact that IgG anti-
folate receptor autoantibodies at similar or higher titres
than those of our patients have been described in normal
individuals and patients with a history of neural tube
defect pregnancies, infertility and oral cleft defects [51],
we are not sure of the pathophysiological significance, if
any, of this observation. Obviously, because of the theore-
tical risk that such antibodies could cross-link MOv18
IgE-bound FRa on cells such as mast cells and basophils,
we will be monitoring the prevalence and evolution of
these antibodies in treated patients in addition to the
precautions referred to above. We will also, as is routine
in studies with biologicals, be monitoring possible anti-
body responses to MOv18 IgE itself.
Systemic anaphylaxis is the most extreme manifesta-
tion of FceRI-mediated type I hypersensitivity. Very little
is known about what predisposes IgE-sensitized indivi-
duals to systemic anaphylaxis. Conventional wisdom is
that systemic anaphylaxis is caused by mast cell media-
tors because episodes are often accompanied by transient
increases in serum histamine and beta-tryptase. There are
however cases where histamine alone is elevated, inter-
preted by some to suggest that anaphylaxis may in some
instances be caused primarily by basophil activation [52].
Insofar as no known test can predict or reliably exclude
whether IgE-sensitized subjects will have systemic ana-
phylactic reactions to allergen exposure [53], none of the
data described in the present study can address this
question, although we find the lack of evidence of FceRI-
mediated effector cell activation in the presence of MOv18
IgE and its target antigen, and also in the presence of
autoantibodies recognizing FRa in a subset of patients,
very reassuring and sufficiently persuasive to proceed
with further toxicity studies and eventual clinical studies
of MOv18 therapy for ovarian carcinoma. The encoura-
ging early safety and efficacy reports using the IgG
anti-FRa antibody (farletuzumab; MORAb-003) and the
chimeric MOv18 IgG1 anti-FRa antibody for ovarian
carcinoma provide a strong case that FRa is a valid
molecular target [15–17, 38, 54–57]. Our previous demon-
stration of superior efficacy of the FRa-specific antibody
MOv18 IgE in comparison with its chimeric IgG1 counter-
part [2, 3, 6, 7] encourages us to continue with our
pre-clinical studies which may mark a new era of im-
proved antibody therapy for solid tumours.
Clinical relevance
Despite the clinical successes of monoclonal antibodies in
cancer therapy, many solid tumours remain unresponsive
to treatment. Using MOv18, an antibody recognizing the
tumour antigen FRa, we previously demonstrated that
substituting the Fc region of the commonly used IgG
antibody class with that of IgE results in superior re-
sponses against solid tumours. IgE antibodies play a role
in the allergic response and the danger of triggering
anaphylaxis during treatment for cancer is not yet fully
elucidated. Using two readouts of the potential for type I
hypersensitivity, however, we provide initial evaluations
supporting the prediction that administration of a tumour
antigen-specific IgE in human blood does not induce
activation of effector cells that may contribute to the
onset of type I hypersensitivity. These preliminary find-
ings contribute to the safety profile of MOv18 IgE before
clinical studies, adding weight to the promise of this novel
approach.
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Abstract
Melanoma, a potentially lethal skin cancer, is widely thought to be immunogenic in nature. While there has been much
focus on T cell-mediated immune responses, limited knowledge exists on the role of mature B cells. We describe an
approach, including a cell-based ELISA, to evaluate mature IgG antibody responses to melanoma from human peripheral
blood B cells. We observed a significant increase in antibody responses from melanoma patients (n = 10) to primary and
metastatic melanoma cells compared to healthy volunteers (n = 10) (P,0.0001). Interestingly, we detected a significant
reduction in antibody responses to melanoma with advancing disease stage in our patient cohort (n = 21) (P,0.0001).
Overall, 28% of melanoma patient-derived B cell cultures (n = 1,800) compared to 2% of cultures from healthy controls
(n = 600) produced antibodies that recognized melanoma cells. Lastly, a patient-derived melanoma-specific monoclonal
antibody was selected for further study. This antibody effectively killed melanoma cells in vitro via antibody-mediated
cellular cytotoxicity. These data demonstrate the presence of a mature systemic B cell response in melanoma patients,
which is reduced with disease progression, adding to previous reports of tumor-reactive antibodies in patient sera, and
suggesting the merit of future work to elucidate the clinical relevance of activating humoral immune responses to cancer.
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Introduction
Malignant melanoma, the most fatal form of skin cancer, arises
from malignantly-transformed melanocytes in the basal layer of
the epidermis. The incidence of melanoma has been increasing at
an accelerated rate in the past few decades amongst fair skinned
populations [1] and advanced forms of the disease are highly
resistant to treatment [2,3]. Thus, an urgent need exists for novel
therapies and earlier diagnosis.
Melanoma is widely thought to be immunogenic, supported by
clinical observations such as the frequency of spontaneous tumor
regressions, the prevalence of melanoma in immunosuppressed
patients, and the partial success of clinically-available immune
modulatory therapies such as the polyclonal immune activating
cytokines IFNa-2b and IL- 2 [4,5,6,7]. Host adaptive immune
responses have been described in melanoma with a main focus on
melanoma specific T cell responses [8,9], and supported by
successful case scenarios using immunotherapeutic strategies such
as dendritic cell vaccines, adoptive T cell therapies, and CTLA4
monoclonal antibodies [7,10,11,12,13].
Limited research has focused on B cells and the specificity of
antibodies they produce in cancer. Promotion of cancer
development by the creation of a pro-inflammatory environment
[14,15] and anti-tumor functions by activating mature T cell
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responses [16] have been proposed as potential roles for B cells in
animal models of cancer. While there may be host immune
responses to malignancy following immunization [17], a variety of
mechanisms involved in tumor escape have been described and
understanding this complex relationship between immunosurveil-
lance and tumor escape in patients is key to the design of effective
immunotherapies [18,19,20,21].
Despite well-characterized tumor-induced immunomodulation,
immunotherapies such as monoclonal antibodies are emerging as
key diagnostic and therapeutic modalities and are now standard of
care for the treatment of various cancers. Antibodies for the
treatment of melanoma aimed at enhancing key pathways of T cell
activation (Cytotoxic T Lymphocyte-Associated Antigen 4, e.g.
Ipilimumab), targeting tumor vasculature (e.g. Bevacizumab), or
tumor-associated antigens (e.g. High Molecular Weight-Melano-
ma Associated Antigen, HMW-MAA) have demonstrated promise
in clinical studies [13,22,23,24]. Antibodies therefore represent an
attractive approach for the treatment of melanoma.
Reports of tumor-specific antibodies in the sera of melanoma
patients date back over forty years [25] and have so far provided
valuable insight into immune responses to cancer. Serological
studies of individuals with melanoma have shown that patients
expressing certain tumor-associated antigens have antibodies
against these antigens, conversely, patients without the antibodies
also lack the corresponding tumor antigens [26]. These studies
have been restricted to few antibodies in sera against known
tumor-associated antigens. Serological studies reported IgG
antibodies recognizing intracellular melanocyte and melanoma-
associated antigens such as tyrosinase, tyrosinase-related protein
(TRP)-1, TRP-2, and melanoma-associated glycoprotein antigen
family (gp100/pmel17) in patients with melanoma. Serum-
resident antibodies to some of these antigens were enhanced
following polyvalent melanoma cell vaccine immunization in
patients with melanoma, suggesting that melanoma-associated
antigens may be immunogenic and that humoral responses to
melanocyte and melanoma antigens may constitute potential
targets for immunotherapy [27]. New antigens, such as the NY-
ESO-1, with restricted expression in normal tissues and wide
distribution in various cancers including melanoma have been
discovered using serological analysis of recombinant cDNA
expression libraries (SEREX) techniques tested against tumor
mRNA and autologous patient sera [28]. SEREX studies from
human melanomas [29] and from one cell line [30] have led to the
discovery of the human testis antigen HOM-MEL-40. Many of
these antigens are primarily intracellular, making them less
attractive targets as monoclonal antibodies. Furthermore, serolog-
ical screens may also be limited by the temporal dynamics of sera
antibodies. Evaluating the reactivity of antibodies secreted by
circulating B cells may therefore provide additional insight to
serological evaluations by interrogating the long-term memory
anti-tumor systemic mature humoral response to cancer.
The production of tumor-specific antibodies in melanoma from
patient-derived B cells in the peripheral blood and tumors has
been reported and has yielded a few antibodies of the IgM and
IgG class [31,32,33,34]. In the past, such studies have been limited
by poor EBV transformation efficiency of human B cells, low
production of immunoglobulin, evaluation of few patients, and
lack of effective, reproducible methods to rapidly screen for tumor-
specific antibodies. To address some of these limitations, we took
advantage of recent advances in growing and immortalizing
memory B cells in culture [35,36], increased the number of
patients evaluated, and developed a novel screening tool to
specifically detect tumor-reactive antibodies against cell surface
antigens on melanoma cells. Our approach entails culture of
patient-derived circulating B cells and screening of the antibodies
they secrete for their reactivity and specificity to melanoma cells
versus melanocytes. Our strategy does not screen for antibodies
against known antigens or evaluate antibodies secreted or
sequestered in the serum at discrete times, but rather uniquely,
the aim here is to monitor tumor cell-reactive IgG antibodies
produced by B cell cultures, elucidating the breadth of the long-
term mature B cell repertoire recognizing melanoma antigens
expressed on the surface of cancer cells.
In this study, we screen for tumor-reactive and tumor-specific
IgG antibodies produced by patient and healthy individual B cell
cultures. This allowed characterization, beyond phenotype, of the
circulating B cell repertoire of individuals with melanoma and
clinical correlations of mature humoral responses and disease
progression. We also provide an example demonstrating that this
screen may facilitate the identification of antibodies able to target
cancer cells.
Results
Detection of Tumor-specific IgG Antibodies Using a
Novel Cell-based ELISA
We developed and optimized a cell-based ELISA for specific
detection of tumor-reactive antibodies in order to obtain a robust
and optimized system for the detection of anti-tumor antibodies
from patients (Figure S1). We first evaluated the sensitivity and
specificity of an IgG antibody against a melanoma cell surface
antigen (HMW-MAA), expressed on A-375 melanoma cells using
immunocytochemistry (cytospins) and live cell flow cytometry. An
anti-HMW-MAA antibody was observed to bind to A-375 cells,
but not melanocytes over a range of concentrations as low as
20 ng/mL using both immunocytochemistry (Figure 1, A) and
flow cytometry (Figure 1, B). Next, we compared the detection of
this antibody bound to melanoma cells in our cell-based ELISA to
the above methods.
Utilizing our novel ELISA, we detected tumor-specific antibod-
ies at concentrations as low 10 ng/mL (Figure 1, C), demonstrat-
ing comparable sensitivity to flow cytometric or immunocyto-
chemical methods. Additionally, we validated our ability to
identify tumor-reactive antibodies from our patient cultures,
compared to equal amounts of non-specific IgG and culture
media (Figure 1, D). We also examined the potential applicability
of this method to identify tumor-specific antibodies in other
cancers using the mammary carcinoma cell line SK-BR-3, which
highly expresses the cell surface tumor-associated antigen HER2/
neu [37]. Trastuzumab (HerceptinTM), a humanized antibody
specific for HER2/neu, was specifically detected compared to an
equal amount of a control IgG employing our method (Figure 1,
D). Thus, we demonstrate that we can detect antibodies against
tumor cell antigens in a sensitive, specific and reproducible
manner.
Melanoma-reactive Antibodies are More Prevalent in
Melanoma Patients than Healthy Volunteers
We first established B cell cultures from the peripheral blood of
melanoma patients to study antibody responses to cancer (Figure
S1). In agreement with a previously published report, we detected
a reduced memory B cell subset in melanoma patients. Melanoma
patient and healthy volunteer B cells were cultured with B cell
purity greater than 90%. Following EBV transformation and
activation with a TLR9 agonist, patient B cells were observed to
proliferate in culture for over eight weeks and 80% of the cells in
these cultures were IgG positive. B cell cultures derived from
healthy volunteers (n = 5) and melanoma patients (n = 5) had
Monitoring B Cell Memory in Melanoma
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Figure 1. Development of a cell-based ELISA to detect tumor-specific antibodies. (A) Immunocytochemistry of cytospin preparations
demonstrates that an antibody against the melanoma-associated antigen HMW-MAA, expressed on the surface of A-375 metastatic melanoma cells,
can detect the antigen at 30 mg/mL (top left), 200 ng/mL (top middle) and 20 ng/mL (top right), while no binding to melanocytes was seen (bottom
left). IgG from 5% human serum (bottom right) did not bind to A-375 cells. (B) Flow cytometry analysis demonstrates specific binding of the HMW-
MAA antibody to A-375 cells (left) at 30 mg/mL (dashed line), 200 ng/mL (dotted line) and 20 ng/mL (solid line), but not to melanocytes (30 mg/mL
HMW-MAA antibody). Isotype control is shown in shaded grey histogram. (C) Detection of anti-HMW-MAA antibody binding to melanoma cells over a
range of antibody concentrations compared to melanocytes by cell-based ELISA. (D) Melanoma-specific antibody HMW-MAA binding to A-375 cells
compared to an IgG isotype control or to culture media (left) utilizing the cell-based ELISA. Breast cancer-specific antibody Trastuzumab binding to
SK_BR-3 cells compared to an IgG isotype control or to culture media (right). Error bars in figures represent 95% confidence intervals.
doi:10.1371/journal.pone.0019330.g001
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comparable mean antibody titers after 18 days, ranging from 1 to
7 mg from each individual, with an overall mean of 2.5 mg (95%
CI = 2.3 to 2.7) per culture arising from 500 B cells per well. We
therefore established antibody-secreting cultures from melanoma
patients with comparable rates of IgG secretion to healthy
volunteers.
We next investigated whether specific antibody responses to
melanoma could be detected from circulating B cells of patients
and healthy volunteers utilizing our cell-based ELISA. Antibody-
secreting B cell cultures from 10 healthy volunteers and 10 patients
(n = 4 stage II, n = 4 stage III, and n=2 stage IV) were evaluated
for reactivity to both metastatic and primary melanoma cells
relative to non-specific human IgG control (calculated as fold
increase above the non-specific human IgG control) employing
our cell-based ELISA. We found a significant (P,0.0001) increase
in the mean reactivity (fold increase) of patient-derived antibody
cultures (n = 600) to metastatic melanoma cells (2.5 fold increase,
95% CI = 2.4 to 2.6) compared to antibody cultures (n = 600)
derived from healthy volunteers (1.1 fold increase, 95% CI = 1.1
to 1.2) (Figure 2, A). A significant (P,0.0001) increase was also
seen in the mean reactivity of patient-derived antibodies to
primary melanoma cells (2.3 fold increase, 95% CI = 2.2 to 2.4)
compared to antibodies from healthy volunteers (1.0 fold increase,
95% CI = 1.0 to 1.1) (Figure 2, B). From this patient cohort, we
thus observed a significantly increased reactivity to primary and
metastatic melanoma cells, compared to healthy volunteers.
Antibody Response to Melanoma Decreases with Disease
Progression
To examine if antibody responses differ according to disease
stage, we studied a cohort of 21 patients diagnosed with stage I, II,
III and IV melanoma (Table 1) and evaluated the reactivity of
antibody cultures (n = 1,800) from these patients to the metastatic
melanoma cell line A-375 utilizing the cell-based ELISA. This
patient cohort was almost exclusively Caucasian. Antibody
reactivity against melanoma cells was quantified relative to a
non-specific human IgG control and measured as fold increase
above this negative control. Patients with local (non-metastatic,
stages I and II) disease had a significantly (P,0.0001) higher mean
antibody response (2.6 fold increase, 95% CI = 2.4 to 2.8)
compared to those with confirmed metastatic disease (stages III
and IV, 1.7 fold increase, 95% CI = 1.7 to 1.8) (Figure 3, A). We
also found an overall significant reduction (P,0.0001) in the mean
reactivity of antibodies secreted in B cell cultures against
melanoma cells from stage II (2.8 fold increase, 95% CI = 2.6
to 3.0, n= 660) to stage III (1.9 fold increase, 95% CI = 1.8 to
2.0, n= 540) and to stage IV patients (1.5 fold increase, 95% CI
1.5 to 1.6, n= 480) (Figure 3, B). The stage I patient was not
evaluated since samples from only one patient (n = 120 B cell
cultures) from the cohort was available to include in this group.
The highest mean antibody reactivity against melanoma cells was
observed in Patients 5 and 6 diagnosed with stage II and III
melanoma, respectively (Table 1). However, we observed variation
in the antibody response among individual patients, with 19 out of
21 patients in our cohort having at least one antibody-producing
culture with optical density values 2.5-fold above the negative IgG
control (Table 1). These findings suggest that despite the
significant reduction in the proportion of tumor-reactive antibody
cultures as a function of disease progression, patients from each of
stage groups had B cells with antibodies that recognized tumor
cells.
Estimations of Melanoma-reactive Antibody Frequencies
from Patient Peripheral Blood B Cell Cultures
We screened for tumor-reactive antibodies from patient B cell
cultures and approximated frequency and specificity of selected
Figure 2. The reactivity of antibodies derived from melanoma patient B cells to primary and metastatic melanoma cells is
compared to healthy volunteers. B cell cultures from melanoma patients secreted antibodies that were significantly more reactive against
melanoma cell lines compared to healthy volunteers using the cell-based ELISA. Mean reactivity of antibody cultures (n = 600) from 10 melanoma
patients to A-375 metastatic melanoma cells (A) and WM-115 primary melanoma cells (B), was compared to 10 healthy volunteer cultures (n = 600)
(P ,0.0001). Fold increase values represent the optical density of each B cell culture relative to the mean optical density of a negative control human
IgG antibody. *** = P,0.001. Error bars in figures represent 95% confidence intervals.
doi:10.1371/journal.pone.0019330.g002
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cultures to tumor cells. For this we screened B cell culture
supernatants against a stringent comparator using a positive
control monoclonal antibody, Trastuzumab, that recognizes the
HER2/neu tumor antigen, expressed on breast cancer cells and on
some melanoma cells [38]. Trastuzumab was selected as a positive
control because of comparable binding across melanoma cell lines
and melanocytes, as shown by mean fluorescence intensities of
antibody binding against a range of these cells (Figure 4, A).
Previous studies screening for tumor-specific antibodies have
selected wells greater than the mean negative control optical
density (OD) + three standard deviations as criteria for positive
tumor-reactive antibodies [39]. Due to the inherent variability of
cell-based assays, and the potential identification of false positive
cultures, we chose more stringent criteria for antibody screening,
by comparing antibodies produced by B cells to a positive control
antibody (. 75% OD of positive control). Based on this antibody
selection criteria (.75% OD of positive control), we estimate that
28% of B cell cultures (n = 1,800) derived from 21 patients, each
arising from 500 B cells, produced antibodies that recognized
metastatic melanoma cells, compared to 2% (n= 600) of cultures
derived from 10 healthy volunteers (Figure 4, B). From these 10
healthy volunteers, 2 individuals had one reactive culture (out of
60 cultures), 1 individual had 10 reactive cultures, and the rest of
the cohort had no reactive cultures.
From our patient cohort, we can roughly estimate the frequency
of B cells that produce an antibody that recognizes melanoma cells
under the assumption that a reactive antibody culture, defined as
having an OD .75% of the positive control, arises from only a
single B cell (1 out of 500 plated per culture). By dividing the total
number positive antibody cultures from the patient cohort by the
total number of B cells evaluated from the patient cohort by the
number of positive antibody cultures, we roughly approximate that
from our patient cohort one out of 1,765 B cells produce an
antibody that may recognize melanoma cells.
To estimate the frequency of melanoma-reactive antibody-
producing B cells in melanoma patients we performed limiting
dilution analysis. We selected a stage II patient, who, we predict,
may have a high antibody response to melanoma, based on our
findings that the antibody responses were highest in this group
(Figure 3, B). For this stage II patient (Patient 15, see Table 1)
from our limiting dilution analysis assays using the cell-based
ELISA, we estimate that one out of 1,790 peripheral blood B cells
produces antibodies that bind to A-375 melanoma cells (Figure 4,
C). For this same patient, the frequency of B cells producing
antibodies that react with melanocytes was also evaluated at the
same B cell densities as melanoma cells. We did not observe a
comparable patient antibody response to melanocytes as we did
to melanoma cells, suggesting a much lower frequency of
Table 1. Reactivity of patient-derived antibody-producing B cell cultures to A-375 metastatic melanoma cells.
Stage Patient ID* Age Sex Ethnicity
Mean fold increase over





I 9 51 F Caucasian 1.1 1 to 1 2.8 2
II 4 75 M Caucasian 2.7 2.6 to 3 4.2 38
II 5 70 M Caucasian 6.1 5.4 to 7 17 63
II 7 69 M Caucasian 1.6 1.4 to 2 4.8 3
II 15 49 F Caucasian 2.6 2.5 to 3 6.2 22
II 1 66 F Caucasian 1.5 1.4 to 2 6.8 5
II 19 63 F Caucasian 1.6 1.5 to 2 3.5 82
II 21 38 M Caucasian 1.3 1.1 to 2 7.7 2
II 20 81 M Caucasian 2 1.9 to 2 3.7 50
2.4 2.2 to 3 6.7 33
III 6 67 M Caucasian 3.2 3 to 3 5.8 14
III 10 54 M Caucasian 1.8 1.6 to 2 3.6 13
III 16 77 M Caucasian 1.8 1.6 to 2 3.8 97
III 17 88 M Caucasian 1.8 1.7 to 2 2.8 40
III 18 68 M Caucasian 1.3 1.2 to 1 2.8 6
III 8 23 M Asian 1 0.8 to 1 2.9 8
1.8 1.7 to 2 3.6 30
IV 11 77 F Caucasian 1.7 1.5 to 2 3.3 92
IV 12 72 F Caucasian 1 0.8 to 1 3.5 10
IV 2 66 M Caucasian 1.8 1.7 to 2 3.1 19
IV 13 55 F Caucasian 1.5 1.4 to 2 2.6 2
IV 3 51 M Caucasian 1.8 1.7 to 2 2.7 8
IV 14 31 F Caucasian 0.7 0.6 to 1 1.3 12
Mean1.4 1.3 to 1.5 24
*Patient ID corresponds to patient number in all figures.
{Fold increases values were calculated by dividing the optical density of B cell culture supernatants by the optical density of a non-specific IgG negative control using a
cell-based ELISA.
{{% of cultures with absorbance values greater than 75% of a positive control antibody using a cell-based ELISA.
doi:10.1371/journal.pone.0019330.t001
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antibodies that bind to normal cells of the same origin (Figure 4,
C left).
Limiting dilution analysis against two additional metastatic (SK-
MEL-28, A-2058) and one primary (WM-115) melanoma cell lines
for the same patient yielded different but comparable frequencies
to A-375 for the metastatic cell lines (SK-MEL-28, 1 out of 1,650
B cells; A-2058, 1 out of 1,170 cells), and a much lower frequency
of antibodies that bind to the primary melanoma line WM-115
which was similar to that observed with primary melanocytes
(Figure 4, C right). For this patient, the data suggest detectable
circulating B cell humoral response frequency against metastatic
melanoma cells and lower frequency for normal human
melanocytes or primary melanoma cells. To further confirm the
frequency observations for the patient-derived circulating B cell
repertoire, we performed additional limiting dilution assays for
another stage II patient (Patient 21, Table 1). For Patient 21, we
estimate 1 out of 2,430 B cells that produces antibodies bind to the
same melanoma cell line tested for Patient 15 (Figure 4, D),
suggesting lower but comparable frequency to those estimated for
B cells from Patient 15. In summary, applying the above
methodology, these results suggest that tumor-reactive antibodies
from circulating B cells are more frequent in melanoma patients
than healthy volunteers and more frequent against a range of
metastatic melanoma cells compared to normal melanocytes.
Screening for Tumor-specific Antibodies and Selection of
a Patient-derived Monoclonal Antibody with In Vitro
Cytotoxicity against Melanoma Cells
We then selected patient-derived, tumor-specific antibodies in
order to further evaluate their reactivity to melanoma cells, and
conducted a preliminary assessment of the potential functional
capabilities of a patient-derived antibody from this screen. B cell
culture wells were selected based on stringent criteria (OD . 75%
positive control antibody), using the cell-based ELISA. Tumor
specificity of antibody cultures was evaluated by comparing
binding of antibodies from these cultures against multiple
melanoma cells (A-375, SK-MEL-2, WM-115) versus normal cells
(Figure 5, A). We observed multiple antibody cultures with a
higher degree of binding to some melanoma cells compared to
melanocytes from the same patient (Patient 3, Figure 5, A; a
selection of five of these cultures is shown on Figure 5, B). Similar
results were obtained when we screened for tumor-specific cultures
from different patients against melanoma cells and melanocytes.
Positive cultures with different binding patterns against four
melanoma cell lines (A-375, SK-MEL-2, SK-MEL-28, WM-115)
and primary human melanocytes were detected (selected cultures
derived from Patients 2, 3, 4 and 6 are shown as examples in
Figure 5, C), reflecting specificity and reactivity of different
antibodies to a range of antigens expressed at different levels in a
number of melanoma cell lines, and some reactivity to antigens
lowly expressed on human melanocytes. Selection of a tumor-
positive antibody culture for sub-cloning and limiting dilution was
based on degree of reactivity to melanoma cells relative to
melanocytes (Figure 5, C).
One B cell culture from Patient 6 was selected for further
evaluation since cell culture supernatants were observed to have a
higher degree of binding to A-375 and SK-MEL-28 cells
compared to melanocytes by ELISA (Figure 5, C; right). After
limiting dilution of this melanoma-reactive B cell culture, a
monoclonal antibody (6_2G3) was further assessed for specificity
to 6 melanoma cell lines, melanocytes and fibroblasts by live cell
flow cytometry (Figure 6). Since more antibody was available after
monoclonal dilution, 2 additional melanoma cell lines along with
dermal fibroblasts were evaluated. In concordance with the cell-
based ELISA findings (Figure 5, C), the 6_2G3 clone bound to a
range of melanoma cell lines, but not to melanocytes (Figure 6).
The antibody had no reactivity against primary human dermal
Figure 3. Prevalence of melanoma-reactive antibodies derived from melanoma patient B cell cultures is reduced in advanced
disease stages. (A) Comparison of mean antibody culture reactivity to A-375 cells (fold increase relative to negative control human IgG antibody)
for patients with localized (non-metastatic, n = 9) and metastatic (n = 12) disease, P,0.0001. (B) Mean reactivity to A-375 cells (fold increase relative to
negative control antibody) of cultures from patients with stage II (n = 8), III (n = 6) and IV (n = 6) melanoma. Antibody reactivity was determined using
a cell-based ELISA. Fold increase values in panels A and B were determined relative to the mean absorbance to a negative control human IgG
antibody. ***P,0.001 and ** P = 0.001 to 0.01. Error bars in figures represent 95% confidence intervals.
doi:10.1371/journal.pone.0019330.g003
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fibroblasts. In summary, by evaluating the specificity of antibodies
to melanoma cells versus melanocytes and fibroblasts we could
identify a melanoma-specific monoclonal antibody clone 6_2G3.
While we had limited amounts of monoclonal antibodies our B cell
culture supernatants after evaluating melanoma-cell specificity, we
were able to conduct a limited functional investigation of this
antibody.
Using clone 6_2G3, we wished to assess whether a patient-
derived antibody has potential cytotoxic activity against tumor
cells. We tested the tumor cell killing potential of this antibody
using a real-time live-dead cell cytotoxicity assay using as targets
metastatic melanoma cells recognized by this clone (Figure 7 &
Supporting Videos S1 and S2). In these experiments, U-937
human monocytic cells which express Fcc receptors served as
effector cells [40] and A-375 melanoma cells were used as target
cells to evaluate antibody-dependent cellular cytotoxicity (ADCC)
of tumor cells mediated by patient-derived IgG antibodies. We
tested two monoclonal antibodies, both derived from Patient 6
(Table 1): (1) the 6_2G3 antibody, which bound to A-375 cells and
not melanocytes and (2) the 6_2D10 antibody, which did not bind
to A-375 cells or melanocytes in the cell based ELISA prior to
limiting dilution, which served as a non-tumor-reactive control
(Figure 7).
After 2 hours in culture, 18% (95% CI = -5 to 41%) of tumor
cells given the melanoma-specific antibody were viable, compared
to 95% (95% CI = 86 to 104%) of the tumor cells given the non-
melanoma specific antibody (P,0.0001) (Figure 7, A, left).
Relative to tumor cell fluorescence at the start of the assay, mean
green/live tumor cell fluorescent intensity was reduced to 64% for
the non-tumor specific antibody (6_2D10) compared to 18% for
the tumor-specific antibody (6_2G3) (Figure 7, A, right). These
results highlight the potential of a patient derived tumor-specific
antibody to kill tumor cells by antibody-dependent cell cytotoxicity
(Figure 7, B and see Videos S1 and S2). For tumor cells treated
with the tumor-specific 6_2G3 antibody, we also observed a
significant (P = 0.0002) reduction in the movement of monocytic
effector cells in contact with tumor (13 mm, 95% CI = 10 to 17
mm) compared to effector cells not in contact with tumor (26 mm,
95% CI= 21 to 31 mm) (Figure 7, C and D). Using the 6_2D10
non-specific antibody, no significant (P=0.3) difference was
observed for the movement of effector cells not in contact with
tumor cells (20 mm, 95% CI= 15 to 25 mm) compared to those in
contact with tumor cells (25 mm, 95% CI= 18 to 31). With this
example, we demonstrate that a patient-derived tumor-specific
antibody is capable of engaging immune effector cells in antibody-
dependent cellular cytotoxicity against tumor cells. Taken
together, these data suggest that systemic melanoma-specific
mature B cell responses may be present in patients with melanoma
and may harbor the potential to be activated against cancer
cells.
Figure 4. Estimations of the frequency of circulating B cells producing melanoma-reactive antibodies relative to a positive control
antibody. (A) Binding of Trastuzumab is consistent across melanoma cell lines and primary human melanocytes evaluated by mean fluorescence
intensity (MFI) above isotype control antibody binding for each cell line. (B) Proportion of B cell cultures (n = 1,800) from 21 melanoma patients arising
from 500 B cells each that produced antibodies that reacted to metastatic melanoma cells compared to cultures (n = 600) from 10 healthy volunteers.
(C) Frequency of B cells producing IgG antibodies able to bind to melanoma cells estimated by limiting dilution analysis for Patient 15 (see Table 1).
The frequency of B cells producing antibodies reactive to the cells of interest was approximated according to Poisson distribution, the number of B
cells at which 37% of the cultures were non-reactive (dotted horizontal line). Frequencies of tumor-reactive B cells against A-375 melanoma cells
versus melanocytes evaluated at the same B cell densities (left) and against four melanoma cell lines (primary WM-115, and metastatic cell lines
derived from different anatomic locations, right). (D) Comparison of the frequency of B cells that react to metastatic melanoma cells between two
stage II patients, estimated by limiting dilution analysis. For these two patients, frequency was estimated to be 1 in 1,790 B cells (Patient 15) and 1 in
2,430 B cells (Patient 21).
doi:10.1371/journal.pone.0019330.g004
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Discussion
We describe an approach to study the circulating B cell-derived
humoral immune response to cancer and apply this to detect
tumor-specific IgG antibodies from melanoma patient B cells. This
strategy has the potential to be applied to any type of cancer.
Findings presented herein complement previous serological
studies, providing added insight into the mature systemic B cell
response to melanoma.
As a first step to evaluate the tumor reactivity and specificity of
patient B cell-derived IgG antibodies, we developed a medium-
throughput cell-based ELISA with melanoma cells to detect
antibodies against tumor cell surface antigens (Figure 1). Cells
were allowed to grow and adhere on to 96-well plates prior to
being preserved by a light fixative (0.5% formaldehyde). While
preserving the cells and allowing for storage and access to multiple
plates at any one time, light fixation with formalin allows
preservation of potentially-antigenic epitopes on the surface of
target cells. Previous studies have reported cell-based ELISA
methods to identify tumor-specific antibodies in melanoma
[39,41], where tumor cells were preserved using strong fixatives
such as glutaraldehyde, known to potentially mask antigenic
epitopes, thus compromising the recognition of antigens by
antibodies [42]. Furthermore, the specificity and sensitivity of
such methods has not been reported using antibodies against
known cell surface antigens. Although many intracellular mela-
noma associated antigens have been described (tyrosinase, TRP-1,
TRP-2, gp100/pmel17), most are also expressed by normal
melanocytes, only a few defined cell surface antigens such as the
High Molecular Weight Melanoma-Associated Antigen (HMW-
MAA) are reported to be expressed on the surface of melanoma
cells, and other antigens show heterogeneous expression among
Figure 5. Selection of patient-derived antibodies that recognize melanoma cells. (A) Multiple antibody cultures from one patient (Patient
3, see Table 1) were screened against 3 melanoma cell lines (A-375, SK-MEL-2 and WM-115) and primary melanocytes using the cell-based ELISA. Fold
increase values represent optical density (OD) values relative to a negative control antibody. (B) Selected cultures from Patient 3 evaluated in A, which
secreted antibodies that bound to the above tumor cell lines are compared to melanocytes. (C) Selected cultures derived from 4 patients were
evaluated against 4 melanoma cells lines and compared to melanocytes.
doi:10.1371/journal.pone.0019330.g005
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patients [43,44]. Thus, this ELISA constitutes an attractive tool to
evaluate broad responses to any naturally-expressed antigens on
the surface of melanoma cells and melanocytes in this context.
This screening methodology has additional potential advantages.
Unlike assays screening against a single recombinant antigen or
antigenic epitope, our method enables the evaluation of antibody
repertoires of patients against a multitude of cell surface antigens
in their native confirmation on the surface of both primary and
metastatic melanoma cells and also melanocytes, providing more
comprehensive information on the broad prevalence of tumor-
reactive and tumor-specific antibodies. Previous studies have
shown concordance of cell line-associated antigens with antigens
expressed on corresponding tumors, making them a suitable
platform for tumor-reactive antibody screening [26,45]. Thus, cell
lines provide a promising alternative source of multiple tumor
antigens in the absence of multiple well-defined, highly expressed,
and readily available recombinant antigens. Unlike flow cytomet-
ric evaluations, the cell-based ELISA does not require the use of
proteolytic enzymes such as trypsin, therefore better preserving
cell surface antigens. Plates of target cells can be prepared, fixed
and frozen in batches, thus allowing for higher throughput
screening for tumor cell-reactive antibodies. It can be applied to
evaluate . 300 culture supernatants against cell lines within a few
hours. In principle, numerous ELISA plates for screening a range
of cell lines with multiple supernatant samples can be processed
simultaneously. Additionally, this methodology may be a potential
tool for immunomonitoring tumor-specific humoral responses to
therapies; selecting patients most likely to benefit from immuno-
therapy; or as a prognostic factor in linking tumor-reactive
humoral responses to clinical outcomes. This assay may also be
utilized to detect surface antigens in a range of cell types, and thus
may be adapted to monitor the B cell-derived antibody repertoire
in different disease contexts.
In agreement with a recent report [46], we also observed a
reduction in the peripheral blood memory B cell compartment of
metastatic melanoma patients. We measured a reduction of the
CD27+ subset of memory B cells in patients with both metastatic
and non-metastatic melanoma compared to healthy volunteers
(Figure S2). Despite the reduction of circulating memory B cells in
our cohort, patient-derived B cells were capable of secreting high
amounts of IgG antibodies when activated in vitro with a TLR 9
agonist, with comparable antibody production to B cells from
healthy individuals, and a high percentage of patient- and healthy
volunteer-derived B cells expressed IgG antibodies within a few
days in culture (80% of B cells from three patients with melanoma,
Figure S2). Thus, while a reduced memory B compartment has
been reported in cancer patients, we show that a melanoma-
reactive portion of this compartment remains in our patient
cohort.
We demonstrated a high prevalence of melanoma patient-
derived antibodies produced by circulating B cells in cancer
patients that recognize melanoma cell lines (Figure 2). We
observed that B cell culture supernatants from different patients
displayed differential binding to each cell line, which reflects
specificity and reactivity of different antibodies to a range of
antigens expressed at different levels in a number of melanoma cell
lines; these may also reflect binding to some antigens lowly
expressed on human melanocytes (Figure 4 and Table 1).
Melanoma patients had a high percentage of melanoma-reactive
antibody-producing B cell cultures, significantly higher than those
from healthy volunteer-derived B cell cultures (Figure 2), with 28%
of melanoma patient-derived B cell cultures recognizing melano-
ma cells, compared to 2% of cultures from healthy volunteers
(Figure 4). Limiting dilution analyses of reactivity against melanoma
cells versus normal melanocytes provided further evidence in
support of the presence and frequency of tumor-reactive B cells in
Figure 6. Selection of a patient derived B antibody that recognizes melanoma cells but not melanocytes. A selected tumor-reactive
culture from a stage III patient (Patient 6) which secreted antibodies that bound to tumor cell lines and compared to melanocytes by ELISA (Figure 5,
C) was sub-cloned, and a monoclonal antibody 6_2G3 was selected and evaluated on live cells by flow cytometry (solid black line histograms) for
reactivity to fibroblasts, melanocytes, and 6 melanoma cell lines. IgG isotype controls are shown in shaded grey histograms.
doi:10.1371/journal.pone.0019330.g006
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Figure 7. A tumor-specific antibody derived from a patient with melanoma is able to induce tumor cell cytotoxicity. Two monoclonal
antibodies were evaluated in vitro using a live cell imaging assay: 6_2G3 clone bound to A-375 cells compared to melanocytes; and 6_2D10, a clone
also from Patient 6 did not, and served as a negative control antibody for these experiments. (A) Cell viability of A-375 melanoma cells incubated with
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patient blood (Figure 4). For one stage II patient evaluated, the data
indicate that metastatic melanoma cells are recognized by a higher
proportion of B cells (estimated on average , 1 in 2,000 mature B
cells) compared to primary melanoma cells or melanocytes,
although in a cohort of 10 patients we measured reactivity of B
cell cultures to both metastatic and primary melanoma cell lines
(Figure 2). Taking into consideration the expected variability in
immune responses among patients, and the array of tumor antigens
these patients may be exposed to, the observations that B cells from
two patients with stage II melanoma yielded comparable reactivity
to metastatic melanoma cells (estimated 1 in 1,790 for Patient 15,
and 1 in 2,430 B cells for Patient 21) indicate the presence and
support the prevalence of a circulating melanoma-reactive B cell
compartment.
While tumor-reactive antibodies were detected from most
melanoma patients studied, antibody responses derived from
circulating B cells against melanoma cells decreased with more
advanced disease stages (Figure 3). Previous serological studies
report serum-resident antibodies against tumor cells in melano-
ma patients, with some evidence that serum antibodies are
diminished in patients with advanced disease [25,47]. It was
unclear whether this was a consequence of the sequestering of
antibodies into tumors with increasing tumor burden in these
patients. Our findings provide further insight by demonstrating
the presence of a circulating long-term mature B cell response to
cancer at all disease stages, against a broad range of naturally
expressed antigens on the surface of primary and metastatic
tumor cells. We also report decreased frequency of tumor-
reactive antibody-producing B cells with advanced disease, thus
supporting the premise that mechanisms of immune tolerance
rather than adsorption of antibodies into tumors in advanced
disease setting may also explain these reductions. One limitation
may arise from screening for antibodies against mostly metastatic
melanoma cells. It is possible that our observations may reflect
reactivity to antigens present in primary disease, which may be
preserved or upregulated in advanced disease setting. While our
findings may not account for reactivity to tumor antigens that
are lost with disease progression, this reduced reactivity to
melanoma we observed may imply weakened immune responses
to a subset of antigens on the surface of melanoma cells. Another
explanation for these observations may be that with advanced
disease, mature circulating B cells home into increasing tumor
sites, thus reducing the circulating tumor-reactive B cell
compartment in these patients. Future studies aimed at
monitoring local B cell responses in tumors may provide further
clues into the dynamics of mature B cell responses at the systemic
and local levels in cancer. Thus, despite well-known weakened
host immune response with disease progression [48], we were
able to detect melanoma-reactive antibodies from patient
circulating B cells, implying that although mature humoral
immune responses are weakened, responses in the form of
mature memory B cells may persist. However, further work
elucidating potential immunomodulatory roles of B cells and
other immune cells in cancer, including the production of IL-10
by B cell population subsets [49], merits consideration.
Although we report the presence of anti-tumor antibodies
produced by patient memory B cells, and these cells were
stimulated ex vivo to secrete antibodies, it is not clear whether
tumor antigen-reactive B cells are activated in patients to secrete
antibodies or whether these humoral responses are capable of
exerting any beneficial anti-tumoral activities in the same patients
in vivo. In the 21 patient cohort at different disease stages in this
study, we were not able to draw any conclusions regarding the
relationship between tumor cell reactivity and clinical disease
progression in the short term (6 months to 2 year follow up) or
associations with any particular disease treatment regimes.
However, monitoring mature memory B cells and their antibody
repertoires together with clinical outcomes in patients over a long
period of time may help identify any correlations between
melanoma-reactive mature memory B cell responses and disease
progression. Additionally, future studies may help identify
particular components of the humoral response which may hold
clinical relevance, and elucidate the potential merits of monitoring
these responses in relation to therapies, or of evaluating humoral
responses as a prognostic factor to clinical outcomes.
An important question therefore relates to whether patient-
derived mature B cell responses have any functional capability to
potently activate immune effector cells against cancer. For this, we
measured the capacity of one antibody clone to kill tumor cells.
Antibody clone 6_2G3 derived from a patient with stage III
disease (Patient 6, Table 1) was not observed to bind to fibroblasts
or melanocytes, but bound to a proportion of melanoma cell lines
tested (Figure 5). Antibodies against tumor-associated antigens can
attack tumor cells via a number of mechanisms including
induction of apoptosis in tumor cells and engaging Fc receptors
on immune cells [50,51,52,53]. Antibodies approved for the
treatment of cancer have been shown to function through one or
more of these mechanisms [54,55]. While our strategy yields fully
human monoclonal antibodies in a matter of a few months, we
were limited in the amount of antibody we could produce from the
B cells to perform functional studies and evaluate reactivity to
patient-derived melanoma tumors. However, we had sufficient
quantity to evaluate whether a patient-derived melanoma tumor-
specific monoclonal antibody could mediate antibody dependent
cellular cytotoxicity (ADCC) in the presence of monocytic effector
cells and tumor cells using a real-time live cell imaging assay. We
show that the tumor-specific 6_2G3 clone is capable of mediating
ADCC in vitro and additionally measured the restricted movement
of monocytic effector cells once in contact with tumor-specific
antibody-coated tumor cells, providing further evidence of ADCC
(Figure 6). These preliminary assessments provide a promising clue
that a potentially active mature B cell response against melanoma
may be present in patients. An example of this possibility was
recently reported by Yuan et al. who demonstrated that
administration of the anti-CTLA-4 antibody ipilimumab led to
serological enhancement of antibodies to the testis antigen NY
human U-937 monocytic cells was compared between samples treated with 6_2G3 or 6_2D10 antibody after 2 hours at 37uC (*** = P,0.001) (left).
Error bars represent 95% confidence intervals. Mean fluorescence intensity of A-375 tumor cells pre-labeled with the live cell dye Calcein AM, and
incubated with U-937 cells and antibody 6_2G3 or 6_2D10 was measured at 0 and 120 min time points (right). (B) Fluorescent images of the live cell
cytotoxicity assays at 30 minute intervals. Live Calcein AM-labeled melanoma tumor cells (green) were incubated with 6_2G3 or 6_2D10 antibody and
U-937 cells (blue) and cell death was evaluated (red). Incorporation of Ethidium homodimer-1 (incorporation of red into tumor cells) was observed
with 6_2G3 but not 6_2D10 (magnification 20x, Scale bar: 100 mm). (C) Movement of U-937 cells tracked and measured over two hours was compared
for cells in contact and those not in contact with tumor cells (*** = P,0.001for 6_2G3 and P=0.3 for 6_2D10 antibody) (upper panel). (D) Images of
U-937 movement in tumor cell cultures treated with 6_2G3, tracked for cells in contact (left) and cells not in contact with tumor cells (right).
Movement is indicated by tracking lines (red to yellow) from the original position of U-937 cells at t = 0 to t = 2 hours (magnification 20x, Scale bar:
50 mm).
doi:10.1371/journal.pone.0019330.g007
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-ESO-1 in patients who responded to the antibody therapy [56]. It
is therefore conceivable that the mature B cell compartment could
be enhanced with immunotherapeutic approaches, and that
monitoring humoral responses to therapeutics may have clinical
relevance.
Harnessing the cancer-specific antibody repertoire of cancer
patients using the methodology described herein may also
potentially offer an alternate strategy to yield IgG antibodies
against cancer antigens. Recent advances reported by Traggiai
et al., evaluating monoclonal antibodies from human memory B
cells have yielded fully-human virus-neutralizing antibodies of
therapeutic relevance for infectious diseases and have contributed
to the dissection of humoral memory responses to vaccinations
[35,57,58]. Here, we focus on B cells from cancer patients such as
melanoma patients, analyze systemic humoral responses to cancer
and demonstrate the presence of tumor-reactive and tumor-
specific antibodies. This approach may offer an advantage over
other approaches such as phage display in that it yields in vivo
affinity-matured human antibodies with naturally paired heavy
and light chains. The patient-derived monoclonal antibody 6_2G3
bound to 2 out of 6 of the melanoma cell lines evaluated compared
to melanocytes, suggesting that this antibody may be against a
protein over-expressed or mutated on the surface of cancer cells.
In light of the efficacy of Trastuzumab, against the HER2/neu
antigen expressed on 20–30% of breast cancers, as a clinically-
validated therapeutic tool for the treatment of an equivalent
proportion of breast cancer patients [59], selection of antibodies
that bind to a portion of cell lines may merit further
characterization. Although the clinical significance of mature
memory B cells expressing antibodies that recognize tumor cells in
patients remains to be elucidated, antibodies derived from these
cells, introduced by passive immunotherapy in therapeutically-
relevant doses, such as those used for Trastuzumab to patients
with breast cancer, merit investigation for any potential relevance
in melanoma. Other potential future benefits of screening patient-
derived B cells from tumor-reactive antibodies may be identifica-
tion of novel cell surface tumor antigens. Future evaluations of
clone 6_2G3 will include sequence analysis and expression cloning
to allow for further analyses of specificity to melanoma tumors,
antigen identification, and for thorough functional assessments.
These data provide additional understanding of the mature B
cell response to melanoma by evaluating antibodies derived from
circulating B cells of cancer patients. The prevalence of mature
humoral responses against cancer cells in patients, as well as the
capacity of a patient-derived antibody to activate effector cells
against melanoma cells indicate the potential functional signifi-
cance of the humoral immune response against cancer.
Materials and Methods
Ethics Statement
Specimens from patients and healthy volunteers were collected
with informed written consent. The work was conducted in strict
accordance with study design approved by the Guy’s Research
Ethics Committee, St. Thomas’ Hospital, London, UK.
Study Subjects and Isolation and Culture of Peripheral
Blood Human B Cells
After obtaining informed consent, peripheral blood was isolated
from healthy volunteers (n = 10) and from patients with melanoma
(n = 21). Patients were staged and classified according to the
American Joint Committee on Cancer Melanoma Staging and
Classification criteria [60]. B cells were isolated by negative
selection using RosetteSepH B cell enrichment cocktail (Stem Cell
Technologies, Vancouver, Canada) according to the manufactur-
er’s instructions. B cell purity was assessed by flow cytometry by
staining for mature B cells (CD22), T cells (CD3), monocytes
(CD14) and plasmacytoid dendritic cells (BDCA3) using fluores-
cently-labeled monoclonal antibodies, all from BD Biosciences,
Oxford, UK (Figure S1). Flow cytometry experiments were
conducted with either the FACSAria or FACSCanto (BD
Biosciences) and flow cytometric data were analyzed using Flow
Jo (Tree Star, Ashland, OR).
B cells were plated at 500 cells per well on 96 well U-bottom
microplates (Nunc, Rochester, NY) along with 3x104 cells per well
of irradiated (30 Gy) autologous PBMCs, obtained by Ficoll
centrifugation, as feeder cells. B cells were grown in RPMI-1640
medium obtained from Gibco (Invitrogen, Carlsbad, CA)
supplemented with 10% fetal calf serum, 1% penicillin-strepto-
mycin, 2.5 ng/mL TLR9 ligand CpG 2006 ODN (Operon,
Ebersberg, Germany), and 30% supernatant of Epstein Barr Virus
(EBV) producing B95-8 cells [35]. For each patient evaluated, 60-
120 B cell cultures originating from 500 B cells each were
established, and cultures were grown in 200 mL per well volumes.
After 18 days, supernatant (40 mL) from each culture well was
screened individually for tumor-specific antibodies and selected B
cultures were sub-cloned by limiting dilution to derive monoclonal
cultures. We plated B cells at 1 cell/well in the presence of 3x104
autologous 30 Gy irradiated autologous PBMC stimulated with
2.5 ng/mL CpG 2006 ODN.
Cell Lines and Culture
Human dermal fibroblasts were a gift from Dr. Christian
Hundhausen, King’s College London, UK. All other cell lines
used were obtained from the American Type Culture Collection
[ATCC] (Manassas, VA). Cell lines were used to identify tumor-
reactive antibodies and to test for cytotoxic activity of antibodies.
Media used for cell lines A-375 (CRL-1619), A-2058 (CRL-
11147), G-361 (CRL-1424), SK-MEL-2 (HTB-68), SK-MEL-28
(HTB-72), SK-BR-3 (HTB-30), U-937 (CRL-1593.2) and WM-
115 (CRL-1675) were obtained from Gibco and supplemented
with 10% fetal calf serum and 1% penicillin-streptomycin. The
human metastatic melanoma cell lines A-375 and A-2058 were
grown in Dulbecco’s Modified Eagle’s Medium. The human
melanoma cell line derived from primary melanoma tissue, WM-
115, and the metastatic melanoma cell lines SK-MEL-2 and SK-
MEL-28 were grown in Eagle’s Minimum Essential Medium. The
human metastatic melanoma cell line G-361, and the human
mammary carcinoma cell line SK-BR-3, which expresses the
Human Epidermal Growth Factor Receptor 2 (HER2/neu), were
grown in McCoy’s medium. The Fc receptor-expressing mono-
cytic-like U-937 cell line was grown in RMPI-1640 medium.
Primary human melanocytes (ATCC, PCS-2000-012) were grown
in Dermal Cell Basal Medium (ATCC) and supplemented with the
Melanocyte Growth Kit (ATCC). Human fibroblasts were grown
in Medium 106 (Invitrogen) and supplemented with Low Serum
Growth Supplement (Invitrogen).
Detection of Antibodies Bound to Tumor Cell Surface
Proteins by Immunocytochemistry and Flow Cytometry
Qualitative detection of tumor-specific antibodies by immuno-
cytochemistry was performed by centrifugation of 26105 cells at
300g using a Shandon CytospinH 4 Cytocentrifuge (Thermo
Fisher Scientific, Waltham, MA) onto glass slides. Cells were fixed
in 0.5% formalin and antibodies, such as those recognizing the
human High Molecular Weight Melanoma-Associated Antigen
(anti-HMW-MAA clone LHM2, Invitrogen, Carlsbad, CA), were
incubated overnight at 4uC and detected following a 2 hour
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incubation at 4uC with a horseradish peroxidase-conjugated anti-
IgG Fc-specific antibody (1:100 dilution in Tris Buffered Saline,
Sigma, Dorset, UK). Slides were stained with DAB chromogenic
substrate (DAKO, Ely, UK) for 5 minutes, washed and
counterstained with Mayer’s hematoxlin (Merck, Darmstadt,
Germany) for one minute, dehydrated and mounted in DPX
mountant (Sigma) prior to assessments.
Antibodies bound to cell surface antigens were also detected on
live cells by flow cytometry. Adherent cells were detached using
StemProH AccutaseH cell disassociation solution (Gibco) and
incubated at 26105 cells per sample with antibody, isotype control
or cell culture supernatants for 30 minutes at 4uC. Antibodies
bound to cells were detected using a FITC-conjugated anti-IgG
Fc-specific antibody (Jackson ImmunoResearch). The binding of
tumor-specific antibodies to cells was compared to an excess of
isotype control IgG1 antibody (Jackson ImmunoResearch).
Binding of Trastuzumab across melanoma cell lines and primary
human melanocytes was evaluated by subtracting the mean
fluorescence intensity (MFI) values of equal amounts of isotype
control. Evaluations are representative of three experiments.
Development of a Cell-based ELISA to Detect Tumor-
specific Antibodies
We developed and employed a novel cell-based ELISA to
identify melanoma-reactive antibodies. Adherent cells of interest
were plated at 36105 cells per in 200 mL of appropriate media well
on 96-well flat bottom tissue culture plates (Corning, Corning, NY)
and were grown in a monolayer at 37uC and 5% CO2 to 80-100%
confluence. Cells were then lightly fixed in 0.5% formaldehyde/
Hank’s Buffered Salt Solution. Plates were then wrapped in foil
and placed in a -80uC freezer until the day of the assay. On the
day of the assay, plates were thawed for 30 minutes, washed 3
times with PBS and then blocked with a 5% non-fat milk/PBS
solution for 2 hours. After removal of the blocking solution, 50 mL
of culture supernatants or tumor-specific antibodies were diluted
1:2 in 1% non-fat milk/PBS solution and then added to each well,
and plates were incubated for 90 minutes at room temperature on
an orbital shaker. Plates were then washed 4 times with PBS/
0.05%Tween (PBS-T). The binding of antibodies to cell surface
proteins was detected following a 45 minute incubation with a goat
anti-human horseradish peroxidase-labeled F(ab)’2 Fc-specific
antibody (Jackson ImmunoResearch, West Grove, PA) diluted
1:250 in 1% milk/PBS-T at room temperature on an orbital
shaker. Wells were then washed 4 times with PBS-T. The color
reaction was developed for 15 minutes with OPD (Sigma) and OD
was measured in an ELISA reader (BMG Labtech, Offenbury,
Germany) at 492 nm (reference wavelength, 650 nm). Each plate
contained triplicate wells of a positive control antibody, Trastu-
zumab (Genentech, South San Francisco, CA), and a negative
control antibody, non-specific human IgG1 (Jackson Immunor-
esearch) at a concentration of 250 ng/mL both diluted in RPMI-
1640 media supplemented with 10% fetal calf serum. Binding of
Trastuzumab to cells and background OD values for the negative
non-specific human IgG control antibody formed the criteria for
inclusion of readouts in the study. Since we were limited by the
volume of culture supernatants for each culture, assays were
repeated only when sufficient culture supernatants were available
to confirm reproducibility of readouts.
Criteria for Evaluating Antibody Responses to Melanoma
Using the Cell-based ELISA
Patient and healthy volunteer antibody responses were assessed
using the cell-based ELISA. We evaluated the reactivity of the
supernatant from each B cell culture to tumor cells relative to
negative and positive control antibodies. In order to compare anti-
tumor antibody responses to metastatic and primary melanoma
cells between patients and healthy volunteers, and among patient
groups, optical densities (OD) were normalized using the following
formula:
Fold increase~
Optical density of B cell culture supernatant
Mean optical density of non{specific IgG1
Additionally, this calculation was used to normalize ELISA results
among multiple melanoma cell lines and primary melanocytes in
order to evaluate the tumor specificity of antibodies.
To evaluate the presence and estimate the frequency of tumor-
reactive antibodies, we selected wells with OD values above 75% of
theOD of the positive control antibody. To compare the percentage
of positive cultures across patients, OD values were normalized
against the positive control. For these evaluations, the mean positive
control OD was assigned a relative absorbance of 1 for each plate
and B cell cultures were converted from OD units to relative
absorbance, and culture wells with relative absorbance values
greater than 0.75 to melanoma cells but not melanocytes were
selected. These criteria were also applied in limiting dilution assays
to estimate the percentage of non-reactive B cell culture well. In
these limiting dilution assays, B cells were plated at different
densities (ranging from 125 to 2,500 B cells) and the percentage of
non-reactive cultures was calculated for different patients and cell
lines as a way to approximate the frequency of B cells producing
melanoma-reactive antibodies using Poisson distribution.
Live Cell Imaging Assays to Measure Antibody-
Dependent Cellular Cytotoxicity
The tumor-killing potential of 2 patient-derived monoclonal
antibodies was assessed: one tumor-specific antibody (6_2G3), and
another antibody that did not recognize tumor cells (6_2D10),
both derived from the same patient (Patient 6). Both antibodies
were simultaneously evaluated using a three-color fluorescent live
cell imaging cytotoxicity assay. A-375 cells were plated overnight
at 2x105 cells per well on 6-well culture plates (Corning). Using a
LIVE/DEADH Viability/Cytotoxicity kit (Molecular Probes,
Eugene, OR) live tumor cells were labeled with 2mM of Calcein
AM 30 minutes prior to cytotoxicity assays, washed in RPMI 1640
supplemented with 10% FCS and 1% penicillin streptomycin, and
re-suspended in media containing 4 mM Ethidium homodimer-1.
Ethidium homodimer-1 incorporates into the DNA of dead cells
and served as a label for cell death in this assay. U-937 monocytic
cells expressing Fcc receptors were used as immune effector cells at
a ratio of 3:1 (effectors: tumor cells) [40]. U-937 monocytes were
incubated with the 6_2G3 or 6_2D10 antibody for 30 minutes,
stained with the CellTrackerTM Blue dye (4-chloromethyl-7-
hydroxycoumarin) (Molecular Probes), washed and added to the
Calcein AM-labelled tumor cell cultures containing Ethidium
homodimer-1. Samples were incubated and images were captured
every 5 minutes for two hours in a humidified temperature
controlled chamber using a Zeiss Axiovert microscope equipped
with a LD-Plan-Neofluar 20x/0.4 Korr/Ph2 objective and
AxioVision software system (Carl Zeiss, Jena, Germany). Follow-
ing incubation, fluorescent intensities of Calcein AM-positive live
tumor cells, as well as incorporation of Ethidium homodimer-1
into cells were measured and cell death was assessed with NIS-
Elements BR 3 software (Nikon). The movement of effector cells in
the cultures was tracked and analyzed using IMARIS software
(Bitplane, Zurich, Switzerland).
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Statistical Methods
Descriptive statistics were generated to examine the distribution
of melanoma-reactive B cell cultures from each patient including
the mean, 95% confidence interval and maximum reactivity to
melanoma cells. A two-sided Student’s t test was used to compare
the mean reactivity of antibody cultures derived from melanoma
patients to healthy volunteers to primary or metastatic melanoma
cell lines and to compare antibody responses between patients with
non-metastatic and metastatic disease. A one-way ANOVA was
used to compare antibody reactivity to a metastatic melanoma cell
line among B cell cultures derived from patients with stage II, III
and IV disease with a Tukey’s post hoc comparison test. A two-
sided Student’s t test was used to compare antibody-mediated
tumor cell killing between tumor-specific and non-specific
monoclonal antibodies derived from the same patient. A two-
sided Student’s t test was also employed to compare the movement
of immune effector cells, pre-incubated with antibodies, in contact
with tumor cells to the movement of immune cells not in contact
with tumor cells. All statistical analyses were performed using
GraphPad Prism software (version 5.03, GraphPad, San Diego,
CA) and error bars in all figures represent 95% confidence
intervals.
Supporting Information
Figure S1 Schematic of cell-based ELISA used to detect
antibodies against tumor cell antigens.
(TIF)
Figure S2 Secretion of IgG antibodies from peripheral blood B
cells derived from patients and healthy volunteers.
(TIF)
Video S1 Real-time live-cell cytotoxicity assay for the 6_2G3
melanoma-specific antibody.
(AVI)
Video S2 Real-time live-cell cytotoxicity assay for the 6_2D10
non-melanoma-specific antibody (negative control).
(AVI)
Videos S1 and S2
These video files show our real-time cytotoxic assays. Video S1
shows real-time functional data of the 6_2G3 melanoma-specific
patient derived antibody which was observed to kill melanoma
cells. Video S2 shows the identical assays shown in Video S1 using
a non-melanoma specific antibody derived from the same patient,
as a negative control. In these assays, live tumor cells are labeled in
green (live cell dye), U-937 monocytic cells are labeled in blue, and
cell death is indicated by the incorporation of red (Ethidium
homodimer-1 incorporation). Frames from these videos are also
displayed in Figure 7, B.
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Abstract Trastuzumab (Herceptin®), a humanized IgG1
antibody raised against the human epidermal growth factor
receptor 2 (HER2/neu), is the main antibody in clinical use
against breast cancer. Pre-clinical evidence and clinical
studies indicate that trastuzumab employs several anti-
tumour mechanisms that most likely contribute to enhanced
survival of patients with HER2/neu-positive breast carcino-
mas. New strategies are aimed at improving antibody-based
therapeutics like trastuzumab, e.g. by enhancing antibody-
mediated eVector function mechanisms. Based on our
previous Wndings that a chimaeric ovarian tumour antigen-
speciWc IgE antibody showed greater eYcacy in tumour
cell killing, compared to the corresponding IgG1 antibody,
we have produced an IgE homologue of trastuzumab. Trast-
uzumab IgE was engineered with the same light- and
heavy-chain variable-regions as trastuzumab, but with an
epsilon in place of the gamma-1 heavy-chain constant
region. We describe the physical characterisation and
ligand binding properties of the trastuzumab IgE and eluci-
date its potential anti-tumour activities in functional assays.
Both trastuzumab and trastuzumab IgE can activate mono-
cytic cells to kill tumour cells, but they operate by diVerent
mechanisms: trastuzumab functions in antibody-dependent
cell-mediated phagocytosis (ADCP), whereas trastuzumab
IgE functions in antibody-dependent cell-mediated cytotox-
icity (ADCC). Trastuzumab IgE, incubated with mast cells
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and HER2/neu-expressing tumour cells, triggers mast cell
degranulation, recruiting against cancer cells a potent
immune response, characteristic of allergic reactions.
Finally, in viability assays both antibodies mediate compa-
rable levels of tumour cell growth arrest. These functional
characteristics of trastuzumab IgE, some distinct from those
of trastuzumab, indicate its potential to complement or
improve upon the existing clinical beneWts of trastuzumab.
Keywords HER2/neu · Trastuzumab · IgE · Monocytes · 
Mast cells · Tumour immunity
Abbreviations
HER2/neu Human epidermal growth factor receptor 2
ADCC Antibody-dependent cell-mediated 
cytotoxicity
ADCP Antibody-dependent cell-mediated 
phagocytosis
FBP Folate binding protein
sFcRI Soluble FcRI -chain
ECDHER2 HER2 protein extracellular domain
CM Complete medium
PI Propidium iodide
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VEGF Vascular endothelial growth factor






HER2/neu (c-erb-B2) is a 185 kDa protein that belongs to
the human epidermal growth factor receptor family. Its
functions include engendering cell signalling and regulat-
ing cell growth, proliferation, diVerentiation and motility
[1]. Approximately 30% of breast carcinomas as well as
other cancers, such as those of the ovary, endometrium,
bladder, prostate and lung, over-express HER2/neu, whilst
its expression in normal tissues is low [2]. Its expression in
breast cancer is thought to play a vital role in the pathogen-
esis of breast tumours and is linked to poor clinical out-
comes [3]. This antigen is now a validated target for cancer
therapeutics.
Trastuzumab (Herceptin®) is an IgG1 antibody raised
against the extracellular domain (ECD) of HER2/neu and is
the main antibody in clinical use for the treatment of
HER2-positive breast cancers [4–6]. Trastuzumab was
approved by the FDA in 1998 for the treatment of meta-
static HER2/neu over-expressing breast cancer and is now
also used as adjuvant therapy for early breast cancers. The
success of trastuzumab in breast cancer therapy has
renewed interest in antibody therapies and provoked further
research into the development of therapeutic antibodies.
However, only a subset of patients treated with trastuzumab
show signiWcant responses and thus there is scope for addi-
tional modalities designed to improve clinical outcomes [7].
Trastuzumab is thought to exert anti-tumour eVects by a
number of mechanisms. The best-deWned mechanism is the
blocking of the hetero-dimerization of HER2/neu receptors
with other HER family members (HER1, HER3) on the
surface of breast cancer cells thereby switching oV vital
tumour cell growth signals [8, 9]. Trastuzumab inhibits
metalloproteinase activity and interferes with signalling via
phosphoinositide 3-kinase (PI3 K) pathways, promoting
apoptosis and cell cycle arrest during the G1 phase.
Another mechanism is thought to be blocking angiogenesis
by inducing expression of anti-angiogenic factors such as
thrombospondin-1 and suppression of pro-angiogenic fac-
tors such as TGF-, VEGF, angiopoietin-1, and plasmino-
gen-activator inhibitor-1 [10]. Clinical and pre-clinical
studies suggest that trastuzumab may also enlist immune
eVector cells to attack and kill tumour cells by cytotoxicity
(ADCC) and phagocytosis (ADCP), and by augmenting
chemotherapy-induced cytotoxicity [11–14]. Studies are
now focusing on strategies aimed at improving the signiW-
cant but circumscribed success of trastuzumab. These
include optimising antigen speciWcity or aYnity and
enhancing antibody-mediated eVector cell functions tar-
geted against tumour cells.
Although there are Wve antibody classes in man, each
with distinctive functions in the immune system, trast-
uzumab, but essentially all monoclonal antibodies approved
for clinical use are IgG1 s. Antibodies of the IgG class
function most eVectively in the circulation [15]. There are
many reasons why IgE antibodies might be more eVective
against tumours that develop in tissues and are therefore
inaccessible to IgGs [16]. The concentration of IgE in the
serum of normal individuals is minute (<150 ng/mL, 1/
10,000 the concentration of IgG) because IgE is seques-
tered in solid tissues, where it is bound with high-aYnity to
receptors on its eVector and antigen-presenting cells [17].
The aYnity of IgE for FcRI (Ka »1011 M¡1) is 102–105
times higher than those of IgGs for their receptors, making
IgE the only antibody strongly retained by eVector cells in
the absence of antigen [17, 18]. The half-life of IgE in tis-
sues (measured in the skin »2 weeks) is longer than that of
IgG (2–3 days) [18, 19]. IgE saturates FcRI at nM concen-
trations, but only 10% of the receptors need be occupied by
IgE and antigen for full mast cell activation and eVector cell
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recruitment to the site of antigen challenge in tissues [17,
20]. IgE antibodies on the surface of tissue mast cells are
cross-linked by antigens to induce the release of histamines,
leukotrienes, proteases, and, importantly, Th2 cell-type
cytokines (IL-3, IL-4, IL-5, IL-6, IL-9, IL-13, TNF-) at
the site of antigen challenge. This results in activation of
the resident immune eVector cells, but also elicits further
recruitment and persistence of an inXammatory cell inWl-
trate, comprising Th2 cells, monocytes, eosinophils and
basophils, from the circulation, which enhances and main-
tains the local immune response [17]. IgE antibodies
directed against a tumour-associated antigen would there-
fore trigger an immediate local eVector cell response
against tumour cells and stimulate a cascade of inXamma-
tion targeted to the tumour cells in situ. These activities
could possibly be highly eVective in immune rejection of
tumours embedded in solid tissues.
Several studies support the ideas IgE antibodies may be
highly eVective tools in cancer therapy [21–28]. We have
previously shown that an antibody of the IgE class is supe-
rior to the corresponding IgG1 antibody against folate bind-
ing protein (FBP) in prolonging survival of mice in two
xenograft models of ovarian cancer [29–32]. Ours and other
studies [23, 27, 33–35] have contributed to the suggestion
that the antibody class may inXuence the nature as well as
the potency of the immune responses elicited against
tumour cells.
In order to examine the mechanisms by which an IgE
version of trastuzumab may act in tumour cell killing, we
have engineered a humanised trastuzumab IgE. Here, we
report the physical characterisation and functional proper-
ties of the engineered trastuzumab IgE, and show that these
properties are distinct from those of trastuzumab (IgG1).
Our data suggests that trastuzumab IgE may potentiate
tumour killing by mechanisms and pathways that might be
highly eVective in cancer therapy.
Materials and methods
Antibodies and reagents
Chimaeric mAbs MOv18 IgE and MOv18 IgG (IgG1 iso-
type) against the human folate binding protein (FBP), NIP
IgE speciWc for the hapten 4-hydroxy-3-nitro-phenacetyl
(NIP) and the recombinant IgE receptor FcRI alpha (sFc-
RI) were prepared as before [29, 36, 37]. ECDHER2, the
soluble human HER2 protein comprising the HER2/neu
extracellular domain (ECD) (90 kDa) was prepared as pre-
viously described [38]. Trastuzumab (Herceptin®) was
from Genentech (San Francisco, CA, USA), goat anti-
human IgE-FITC was from VECTOR Laboratories Ltd.
(Peterborough, UK) and anti-CD89-PE and anti-CD33-
APC mAbs were from BD Biosciences (Oxford, UK). Anti-
bodies to Fc and Fc receptors, human IgG isotype-
matched control and goat anti-mouse-Ig-FITC Abs were
from Dako (Glostrup, Denmark). PI, CFSE, and tissue cul-
ture reagents were from Invitrogen (Paisley, UK).
Generation of trastuzumab IgE antibody
The cDNA derived from the protein sequences of the heavy
and light chains of the trastuzumab variable regions was
synthesised (Gene Art AG, Regensburg, Germany) based
on the published protein sequence of trastuzumab (source:
http://www.pdb.org; 1n8z) [39]. This cDNA was then
cloned into two vectors based on a pTT vector backbone,
one containing the epsilon heavy chain of IgE (humighae2,
accession no: L00022; Kenten et al. 1982), the other con-
taining the human kappa light chain constant region cDNA
(IGKC, accession no: BC110394) [40, 41] (Fig. 1). For full
amino acid sequences for trastuzumab IgE see Supplemen-
tary Table I (Supplementary Data). For transfection into
compatible HEK293 cells, vector DNA was produced using
the HiSpeed Plasmid Maxi Kit® (Qiagen®), according to
the manufacturer’s instructions. HEK293 cells were har-
vested and seeded at 4 £ 105 cells/mL and allowed to
adhere before being transfected with 1 g of DNA with the
aid of 2 g of PEI (Polyethenylenimine, MW: 25 kDa;
Polysciences Inc., Warrington, PA, USA) per 4 £ 107 cells
[40]. Supernatants were harvested 2–4 weeks later and anti-
bodies were puriWed by aYnity chromatography as previ-
ously described [29]. Antibody purity was conWrmed by
HPLC analysis.
Fig. 1 Schematic representation of the design of trastuzumab IgE
antibody. To engineer trastuzumab IgE, the variable heavy and light
chains of trastuzumab (IgG1, left; regions indicated with stars) were
inserted into the epsilon heavy chain regions of IgE and the epsilon
heavy chain was combined with the kappa light chain to produce the
corresponding trastuzumab IgE antibody (right). The resulting engi-
neered IgE molecule should recognise the HER2/neu antigen and IgE
receptors (see Supplementary Table I, Supplementary Data for full
sequence). Glycosylation sites are depicted by black circles
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Kinetic assays of antibody binding to HER2 and FcRI
Kinetic studies were performed using surface plasmon res-
onance (SPR) analysis to examine the speciWcities and
binding aYnities of trastuzumab (IgG1) and trastuzumab
IgE antibodies to the soluble ECDHER2 protein and to the
soluble high-aYnity IgE receptor alpha subunit (sFcRI),
each immobilised on the biosensor surface. Kinetics of
trastuzumab IgE binding to immobilised FcRI on the bio-
sensor surface were compared to the well-characterised chi-
maeric antibody NIP IgE. All experiments were performed
at 24°C on a Biacore 3000 instrument (Biacore Int. SA,
Switzerland). Methods and kinetic analysis have been
described previously [36, 42, 43]. In these experiments,
antibodies were tested at a concentration range of 125–7.8
nM, coupling density was typically restricted to 200RU,
Xow rate 20 L/min, and exposure time to analyte 360 s.
Cell culture
The human monocytic cell line U937 [44] (kindly provided
by Prof. J.-P. Kinet, Harvard University, Boston, MA, USA)
was grown in RPMI 1640 medium, 10% FCS, 2 mM l-gluta-
mine, penicillin (5,000 U/mL) and streptomycin (100 g/
mL). The murine colon adenocarcinoma cell lines CT26 [45,
46] and CT26-HER2/neuHer2+ transfected with the HER2/
neu antigen [47] were grown in Iscove’s medium (IMDM),
5% FCS, 2 mM l-glutamine, penicillin (5,000 U/mL) and
streptomycin (100 g/mL). The human breast adenocarci-
noma cell line SKBR3 (ATCC, No. HTB-30), that naturally
expresses the HER2/neu antigen, was grown in DMEM,
10% FCS, 2 mM l-glutamine, penicillin (5,000 U/mL) and
streptomycin (100 g/mL). The rat basophilic leukaemia
mast cell line RBL-SX38 [48] (Prof. J.-P. Kinet, Harvard
University, Boston, MA, USA) expresses the human form of
the FcRI receptor and was maintained in MEM supple-
mented with 10% FCS, 250 g/mL Geneticin, 2 mM l-gluta-
mine, penicillin (5,000 U/mL) and streptomycin (100 g/
mL). All cells were maintained at 37°C in 5% CO2.
Flow cytometric assessments of antibody binding 
to receptors on cells
For Xow cytometric assessments of antibody binding to the
tumour-associated antigens FBP and HER2/neu and to Fc
(IgE) and Fc (IgG) receptors on receptor-expressing cells,
cells were incubated with 0.5 g/mL mAbs for 30 min at
4°C, followed by two washes in FACS buVer (PBS, 5%
normal goat serum). Cells were then given anti-human IgE-
FITC or anti-human IgG-FITC (10 g/mL) for 30 min at
4°C, washed in FACS buVer and Wxed in 1% paraformalde-
hyde-FACS buVer prior to acquisition and analysis on a
dual laser FACSCalibur™ (BD Biosciences). For quantita-
tive assessments of Fc and Fc cell surface receptors,
2 £ 105 U937 cells/sample were stained with mouse mAbs
by indirect immunoXuorescence using the QIFIKIT®
(Dako). U937 cells, setup beads and calibration beads were
given goat anti-mouse IgG-FITC, followed by two washes
in FACS buVer and analysis by Xow cytometry on a
FACSAria II Xow system (BD Biosciences). The numbers
of receptors per cell were calculated against Xuorescent cal-
ibrating bead standards using linear regression.
Flow cytometric ADCC/ADCP assay
Treatment of tumour cells
We employed our previously described novel three-colour
Xow cytometric assay to simultaneously measure tumour cell
cytotoxicity (ADCC) and phagocytosis (ADCP) of HER2/
neu-positive tumour cells by human eVector cells [30, 31, 49].
CT26-HER2/neu or SKBR3 cells were stained 24 h prior to
assays with 7.5 M CFSE in PBS for 10 min at 37°C, washed
in RPMI 1640 medium, 10% FCS, 2 mM L-glutamine, and
returned to normal culture conditions. The following day,
CFSE-labelled tumour cells were washed, mixed with
unstained eVector cells at E:T ratio of 2:1 with or without anti-
bodies, followed by incubation for 2.5 h at 37°C. Antibodies
were tested at concentrations of 0.05, 0.5 and 5 g/mL.
Three-colour Xow cytometric assay setup
CFSE-labelled tumour cells were detected in FL1 (530/
30 nm band pass Wlter), PE-labelled monocytic eVector
cells in FL2 (582/42 nm band pass Wlter) and PI+ dead cells
in FL3 (670 nm LP band pass Wlter) channels, whilst con-
trol samples were set for compensation adjustments
between Xuorochromes. Two dual colour Xow cytometric
dot plots were generated to calculate ADCC and ADCP as
previously described [30, 31, 49]. BrieXy, one dot plot
depicted CFSE + tumour cells and PI + cells, allowing
quantitation of tumour targets killed externally by eVector
cells (ADCC, cytotoxicity) (CFSE +/PI + cells). The
second dot plot depicted CFSE + tumour cells and
CD89-PE + eVector cells in order to quantitate total
CFSE + tumour cells and the number of tumour cells
present within PE + eVector cells, depicting phagocytosis
(ADCP) by eVector cells (CFSE +/PE + cells) [49]. This
dot plot would also indicate any non-speciWc uptake of
CFSE Xuorescence by PE + U937 eVector cells.
Confocal imaging of cell contact and antibody-mediated 
tumour cell phagocytosis
U937 monocytes, which served as eVector cells, were
incubated on Lab-Tec II glass chamber slides (SLS Ltd,
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Manchester, UK) with CFSE-labelled CT26-HER2/neu
tumour cells at an original E:T ratio of 2:1. Treatments
were performed as above. Mixed cell cultures were incu-
bated for 3 h with MOv18 IgG, MOv18 IgE, trastuzumab
(IgG1) or trastuzumab IgE antibodies. At the end of the
incubations, cells were then given anti-CD33-APC for
40 min at 4°C, to label monocytic cells. Cells were then
washed, Wxed in 4% paraformaldehyde-FACS buVer and
mounted with Xuorescence preserver (Dako). Fluores-
cence microscopy was performed on a Zeiss Axiovert
200 confocal microscope (63 £ oil immersion objec-
tive). Acquisition and analysis was performed with
UltraView software (PerkinElmer, Waltham, MA,
USA).
In vitro degranulation assays
The ability of the engineered trastuzumab IgE to trigger
degranulation was measured in vitro using the rat baso-
philic mast cell line RBL-SX38. This cell line expresses
the human form of the FcRI receptor as a 2 tetramer,
the form naturally expressed on the surface of human mast
cells [48, 50, 51]. For degranulation experiments cells
were plated at 2 £ 104 per well in 100 L in 96 well Xat-
bottomed tissue culture plates and incubated overnight at
37°C in a humidiWed CO2 incubator. The following day,
cells were sensitised with IgE diluted in culture medium at
100 ng/mL, incubated for two hours at 37°C and washed
twice with HBSS, 1% BSA (wash buVer). Cell degranulation
was triggered for 30 min either with 100 L of anti-human
IgE polyclonal rabbit mAb (Dako) (Wnal concentration:
100 ng/mL), or HER2/neu-expressing CT26 cells added at
diVerent concentrations (1 £ 103 to 5 £ 105 per well) in
wash buVer at 37ºC. Degranulation was terminated by
placing the cells on ice and the supernatants removed
for quantiWcation of mediator release. Control supernatants
were either from individual or mixed cell populations
alone treated with no antigen for background release, or
wash buVer plus 0.1% Triton-X-100 (Tx) for total release.
Degranulation was measured by quantiWcation of -hexos-
aminidase release, assayed using a Xuorogenic substrate
(4-methylumbelliferyl-N-acetyl--D-glucosaminide) pre-
pared according to a standard protocol [51, 52]. Superna-
tants were incubated in black 96 well plates with an equal
volume of substrate at 37°C for 2 h and quenched with
0.5 M Tris. Fluorescence was measured using a Thermo
Fluoskan II Wtted with a 350 nm excitation and a 450 nm
emission Wlters. All measurements were made in triplicate
for each concentration and release was expressed as a per-
centage of total content determined by treatment with 0.1%
Triton-X-100 solution in HBSS, 1% BSA. Background
release, subtracted from all values, was always <10% of
total release.
Cell viability assay
Tumour cell viability was analysed by the MTS assay
(tetrazolium compound 3-(4,5-dimethylthiazol-2-yl)-
5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazo-
lium inner salt) using phenazine methosulfate (PMS) as a
reducing agent (CellTiter 96® AQueous One Solution Cell
Proliferation Assay kit, Promega, Southampton, UK). Cells
were seeded in 96-well plates at 4 £ 104 cells per well and
allowed to adhere overnight under standard culture condi-
tions prior to assays. Cells were exposed to 0.5 g/mL
trastuzumab, trastuzumab IgE, MOv18 IgG or MOv18 IgE
antibodies over a period of 4, 24, and 48 h. Control groups
received media alone, or 0.9% v/v Triton-X-100 for 30 min
prior to addition of MTS. Following treatments, MTS/PMS
solution prepared according to the manufacturer’s instruc-
tions were added at 20 L per well and cells were incubated
for a further 1 h prior to recording absorbance at 490 nm
with a 96-well plate reader. The quantity of formazan prod-
uct as measured by the amount of 490 nm absorbance is
directly proportional to the number of living cells in cul-
ture.
Data handling and statistical analysis
In surface plasmon resonance assays, mean values §SD
were calculated from three measurements. Flow cytometry
experiments of receptor binding and blocking were
repeated at least three times. In vitro ADCC/ADCP assays
were performed in triplicate and data are shown as mean
ADCC § SD and ADCP § SD of a number (n) of indepen-
dent experiments (see Supplementary Table II in Supple-
mentary Data). Statistical analyses of in vitro ADCC/
ADCP assays and microscopic measurements of eVector-
tumour cell interactions were performed by means of the
unpaired two-tailed Student’s t test, and signiWcance was
accepted at P < 0.05.
Results
Binding of trastuzumab IgE to antigen and FcRI
We have compared the kinetics of binding of the engi-
neered trastuzumab IgE and trastuzumab (IgG1) to HER2/
neu ECDHER2 immobilised on a biosensor surface by
surface plasmon resonance (Fig. 2a; Table 1). The two
antibodies exhibited similar rates of association and
dissociation from their complexes with ECDHER2 (ka, kd,
mean § SD, Table 1). These data demonstrate that trast-
uzumab IgE exhibits the expected interaction with
ECDHER2, and the calculated aYnity values of both trast-
uzumab IgE and IgG1 (Ka of 1010) are similar to those
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previously reported for the IgG1 [6, 53]. Comparison of
sensograms representing binding of trastuzumab IgE and
the chimaeric NIP IgE to the immobilised soluble alpha-
chain of FcRI (sFcRI) demonstrates that both antibodies
bind to the high-aYnity IgE receptor with the expected
kinetics and aYnity (ka, kd, mean § SD; Fig. 2b; Table 1).
In particular, both antibodies demonstrate the documented
slow dissociation rate that is characteristic of the complex
of IgE with FcRI (Fig. 2b) [36, 42, 43]. As expected, trast-
uzumab (IgG1) did not bind to the IgE receptor (Fig. 2b,
right panel).
Trastuzumab interaction with receptors on monocytic 
eVector and tumour cells
Flow cytometric assessments of trastuzumab and trast-
uzumab IgE interactions with HER2/neu and Ig (Fc and
Fc) receptors on the surface of cells served two purposes.
The Wrst was to conWrm that the antibodies recognise their
native receptors as presented on cell surfaces. The second
was to explore the mechanisms employed by trastuzumab
and trastuzumab IgE together with human monocytic cells
to target and kill HER2/neu receptor-expressing tumour
cells. For this, we analysed the interactions of these anti-
bodies with U937 monocytic cells, which served as eVector
cells, and with the CT26 cells transfected to express the
human HER2/neu receptor on the cell surface (CT26-
HER2/neu) [46], used as target cells.
The expression of IgG receptors FcRI, FcRII and
FcRIII and of IgE receptors FcRI and CD23 on U937
cells were also measured (Table 2). U937 monocytes
express FcRI (»12,000 molecules per cell) and FcRII
(»19,000 molecules per cell) but very low levels of FcRIII
(»700 molecules per cell). In agreement with our previ-
ously published data [30], we measured approximately
22,000 molecules of FcRI are expressed per cell, whilst
the expression of CD23 was low (»2,200 molecules/cell).
Consistent with the abundant expression of Fc receptors
on the surface of U937 cells, trastuzumab bound to Fc
receptors expressed on the surface of 99.8% of U937 mono-
Fig. 2 Comparative SPR analy-
sis of trastuzumab IgE and trast-
uzumab (IgG1) kinetics of 
binding to immobilised HER2 
receptor ECDHER2 (a) and to im-
mobilised FcRI (b). Data were 
recorded using a Biacore 3000 
(Xow rate 20 L/min). Antibod-
ies were tested at concentrations 
ranging from 125 to 7.8 nM. All 
values derived from the Wtting 
procedures are given in Table 1
Table 1 Calculated kinetic values of trastuzumab IgE binding to HER2 and FcRI
Kinetic parameters and aYnity constants derived from the SPR analysis of NIP IgE and trastuzumab IgE binding to immobilised sFcRI and trast-
uzumab (IgG1) and trastuzumab IgE binding to immobilised ECDHER2. Both IgEs and trastuzumab were analysed using a 1:1 model of association
from which association and dissociation constants were derived for each component (shown § SD for at least Wve determinations in the concen-
tration range 125–7.8 nM)
Constant ECDHER2 surface sFcRI surface
Trastuzumab IgE Trastuzumab (IgG1) Trastuzumab IgE NIP IgE
ka (M¡1 s¡1) (3.5 § 1.4) £ 105 (7.3 § 3.5) £ 105 (4.8 § 2.3) £ 105 (2.3 § 1.1) £ 105
kd (s¡1) (2.4 § 0.3) £ 10¡5 (1.8 § 0.9) £ 10¡5 (2.3 § 0.5) £ 10¡5 (2.6 § 0.5) £ 10¡5
Ka (M¡1) 1.5 £ 1010 4.2 £ 1010 2.1 £ 1010 1.0 £ 1010
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cytic cells (Fig. 3a, upper left), as did the chimaeric antibody
MOv18 IgG, speciWc for the ovarian tumour antigen FBP,
used as positive control (Fig. 3a, upper right). Trastuzumab
also bound to 79.8% of CT26-HER2/neu cells (Fig. 3a, bot-
tom left), whilst only background binding of the MOv18
IgG was detected (5.2%) (Fig. 3a, bottom right). These data
conWrm the speciWcity of the antibody for the human HER2/
neu antigen expressed on the surface of tumour cells as well
as to the Fc receptors expressed by monocytic cells.
Trastuzumab-mediated killing of tumour cells
We employed our previously developed three-colour Xow
cytometric assay to simultaneously measure trastuzumab
ADCC and ADCP of HER2/neu-expressing tumour cells
[49] (Fig. 3b, c). The CT26-HER2/neu cells were used as
tumour targets and human U937 monocytes were employed
to provide eVector cells. The green-Xuorescent dye CFSE
was used to stain live CT26-HER2/neu cells prior to incu-
bation with U937 monocytes and, after the incubation,
U937 cells were stained with anti-CD89-PE and dead cells
with propidium iodide (PI). Two colour Xow cytometric dot
plots show that after 2.5 h in culture, U937 cells mixed with
trastuzumab and CT26-HER2/neu mediated little ADCC
above that seen with samples incubated with the MOv18
IgG (5.3 vs. 4.8%; Fig. 3b, top panels, top right boxes for
double positive CFSE +/PI + cells). Two-colour Xow cyto-
metric dot plots also showed that incubation with trast-
uzumab induced appreciable tumour cell ADCP compared
to control MOv18 IgG (30.6 vs. 4.9%; Fig. 3b, bottom pan-
els; top right boxes for double positive CFSE +/PE + cells).
Flow cytometric ADCC/ADCP assay measurements con-
Wrmed that trastuzumab at an optimal concentration of
0.5 g/mL mediated signiWcant levels of ADCP of CT26-
HER2/neu tumour cells by monocytic cells. Levels of
ADCP increased »10% above those of the MOv18 IgG and
no antibody controls (Fig. 3c and Supplementary Table II,
Supplementary Data). Statistically signiWcant levels of
ADCC were not measured with any of the conditions tested
here (Supplementary Table II, Supplementary Data). These
data suggest that trastuzumab-IgG1 mediates ADCP, but
not ADCC of tumour cells by monocytic cells.
Cell viability assays demonstrated that CT26-HER2/neu
tumour cells were susceptible to the anti-proliferative eVects
of trastuzumab (IgG1). These eVects were detected after
24 h (89 vs. 96.6% cell viability for trastuzumab and
MOv18 IgG, respectively) and 48 h incubation (87.5 vs.
104.5% cell viability for trastuzumab and MOv18 IgG,
respectively). No cell growth arrest was detected with trast-
uzumab after exposure to antibody for 4 h (104.6 and 100%
viability for trastuzumab and MOv18 IgG, respectively
(Supplementary Fig. 1, Supplementary Data). This con-
Wrmed that tumour cell death measured with the ADCC/
ADCP assays after 3 h exposure to antibodies was not the
result of receptor hetero-dimerisation blocking by trast-
uzumab alone. Thus, the rapid cell death detected by the
ADCC/ADCP assay was most likely mediated by Fc recep-
tors on U937 monocytes in combination with trastuzumab.
The tumour-targeting and phagocytic activities of
trastuzumab measured in the ADCC/ADCP assays were
conWrmed by confocal microscopical imaging (Fig. 3d).
CT26-HER2/neu cells were pre-labelled with CFSE (green),
incubated with U937 cells at and E:T ratio of 2:1, combined
with antibodies, incubated for 3 h on glass chamber slides, and
U937 cells were labelled with anti-CD33-APC mAb (red).
In samples incubated with trastuzumab, enhanced contact
between CT26-HER2/neu tumour cells (green) and U937
monocytic cells (red) was evident, and in many instances two
or more monocytic cells were observed in contact with a sin-
gle tumour cell (Fig. 3d, left, white arrows). We also observed
phagocytosis of tumour cells, clearly visible in the merged
image of the green tumour cells inside the red U937 cells:
most monocytic cells in contact with tumour cells appeared to
contain tumour cell material (Fig. 3d, left; white arrows). In
contrast to these observations, neither contact nor phagocytosis
were observed in samples given MOv18 IgG examined after
3 h in the same culture conditions (Fig. 3d, right). To conWrm
the microscopic observations, the frequency of interactions
between eVector and target cells were measured (Table 3).
Incubation with trastuzumab led to enhanced contact (24.5%
of tumour cells) between tumour and U937 monocytes after
3 h compared to 7.9% contact observed in samples incubated
with MOv18 IgG. Most of the U937 monocytes in contact
with tumour cells contained tumour cell material (20.4% of
tumour cells), suggesting tumour cell phagocytosis, rarely
seen with MOv18 IgG (3.5%). Findings from microscopic
observations and measurements of cell-cell interactions are in
agreement with our ADCC/ADCP assays suggesting that
trastuzumab mediated tumour cell killing by phagocytosis.
Trastuzumab IgE interaction with HER2/neu and IgE 
receptors on monocytic eVector cells and tumour cells
We analysed the interactions of trastuzumab IgE with its
Fc receptors on U937 monocytic cells and with human
Table 2 QuantiWcation of IgE and IgG Receptors on U937 Mono-
cytes
Surface antigen Number of molecules per cell 
(mean § SD) (n = 9)
CD23 2.2 £ 103 § 1.3 £ 103
FcRI 21.8 £ 103 § 4.8 £ 103
FcRI 12.1 £ 103 § 3.9 £ 103
FcRII 19.0 £ 103 § 3.9 £ 103
FcRIII 0.7 £ 103 § 0.4 £ 103
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HER2/neu on the surface of CT26-HER2/neu cells. Trast-
uzumab IgE bound to Fc receptors expressed on the sur-
face of U937 monocytic cells (53.6% of cells) (Fig. 4a,
upper left), in a manner indistinguishable from the positive
control MOv18 IgE (60.6% of cells) (Fig. 4a, upper right).
Lower levels of trastuzumab IgE binding to Fc receptors,
Fig. 3 a Flow cytometric analysis of binding to Fc receptor-express-
ing U937 monocytic cells for trastuzumab (IgG1) (top left) and the chi-
maeric MOv18 IgG antibody against the ovarian cancer antigen FBP
(top right). Flow cytometric analysis of binding to the HER2/neu anti-
gen on the surface of CT26-HER2/neu cells for trastuzumab (bottom
left) and the chimaeric MOv18 IgG antibody against FBP (bottom
right) (Monoclonal antibodies: solid lines; secondary antibody con-
trols: grey histograms). b Trastuzumab-mediated killing of CT26-
HER2/neu tumour cells by U937 monocytes: two-colour Xow cytomet-
ric dot plots detected no ADCC but appreciable ADCP after 2.5 h in
culture. CFSE-labelled tumour cells (x-axis) and dead tumour cells la-
belled with Propidium Iodide (PI) (y-axis), double-positive cells depict
tumour cells killed by ADCC (CFSE+/PI+, upper right boxes, values
are % ADCC) (top). CFSE-labelled tumour cells phagocytosed by
U937 cells labelled with CD89-PE mAb (y-axis, upper left), double
positive cells, CFSE+/PE+ (upper right boxes, values are % ADCP)
(bottom). c QuantiWcation of trastuzumab-mediated CT26-HER2/neu
tumour cell killing by U937 monocytes after 2.5 h using the ADCC/
ADCP assay. Cytotoxicity: black bars; phagocytosis: white bars. Re-
sults are means § SD of six independent experiments. SigniWcance of
values compared to samples given MOv18 IgG (top) or no antibody
(bottom) by the Student’s t test: n/sP > 0.05, *P < 0.05, **P < 0.005,
***P < 0.0005. d Representative confocal Xuorescence images of
CT26-HER2/neu-U937 interactions potentiated by trastuzumab.
CFSE-stained CT26-HER2/neu tumour cells (green) and CD33-APC
labelled U937 cells (red) combined at an original E:T ratio of 2:1 and
incubated for 3 h in culture. U937 cells (red) given trastuzumab IgG
(left) showed enhanced contact with tumour cells (green) and phago-
cytosis of tumour cells (green CFSE inside U937 monocytes, white
arrows). Neither eVector-target cell contact nor phagocytosis was
observed when cells were incubated with control MOv18 IgG antibody
(right). Original magniWcation £63 (scale bar 15 m)
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compared to binding of trastuzumab binding to Fc recep-
tors, are consistent with lower expression of IgE receptors
on U937 cells (Table 2) and our previous Wndings that
MOv18 IgE bound to only a fraction of FcRI receptors on
these cells [30]. Trastuzumab IgE also recognised the
HER2/neu receptor since it bound to 89.3% of CT26-
HER2/neu cells (Fig. 4a, bottom left), similarly, to trast-
uzumab (91.5% cells, Fig. 4a, bottom middle), whilst only
background binding of trastuzumab IgE was detected in
untransfected CT26 cells, which do not express the HER2/
neu receptor (5.2%) (Fig. 4a, bottom right). These data con-
Wrm the speciWcity of the engineered IgE antibody for the
human HER2/neu antigen as well as for the Fc receptors
expressed on the surface of the monocytic cells.
Assessments of the functional properties of trastuzumab 
IgE
Monocytic cells and IgE-mediated tumour cell killing
We wished to assess whether our engineered trastuzumab
IgE was biologically active and thus sought to characterise
its biological properties using two functional assays. One
related to the ability of this antibody to mediate tumour cell
targeting and killing by human eVector cells and was
assessed using our three-colour Xow cytometric ADCC/
ADCP assay. As done above for trastuzumab, the CT26-
HER2/neu cells were used as tumour targets and human
U937 monocytes were employed to provide eVector cells.
Using this method, we observed that incubation of CT26-
HER2/neu and U937 cells with trastuzumab IgE was asso-
ciated with increased tumour cell death by cytotoxicity
(ADCC) (Fig. 4b, c). This was evident by the increased
population of CFSE +/PI + tumour cells in samples incu-
bated with trastuzumab IgE (Fig. 4b, upper right, top right
boxes for CFSE +/PI + tumour cells), compared to those
with the control MOv18 IgE (18.7 vs. 4.6%; Fig. 4b, upper
left). In contrast to trastuzumab, the neither the trastuzumab
nor the MOv18 IgE enhanced the phagocytosis of tumour
cells, as seen in the double positive CFSE +/PE + cell pop-
ulation (4.7 vs. 4.3%; Fig. 4b, bottom panel, top right boxes
for CFSE +/PE + tumour cells). These results also con-
Wrmed that phagocytic killing by trastuzumab and U937
monocytes, measured by the ADCC/ADCP assays (Fig. 3),
were a result of Fc receptor functions of this antibody
rather than non-speciWc uptake of killed tumour cells.
Therefore, Xow cytometric ADCC/ADCP assay mea-
surements conWrmed that trastuzumab IgE, at an optimal
concentration of 0.5 g/mL mediated signiWcant levels of
ADCC of CT26-HER2/neu cells by the monocytic cells
(Fig. 4c). Levels of ADCC increased by »10% above those
of the MOv18 IgE, tested at the same concentrations, and
the no antibody controls (Fig. 4c and Supplementary Table
II, Supplementary Data). Statistically signiWcant levels of
ADCP were not measured in this assay system (P > 0.05;
Supplementary Table II, Supplementary Data). These data
suggest that trastuzumab IgE mediates tumour killing by a
mechanism diVerent from trastuzumab, directing mono-
cytes to act in ADCC instead of ADCP against the tumour
cells.
Interestingly, the antibody concentration (0.5 g/mL)
required to achieve maximum tumour cell killing by mono-
cytes in these assays was the same for IgG and IgE (Fig. 3c,
Fig. 4c and Supplementary Table II, Supplementary Data).
Furthermore, when compared directly in ADCC/ADCP
assays, the two IgE antibodies mediated similar levels of
total tumour cell killing (35% of tumour cells by IgE vs.
36% of tumour cells by IgG; Table 4). Our data show that
IgE is as eVective as IgG in recruiting monocytes to kill
tumour cells in vitro and warrant further studies to compare
the anti-tumour eVector cell functions of these antibodies
in vivo.
Trastuzumab IgE-mediated interactions of monocytic 
and tumour cells
The tumour-targeting activities of trastuzumab IgE mea-
sured in the ADCC/ADCP assays were studied by confocal
microscopical imaging (Fig. 4d). CT26-HER2/neu cells
were pre-labelled with CFSE (green), incubated with U937
cells, combined with antibodies for 3 h on glass chamber
slides, and U937 cells were labelled with anti-CD33-APC
(red). In samples incubated with trastuzumab IgE, contact
between CT26-HER2/neu tumour cells and U937 mono-
cytic cells, was clearly evident, and two or more monocytic
cells were frequently observed in contact with or in close
proximity to a single tumour cell (Fig. 4d, left; white
arrows). However, in contrast to our observations with
Table 3 Microscopic Measurements of CT26-HER2/neu: U937 Cell
Interactions
Data were collected by counting eVector: target cell contact or target
cell phagocytosis per microscopic Weld at a magniWcation of 40£ and
percentage values were calculated. Mean values were calculated from
ten microscopic Welds for each condition and are shown § SD. Stu-
dent’s t test was used to generate signiWcance of values compared to
samples given the corresponding MOv18
n/s P > 0.05; * P < 0.05; ** P < 0.005; *** P < 0.0005
Antibody E:T contact CT26-HER2/neu 
phagocytosis
(mean § SD) (%) (mean § SD) (%)
Trastuzumab (IgG1) 24.5 § 10.5** 20.43 § 9.2***
MOv18 IgG 7.9 § 11.2 3.5 § 5.9
Trastuzumab IgE 29.2 § 13.9*** 4.7 § 5.8 n/s
MOv18 IgE 5.1 § 5.2 2.2 § 5.1
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Fig. 4 a Flow cytometric analysis of binding to IgE receptor-expressing
U937 monocytic cells for trastuzumab IgE (top left) and the chimaeric
MOv18 IgE antibody against the ovarian cancer antigen FBP (top right).
Flow cytometric analysis of trastuzumab IgE (bottom left) and trastuzumab
(IgG1) antibody (bottom middle) binding to the HER2/neu antigen on the
surface of HER2/neu-expressing CT26-HER2/neu cells, and lack of trast-
uzumab IgE binding to HER2/neu-negative CT26 tumour cells (bottom
right). (Monoclonal antibodies: solid lines; secondary antibody controls:
grey histograms). b Trastuzumab IgE-mediated killing of CT26-HER2/
neu tumour cells by U937 monocytes: two-colour Xow cytometric dot
plots detected ADCC but no ADCP after 2.5 h in culture. CFSE-labelled
tumour cells (x-axis) and dead tumour cells labelled with Propidium Iodide
(PI) (y-axis), double-positive cells depict tumour cells killed by ADCC
(CFSE+/PI+, upper right boxes, values are % ADCC) (top). CFSE-labelled
tumour cells phagocytosed by U937 cells labelled with CD89-PE mAb
(y-axis) are double positive CFSE+/PE+ cells (upper right boxes, values
are % ADCP) (bottom). c Quantitation of trastuzumab IgE-mediated
CT26-HER2/neu tumour cell killing by U937 monocytes after 2.5 h using
the ADCC/ADCP assay, at diVerent antibody concentrations. Cytotoxic-
ity: black bars; phagocytosis: white bars. Results are mean § SD of Wve
independent experiments. SigniWcance of values compared to samples giv-
en MOv18 IgE (top) or no antibody (bottom) by the Student’s t test:
n/sP > 0.05, *P < 0.05, **P < 0.005, ***P < 0.0005. d Typical confocal
Xuorescence images of CT26-HER2/neu-U937 interactions potentiated by
trastuzumab IgE. CFSE-stained CT26-HER2/neu tumour cells (green)
and anti-CD33-APC labelled U937 cells (red) combined at an original E:T
ratio of 2:1 and incubated for 3 h in culture. U937 cells (red) given trast-
uzumab IgE (left) exhibited enhanced contact with tumour cells (green)
but no phagocytosis of tumour cells was observed (no green CFSE Xuo-
rescence detected inside U937 cells; white arrows). No eVector-target cell
contact was observed when cells were incubated with control MOv18 IgE
antibody (right). Original magniWcation £63 (scale bar 15 m)
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trastuzumab, trastuzumab IgE did not appear to enhance
phagocytosis, since no green tumour material was observed
inside the red U937 cells (Fig. 4d, left). As expected, rare
contact was observed with the control antibody MOv18
IgE, examined in the same culture conditions (Fig. 4d,
right). Measurements of interactions between eVector and
target cells (Table 3) showed that trastuzumab IgE medi-
ated enhanced eVector: target cell contact (29.2% of tumour
cells) after 3 h, compared to 5.1% contact in samples given
MOv18 IgG. A very small proportion of the U937 mono-
cytes in contact with tumour cells contained tumour cell
material (4.7% of tumour cells), suggesting little tumour
cell phagocytosis was mediated by trastuzumab IgE. Micro-
scopic observations and measurements of eVector: tumour
cell interactions are in agreement with our ADCC/ADCP
assays and are consistent with a role for trastuzumab IgE in
mediating tumour cell death by cytotoxicity.
Trastuzumab IgE activity in mast cell degranulation assays
The second functional assay examined the capacity of trast-
uzumab IgE to stimulate mast cells by way of the high-
aYnity IgE receptor FcRI, and trigger their degranulation.
This is a test of the potency of IgE to activate these eVector
cells, and occurs only following cross-linking of FcRI-
bound IgE by multivalent antigen, by anti-human IgE poly-
clonal antibodies or by antigen-expressing target cells. We
used a previously established system, designed to evaluate
the functional activities of IgE antibodies [48]. The assay
utilises the rat basophilic mast cell line RBL-SX38, trans-
fected to express all four subunits (2) of human FcRI
[48]. Flow cytometric evaluations conWrmed that trast-
uzumab IgE bound to cell surface FcRI of the RBL-SX38
cells (45.3% of cells), similar to the previously character-
ised chimaeric MOv18 IgE (Fig. 5a). To assess the ability
of trastuzumab IgE to cause degranulation of RBL-SX38
cells, we measured -hexosaminidase release upon cell
stimulation and cross-linking by tumour cells (Fig. 5b).
Mast cells alone and mast cells stimulated with trastuzumab
IgE in the absence of cross-linking by anti-IgE antibody,
triggered minimal mast cell degranulation [54]. Mast cells
stimulated with trastuzumab IgE in the presence of anti-IgE
antibody triggered a strong degranulation response
(»40%), compared to negligible degranulation measured
with controls.
We also examined whether the engineered trastuzumab
IgE cross-linked by HER2/neu–expressing tumour cells
was capable of stimulating mast cells in an antigen-dependent
manner. Trastuzumab IgE induced strong degranulation of
RBL-SX38 cells following stimulation with CT26-HER2/
neu cells, which express HER2/neu, whilst untransfected
CT26, which do not express HER2/neu, did not potentiate
-hexosaminidase release (Fig. 5b). Furthermore, CT26-
HER2/neu tumour cells with trastuzumab IgE potentiated
signiWcant -hexosaminidase release that was decreased
proportionally to the decreasing number of tumour cells per
sample. These results clearly demonstrate the functional
activity of trastuzumab IgE-CT26-HER2/neu cells in
triggering mast cell activation and mediator release, and
conWrm that the IgE possesses biological activities that
could be speciWcally directed against HER2/neu-expressing
tumour cells in cancer patients.
Trastuzumab IgE targeting of SKBR3 breast cancer cells
ADCC/ADCP assays using the human breast adenocarci-
noma cell line SKBR3, which naturally express the HER2/
neu antigen, conWrm that trastuzumab and trastuzumab IgE
can focus U937 eVector cells to kill SKBR3 cells (Fig. 6).
As with CT26-HER2/neu cells (Figs. 3, 4), trastuzumab
acted in ADCP of tumour cells (Fig. 6a) whilst trastuzumab
IgE killed by ADCC (Fig. 3b). These Wndings demonstrate
the functional properties of trastuzumab IgE focusing eVec-
tor cell functions against native HER2/neu-expressing
breast tumour cells.
Since trastuzumab (IgG1) can potentiate anti-tumour
eVects by blocking hetero-dimerisation of HER2/neu recep-
tors with other HER family members on the surface of
breast cancer cells, switching oV tumour cell growth signals
[8, 9], the anti-proliferative properties of the engineered
trastuzumab IgE were examined using the MTS cell viabil-
ity assay (Fig. 6c). Neither trastuzumab nor trastuzumab
IgE had any anti-tumour growth eVects after 4 h incubation
with SKBR3 cells (99.3 and 98.6% viability for IgG and
IgE, respectively). Decreased tumour cell viability was
measured after 24 h (88.3 and 83.6% for IgG and IgE,
respectively) and more prominent eVects were measured
after 48 h exposure of tumour cells to the antibodies (72.2
and 64.0% for IgG and IgE, respectively). Control MOv18
IgG and MOv18 IgE antibodies did not aVect SKBR3 cell
viability (mean values ranging from 93.0 to 103.8% viability).
Table 4 % Total tumour cell death by U937 monocytes and antibodies
SigniWcance comparing trastuzumab (IgG1) and trastuzumab IgE to
samples given no antibody (left brackets), MOv18 IgG/IgE (middle
brackets) and signiWcance comparing trastuzumab (IgG1) to trast-
uzumab IgE (right bracket)
Comparisons by the Student’s t test: (n/s)P > 0.05; (*)P < 0.05;
(**)P < 0.005; (***)P < 0.0005
Antibody Tumour cell death § SD 
(n = 6) (%)
No ab 12.5 § 3.1
MOv18 IgG 18.5 § 6.6
Trastuzumab (IgG1) 0.5 g/mL 36.1 § 2.2 (***)(***)
MOv18 IgE 19.8 § 3.2
Trastuzumab IgE 0.5 g/mL 34.8 § 3.5 (***)(***)(n/s)
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These data strongly suggest that trastuzumab IgE possesses
similar properties to trastuzumab in blocking tumour growth
after 24 and 48 h in culture.
Discussion
In our previous studies, we reported the anti-tumour activi-
ties of MOv18 IgE, a chimaeric antibody against the ovar-
ian tumour-associated antigen FBP, compared to the
corresponding antibody of the IgG class [29–32, 49]. Our
studies now form part of a growing body of evidence sug-
gesting that IgE antibodies may have a role in cancer ther-
apy [21–23, 27, 28, 33–35, 55]. The emergence of the
human epidermal growth factor receptor HER2/neu as a
well-validated target for cancer therapeutics [1–4] and the
well-documented but circumscribed success of the human-
ised anti-HER2/neu IgG1 antibody trastuzumab, approved
for the treatment of breast cancer [5–7], rendered the propo-
sition to produce an IgE equivalent moiety timely and rele-
vant in the Weld of biological therapeutics for cancer. For
this, we have engineered a humanised trastuzumab IgE
antibody and here we describe the binding characteristics
and biological properties of this molecule.
The kinetics of antigen binding and cell binding data
suggest that trastuzumab IgE possesses HER2/neu binding
properties that are similar to those observed and measured for
trastuzumab (Table 1; Figs. 2, 3, 4). Similar to other well-
characterised IgE antibodies (MOv18 IgE and NIP IgE),
trastuzumab IgE bound to its high-aYnity receptor FcRI as
expected (Table 1; Figs. 2, 4). Furthermore, using functional
assays, this study demonstrates the biological activity of
trastuzumab IgE antibody in directing eVector cells to target
tumour cells in a tumour antigen-speciWc manner (Figs. 4, 5).
Fig. 5 a Flow cytometric analysis of MOv18 IgE (left) and trast-
uzumab IgE (right) binding to human FcRI receptor-expressing RBL-
SX38 cells. (Monoclonal antibodies: solid lines; secondary antibody
controls: grey histograms). b EVects of trastuzumab IgE cross-linking
on mast cell degranulation. Cells alone or sensitised with trastuzumab
IgE, CT26 tumour cells or CT26-HER2/neu tumour cells at diVerent
concentrations. Trastuzumab IgE was cross-linked with anti-IgE poly-
clonal antibody to conWrm its mast cell degranulation activity. Degran-
ulation was monitored by -hexosaminidase activity released into
culture supernatants in all experiments. Data are mean § SD of three
measurements in a representative of three diVerent experiments with
similar results
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Using our ADCC/ADCP assays and microscopic
images, we made a number of observations relating to the
eVector functions of trastuzumab (IgG1) and trastuzumab
IgE. Trastuzumab triggered appreciable levels of mono-
cyte-mediated tumour cell phagocytosis by human mono-
cytic cells (Figs. 3b, c, 6a), also clearly observed in
confocal images by the presence of tumour cell material
ingested by monocytic cells in contact with tumour cells
(Fig. 3d; Table 3). Whilst the signalling and tumour growth
arrest activities of trastuzumab and their role in its clinical
eYcacy have been the subject of many studies, the anti-
tumour mechanisms relating to eVector cell functions of
trastuzumab have been less extensively investigated [7, 8,
10–14]. ADCC is a known anti-tumour mechanism of
trastuzumab [11, 13, 14]. ADCP is not a widely described
function attributed to trastuzumab, but our data are consis-
tent with ADCP as a potential anti-tumour mechanism for
trastuzumab with human macrophages, as reported by
Lazar et al. [12].
Surprisingly, no trastuzumab-dependent monocyte-
mediated cytotoxicity (ADCC) of tumour cells was detected
above that seen in the controls in our ADCC/ADCP assays.
Using our ADCC/ADCP assay to simultaneously measure
the contributions of ADCC and ADCP [30, 31, 49], we
detected only ADCP killing of tumour cells by trast-
uzumab. There are several possible explanations for the dis-
crepancy between the present results and earlier reports. (1)
Previous assays on the eVector cell functions of trast-
uzumab, in combination with either unfractionated or puri-
Wed human eVector cell populations, did not assess the
contributions of ADCP in the death of tumour cells [11–
14]. It is therefore possible that ADCP-mediated tumour
cell death may have been scored as ADCC if the assays
measured total loss of tumour cells; (2) U937 monocytes
express FcRI and FcRII, but very low levels of FcRIII
(Table 2), and thus it is possible that the absence of appreciable
levels of FcRIII may result in low levels of ADCC [18];
(3) The previously reported tumour cell trastuzumab ADCC
Fig. 6 a Quantitation of 
trastuzumab (IgG1)-mediated 
tumour cell killing of SKBR3 
human breast tumour cells by 
U937 monocytes after 2.5 h 
using the ADCC/ADCP assay. 
b Quantitation of trastuzumab 
IgE-mediated tumour cell killing 
of SKBR3 human breast tumour 
cells by U937 monocytes after 
2.5 h using the ADCC/ADCP 
assay. Cytotoxicity: black bars; 
phagocytosis: white bars. 
Results are means § SD 
of 5 independent experiments. 
SigniWcance of values compared 
to samples given MOv18 IgG/
IgE (top) or no antibody 
(bottom) by the Student’s t test: 
n/sP > 0.05, *P < 0.05, 
**P < 0.005, ***P < 0.0005. 
c Cell viability assays (MTS) 
demonstrating levels of suscepti-
bility of SKBR3 breast cancer 
cells to trastuzumab (IgG1), 
trastuzumab IgE, MOv18 IgG 
and MOv18 IgE antibodies at 4, 
24 and 48 h in culture. Each data 
point represents mean % cell 
viability § SD (n = 4)
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may have been mediated by other IgG receptor-bearing
eVector cells in peripheral blood lymphocytes, such as NK
cells and neutrophils, as previously shown [11–14].
When compared to the FBP-speciWc MOv18 IgE anti-
body in the same assay, trastuzumab IgE activated mono-
cytic eVector cells to exhibit signiWcantly enhanced contact
with tumour cells and to eVectively kill HER2/neu-express-
ing tumour cells (Fig. 4d; Table 3). Trastuzumab IgE
directed monocytes to kill HER2/neu-transfected tumour
cells and also tumour cells naturally-expressing the HER2/
neu antigen by ADCC (cytotoxicity), a mechanism clearly
diVerent from that of the anti-tumour mechanism employed
by trastuzumab in the same assay system (Figs. 3, 4, 6).
This may reXect the speciWc binding of trastuzumab IgE to
the high-aYnity receptor FcRI. Evidence presented in our
previous studies on the mechanism of MOv18 IgE mono-
cyte-mediated tumour cell killing, suggested that binding of
IgE to its high-aYnity receptor FcRI on monocytes trig-
gered tumour cell death by a cytotoxic mechanism, whilst
binding to the low-aYnity receptor CD23 resulted in
tumour cell death by ADCP. U937 monocytes express low
levels of CD23 (»2,200 molecules/cell, Table 2) and, as
observed in our studies with MOv18 IgE, these receptor
levels are too low to mediate ADCP of tumour cells [30].
The function of trastuzumab IgE eVected through CD23
remains to be explored and may reveal additional tumour
cell killing properties of the trastuzumab IgE.
Our assays clearly indicated that the levels of tumour
cell killing mediated by trastuzumab IgE were equivalent to
those by trastuzumab (IgG) at the same optimal doses and
in the same assay system (Figs. 3, 4, Table 4). This was true
despite the relatively low levels of IgE binding on the sur-
face of U937 cells, compared to IgG (Figs. 3a, 4a), in
agreement with previous Wndings [30] suggesting the
potency of IgE-mediated eVector functions [20–23, 27, 28,
35, 56]. IgE has much higher aYnity for FcRI
(Ka = 1010 M¡1) than IgG1 has for any of its three Fc
receptors, especially for FcRIII (Ka = 105 M¡1), the main
receptor associated with tumour cell killing [17, 18, 57].
The relatively high aYnities of the IgE-FcRI interaction
may compensate for the lower binding of IgE on U937
monocytes, resulting in comparable levels of tumour cell
killing. These data clearly indicate the biological function
of trastuzumab IgE in focusing monocytic cells to kill
HER2/neu-expressing tumour cells as eVectively as, but
through a mechanism diVerent from, trastuzumab.
The antibody concentration (0.5 g/mL) required to
achieve maximum tumour cell killing by ADCC/ADCP
was the same for IgG and IgE in our in vitro assays (Figs. 3,
4). In addition, our cell viability data clearly show that
trastuzumab IgE, at concentrations found optimal for eVec-
tor cell responses (0.5 g/mL), maintains the ability to
mediate tumour cell growth arrest over a period of 48 h in
culture and at levels similar to those measured for trast-
uzumab (Fig. 6c). The concentration found optimal for the
in vitro eVector cell functions of trastuzumab IgE was ten-
fold lower than our previously reported optimal concentra-
tions required for MOv18 IgG and IgE-mediated (5 g/mL)
killing of ovarian tumour cells in equivalent in vitro assays
[30–32]. This may suggest that lower levels of trastuzumab
IgE may be required for in vivo activities compared to
those used for MOv18 IgG and MOv18 IgE studies. The
IgE responses measured and observed in our assays support
the conclusion that trastuzumab IgE functions with similar
potency, but through mechanisms diVerent from those of
trastuzumab in vitro, warranting further exploration of this
engineered antibody in more clinically relevant models. It
is possible, however, that trastuzumab IgE may be more
eVective than trastuzumab (IgG1) in vivo for the reasons
cited in the Introduction or that a combination of trast-
uzumab and trastuzumab IgE could have potential synergis-
tic anti-tumour eVects.
We also assessed the potential of the engineered trast-
uzumab IgE to activate other potent IgE receptor-bearing
eVector cells. For this, we have utilised a functional assay
that exempliWes the unique properties of IgE to generate
and enhance immune eVector functions that can be targeted
against cancer cells. Trastuzumab IgE bound to the human
FcRI 2 receptor on the surface of mast cells can be
cross-linked by HER2/neu-expressing tumour cells to trig-
ger mast cell degranulation in an antigen-speciWc manner
(Fig. 5). Tissue mast cell degranulation is a known biologi-
cal property of the IgE antibody class. Mediators released
by degranulated mast cells initiate and potentiate eVector
cell recruitment to the site of tumour antigen challenge,
which can be expected to lead to activation and stimulation
of recruited and locally present eVector cells to act in the
ADCC and ADCP of tumour cells. Mast cell activation by
IgE may thus serve as a potential trigger of a strong, local,
tumour antigen-speciWc IgE immune response against
cancer.
This is the Wrst study describing the properties of an
engineered trastuzumab IgE. Based on the considerable evi-
dence pointing to a number of advantages that IgE may
have in tumour cell surveillance and killing, compared to
IgG, our work points to the importance and value of further
research to investigate the eYcacy and mechanisms of
action of tumour antigen-speciWc antibodies of diVerent
classes, in particular IgE and may help to realise the full
potential of antibodies for immunotherapy of cancer.
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Primers Sequence Comany 
Cg2 AGGTCTAGAGACSGATGGGCCCTTGGTGGA eurofins mwg operon 
VH2F GTCTTGTCCCAGGTCAACTTAAGGGAGTCTT eurofins mwg operon 
VH4F CAGGTGCAGCTGCAGGAGTCGG eurofins mwg operon 
VH5F GAGGTGCAGCTGCTGCAGTCTG eurofins mwg operon 
VH6F CTGTCACAGGTACAGCTGCAGCAGTCAG eurofins mwg operon 
VH1L CCATGGACTGGACCTGGA eurofins mwg operon 
VH2L CAGATGGACATACTTTGTTCCAC eurofins mwg operon 
VH3L CCATGGAGTTTGGGCTGAGC eurofins mwg operon 
VH4L CGATGAAACACCTGTGGTTCTT eurofins mwg operon 
VH5L ATGGGGTCAACCGCCATCCT eurofins mwg operon 
VH6L GATGTCTGTCTCCTTCCTCAT eurofins mwg operon 
Cg1 GCCAGGGGGAAGACSCATG eurofins mwg operon 
VH1F CAGGTGCAGCTGGTGCAGTCTG eurofins mwg operon 
VH3F GAGGTGCAGCTGGTGGAGTCTG eurofins mwg operon 
L-Vk1/2 ATGAGGGTCCCCGCTCAGCTGCTGG eurofins mwg operon 
L-Vk3 CTCTTCCTCCTGCTACTCTGGCTCCCAG eurofins mwg operon 
L-Vk4 ATTTCTCTGTTGCTCTGGATCTCTG eurofins mwg operon 
Ck 543-566 GTTTCTCGTAGTCTGCTTTGCTCA eurofins mwg operon 
Pan-Vk ATGACCCAGACTCCATCCACCCTG eurofins mwg operon 
Ck 494-516 GTGCTGTCCTTGCTGTCCTGCT eurofins mwg operon 
L-lambda 1 for GGTCCTGGGCCCAGTCTGTGCTG eurofins mwg operon 
L-lambda 2 for GGTCCTGGGCCCAGTCTGCCCTG eurofins mwg operon 
L-lambda 3 for GCTCTGTGACCTCCTATGAGCTG eurofins mwg operon 
L-lambda 4/5 for GGTCTCTCTCGCAGCCTGTGCTG eurofins mwg operon 
L-lambda 6 for GTTCTTGGGCCAATTTTATGCTG eurofins mwg operon 
L-lambda 7 for GGTCCAATTCCCAGGCTGTGGTG eurofins mwg operon 
L-lambda 8 for GAGTGGATTCTCAGACTGTGGTG eurofins mwg operon 
C lambda rev CACCAGTGTGGCCTTGTTGGCTTG eurofins mwg operon 
F-lambda1 CAGTCTGTGTTGACGCAGCC eurofins mwg operon 
F-lambda2  CAGTCTGCCCTGACTCAGCC eurofins mwg operon 
F-lambda3 TCTTATGAGCTGACACAGCCAC eurofins mwg operon 
F-lambda3l TCTTCTGAGCTGACTCAGGACCC eurofins mwg operon 
F-lambda4ab CAGCTTGTGCTGACTCAATC eurofins mwg operon 
F-lambda4c CTGCCTGTGCTGACTCAGC eurofins mwg operon 
F-lambda5/9 CAGCCTGTGCTGACTCAGC eurofins mwg operon 
F-lambda6 AATTTTATGCTGACTCAGCCCCACT eurofins mwg operon 
F-lambda7/8 CAGACTGTGGTGACCCAGGAG eurofins mwg operon 
F-lambda10 CAGGCAGGGCTGACTCAG eurofins mwg operon 
C lambda-2 GGGTGGGAACAGAGTGACC eurofins mwg operon 
J segment F ACCCTGGTCACCGTCTCCTCA Applied Biosytems 
Mature IgG R TTCTGGAAGTAGTCCTTGACCA Applied Biosytems 
Mature IgE R TGCAGCAGCGGGTCAAG Applied Biosytems 
 
  
Sample ID RNA yield 
260/280 
Ratio  Sample ID RNA yield 
260/280 
Ratio 
LNM1 407.2 2.04  LRTAN1 1075.9 2.07 
LN1 257 2.11  LRTAN2 1069.5 2.06 
LN2 619.9 2.08  N63 454.54 2 
LN3 306.3 2.03  N73 461.7 2.02 
LN4 452.9 2.1  N101 330.3 2.06 
LN5 1953.2 1.97  N131 447.78 2.2 
LNM2 1344.9 1.99  N144 346.3 1.99 
LNM3 1275.6 2  N148 429.5 2.03 
LNM4 1242.4 1.99  M269 458.89 2.08 
LNM5 857.5 2  M254 362.35 2.01 
LNM6 1578.3 1.97  M245 502.42 2.01 
LN6 439.8 2.07  M221 189.72 1.89 
LN7 169.4 2.1  M215 213.34 1.96 
LN8 349.7 <1.8  M81 21.8 1.92 
LN9 1095.3 <1.8  M91 1 1.57 
LN10 126.5 <1.8  M92 290.5 2.06 
LN11 451.2 <1.8  M103 330.6 2.03 
LNM7 76.7 2.13     
LNM8 231 2.07     
LNM9 225 2.08     
LNM10 80.8 2.09     
LNM11 567.2 2.01     
LN12 96.5 2.05     
LNM12 702.3 2.07     
LNM13 609.5 2.07     
LN13 1643 1.99     
LN14 558.3 2.07     
LN15 405.2 2.05     
LN16 246.5 2.07     
LNM14 319.3 2.06     
LN17 186.3 2.06     
LNM15 326.1 2.05     
LN18 329.6 1.95     
LNM16 439.1 1.93     
LN19 231.5 2.05     
LN20 1539.7 1.91     
LN21 131.7 2.06     
LNM17 354.7 2.07     
M128 255 2.05     
M129 137.4 2.06     
M171 132.2 2.08     
M72 594.2 2.09     
M147 63.3 2.02     
M173 412.6 2.07     
WM115 104 2.08     
M78 90.6 2.04     
M80 148.2 2.05     
 
  
Taqman Probes Sequence Catalogue No.  
Mature IgG 6-FAM-CTCAGCCAGGACCAAG-MGB  (Custom-made) 
Mature IgE FAM-TCACAGCTCCACACAGAG-MGB  (Custom-made) 
β2-Microglobulin VIC----MGB Hs00984230_m1 
CD22 FAM----MGB HS0023533_m1 
GAPDH VIC----MGB HS4310884_m1 
VEGF FAM----MGB HS00174379_m1 
IFN- FAM----MGB HS00174379_m1 
IL-4 FAM----MGB HS00174379_m1 
Il-10 FAM----MGB HS00174379_m1 
 
